Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/010913

International filing date: 31 March 2005 (31.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/559,042
Filing date: 01 April 2004 (01.04.2004)

Date of receipt at the International Bureau: 12 August 2005 (12.08.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1352383

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

August 02, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: *60/559,042*
FILING DATE: *April 01, 2004*
RELATED PCT APPLICATION NUMBER: *PCT/US05/10913*

Certified by

Jon W. Dudas

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PTO/SB/16 (08-03)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EL 961008104 US

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Steven	MAH	San Diego, California
Andreas	BRAUN	San Diego, California
Stefan M.	KAMMERER	San Diego, California

Additional inventors are being named on the 1 *separately numbered sheets attached hereto*

TITLE OF THE INVENTION (500 characters max)

METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF

Direct all correspondence to: **CORRESPONDENCE ADDRESS**

[x] Customer Number: 25225

OR

[ ] Firm or Individual Name

Address

City | State | Zip

Country | Telephone | Fax

ENCLOSED APPLICATION PARTS (*check all that apply*)

[x] Specification *Number of Pages* 162 [ ] CD(s), Number

[x] Drawing(s) *Number of Sheets* 1 [x] Other (specify): Return Receipt Postcard

[x] Application Data Sheet. See 37 CFR 1.76 (4 pages)

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

[x] Applicant claims small entity status. See 37 CFR 1.27.

[ ] A check or money order is enclosed to cover the filing fees.

[x] The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 03-1952

[ ] Payment by credit card. Form PTO-2038 is attached.

FILING FEE AMOUNT ($): 80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

[x] No [ ] Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE

TYPED OR PRINTED NAME Bruce D. Grant

TELEPHONE (858) 720-7962

Date April 1, 2004

REGISTRATION NO. *(if appropriate)* 47,608

Docket Number: 524593008900

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 961008104 US, in an envelope addressed to: Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 4/1/04 Signature: (Deborah Wykes)

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (08-03)
Approved for use through 07/31/06. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number	524593008900

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Matthew Roberts	NELSON	San Marcos, California
Rikard Henry	RENELAND	San Diego, California
Maria L.	LANGDOWN	San Diego, California

sd-189448

METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF

Field of the Invention

[0001] The invention relates to genetic methods for identifying risk of osteoarthritis and treatments that specifically target such diseases.

Background

[0002] Osteoarthritis (OA) is a chronic disease usually affecting weight-bearing synovial joints. There are approximately 20 million Americans affected by OA and it is the leading cause of disability in the United States. In addition to extensive human suffering, OA also accounts for nearly all knee replacements and more than half of all hip replacements in the United States. Despite its prevalence, OA is poorly understood and there are few treatments available besides anti-inflammatory drugs and joint replacement.

[0003] Most commonly affecting middle-aged and older people, OA can range from very mild to very severe. It affects hands and weight-bearing joints such as knees, hips, feet and the back. Knee OA can be as disabling as any cardiovascular disease except stroke.

[0004] OA is characterized by the breakdown of cartilage in joints. Cartilage in joints cushions the ends of bones, and cartilage breakdown causes bones to rub against each other, causing pain and loss of movement. Type II collagen is the main component of cartilage, comprising 15-25% of the wet weight, approximately half the dry weight, and representing 90-95% of the total collagen content in the tissue. It forms fibrils that endow cartilage with tensile strength (Mayne, R. Arthritis Rhuem. 32:241-246 (1989)).

Summary

[0005] It has been discovered that certain polymorphic variations in human genomic DNA are associated with osteoarthritis. In particular, polymorphic variants in a locus containing a *ADAMTS2* region in human genomic DNA have been associated with risk of osteoarthritis.

[0006] Thus, featured herein are methods for identifying a subject at risk of osteoarthritis and/or a risk of osteoarthritis in a subject, which comprise detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in or around the loci described herein in a human nucleic acid sample. In an embodiment, two or more polymorphic variations are detected in two or more regions of which one is the *ADAMTS2* region. In certain embodiments, 3 or more, or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more polymorphic variants are detected.

[0007] Also featured are nucleic acids that include one or more polymorphic variations associated with occurrence of osteoarthritis, as well as polypeptides encoded by these nucleic acids. In addition, provided are methods for identifying candidate therapeutic molecules for treating osteoarthritis, as well as methods for treating osteoarthritis in a subject by identifying a subject at risk of osteoarthritis and treating the subject with a suitable prophylactic, treatment or therapeutic molecule.

[0008] Also provided are compositions comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and/or a *ADAMTS2* nucleic acid, with a RNAi, siRNA, antisense DNA or RNA, or ribozyme nucleic acid designed from a *ADAMTS2* nucleotide sequence. In an embodiment, the RNAi, siRNA, antisense DNA or RNA, or ribozyme nucleic acid is designed from a *ADAMTS2* nucleotide sequence that includes one or more polymorphic variations associated with osteoarthritis, and in some instances, specifically interacts with such a nucleotide sequence. Further, provided are arrays of nucleic acids bound to a solid surface, in which one or more nucleic acid molecules of the array have a *ADAMTS2* nucleotide sequence, or a fragment or substantially identical nucleic acid thereof, or a complementary nucleic acid of the foregoing. Featured also are compositions comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and/or a *ADAMTS2* polypeptide, with an antibody that specifically binds to the polypeptide. Thus, featured is an antibody that specifically binds to an epitope in the polypeptide that includes an amino acid encoded by a polymorphic site associated with osteoarthritis. In certain embodiments, the antibody specifically binds to an epitope comprising a valine or isoleucine encoded by rs398829 (e.g., an antibody that binds to an epitope comprising a valine at position 245 in an *ADAMTS2* polypeptide) A valine at position 245 is associated with increased risk of osteoarthitis.

Brief Description of the Drawings

[0009] Figure 1 shows proximal SNPs in a *ADAMTS2* region in genomic DNA. The position of each SNP in the chromosome is shown on the x-axis and the y-axis provides the negative logarithm of the p-value comparing the estimated allele to that of the control group. Also shown in the figure are exons and introns of the region in the approximate chromosomal positions.

Detailed Description

[0010] It has been discovered that a polymorphic variant in a locus containing a *ADAMTS2* region is associated with occurrence of osteoarthritis in subjects. Thus, detecting genetic determinants associated with an increased risk of osteoarthritis occurrence can lead to early identification of a predisposition to osteoarthritis and early prescription of preventative measures. Also, associating a *ADAMTS2* polymorphic variant with osteoarthritis has provided new targets for screening molecules useful in treatments of osteoarthritis.

Osteoarthritis and Sample Selection

[0011] Osteoarthritis (OA), or degenerative joint disease, is one of the oldest and most common types of arthritis. It is characterized by the breakdown of the joint's cartilage. Cartilage is the part of the joint that cushions the ends of bones, and its breakdown causes bones to rub against each other, causing pain and loss of movement. Type II collagen is the main component of cartilage, comprising 15-25% of the wet weight, approximately half the dry weight, and representing 90-95% of the total collagen content in the tissue. It forms fibrils that endow cartilage with tensile strength (Mayne, R. Arthritis Rhuem. 32:241-246 (1989)).

[0012] Most commonly affecting middle-aged and older people, OA can range from very mild to very severe. It affects hands and weight-bearing joints such as knees, hips, feet and the back. Knee OA can be as disabling as any cardiovascular disease except stroke. Whereas Ehlers-Danlos syndrome type VIIC is characterized by the retention of the N-terminal propeptide of type I collagen, osteoarthritis has been characterized by increased levels of type II collagen in osteoarthritic cartilage as measured by elevated C-propeptide concentrations (Nelson et al. (1998) J. Clin. Invest. 102(12):2115-2125).

[0013] Osteoarthritis affects an estimated 20.7 million Americans, mostly after age 45, with women more commonly affected than men. Physicians make a diagnosis of OA based on a physical exam and history of symptoms. X-rays are used to confirm diagnosis. Most people over 60 reflect the disease on X-ray, and about one-third have actual symptoms.

[0014] There are many factors that can cause OA. Obesity may lead to osteoarthritis of the knees. In addition, people with joint injuries due to sports, work-related activity or accidents may be at increased risk of developing OA.

[0015] Genetics has a role in the development of OA. Some people may be born with defective cartilage or with slight defects in the way that joints fit together. As a person ages, these defects may cause early cartilage breakdown in the joint or the inability to repair damaged or deteriorated cartilage in the joint.

[0016] Inclusion or exclusion of samples for an osteoarthritis pool may bc based upon the following criteria: ethnicity (e.g., samples derived from an individual characterized as Caucasian); parental ethnicity (e.g., samples derived from an individual of British paternal and maternal descent); relevant phenotype information for the individual (e.g., case samples derived from individuals diagnosed with specific knee osteoarthritis (OA) and were recruited from an OA knee replacement clinic). Control samples may be selected based on relevant phenotype information for the individual (e.g., derived from individuals free of OA at several sites (knee, hand, hip etc)); and no family history of OA and/or rheumatoid arthritis. Additional phenotype information collected for both cases and controls may include age of the individual, gender, family history of OA, diagnosis with osteoarthritis (joint location of OA, date of primary diagnosis, age of individual as of primary diagnosis), knee history (current symptoms,

any major knee injury, menisectomy, knee replacement surgery, age of surgery), HRT history, osteoporosis diagnosis.

[0017] Based in part upon selection criteria set forth above, individuals having osteoarthritis can be selected for genetic studies. Also, individuals having no history of osteoarthritis often are selected for genetic studies, as described hereafter.

Polymorphic Variants Associated with Osteoarthritis

[0018] A genetic analysis provided herein linked osteoarthritis with polymorphic variant nucleic acid sequences in the human genome. As used herein, the term "polymorphic site" refers to a region in a nucleic acid at which two or more alternative nucleotide sequences are observed in a significant number of nucleic acid samples from a population of individuals. A polymorphic site may be a nucleotide sequence of two or more nucleotides, an inserted nucleotide or nucleotide sequence, a deleted nucleotide or nucleotide sequence, or a microsatellite, for example. A polymorphic site that is two or more nucleotides in length may be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more, 20 or more, 30 or more, 50 or more, 75 or more, 100 or more, 500 or more, or about 1000 nucleotides in length, where all or some of the nucleotide sequences differ within the region. A polymorphic site is often one nucleotide in length, which is referred to herein as a "single nucleotide polymorphism" or a "SNP."

[0019] Where there are two, three, or four alternative nucleotide sequences at a polymorphic site, each nucleotide sequence is referred to as a "polymorphic variant" or "nucleic acid variant." Where two polymorphic variants exist, for example, the polymorphic variant represented in a minority of samples from a population is sometimes referred to as a "minor allele" and the polymorphic variant that is more prevalently represented is sometimes referred to as a "major allele." Many organisms possess a copy of each chromosome (*e.g.*, humans), and those individuals who possess two major alleles or two minor alleles are often referred to as being "homozygous" with respect to the polymorphism, and those individuals who possess one major allele and one minor allele are normally referred to as being "heterozygous" with respect to the polymorphism. Individuals who are homozygous with respect to one allele are sometimes predisposed to a different phenotype as compared to individuals who are heterozygous or homozygous with respect to another allele.

[0020] In genetic analysis that associate polymorphic variants with osteoarthritis, samples from individuals having osteoarthritis and individuals not having osteoarthritis often are allelotyped and/or genotyped. The term "allelotype" as used herein refers to a process for determining the allele frequency for a polymorphic variant in pooled DNA samples from cases and controls. By pooling DNA from each group, an allele frequency for each SNP in each group is calculated. These allele frequencies are then compared to one another. The term "genotyped" as used herein refers to a process for determining a

genotype of one or more individuals, where a "genotype" is a representation of one or more polymorphic variants in a population.

[0021] A genotype or polymorphic variant may be expressed in terms of a "haplotype," which as used herein refers to two or more polymorphic variants occurring within genomic DNA in a group of individuals within a population. For example, two SNPs may exist within a gene where each SNP position includes a cytosine variation and an adenine variation. Certain individuals in a population may carry one allele (heterozygous) or two alleles (homozygous) having the gene with a cytosine at each SNP position. As the two cytosines corresponding to each SNP in the gene travel together on one or both alleles in these individuals, the individuals can be characterized as having a cytosine/cytosine haplotype with respect to the two SNPs in the gene.

[0022] As used herein, the term "phenotype" refers to a trait which can be compared between individuals, such as presence or absence of a condition, a visually observable difference in appearance between individuals, metabolic variations, physiological variations, variations in the function of biological molecules, and the like. An example of a phenotype is occurrence of osteoarthritis.

[0023] Researchers sometimes report a polymorphic variant in a database without determining whether the variant is represented in a significant fraction of a population. Because a subset of these reported polymorphic variants are not represented in a statistically significant portion of the population, some of them are sequencing errors and/or not biologically relevant. Thus, it is often not known whether a reported polymorphic variant is statistically significant or biologically relevant until the presence of the variant is detected in a population of individuals and the frequency of the variant is determined. Methods for detecting a polymorphic variant in a population are described herein, specifically in Example 2. A polymorphic variant is statistically significant and often biologically relevant if it is represented in 5% or more of a population, sometimes 10% or more, 15% or more, or 20% or more of a population, and often 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more of a population.

[0024] A polymorphic variant may be detected on either or both strands of a double-stranded nucleic acid. Also, a polymorphic variant may be located within an intron or exon of a gene or within a portion of a regulatory region such as a promoter, a 5′ untranslated region (UTR), a 3′ UTR, and in DNA (*e.g.*, genomic DNA (gDNA) and complementary DNA (cDNA)), RNA (*e.g.*, mRNA, tRNA, and rRNA), or a polypeptide. Polymorphic variations may or may not result in detectable differences in gene expression, polypeptide structure, or polypeptide function.

[0025] It was determined that polymorphic variations associated with an increased risk of osteoarthritis existed in a *ADAMTS2* region in SEQ ID NO: 1. In certain embodiments, a polymorphic variant at position rs398829 in the human genome was associated with an increased risk of osteoarthritis, and in a specific embodiment, a guanine at position rs398829 was associated with an increased risk of osteoarthritis.

[0026] Polymorphic variants in and around the *ADAMTS2* locus were tested for association with osteoarthritis. These include polymorphic variants at positions in SEQ ID NO: 1 selected from the group consisting of 210, 3608, 3609, 4318, 5593, 5629, 5639, 5640, 8943, 17968, 19887, 21034, 21085, , 21596, 23379, 23432, 24007, 26121, 26273, 26755, 27411, 27710, 27842, 28379, 29603, 31232, 31504, 32583, 32794, 32840, 33044, 33150, 33218, 33513, 33959, 34486, 36289, 36570, 38247, 38477, 38518, 38529, 38667, 39781, 39856, 39927, 40506, 41869, 42452, 44788, 46059, 46846, 47712, 48796, 49441, 49602, 49723, 50050, 50171, 50477, 50818, 50833, 50881, 50882, 51386, 51534, 52317, 52368, 52970, 53023, 53356, 53882, 54553, 55475, 55530, 55691, 55848, 55879, 56316, 56911, 57320, 57391, 57437, 57478, 57500, 59111, 59333, 59715, 59804, 59851, 59929, 60052, 60240, 60359, 60381, 60456, 60724, 60875, 60968, 60978, 60998, 61557, 62091, 62645, 62943, 63131, 63145, 63406, 63427, 63554, 63661, 64093, 64153, 64409, 64544, 65257, 65626,65739 , 66392, 66720, 69177, 69336, 69636, 69823, 69928, 70547, 70633, 71805, 72181, 72200, 72474, 72567, 72973, 73468, 73889, 75730, 75970, 76114, 76342, 76449, 76465, 76791, 78042, 80758, 80778, 81356, 81576, 81689, 81759, 81950, 82562, 83591, 83700, 83821, 83842, 83923, 83929, 84021, 84175, 84417, 84747, 85746, 86129, 86335, 87315, 87648, 87764, 87770, 88221, 90474, 91148, 91150, 91160, 91733, 91772, 91785, 93140, 93148, 96080, 96157, 96313, 96759, 97026, 97320, 97732, 98713, 99707, 99959, 100009, 100020, 100065, 100086, 101270, 101276, 101371, 101376, 101439, 101820, 102392, 102602, 102604, 102896, 189104, 189134 and 189205. Polymorphic variants at the following positions in SEQ ID NO: 1 in particular were associated with an increased risk of osteoarthritis: 5640, 33150, 38247, 38529, 46846, 49723, 50050, 63427, 73889, 189104 and rs428901, where specific embodiments are directed to positions 46846, 73889, 189104 and/or rs428901. In particular, the following polymorphic variants in SEQ ID NO: 1 were associated with risk of osteoarthritis: a cytosine at position 5640, a cytosine at position 33150, an adenine at position 38247, a thymine at position 38529, an adenine at position 46846, a cytosine at position 49723, a cytosine at position 50050, a cytosine a position 63427, a guanine at position 73889, a thymine at position 189104, and an adenine at position rs428901.

[0027] Based in part upon analyses summarized in Figure 1, a region with significant association has been identified in a locus associated with osteoarthritis. Any polymorphic variants associated with osteoarthritis in a region of significant association can be utilized for embodiments described herein. For example, polymorphic variants in a region spanning chromosome positions 178746000 to 178751000 (approximately 5,000 nucleotides in length) in a *ADAMTS2* locus have significant association (chromosome positions are within NCBI's Genome build 34).

Additional Polymorphic Variants Associated with Osteoarthritis

[0028] Also provided is a method for identifying polymorphic variants proximal to an incident, founder polymorphic variant associated with osteoarthritis. Thus, featured herein are methods for

identifying a polymorphic variation associated with osteoarthritis that is proximal to an incident polymorphic variation associated with osteoarthritis, which comprises identifying a polymorphic variant proximal to the incident polymorphic variant associated with osteoarthritis, where the incident polymorphic variant is in a *ADAMTS2* nucleotidc sequence. The nucleotide sequence often comprises a polynucleotide sequence selected from the group consisting of (a) a polynucleotide sequence of SEQ ID NO: 1-3; (b) a polynucleotide sequence that encodes a polypeptide having an amino acid sequence encoded by a polynucleotide sequence of SEQ ID NO: 1-3; and (c) a polynucleotide sequence that encodes a polypeptide having an amino acid sequence that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3 or a polynucleotide sequence 90% or more identical to the polynucleotide sequence of SEQ ID NO: 1-3. The presence or absence of an association of the proximal polymorphic variant with osteoarthritis then is determined using a known association method, such as a method described in the Examples hereafter. In an embodiment, the incident polymorphic variant is a polymorphic variant associated with osteoarthritis described herein. In another embodiment, the proximal polymorphic variant identified sometimes is a publicly disclosed polymorphic variant, which for example, sometimes is published in a publicly available database. In other embodiments, the polymorphic variant identified is not publicly disclosed and is discovered using a known method, including, but not limited to, sequencing a region surrounding the incident polymorphic variant in a group of nucleic samples. Thus, multiple polymorphic variants proximal to an incident polymorphic variant are associated with osteoarthritis using this method.

[0029] The proximal polymorphic variant often is identified in a region surrounding the incident polymorphic variant. In certain embodiments, this surrounding region is about 50 kb flanking the first polymorphic variant (*e.g.* about 50 kb 5' of the first polymorphic variant and about 50 kb 3' of the first polymorphic variant), and the region sometimes is composed of shorter flanking sequences, such as flanking sequences of about 40 kb, about 30 kb, about 25 kb, about 20 kb, about 15 kb, about 10 kb, about 7 kb, about 5 kb, or about 2 kb 5' and 3' of the incident polymorphic variant. In other embodiments, the region is composed of longer flanking sequences, such as flanking sequences of about 55 kb, about 60 kb, about 65 kb, about 70 kb, about 75 kb, about 80 kb, about 85 kb, about 90 kb, about 95 kb, or about 100 kb 5' and 3' of the incident polymorphic variant.

[0030] In certain embodiments, polymorphic variants associated with osteoarthritis are identified iteratively. For example, a first proximal polymorphic variant is associated with osteoarthritis using the methods described above and then another polymorphic variant proximal to the first proximal polymorphic variant is identified (*e.g.*, publicly disclosed or discovered) and the presence or absence of an association of one or more other polymorphic variants proximal to the first proximal polymorphic variant with osteoarthritis is determined.

[0031] The methods described herein are useful for identifying or discovering additional polymorphic variants that may be used to further characterize a gene, region or loci associated with a condition, a disease (*e.g.*, osteoarthritis), or a disorder. For example, allelotyping or genotyping data from the additional polymorphic variants may be used to identify a functional mutation or a region of linkage disequilibrium. In certain embodiments, polymorphic variants identified or discovered within a region comprising the first polymorphic variant associated with osteoarthritis are genotyped using the genetic methods and sample selection techniques described herein, and it can be determined whether those polymorphic variants are in linkage disequilibrium with the first polymorphic variant. The size of the region in linkage disequilibrium with the first polymorphic variant also can be assessed using these genotyping methods. Thus, provided herein are methods for determining whether a polymorphic variant is in linkage disequilibrium with a first polymorphic variant associated with osteoarthritis, and such information can be used in prognosis/diagnosis methods described herein.

Isolated Nucleic Acids

[0032] Featured herein are isolated *ADAMTS2* nucleic acid variants depicted in SEQ ID NO: 1-3, and substantially identical nucleic acids thereof. A nucleic acid variant may be represented on one or both strands in a double-stranded nucleic acid or on one chromosomal complement (heterozygous) or both chromosomal complements (homozygous). *ADAMTS2* exists in two forms, a "long" form comprising a molecule approximately 130 kDa in length (e.g., SEQ ID NO: 2 for cDNA sequence and SEQ ID NO: 4 for amino acid sequence), and a "short" form comprising a molecule approximately 70 kDa in length (e.g., SEQ ID NO: 3 for cDNA sequence and SEQ ID NO: 5 for amino acid sequence). Provided herein are polynucleotide sequences encoding both the short and long forms of ADAMTS2.

[0033] As used herein, the term "nucleic acid" includes DNA molecules (*e.g.*, a complementary DNA (cDNA) and genomic DNA (gDNA)) and RNA molecules (*e.g.*, mRNA, rRNA, siRNA and tRNA) and analogs of DNA or RNA, for example, by use of nucleotide analogs. The nucleic acid molecule can be single-stranded and it is often double-stranded. The term "isolated or purified nucleic acid" refers to nucleic acids that are separated from other nucleic acids present in the natural source of the nucleic acid. For example, with regard to genomic DNA, the term "isolated" includes nucleic acids which are separated from the chromosome with which the genomic DNA is naturally associated. An "isolated" nucleic acid is often free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and/or 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of 5' and/or 3' nucleotide sequences which flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular

material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. As used herein, the term "gene" refers to a nucleotide sequence that encodes a polypeptide.

[0034] Also included herein are nucleic acid fragments. These fragments often have a nucleotide sequence identical to a nucleotide sequence of SEQ ID NO: 1-3, a nucleotide sequence substantially identical to a nucleotide sequence of SEQ ID NO: 1-3, or a nucleotide sequence that is complementary to the foregoing. The nucleic acid fragment may be identical, substantially identical or homologous to a nucleotide sequence in an exon or an intron in a nucleotide sequence of SEQ ID NO: 1-3, and may encode a domain or part of a domain of a polypeptide. Sometimes, the fragment will comprises one or more of the polymorphic variations described herein as being associated with osteoarthritis. The nucleic acid fragment is often 50, 100, or 200 or fewer base pairs in length, and is sometimes about 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 2000, 3000, 4000, 5000, 10000, 15000, or 20000 base pairs in length. A nucleic acid fragment that is complementary to a nucleotide sequence identical or substantially identical to a nucleotide sequence in SEQ ID NO: 1-3 and hybridizes to such a nucleotide sequence under stringent conditions is often referred to as a "probe." Nucleic acid fragments often include one or more polymorphic sites, or sometimes have an end that is adjacent to a polymorphic site as described hereafter.

[0035] An example of a nucleic acid fragment is an oligonucleotide. As used herein, the term "oligonucleotide" refers to a nucleic acid comprising about 8 to about 50 covalently linked nucleotides, often comprising from about 8 to about 35 nucleotides, and more often from about 10 to about 25 nucleotides. The backbone and nucleotides within an oligonucleotide may be the same as those of naturally occurring nucleic acids, or analogs or derivatives of naturally occurring nucleic acids, provided that oligonucleotides having such analogs or derivatives retain the ability to hybridize specifically to a nucleic acid comprising a targeted polymorphism. Oligonucleotides described herein may be used as hybridization probes or as components of prognostic or diagnostic assays, for example, as described herein.

[0036] Oligonucleotides are typically synthesized using standard methods and equipment, such as the ABI™3900 High Throughput DNA Synthesizer and the EXPEDITE™ 8909 Nucleic Acid Synthesizer, both of which are available from Applied Biosystems (Foster City, CA). Analogs and derivatives are exemplified in U.S. Pat. Nos. 4,469,863; 5,536,821; 5,541,306; 5,637,683; 5,637,684; 5,700,922; 5,717,083; 5,719,262; 5,739,308; 5,773,601; 5,886,165; 5,929,226; 5,977,296; 6,140,482; WO 00/56746; WO 01/14398, and related publications. Methods for synthesizing oligonucleotides comprising such analogs or derivatives are disclosed, for example, in the patent publications cited above

and in U.S. Pat. Nos. 5,614,622; 5,739,314; 5,955,599; 5,962,674; 6,117,992; in WO 00/75372; and in related publications.

[0037] Oligonucleotides may also be linked to a second moiety. The second moiety may be an additional nucleotide sequence such as a tail sequence (*e.g.*, a polyadenosine tail), an adapter sequence (*e.g.*, phage M13 universal tail sequence), and others. Alternatively, the second moiety may be a non-nucleotide moiety such as a moiety which facilitates linkage to a solid support or a label to facilitate detection of the oligonucleotide. Such labels include, without limitation, a radioactive label, a fluorescent label, a chemiluminescent label, a paramagnetic label, and the like. The second moiety may be attached to any position of the oligonucleotide, provided the oligonucleotide can hybridize to the nucleic acid comprising the polymorphism.

Uses for Nucleic Acid Sequence

[0038] Nucleic acid coding sequences may be used for diagnostic purposes for detection and control of polypeptide expression. Also, included herein are oligonucleotide sequences such as antisense RNA, small-interfering RNA (siRNA) and DNA molecules and ribozymes that function to inhibit translation of a polypeptide. Antisense techniques and RNA interference techniques are known in the art and are described herein.

[0039] Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, hammerhead motif ribozyme molecules may be engineered that specifically and efficiently catalyze endonucleolytic cleavage of RNA sequences corresponding to or complementary to *ADAMTS2* nucleotide sequences. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between fifteen (15) and twenty (20) ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

[0040] Antisense RNA and DNA molecules, siRNA and ribozymes may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated

into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

[0041] DNA encoding a polypeptide also may have a number of uses for the diagnosis of diseases, including osteoarthritis, resulting from aberrant expression of a target gene described herein. For example, the nucleic acid sequence may be used in hybridization assays of biopsies or autopsies to diagnose abnormalities of expression or function (*e.g.*, Southern or Northern blot analysis, in situ hybridization assays).

[0042] In addition, the expression of a polypeptide during embryonic development may also be determined using nucleic acid encoding the polypeptide. As addressed, *infra*, production of functionally impaired polypeptide is the cause of various disease states, such as osteoarthritis. *In situ* hybridizations using polypeptide as a probe may be employed to predict problems related to osteoarthritis. Further, as indicated, *infra*, administration of human active polypeptide, recombinantly produced as described herein, may be used to treat disease states related to functionally impaired polypeptide. Alternatively, gene therapy approaches may be employed to remedy deficiencies of functional polypeptide or to replace or compete with dysfunctional polypeptide.

Expression Vectors, Host Cells, and Genetically Engineered Cells

[0043] Provided herein are nucleic acid vectors, often expression vectors, which contain a *ADAMTS2* nucleotide sequence, or a substantially identical sequence thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked and can include a plasmid, cosmid, or viral vector. The vector can be capable of autonomous replication or it can integrate into a host DNA. Viral vectors may include replication defective retroviruses, adenoviruses and adeno-associated viruses for example.

[0044] A vector can include a *ADAMTS2* nucleotide sequence in a form suitable for expression of an encoded target polypeptide or target nucleic acid in a host cell. A "target polypeptide" is a polypeptide encoded by a *ADAMTS2* nucleotide sequence, or a substantially identical nucleotide sequence thereof. The recombinant expression vector typically includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. The term "regulatory sequence" includes promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence, as well as tissue-specific regulatory and/or inducible sequences. The design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of polypeptide desired, and the like. Expression vectors can be introduced into host cells to produce target polypeptides, including fusion polypeptides.

[0045] Recombinant expression vectors can be designed for expression of target polypeptides in prokaryotic or eukaryotic cells. For example, target polypeptides can be expressed in *E. coli*, insect cells (*e.g.*, using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology 185*, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

[0046] Expression of polypeptides in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion polypeptides. Fusion vectors add a number of amino acids to a polypeptide encoded therein, usually to the amino terminus of the recombinant polypeptide. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant polypeptide; 2) to increase the solubility of the recombinant polypeptide; and 3) to aid in the purification of the recombinant polypeptide by acting as a ligand in affinity purification. Often, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant polypeptide to enable separation of the recombinant polypeptide from the fusion moiety subsequent to purification of the fusion polypeptide. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith & Johnson, *Gene 67:* 31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding polypeptide, or polypeptide A, respectively, to the target recombinant polypeptide.

[0047] Purified fusion polypeptides can be used in screening assays and to generate antibodies specific for target polypeptides. In a therapeutic embodiment, fusion polypeptide expressed in a retroviral expression vector is used to infect bone marrow cells that are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (*e.g.*, six (6) weeks).

[0048] Expressing the polypeptide in host bacteria with an impaired capacity to proteolytically cleave the recombinant polypeptide is often used to maximize recombinant polypeptide expression (Gottesman, S., *Gene Expression Technology: Methods in Enzymology, Academic Press, San Diego, California 185:* 119-128 (1990)). Another strategy is to alter the nucleotide sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al., Nucleic Acids Res. 20:* 2111-2118 (1992)). Such alteration of nucleotide sequences can be carried out by standard DNA synthesis techniques.

[0049] When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. Recombinant mammalian expression vectors are

often capable of directing expression of the nucleic acid in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Non-limiting examples of suitable tissue-specific promoters include an albumin promoter (liver-specific; Pinkert *et al., Genes Dev. 1:* 268-277 (1987)), lymphoid-specific promoters (Calame & Eaton, *Adv. Immunol. 43:* 235-275 (1988)), promoters of T cell receptors (Winoto & Baltimore, *EMBO J. 8:* 729-733 (1989)) promoters of immunoglobulins (Banerji *et al., Cell 33:* 729-740 (1983); Queen & Baltimore, *Cell 33:* 741-748 (1983)), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne & Ruddle, *Proc. Natl. Acad. Sci. USA 86:* 5473-5477 (1989)), pancreas-specific promoters (Edlund *et al., Science 230:* 912-916 (1985)), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are sometimes utilized, for example, the murine hox promoters (Kessel & Gruss, *Science 249:* 374-379 (1990)) and the α-fetopolypeptide promoter (Campes & Tilghman, *Genes Dev. 3:* 537-546 (1989)).

[0050] A *ADAMTS2* nucleic acid also may be cloned into an expression vector in an antisense orientation. Regulatory sequences (*e.g.*, viral promoters and/or enhancers) operatively linked to a *ADAMTS2* nucleic acid cloned in the antisense orientation can be chosen for directing constitutive, tissue specific or cell type specific expression of antisense RNA in a variety of cell types. Antisense expression vectors can be in the form of a recombinant plasmid, phagemid or attenuated virus. For a discussion of the regulation of gene expression using antisense genes *see, e.g.,* Weintraub *et al.,* Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) (1986).

[0051] Also provided herein are host cells that include a *ADAMTS2* nucleotide sequence within a recombinant expression vector or a fragment of such a nucleotide sequence which facilitate homologous recombination into a specific site of the host cell genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. Such terms refer not only to the particular subject cell but rather also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic or eukaryotic cell. For example, a target polypeptide can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

[0052] Vectors can be introduced into host cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, transduction/infection, DEAE-dextran-mediated transfection, lipofection, or electroporation.

[0053] A host cell provided herein can be used to produce (*i.e.*, express) a target polypeptide or a substantially identical polypeptide thereof. Accordingly, further provided are methods for producing a target polypeptide using host cells described herein. In one embodiment, the method includes culturing host cells into which a recombinant expression vector encoding a target polypeptide has been introduced in a suitable medium such that a target polypeptide is produced. In another embodiment, the method further includes isolating a target polypeptide from the medium or the host cell.

[0054] Also provided are cells or purified preparations of cells which include a *ADAMTS2* transgene, or which otherwise misexpress target polypeptide. Cell preparations can consist of human or non-human cells, *e.g.*, rodent cells, *e.g.*, mouse or rat cells, rabbit cells, or pig cells. In preferred embodiments, the cell or cells include a *ADAMTS2* transgene (*e.g.*, a heterologous form of a *ADAMTS2* gene, such as a human gene expressed in non-human cells). The transgene can be misexpressed, *e.g.*, overexpressed or underexpressed. In other preferred embodiments, the cell or cells include a gene which misexpress an endogenous target polypeptide (*e.g.*, expression of a gene is disrupted, also known as a knockout). Such cells can serve as a model for studying disorders which are related to mutated or mis-expressed alleles or for use in drug screening. Also provided are human cells (*e.g.*, a hematopoietic stem cells) transfected with a *ADAMTS2* nucleic acid.

[0055] Also provided are cells or a purified preparation thereof (*e.g.*, human cells) in which an endogenous *ADAMTS2* nucleic acid is under the control of a regulatory sequence that does not normally control the expression of the endogenous gene. The expression characteristics of an endogenous gene within a cell (*e.g.*, a cell line or microorganism) can be modified by inserting a heterologous DNA regulatory element into the genome of the cell such that the inserted regulatory element is operably linked to the corresponding endogenous gene. For example, an endogenous corresponding gene (*e.g.*, a gene which is "transcriptionally silent," not normally expressed, or expressed only at very low levels) may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell. Techniques such as targeted homologous recombinations, can be used to insert the heterologous DNA as described in, *e.g.*, Chappel, US 5,272,071; WO 91/06667, published on May 16, 1991.

Transgenic Animals

[0056] Non-human transgenic animals that express a heterologous target polypeptide (*e.g.*, expressed from a *ADAMTS2* nucleic acid or substantially identical sequence thereof) can be generated. Such animals are useful for studying the function and/or activity of a target polypeptide and for identifying and/or evaluating modulators of the activity of *ADAMTS2* nucleic acids and encoded polypeptides. As used herein, a "transgenic animal" is a non-human animal such as a mammal (*e.g.*, a non-human primate such as chimpanzee, baboon, or macaque; an ungulate such as an equine, bovine, or

caprine; or a rodent such as a rat, a mouse, or an Israeli sand rat), a bird (*e.g.*, a chicken or a turkey), an amphibian (*e.g.*, a frog, salamander, or newt), or an insect (*e.g.*, *Drosophila melanogaster*), in which one or more of the cells of the animal includes a transgene. A transgene is exogenous DNA or a rearrangement (*e.g.*, a deletion of endogenous chromosomal DNA) that is often integrated into or occurs in the genome of cells in a transgenic animal. A transgene can direct expression of an encoded gene product in one or more cell types or tissues of the transgenic animal, and other transgenes can reduce expression (*e.g.*, a knockout). Thus, a transgenic animal can be one in which an endogenous nucleic acid homologous to a *ADAMTS2* nucleic acid has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal (*e.g.*, an embryonic cell of the animal) prior to development of the animal.

[0057] Intronic sequences and polyadenylation signals can also be included in the transgene to increase expression efficiency of the transgene. One or more tissue-specific regulatory sequences can be operably linked to a *ADAMTS2* nucleotide sequence to direct expression of an encoded polypeptide to particular cells. A transgenic founder animal can be identified based upon the presence of a *ADAMTS2* nucleotide sequence in its genome and/or expression of encoded mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a *ADAMTS2* nucleotide sequence can further be bred to other transgenic animals carrying other transgenes.

[0058] Target polypeptides can be expressed in transgenic animals or plants by introducing, for example, a *ADAMTS2* nucleic acid into the genome of an animal that encodes the target polypeptide. In preferred embodiments the nucleic acid is placed under the control of a tissue specific promoter, *e.g.*, a milk or egg specific promoter, and recovered from the milk or eggs produced by the animal. Also included is a population of cells from a transgenic animal.

Target Polypeptides

[0059] Also featured herein are isolated target polypeptides, which are encoded by a *ADAMTS2* nucleotide sequence (e.g., SEQ ID NO: 1-3), or a substantially identical nucleotide sequence thereof. *ADAMTS2* exists in two forms, a "long" form comprising a molecule approximately 130 kDa in length (e.g., SEQ ID NO: 4), and a "short" form comprising a molecule approximately 70 kDa in length (e.g., SEQ ID NO: 5). Thus featured herein are isolated *ADAMTS2* polypeptides, which include long and short isoforms, and substantially identical polypeptides thereof. An *ADAMTS2* polypeptide is a polypeptide encoded by an *ADAMTS2* nucleic acid, where one nucleic acid can encode one or more different polypeptides. The term "polypeptide" as used herein includes proteins and peptides. An "isolated" or "purified" polypeptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical

precursors or other chemicals when chemically synthesized. In one embodiment, the language "substantially free" means preparation of a target polypeptide having less than about 30%, 20%, 10% and more preferably 5% (by dry weight), of non-target polypeptide (also referred to herein as a "contaminating protein"), or of chemical precursors or non-target chemicals. When the target polypeptide or a biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, specifically, where culture medium represents less than about 20%, sometimes less than about 10%, and often less than about 5% of the volume of the polypeptide preparation. Isolated or purified target polypeptide preparations are sometimes 0.01 milligrams or more or 0.1 milligrams or more, and often 1.0 milligrams or more and 10 milligrams or more in dry weight.

[0060] Further included herein are target polypeptide fragments. The polypeptide fragment may be a domain or part of a domain of a target polypeptide. The polypeptide fragment may have increased, decreased or unexpected biological activity. The polypeptide fragment is often 50 or fewer, 100 or fewer, or 200 or fewer amino acids in length, and is sometimes 300, 400, 500, 600, 700, or 900 or fewer amino acids in length. Thus, featured herein are *ADAMTS2* polypeptides and biologically active or antigenic fragments thereof useful as reagents or targets in assays applicable to treatment and diagnosis of osteoarthritis. In another embodiment, provided herein are *ADAMTS2* polypeptides having a *ADAMTS2* activity (e.g., a zinc binding activity, a metalloprotease activity, a procollagen II processing or synthesis activity, or a collagen II synthesis activity in vitro or in vivo). In certain embodiments, the polypeptides are *ADAMTS2* proteins including at least one propeptide domain, at least one metalloproteinase domain, at least one disintegrin-like domain, at least one, two, three, and often four thrombospondin domains, and sometimes having a *ADAMTS2* activity, e.g., a *ADAMTS2* activity as described herein. *ADAMTS2* polypeptides and fragments thereof often have biological activity, such as excising the N-propeptide of type II procollagens. Methods for monitoring and quantifying this biological activity are known (e.g., Colige et al., J. Biol. Chem. 270: 16724-16730 (1995)).

[0061] Human *ADAMTS2* protein (SEQ ID NO: 4-5) includes a signal sequence of about 29 amino acids (from amino acid 1 to about amino acid 29 of SEQ ID NO: 4-5). The *ADAMTS2* protein without the signal sequence can be approximately 1182 amino acid residues in length (from about amino acid 30 to amino acid 1211 of SEQ ID NO: 4) or approximately 485 amino acid residues in length (from about amino acid 30 to amino acid 514 of SEQ ID NO: 5). Human *ADAMTS2* protein includes a "pro" region homologous to the reprolysin family propeptide, which is typically post-translationally cleaved upon conversion of the inactive (or pro-domain containing) protein to the catalytically active metalloprotease. The prodomain region of human *ADAMTS2* protein corresponds to about amino acids 30 to 251, 30 to 252, 30 to 253, 30 to 254, 30 to 255, 30 to 256, 30 to 257, 30 to 258 or 30 to 259 of SEQ ID NO: 4-5, where it is understood that the active form of *ADAMTS2* does not contain the propeptide domain.

[0062] Upon cleavage, catalytically active mature protein can be approximately 960, 959, 958, 957, 956, 955, 954, 953 or 952 amino acids in length (from about amino acid 252, 253, 254, 255, 256, 257, 258, 259 or 260 to amino acid 1211 of SEQ ID NO: 4) or approximately 261, 260, 259, 258, 257, 256, 255, 254 or 253 amino acid residues in length (from about amino acid 252, 253, 254, 255, 256, 257, 258, 259 or 260 to amino acid 514 of SEQ ID NO: 5).

[0063] Human *ADAMTS2* contains the following regions or other structural features: a signal sequence at about amino acids 1-29 of SEQ ID NO: 4-5; a reprolysin family propeptide domain located at about amino acid residues 30 to 251, 30 to 252, 30 to 253, 30 to 254, 30 to 255, 30 to 256, 30 to 257, 30 to 258 or 30 to 259 of SEQ ID NO: 4-5; a zinc-metalloprotease catalytic domain at about amino acids 251 to 479, 252 to 479, 253 to 479, 254 to 479, 255 to 479, 256 to 479, 257 to 479, 258 to 479 or 259 to 479 of SEQ ID NO: 4-5; a disintegrin domain at about amino acids 480 to 560 of SEQ ID NO: 4; a cysteine-rich domain at about amino acids 618 to 722 of SEQ ID NO: 4; four thrombospondin motifs-2 motifs at about amino acids 561 to 616, 854 to 912, 914 to 971, and 975 to 1029 of SEQ ID NO: 4; and eight N-glycosylation sites located at about amino acids 112, 251, 949, 993, 1031, 1098, 1145, and 1150 of SEQ ID NO: 4.

[0064] In other embodiments, provided are methods of increasing the synthesis of procollagen II comprising providing or administering to individuals in need of increasing levels of type II collagen the pharmaceutical or physiologically acceptable composition comprising active human *ADAMTS2* protein or fragment thereof, where *ADAMTS2* polypeptide fragments having activity are selected from amino acids 252-1211, 253-1211, 254-1211, 255-1211, 256-1211, 257-1211, 258-1211, 259-1211 or 260-1211 of SEQ ID NO: 4, where it is understood that the active form of *ADAMTS2* does not contain the propeptide domain.

[0065] Substantially identical target polypeptides may depart from the amino acid sequences of target polypeptides in different manners. For example, conservative amino acid modifications may be introduced at one or more positions in the amino acid sequences of target polypeptides. A "conservative amino acid substitution" is one in which the amino acid is replaced by another amino acid having a similar structure and/or chemical function. Families of amino acid residues having similar structures and functions are well known. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Also, essential and non-essential amino acids may be replaced. A "non-essential" amino acid is one that can be altered without abolishing or substantially altering the biological function of a target polypeptide, whereas altering an "essential" amino acid abolishes or substantially alters the

biological function of a target polypeptide. Amino acids that are conserved among target polypeptides are typically essential amino acids. In certain embodiments, the polypeptide includes one or more non-synonymous polymorphic variants associated with osteoarthritis.

[0066] Also, target polypeptides may exist as chimeric or fusion polypeptides. As used herein, a target "chimeric polypeptide" or target "fusion polypeptide" includes a target polypeptide linked to a non-target polypeptide. A "non-target polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a polypeptide which is not substantially identical to the target polypeptide, which includes, for example, a polypeptide that is different from the target polypeptide and derived from the same or a different organism. The target polypeptide in the fusion polypeptide can correspond to an entire or nearly entire target polypeptide or a fragment thereof. The non-target polypeptide can be fused to the N-terminus or C-terminus of the target polypeptide.

[0067] Fusion polypeptides can include a moiety having high affinity for a ligand. For example, the fusion polypeptide can be a GST-target fusion polypeptide in which the target sequences are fused to the C-terminus of the GST sequences, or a polyhistidine-target fusion polypeptide in which the target polypeptide is fused at the N- or C-terminus to a string of histidine residues. Such fusion polypeptides can facilitate purification of recombinant target polypeptide. Expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide), and a nucleotide sequence in SEQ ID NO: 1-3, or a substantially identical nucleotide sequence thereof, can be cloned into an expression vector such that the fusion moiety is linked in-frame to the target polypeptide. Further, the fusion polypeptide can be a target polypeptide containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression, secretion, cellular internalization, and cellular localization of a target polypeptide can be increased through use of a heterologous signal sequence. Fusion polypeptides can also include all or a part of a serum polypeptide (*e.g.*, an IgG constant region or human serum albumin).

[0068] Target polypeptides can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. Administration of these target polypeptides can be used to affect the bioavailability of a substrate of the target polypeptide and may effectively increase target polypeptide biological activity in a cell. Target fusion polypeptides may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a target polypeptide; (ii) mis-regulation of the gene encoding the target polypeptide; and (iii) aberrant post-translational modification of a target polypeptide. Also, target polypeptides can be used as immunogens to produce anti-target antibodies in a subject, to purify target polypeptide ligands or binding partners, and in screening assays to identify molecules which inhibit or enhance the interaction of a target polypeptide with a substrate.

[0069] In addition, polypeptides can be chemically synthesized using techniques known in the art (See, *e.g.*, Creighton, 1983 Proteins. New York, N.Y.: W. H. Freeman and Company; and Hunkapiller et

al., (1984) Nature July 12 -18;310(5973):105-11). For example, a relative short fragment can be synthesized by use of a peptide synthesizer. Furthermore, if desired, non-classical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the fragment sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, a-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoroamino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

[0070] Polypeptides and polypeptide fragments sometimes are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; and the like. Additional post-translational modifications include, for example, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. The polypeptide fragments may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the polypeptide.

[0071] Also provided are chemically modified derivatives of polypeptides that can provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (*see e.g.*, U.S. Pat. No: 4,179,337. The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

[0072] The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if

any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

[0073] The polymers should be attached to the polypeptide with consideration of effects on functional or antigenic domains of the polypeptide. There are a number of attachment methods available to those skilled in the art (*e.g.*, EP 0 401 384 (coupling PEG to G-CSF) and Malik et al. (1992) Exp Hematol. September;20(8):1028-35 (pegylation of GM-CSF using tresyl chloride)). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues, glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. For therapeutic purposes, the attachment sometimes is at an amino group, such as attachment at the N-terminus or lysine group.

[0074] Proteins can be chemically modified at the N-terminus. Using polyethylene glycol as an illustration of such a composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, and the like), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus may be accomplished by reductive alkylation, which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

Substantially Identical Nucleic Acids and Polypeptides

[0075] Nucleotide sequences and polypeptide sequences that are substantially identical to a *ADAMTS2* nucleotide sequence and the target polypeptide sequences encoded by those nucleotide sequences, respectively, are included herein. The term "substantially identical" as used herein refers to two or more nucleic acids or polypeptides sharing one or more identical nucleotide sequences or polypeptide sequences, respectively. Included are nucleotide sequences or polypeptide sequences that are 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more (each often within a 1%, 2%, 3% or 4% variability) identical to a *ADAMTS2* nucleotide sequence or the encoded target polypeptide amino acid sequences. One test for determining

whether two nucleic acids are substantially identical is to determine the percent of identical nucleotide sequences or polypeptide sequences shared between the nucleic acids or polypeptides.

[0076] Calculations of sequence identity are often performed as follows. Sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The length of a reference sequence aligned for comparison purposes is sometimes 30% or more, 40% or more, 50% or more, often 60% or more, and more often 70% or more, 80% or more, 90% or more, or 100% of the length of the reference sequence. The nucleotides or amino acids at corresponding nucleotide or polypeptide positions, respectively, are then compared among the two sequences. When a position in the first sequence is occupied by the same nucleotide or amino acid as the corresponding position in the second sequence, the nucleotides or amino acids are deemed to be identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, introduced for optimal alignment of the two sequences.

[0077] Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. Percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of Meyers & Miller, *CABIOS 4:* 11-17 (1989), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. Also, percent identity between two amino acid sequences can be determined using the Needleman & Wunsch, *J. Mol. Biol. 48:* 444-453 (1970) algorithm which has been incorporated into the GAP program in the GCG software package (available at the http address www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. Percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at http address www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A set of parameters often used is a Blossum 62 scoring matrix with a gap open penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

[0078] Another manner for determining if two nucleic acids are substantially identical is to assess whether a polynucleotide homologous to one nucleic acid will hybridize to the other nucleic acid under stringent conditions. As use herein, the term "stringent conditions" refers to conditions for hybridization and washing. Stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. , 6.3.1-6.3.6 (1989). Aqueous and non-aqueous methods are described in that reference and either can be used. An example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C,

followed by one or more washes in 0.2X SSC, 0.1% SDS at 50°C. Another example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 55°C. A further example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C. Often, stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. More often, stringency conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C.

[0079] An example of a substantially identical nucleotide sequence to a nucleotide sequence in SEQ ID NO: 1-3 is one that has a different nucleotide sequence but still encodes the same polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO: 1-3. Another example is a nucleotide sequence that encodes a polypeptide having a polypeptide sequence that is more than 70% or more identical to, sometimes more than 75% or more, 80% or more, or 85% or more identical to, and often more than 90% or more and 95% or more identical to a polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3.

[0080] Nucleotide sequences in SEQ ID NO: 1-3 and amino acid sequences of encoded polypeptides can be used as "query sequences" to perform a search against public databases to identify other family members or related sequences, for example. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul *et al., J. Mol. Biol. 215:* 403-10 (1990). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to nucleotide sequences in SEQ ID NO: 1-3. BLAST polypeptide searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to polypeptides encoded by the nucleotide sequences of SEQ ID NO: 1-3. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al., Nucleic Acids Res. 25(17):* 3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used (*see* the http address www.ncbi.nlm.nih.gov).

[0081] A nucleic acid that is substantially identical to a nucleotide sequence in SEQ ID NO: 1-3 may include polymorphic sites at positions equivalent to those described herein when the sequences are aligned. For example, using the alignment procedures described herein, SNPs in a sequence substantially identical to a sequence in SEQ ID NO: 1-3 can be identified at nucleotide positions that match (*i.e.*, align) with nucleotides at SNP positions in each nucleotide sequence in SEQ ID NO: 1-3. Also, where a polymorphic variation results in an insertion or deletion, insertion or deletion of a nucleotide sequence

from a reference sequence can change the relative positions of other polymorphic sites in the nucleotide sequence.

[0082] Substantially identical nucleotide and polypeptide sequences include those that are naturally occurring, such as allelic variants (same locus), splice variants, homologs (different locus), and orthologs (different organism) or can be non-naturally occurring. Non-naturally occurring variants can be generated by mutagenesis techniques, including those applied to polynucleotides, cells, or organisms. The variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions (as compared in the encoded product). Orthologs, homologs, allelic variants, and splice variants can be identified using methods known in the art. These variants normally comprise a nucleotide sequence encoding a polypeptide that is 50% or more, about 55% or more, often about 70-75% or more or about 80-85% or more, and sometimes about 90-95% or more identical to the amino acid sequences of target polypeptides or a fragment thereof. Such nucleic acid molecules can readily be identified as being able to hybridize under stringent conditions to a nucleotide sequence in SEQ ID NO: 1-3 or a fragment of this sequence. Nucleic acid molecules corresponding to orthologs, homologs, and allelic variants of a nucleotide sequence in SEQ ID NO: 1-3 can further be identified by mapping the sequence to the same chromosome or locus as the nucleotide sequence in SEQ ID NO: 1-3.

[0083] Also, substantially identical nucleotide sequences may include codons that are altered with respect to the naturally occurring sequence for enhancing expression of a target polypeptide in a particular expression system. For example, the nucleic acid can be one in which one or more codons are altered, and often 10% or more or 20% or more of the codons are altered for optimized expression in bacteria (*e.g.*, *E. coli*.), yeast (*e.g.*, *S. cervesiae*), human (*e.g.*, 293 cells), insect, or rodent (*e.g.*, hamster) cells.

Methods for Identifying Risk of Osteoarthritis

[0084] Methods for prognosing and diagnosing osteoarthritis are included herein. These methods include detecting the presence or absence of one or more polymorphic variations in a nucleotide sequence associated with osteoarthritis, such as variants in or around the loci set forth herein, or a substantially identical sequence thereof, in a sample from a subject, where the presence of a polymorphic variant described herein is indicative of a risk of osteoarthritis. Determining a risk of osteoarthritis sometimes refers to determining whether an individual is at an increased risk of osteoarthritis (*e.g.*, intermediate risk or higher risk).

[0085] Thus, featured herein is a method for identifying a subject who is at risk of osteoarthritis, which comprises detecting an aberration associated with osteoarthritis in a nucleic acid sample from the

subject. An embodiment is a method for detecting a risk of osteoarthritis in a subject, which comprises detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject, where the nucleotide sequence comprises a polynucleotide sequence selected from the group consisting of: (a) a nucleotide sequence of SEQ ID NO: 1-3; (b) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3; (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-3; and (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising the polymorphic site; whereby the presence of the polymorphic variation is indicative of a predisposition to osteoarthritis in the subject. In some embodiments, a polymorphic variation at position 733 of SEQ ID NO: 2-3 may be detected (e.g., a guanine in these sequences or a cytosine in a complementary sequence are associated with increased risk of osteoarthritis). In certain embodiments, polymorphic variants at the positions described herein are detected for determining a risk of osteoarthritis, and polymorphic variants at positions in linkage disequilibrium with these positions are detected for determining a risk of osteoarthritis. As used herein, "SEQ ID NO: 1-3" refers to individual sequences in SEQ ID NO: 1, 2 or 3, each sequence being separately applicable to embodiments described herein.

[0086] Risk of osteoarthritis sometimes is expressed as a probability, such as an odds ratio, percentage, or risk factor. Risk often is based upon the presence or absence of one or more polymorphic variants described herein, and also may be based in part upon phenotypic traits of the individual being tested. Methods for calculating risk based upon patient data are well known (*see, e.g.*, Agresti, *Categorical Data Analysis*, 2nd Ed. 2002. Wilcy). Allelotyping and genotyping analyses may be carried out in populations other than those exemplified herein to enhance the predictive power of the prognostic method. These further analyses are executed in view of the exemplified procedures described herein, and may be based upon the same polymorphic variations or additional polymorphic variations.

[0087] In certain embodiments, determining the presence of a combination of two or more polymorphic variants associated with osteoarthritis in one or more genetic loci (e.g., one or more genes) of the sample is determined to identify, quantify and/or estimate, risk of osteoarthritis. The risk often is the probability of having or developing osteoarthritis. The risk sometimes is expressed as a relative risk with respect to a population average risk of osteoarthritis, and sometimes is expressed as a relative risk with respect to the lowest risk group. Such relative risk assessments often are based upon penetrance values determined by statistical methods, and are particularly useful to clinicians and insurance companies for assessing risk of osteoarthritis (e.g., a clinician can target appropriate detection, prevention and therapeutic regimens to a patient after determining the patient's risk of osteoarthritis, and an

insurance company can fine tune actuarial tables based upon population genotype assessments of osteoarthritis risk). Risk of osteoarthritis sometimes is expressed as an odds ratio, which is the odds of a particular person having a genotype has or will develop osteoarthritis with respect to another genotype group (e.g., the most disease protective genotype or population average). In related embodiments, the determination is utilized to identify a subject at risk of osteoarthritis. In an embodiment, two or more polymorphic variations are detected in two or more regions in human genomic DNA associated with increased risk of osteoarthritis, such as a locus containing a *ADAMTS2*, for example. In certain embodiments, 3 or more, or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more polymorphic variants are detected in the sample. In specific embodiments, polymorphic variants are detected in a *ADAMTS2* region, for example. In certain embodiments, polymorphic variants are detected at other genetic loci (e.g., the polymorphic variants can be detected in *ADAMTS2* in addition to other loci or only in other loci), where the other loci include but are not limited to those described in concurrently-filed patent applications having attorney docket number 524593008700, 524593008800, 524593009000 or 524593009200, which is incorporated herein by reference in its entirety.

[0088] Results from prognostic tests may be combined with other test results to diagnose osteoarthritis. For example, prognostic results may be gathered, a patient sample may be ordered based on a determined predisposition to osteoarthritis, the patient sample is analyzed, and the results of the analysis may be utilized to diagnose osteoarthritis. Also osteoarthritis diagnostic method can be developed from studies used to generate prognostic methods in which populations are stratified into subpopulations having different progressions of osteoarthritis. In another embodiment, prognostic results may be gathered, a patient's risk factors for developing osteoarthritis (*e.g.*, age, weight, race, diet) analyzed, and a patient sample may be ordered based on a determined predisposition to osteoarthritis.

[0089] The nucleic acid sample typically is isolated from a biological sample obtained from a subject. For example, nucleic acid can be isolated from blood, saliva, sputum, urine, cell scrapings, and biopsy tissue. The nucleic acid sample can be isolated from a biological sample using standard techniques, such as the technique described in Example 2. As used herein, the term "subject" refers primarily to humans but also refers to other mammals such as dogs, cats, and ungulates (*e.g.*, cattle, sheep, and swine). Subjects also include avians (*e.g.*, chickens and turkeys), reptiles, and fish (*e.g.*, salmon), as embodiments described herein can be adapted to nucleic acid samples isolated from any of these organisms. The nucleic acid sample may be isolated from the subject and then directly utilized in a method for determining the presence of a polymorphic variant, or alternatively, the sample may be isolated and then stored (*e.g.*, frozen) for a period of time before being subjected to analysis.

[0090] The presence or absence of a polymorphic variant is determined using one or both chromosomal complements represented in the nucleic acid sample. Determining the presence or absence of a polymorphic variant in both chromosomal complements represented in a nucleic acid sample from a

subject having a copy of each chromosome is useful for determining the zygosity of an individual for the polymorphic variant (*i.e.*, whether the individual is homozygous or heterozygous for the polymorphic variant). Any oligonucleotide-based diagnostic may be utilized to determine whether a sample includes the presence or absence of a polymorphic variant in a sample. For example, primer extension methods, ligase sequence determination methods (*e.g.*, U.S. Pat. Nos. 5,679,524 and 5,952,174, and WO 01/27326), mismatch sequence determination methods (*e.g.*, U.S. Pat. Nos. 5,851,770; 5,958,692; 6,110,684; and 6,183,958), microarray sequence determination methods, restriction fragment length polymorphism (RFLP), single strand conformation polymorphism detection (SSCP) (*e.g.*, U.S. Pat. Nos. 5,891,625 and 6,013,499), PCR-based assays (*e.g.*, TAQMAN® PCR System (Applied Biosystems)), and nucleotide sequencing methods may be used.

[0091] Oligonucleotide extension methods typically involve providing a pair of oligonucleotide primers in a polymerase chain reaction (PCR) or in other nucleic acid amplification methods for the purpose of amplifying a region from the nucleic acid sample that comprises the polymorphic variation. One oligonucleotide primer is complementary to a region 3' of the polymorphism and the other is complementary to a region 5' of the polymorphism. A PCR primer pair may be used in methods disclosed in U.S. Pat. Nos. 4,683,195; 4,683,202, 4,965,188; 5,656,493; 5,998,143; 6,140,054; WO 01/27327; and WO 01/27329 for example. PCR primer pairs may also be used in any commercially available machines that perform PCR, such as any of the GENEAMP® Systems available from Applied Biosystems. Also, those of ordinary skill in the art will be able to design oligonucleotide primers based upon a *ADAMTS2* nucleotide sequence using knowledge available in the art.

[0092] Also provided is an extension oligonucleotide that hybridizes to the amplified fragment adjacent to the polymorphic variation. As used herein, the term "adjacent" refers to the 3' end of the extension oligonucleotide being often 1 nucleotide from the 5' end of the polymorphic site, and sometimes 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the 5' end of the polymorphic site, in the nucleic acid when the extension oligonucleotide is hybridized to the nucleic acid. The extension oligonucleotide then is extended by one or more nucleotides, and the number and/or type of nucleotides that are added to the extension oligonucleotide determine whether the polymorphic variant is present. Oligonucleotide extension methods are disclosed, for example, in U.S. Pat. Nos. 4,656,127; 4,851,331; 5,679,524; 5,834,189; 5,876,934; 5,908,755; 5,912,118; 5,976,802; 5,981,186; 6,004,744; 6,013,431; 6,017,702; 6,046,005; 6,087,095; 6,210,891; and WO 01/20039. Oligonucleotide extension methods using mass spectrometry are described, for example, in U.S. Pat. Nos. 5,547,835; 5,605,798; 5,691,141; 5,849,542; 5,869,242; 5,928,906; 6,043,031; and 6,194,144, and a method often utilized is described herein in Example 2.

[0093] A microarray can be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A microarray may include any oligonucleotides described herein, and

methods for making and using oligonucleotide microarrays suitable for diagnostic use are disclosed in U.S. Pat. Nos. 5,492,806; 5,525,464; 5,589,330; 5,695,940; 5,849,483; 6,018,041; 6,045,996; 6,136,541; 6,142,681; 6,156,501; 6,197,506; 6,223,127; 6,225,625; 6,229,911; 6,239,273; WO 00/52625; WO 01/25485; and WO 01/29259. The microarray typically comprises a solid support and the oligonucleotides may be linked to this solid support by covalent bonds or by non-covalent interactions. The oligonucleotides may also be linked to the solid support directly or by a spacer molecule. A microarray may comprise one or more oligonucleotides complementary to a polymorphic site set forth herein.

[0094] A kit also may be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A kit often comprises one or more pairs of oligonucleotide primers useful for amplifying a fragment of a nucleotide sequence of SEQ ID NO: 1-3 or a substantially identical sequence thereof, where the fragment includes a polymorphic site. The kit sometimes comprises a polymerizing agent, for example, a thermostable nucleic acid polymerase such as one disclosed in U.S. Pat. Nos. 4,889,818 or 6,077,664. Also, the kit often comprises an elongation oligonucleotide that hybridizes to a *ADAMTS2* nucleotide sequence in a nucleic acid sample adjacent to the polymorphic site. Where the kit includes an elongation oligonucleotide, it also often comprises chain elongating nucleotides, such as dATP, dTTP, dGTP, dCTP, and dITP, including analogs of dATP, dTTP, dGTP, dCTP and dITP, provided that such analogs are substrates for a thermostable nucleic acid polymerase and can be incorporated into a nucleic acid chain elongated from the extension oligonucleotide. Along with chain elongating nucleotides would be one or more chain terminating nucleotides such as ddATP, ddTTP, ddGTP, ddCTP, and the like. In an embodiment, the kit comprises one or more oligonucleotide primer pairs, a polymerizing agent, chain elongating nucleotides, at least one elongation oligonucleotide, and one or more chain terminating nucleotides. Kits optionally include buffers, vials, microtiter plates, and instructions for use.

[0095] An individual identified as being at risk of osteoarthritis may be heterozygous or homozygous with respect to the allele associated with a higher risk of osteoarthritis. A subject homozygous for an allele associated with an increased risk of osteoarthritis is at a comparatively high risk of osteoarthritis, a subject heterozygous for an allele associated with an increased risk of osteoarthritis is at a comparatively intermediate risk of osteoarthritis, and a subject homozygous for an allele associated with a decreased risk of osteoarthritis is at a comparatively low risk of osteoarthritis. A genotype may be assessed for a complementary strand, such that the complementary nucleotide at a particular position is detected.

[0096] Also featured are methods for determining risk of osteoarthritis and/or identifying a subject at risk of osteoarthritis by contacting a polypeptide or protein encoded by a *ADAMTS2* nucleotide sequence from a subject with an antibody that specifically binds to an epitope associated with increased

risk of osteoarthritis in the polypeptide (e.g., an epitope comprising a valine at position 245 in an *IR1LR1* polypeptide).

Applications of Prognostic and Diagnostic Results to Pharmacogenomic Methods

[0097] Pharmacogenomics is a discipline that involves tailoring a treatment for a subject according to the subject's genotype as a particular treatment regimen may exert a differential effect depending upon the subject's genotype. For example, based upon the outcome of a prognostic test described herein, a clinician or physician may target pertinent information and preventative or therapeutic treatments to a subject who would be benefited by the information or treatment and avoid directing such information and treatments to a subject who would not be benefited (*e.g.*, the treatment has no therapeutic effect and/or the subject experiences adverse side effects).

[0098] The following is an example of a pharmacogenomic embodiment. A particular treatment regimen can exert a differential effect depending upon the subject's genotype. Where a candidate therapeutic exhibits a significant interaction with a major allele and a comparatively weak interaction with a minor allele (*e.g.*, an order of magnitude or greater difference in the interaction), such a therapeutic typically would not be administered to a subject genotyped as being homozygous for the minor allele, and sometimes not administered to a subject genotyped as being heterozygous for the minor allele. In another example, where a candidate therapeutic is not significantly toxic when administered to subjects who are homozygous for a major allele but is comparatively toxic when administered to subjects heterozygous or homozygous for a minor allele, the candidate therapeutic is not typically administered to subjects who are genotyped as being heterozygous or homozygous with respect to the minor allele.

[0099] The methods described herein are applicable to pharmacogenomic methods for preventing, alleviating or treating osteoarthritis. For example, a nucleic acid sample from an individual may be subjected to a prognostic test described herein. Where one or more polymorphic variations associated with increased risk of osteoarthritis are identified in a subject, information for preventing or treating osteoarthritis and/or one or more osteoarthritis treatment regimens then may be prescribed to that subject.

[0100] In certain embodiments, a treatment or preventative regimen is specifically prescribed and/or administered to individuals who will most benefit from it based upon their risk of developing osteoarthritis assessed by the methods described herein. Thus, provided are methods for identifying a subject predisposed to osteoarthritis and then prescribing a therapeutic or preventative regimen to individuals identified as having a predisposition. Thus, certain embodiments are directed to a method for reducing osteoarthritis in a subject, which comprises: detecting the presence or absence of a polymorphic variant associated with osteoarthritis in a nucleotide sequence in a nucleic acid sample from a subject, where the nucleotide sequence comprises a polynucleotide sequence selected from the group consisting of: (a) a nucleotide sequence of SEQ ID NO: 1-3; (b) a nucleotide sequence which encodes a polypeptide

consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3; (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-3; and (d) a fragment of a polynucleotide sequence of (a), (b), or (c); and prescribing or administering a treatment regimen to a subject from whom the sample originated where the presence of a polymorphic variation associated with osteoarthritis is detected in the nucleotide sequence. In these methods, predisposition results may be utilized in combination with other test results to diagnose osteoarthritis.

[0101] Certain preventative treatments often are prescribed to subjects having a predisposition to osteoarthritis and where the subject is diagnosed with osteoarthritis or is diagnosed as having symptoms indicative of an early stage of osteoarthritis. The treatment sometimes is preventative (*e.g.*, is prescribed or administered to reduce the probability that osteoarthritis arises or progresses), sometimes is therapeutic, and sometimes delays, alleviates or halts the progression of osteoarthritis. Any known preventative or therapeutic treatment for alleviating or preventing the occurrence of osteoarthritis is prescribed and/or administered. For example, the treatment often is directed to decreasing pain and improving joint movement. Examples of OA treatments include exercises to keep joints flexible and improve muscle strength. Different medications to control pain, including corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., Voltaren); cyclooxygenase-2 (COX-2) inhibitors (e.g., Celebrex, Vioxx, Mobic, and Bextra); monoclonal antibodies (e.g., Remicade); tumor necrosis factor inhibitors (e.g., Enbrel); or injections of glucocorticoids, hyaluronic acid or chondrotin sulfate into joints that are inflamed and not responsive to NSAIDS. Orally administered chondroitin sulfate also may be used as a therapeutic, as it may increase hyaluronic acid levels and viscosity of synovial fluid, and decrease collagenase levels in synovial fluid. Also, glucosamine can serve as an OA therapeutic as delivering it into joints may inhibit enzymes involved in cartilage degradation and enhance the production of hyaluronic acid. For mild pain without inflammation, acetaminophen may be used. Other treatments include: heat/cold therapy for temporary pain relief; joint protection to prevent strain or stress on painful joints; surgery to relieve chronic pain in damaged joints; and weight control to prevent extra stress on weight-bearing joints.

[0102] As therapeutic approaches for treating osteoarthritis continue to evolve and improve, the goal of treatments for osteoarthritis related disorders is to intervene even before clinical signs first manifest. Thus, genetic markers associated with susceptibility to osteoarthritis prove useful for early diagnosis, prevention and treatment of osteoarthritis.

[0103] As osteoarthritis preventative and treatment information can be specifically targeted to subjects in need thereof (*e.g.*, those at risk of developing osteoarthritis or those in an early stage of osteoarthritis), provided herein is a method for preventing or reducing the risk of developing

osteoarthritis in a subject, which comprises: (a) detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) identifying a subject with a predisposition to osteoarthritis, whereby the presence of the polymorphic variation is indicative of a predisposition to osteoarthritis in the subject; and (c) if such a predisposition is identified, providing the subject with information about methods or products to prevent or reduce osteoarthritis or to delay the onset of osteoarthritis. Also provided is a method of targeting information or advertising to a subpopulation of a human population based on the subpopulation being genetically predisposed to a disease or condition, which comprises: (a) detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) identifying the subpopulation of subjects in which the polymorphic variation is associated with osteoarthritis; and (c) providing information only to the subpopulation of subjects about a particular product which may be obtained and consumed or applied by the subject to help prevent or delay onset of the disease or condition.

[0104] Pharmacogenomics methods also may be used to analyze and predict a response to osteoarthritis treatment or a drug. For example, if pharmacogenomics analysis indicates a likelihood that an individual will respond positively to osteoarthritis treatment with a particular drug, the drug may be administered to the individual. Conversely, if the analysis indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects. The response to a therapeutic treatment can be predicted in a background study in which subjects in any of the following populations are genotyped: a population that responds favorably to a treatment regimen, a population that does not respond significantly to a treatment regimen, and a population that responds adversely to a treatment regimen (*e.g.*, exhibits one or more side effects). These populations are provided as examples and other populations and subpopulations may be analyzed. Based upon the results of these analyses, a subject is genotyped to predict whether he or she will respond favorably to a treatment regimen, not respond significantly to a treatment regimen, or respond adversely to a treatment regimen.

[0105] The tests described herein also are applicable to clinical drug trials. One or more polymorphic variants indicative of response to an agent for treating osteoarthritis or to side effects to an agent for treating osteoarthritis may be identified using the methods described herein. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

[0106] Thus, another embodiment is a method of selecting an individual for inclusion in a clinical trial of a treatment or drug comprising the steps of: (a) obtaining a nucleic acid sample from an individual; (b) determining the identity of a polymorphic variation which is associated with a positive response to the treatment or the drug, or at least one polymorphic variation which is associated with a negative response to the treatment or the drug in the nucleic acid sample, and (c) including the individual in the clinical trial if the nucleic acid sample contains said polymorphic variation associated with a positive response to the treatment or the drug or if the nucleic acid sample lacks said polymorphic variation associated with a negative response to the treatment or the drug. In addition, the methods described herein for selecting an individual for inclusion in a clinical trial of a treatment or drug encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination. The polymorphic variation may be in a sequence selected individually or in any combination from the group consisting of (i) a nucleotide sequence of SEQ ID NO: 1-3; (ii) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3; (iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-3; and (iv) a fragment of a polynucleotide sequence of (i), (ii), or (iii) comprising the polymorphic site. The including step (c) optionally comprises administering the drug or the treatment to the individual if the nucleic acid sample contains the polymorphic variation associated with a positive response to the treatment or the drug and the nucleic acid sample lacks said biallelic marker associated with a negative response to the treatment or the drug.

[0107] Also provided herein is a method of partnering between a diagnostic/prognostic testing provider and a provider of a consumable product, which comprises: (a) the diagnostic/prognostic testing provider detects the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) the diagnostic/prognostic testing provider identifies the subpopulation of subjects in which the polymorphic variation is associated with osteoarthritis; (c) the diagnostic/prognostic testing provider forwards information to the subpopulation of subjects about a particular product which may be obtained and consumed or applied by the subject to help prevent or delay onset of the disease or condition; and (d) the provider of a consumable product forwards to the diagnostic test provider a fee every time the diagnostic/prognostic test provider forwards information to the subject as set forth in step (c) above.

Compositions Comprising Osteoarthritis-Directed Molecules

[0108] Featured herein is a composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and one or more molecules specifically directed and targeted to a nucleic acid

comprising a *ADAMTS2* nucleotide sequence or amino acid sequence. Such directed molecules include, but are not limited to, a compound that binds to a *ADAMTS2* nucleotide sequence or amino acid sequence referenced herein; a RNAi or siRNA molecule having a strand complementary or substantially complementary to a *ADAMTS2* nucleotide sequence (e.g., hybridizes to a *ADAMTS2* nucleotide sequence under conditions of high stringency); an antisense nucleic acid complementary or substantially complementary to an RNA encoded by a *ADAMTS2* nucleotide sequence (e.g., hybridizes to a *ADAMTS2* nucleotide sequence under conditions of high stringency); a ribozyme that hybridizes to a *ADAMTS2* nucleotide sequence (e.g., hybridizes to a *ADAMTS2* nucleotide sequence under conditions of high stringency); a nucleic acid aptamer that specifically binds a polypeptide encoded by *ADAMTS2* nucleotide sequence; and an antibody that specifically binds to a polypeptide encoded by *ADAMTS2* nucleotide sequence or binds to a nucleic acid having such a nucleotide sequence. In specific embodiments, the osteoarthritis directed molecule interacts with a nucleic acid or polypeptide variant associated with osteoarthritis, such as variants referenced herein. In other embodiments, the ostcoarthritis directed molecule interacts with a polypeptide involved in a signal pathway of a polypeptide encoded by a *ADAMTS2* nucleotide sequence, or a nucleic acid comprising such a nucleotide sequence.

[0109] Compositions sometimes include an adjuvant known to stimulate an immune response, and in certain embodiments, an adjuvant that stimulates a T-cell lymphocyte response. Adjuvants are known, including but not limited to an aluminum adjuvant (e.g., aluminum hydroxide); a cytokine adjuvant or adjuvant that stimulates a cytokine response (e.g., interleukin (IL)-12 and/or gamma-interferon cytokines); a Freund-type mineral oil adjuvant emulsion (e.g., Freund's complete or incomplete adjuvant); a synthetic lipoid compound; a copolymer adjuvant (e.g., TitreMax); a saponin; Quil A; a liposome; an oil-in-water emulsion (e.g., an emulsion stabilized by Tween 80 and pluronic polyoxyethlene/polyoxypropylene block copolymer (Syntex Adjuvant Formulation); TitreMax; detoxified endotoxin (MPL) and mycobacterial cell wall components (TDW, CWS) in 2% squalene (Ribi Adjuvant System)); a muramyl dipeptide; an immune-stimulating complex (ISCOM, e.g., an Ag-modified saponin/cholesterol micelle that forms stable cage-like structure); an aqueous phase adjuvant that does not have a depot effect (e.g., Gerbu adjuvant); a carbohydrate polymer (e.g., AdjuPrime); L-tyrosine; a manide-oleate compound (e.g., Montanide); an ethylene-vinyl acetate copolymer (e.g., Elvax 40W1,2); or lipid A, for example. Such compositions are useful for generating an immune response against osteoarthritis directed molecule (e.g., an HLA-binding subsequence within a polypeptide encoded by a *ADAMTS2* nucleotide sequence). In such methods, a peptide having an amino acid subsequence of a polypeptide encoded by a *ADAMTS2* nucleotide sequence is delivered to a subject, where the subsequence binds to an HLA molecule and induces a CTL lymphocyte response. The peptide sometimes is delivered to the subject as an isolated peptide or as a minigene in a plasmid that encodes the

peptide. Methods for identifying HLA-binding subsequences in such polypeptides are known (see e.g., publication WO02/20616 and PCT application US98/01373 for methods of identifying such sequences).

[0110] The cell may be in a group of cells cultured *in vitro* or in a tissue maintained *in vitro* or present in an animal *in vivo* (e.g., a rat, mouse, ape or human). In certain embodiments, a composition comprises a component from a cell such as a nucleic acid molecule (e.g., genomic DNA), a protein mixture or isolated protein, for example. The aforementioned compositions have utility in diagnostic, prognostic and pharmacogenomic methods described previously and in therapeutics described hereafter. Certain osteoarthritis directed molecules are described in greater detail below.

Compounds

[0111] Compounds can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive (see, e.g., Zuckermann et al., J. Med. Chem.37: 2678-85 (1994)); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; "one-bead one-compound" library methods; and synthetic library methods using affinity chromatography selection. Biological library and peptoid library approaches are typically limited to peptide libraries, while the other approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, Anticancer Drug Des. 12: 145, (1997)). Examples of methods for synthesizing molecular libraries are described, for example, in DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 90: 6909 (1993); Erb et al., Proc. Natl. Acad. Sci. USA 91: 11422 (1994); Zuckermann et al., J. Med. Chem. 37: 2678 (1994); Cho et al., Science 261: 1303 (1993); Carrell et al., Angew. Chem. Int. Ed. Engl. 33: 2059 (1994); Carell et al., Angew. Chem. Int. Ed. Engl. 33: 2061 (1994); and in Gallop et al., J. Med. Chem. 37: 1233 (1994).

[0112] Libraries of compounds may be presented in solution (e.g., Houghten, Biotechniques 13: 412-421 (1992)), or on beads (Lam, Nature 354: 82-84 (1991)), chips (Fodor, Nature 364: 555-556 (1993)), bacteria or spores (Ladner, United States Patent No. 5,223,409), plasmids (Cull et al., Proc. Natl. Acad. Sci. USA 89: 1865-1869 (1992)) or on phage (Scott and Smith, Science 249: 386-390 (1990); Devlin, Science 249: 404-406 (1990); Cwirla et al., Proc. Natl. Acad. Sci. 87: 6378-6382 (1990); Felici, J. Mol. Biol. 222: 301-310 (1991); Ladner supra.).

[0113] A compound sometimes alters expression and sometimes alters activity of a polypeptide target and may be a small molecule. Small molecules include, but are not limited to, peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole,

organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

Antisense Nucleic Acid Molecules, Ribozymes, RNAi, siRNA and Modified Nucleic Acid Molecules

[0114] An "antisense" nucleic acid refers to a nucleotide sequence complementary to a "sense" nucleic acid encoding a polypeptide, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. The antisense nucleic acid can be complementary to an entire coding strand, or to a portion thereof or a substantially identical sequence thereof. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence (e.g., 5' and 3' untranslated regions in SEQ ID NO: 1).

[0115] An antisense nucleic acid can be designed such that it is complementary to the entire coding region of an mRNA encoded by a nucleotide sequence (e.g., SEQ ID NO: 1), and often the antisense nucleic acid is an oligonucleotide antisense to only a portion of a coding or noncoding region of the mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the mRNA, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length. The antisense nucleic acids, which include the ribozymes described hereafter, can be designed to target a *ADAMTS2* nucleotide sequence, often a variant associated with osteoarthritis, or a substantially identical sequence thereof. Among the variants, minor alleles and major alleles can be targeted, and those associated with a higher risk of osteoarthritis are often designed, tested, and administered to subjects.

[0116] An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using standard procedures. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0117] When utilized as therapeutics, antisense nucleic acids typically are administered to a subject (e.g., by direct injection at a tissue site) or generated in situ such that they hybridize with or bind to

cellular mRNA and/or genomic DNA encoding a polypeptide and thereby inhibit expression of the polypeptide, for example, by inhibiting transcription and/or translation. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then are administered systemically. For systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, for example, by linking antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. Antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. Sufficient intracellular concentrations of antisense molecules are achieved by incorporating a strong promoter, such as a pol II or pol III promoter, in the vector construct.

[0118] Antisense nucleic acid molecules sometimes are alpha-anomeric nucleic acid molecules. An alpha-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual beta-units, the strands run parallel to each other (Gaultier et al., Nucleic Acids. Res. 15: 6625-6641 (1987)). Antisense nucleic acid molecules can also comprise a 2'-o-methylribonucleotide (Inoue et al., Nucleic Acids Res. 15: 6131-6148 (1987)) or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215: 327-330 (1987)). Antisense nucleic acids sometimes are composed of DNA or PNA or any other nucleic acid derivatives described previously.

[0119] In another embodiment, an antisense nucleic acid is a ribozyme. A ribozyme having specificity for a *ADAMTS2* nucleotide sequence can include one or more sequences complementary to such a nucleotide sequence, and a sequence having a known catalytic region responsible for mRNA cleavage (see e.g., U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach, Nature 334: 585-591 (1988)). For example, a derivative of a Tetrahymena L-19 IVS RNA is sometimes utilized in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a mRNA (see e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742). Also, target mRNA sequences can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules (see e.g., Bartel & Szostak, Science 261: 1411-1418 (1993)).

[0120] Osteoarthritis directed molecules include in certain embodiments nucleic acids that can form triple helix structures with a *ADAMTS2* nucleotide sequence, or a substantially identical sequence thereof, especially one that includes a regulatory region that controls expression of a polypeptide. Gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of a nucleotide sequence referenced herein or a substantially identical sequence (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of a gene in target cells (see e.g., Helene, Anticancer Drug Des. 6(6): 569-84 (1991); Helene et al., Ann. N.Y. Acad. Sci. 660: 27-36 (1992); and Maher, Bioassays 14(12): 807-15 (1992). Potential sequences that can be targeted for triple helix formation can be increased by creating a so-called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one

strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

[0121] Osteoarthritis directed molecules include RNAi and siRNA nucleic acids. Gene expression may be inhibited by the introduction of double-stranded RNA (dsRNA), which induces potent and specific gene silencing, a phenomenon called RNA interference or RNAi. See, e.g., Fire et al., US Patent Number 6,506,559; Tuschl et al. PCT International Publication No. WO 01/75164; Kay et al. PCT International Publication No. WO 03/010180A1; or Bosher JM, Labouesse, Nat Cell Biol 2000 Feb;2(2):E31-6. This process has been improved by decreasing the size of the double-stranded RNA to 20-24 base pairs (to create small-interfering RNAs or siRNAs) that "switched off" genes in mammalian cells without initiating an acute phase response, i.e., a host defense mechanism that often results in cell death (see, e.g., Caplen et al. Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9742-7 and Elbashir et al. Methods 2002 Feb;26(2):199-213). There is increasing evidence of post-transcriptional gene silencing by RNA interference (RNAi) for inhibiting targeted expression in mammalian cells at the mRNA level, in human cells. There is additional evidence of effective methods for inhibiting the proliferation and migration of tumor cells in human patients, and for inhibiting metastatic cancer development (see, e.g., U.S. Patent Application No. US2001000993183; Caplen et al. Proc Natl Acad Sci U S A; and Abderrahmani et al. Mol Cell Biol 2001 Nov21(21):7256-67).

[0122] An "siRNA" or "RNAi" refers to a nucleic acid that forms a double stranded RNA and has the ability to reduce or inhibit expression of a gene or target gene when the siRNA is delivered to or expressed in the same cell as the gene or target gene. "siRNA" refers to short double-stranded RNA formed by the complementary strands. Complementary portions of the siRNA that hybridize to form the double stranded molecule often have substantial or complete identity to the target molecule sequence. In one embodiment, an siRNA refers to a nucleic acid that has substantial or complete identity to a target gene and forms a double stranded siRNA.

[0123] When designing the siRNA molecules, the targeted region often is selected from a given DNA sequence beginning 50 to 100 nucleotides downstream of the start codon. See, e.g., Elbashir et al,. Methods 26:199-213 (2002). Initially, 5' or 3' UTRs and regions nearby the start codon were avoided assuming that UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. Sometimes regions of the target 23 nucleotides in length conforming to the sequence motif AA(N19)TT (N, an nucleotide), and regions with approximately 30% to 70% G/C-content (often about 50% G/C-content) often are selected. If no suitable sequences are found, the search often is extended using the motif NA(N21). The sequence of the sense siRNA sometimes corresponds to (N19) TT or N21 (position 3 to 23 of the 23-nt motif), respectively. In the latter case, the 3' end of the sense siRNA often is converted to TT. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and

antisense 3' overhangs. The antisense siRNA is synthesized as the complement to position 1 to 21 of the 23-nt motif. Because position 1 of the 23-nt motif is not recognized sequence-specifically by the antisense siRNA, the 3'-most nucleotide residue of the antisense siRNA can be chosen deliberately. However, the penultimate nucleotide of the antisense siRNA (complementary to position 2 of the 23-nt motif) often is complementary to the targeted sequence. For simplifying chemical synthesis, TT often is utilized. siRNAs corresponding to the target motif NAR(N17)YNN, where R is purine (A,G) and Y is pyrimidine (C,U), often are selected. Respective 21 nucleotide sense and antisense siRNAs often begin with a purine nucleotide and can also be expressed from pol III expression vectors without a change in targeting site. Expression of RNAs from pol III promoters often is efficient when the first transcribed nucleotide is a purine.

[0124] The sequence of the siRNA can correspond to the full length target gene, or a subsequence thereof. Often, the siRNA is about 15 to about 50 nucleotides in length (e.g., each complementary sequence of the double stranded siRNA is 15-50 nucleotides in length, and the double stranded siRNA is about 15-50 base pairs in length, sometimes about 20-30 nucleotides in length or about 20-25 nucleotides in length, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. The siRNA sometimes is about 21 nucleotides in length. Methods of using siRNA are well known in the art, and specific siRNA molecules may be purchased from a number of companies including Dharmacon Research, Inc.

[0125] Antisense, ribozyme, RNAi and siRNA nucleic acids can be altered to form modified nucleic acid molecules. The nucleic acids can be altered at base moieties, sugar moieties or phosphate backbone moieties to improve stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup et al., Bioorganic & Medicinal Chemistry 4 (1): 5-23 (1996)). As used herein, the terms "peptide nucleic acid" or "PNA" refers to a nucleic acid mimic such as a DNA mimic, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of a PNA can allow for specific hybridization to DNA and RNA under conditions of low ionic strength. Synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described, for example, in Hyrup et al., (1996) supra and Perry-O'Keefe et al., Proc. Natl. Acad. Sci. 93: 14670-675 (1996).

[0126] PNA nucleic acids can be used in prognostic, diagnostic, and therapeutic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNA nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping); as "artificial restriction enzymes" when used in combination with other enzymes, (e.g., S1 nucleases (Hyrup (1996) supra)); or as probes or primers for DNA sequencing or hybridization (Hyrup et al., (1996) supra; Perry-O'Keefe supra).

[0127] In other embodiments, oligonucleotides may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across cell membranes (see e.g., Letsinger et al., Proc. Natl. Acad. Sci. USA 86: 6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci. USA 84: 648-652 (1987); PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, e.g., Krol et al., Bio-Techniques 6: 958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res. 5: 539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

[0128] Also included herein are molecular beacon oligonucleotide primer and probe molecules having one or more regions complementary to a *ADAMTS2* nucleotide sequence, or a substantially identical sequence thereof, two complementary regions one having a fluorophore and one a quencher such that the molecular beacon is useful for quantifying the presence of the nucleic acid in a sample. Molecular beacon nucleic acids are described, for example, in Lizardi et al., U.S. Patent No. 5,854,033; Nazarenko et al., U.S. Patent No. 5,866,336, and Livak et al., U.S. Patent 5,876,930.

Antibodies

[0129] The term "antibody" as used herein refers to an immunoglobulin molecule or immunologically active portion thereof, i.e., an antigen-binding portion. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and $F(ab')_2$ fragments which can be generated by treating the antibody with an enzyme such as pepsin. An antibody sometimes is a polyclonal, monoclonal, recombinant (e.g., a chimeric or humanized), fully human, non-human (e.g., murine), or a single chain antibody. An antibody may have effector function and can fix complement, and is sometimes coupled to a toxin or imaging agent.

[0130] A full-length polypeptide or antigenic peptide fragment encoded by a nucleotide sequence referenced herein can be used as an immunogen or can be used to identify antibodies made with other immunogens, e.g., cells, membrane preparations, and the like. An antigenic peptide often includes at least 8 amino acid residues of the amino acid sequences encoded by a nucleotide sequence referenced herein, or substantially identical sequence thereof, and encompasses an epitope. Antigenic peptides sometimes include 10 or more amino acids, 15 or more amino acids, 20 or more amino acids, or 30 or more amino acids. Hydrophilic and hydrophobic fragments of polypeptides sometimes are used as immunogens.

[0131] Epitopes encompassed by the antigenic peptide are regions located on the surface of the polypeptide (e.g., hydrophilic regions) as well as regions with high antigenicity. For example, an Emini surface probability analysis of the human polypeptide sequence can be used to indicate the regions that

have a particularly high probability of being localized to the surface of the polypeptide and are thus likely to constitute surface residues useful for targeting antibody production. The antibody may bind an epitope on any domain or region on polypeptides described herein.

[0132] Also, chimeric, humanized, and completely human antibodies are useful for applications which include repeated administration to subjects. Chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, can be made using standard recombinant DNA techniques. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al International Application No. PCT/US86/02269; Akira, et al European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al European Patent Application 173,494; Neuberger et al PCT International Publication No. WO 86/01533; Cabilly et al U.S. Patent No. 4,816,567; Cabilly et al European Patent Application 125,023; Better et al., Science 240: 1041-1043 (1988); Liu et al., Proc. Natl. Acad. Sci. USA 84: 3439-3443 (1987); Liu et al., J. Immunol. 139: 3521-3526 (1987); Sun et al., Proc. Natl. Acad. Sci. USA 84: 214-218 (1987); Nishimura et al., Canc. Res. 47: 999-1005 (1987); Wood et al., Nature 314: 446-449 (1985); and Shaw et al., J. Natl. Cancer Inst. 80: 1553-1559 (1988); Morrison, S. L., Science 229: 1202-1207 (1985); Oi et al., BioTechniques 4: 214 (1986); Winter U.S. Patent 5,225,539; Jones et al., Nature 321: 552-525 (1986); Verhoeyan et al., Science 239: 1534; and Beidler et al., J. Immunol. 141: 4053-4060 (1988).

[0133] Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. See, for example, Lonberg and Huszar, Int. Rev. Immunol. 13: 65-93 (1995); and U.S. Patent Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; and 5,545,806. In addition, companies such as Abgenix, Inc. (Fremont, CA) and Medarex, Inc. (Princeton, NJ), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above. Completely human antibodies that recognize a selected epitope also can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody (e.g., a murine antibody) is used to guide the selection of a completely human antibody recognizing the same epitope. This technology is described for example by Jespers et al., Bio/Technology 12: 899-903 (1994).

[0134] An antibody can be a single chain antibody. A single chain antibody (scFV) can be engineered (see, e.g., Colcher et al., Ann. N Y Acad. Sci. 880: 263-80 (1999); and Reiter, Clin. Cancer Res. 2: 245-52 (1996)). Single chain antibodies can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target polypeptide.

[0135] Antibodies also may be selected or modified so that they exhibit reduced or no ability to bind an Fc receptor. For example, an antibody may be an isotype or subtype, fragment or other mutant, which

does not support binding to an Fc receptor (e.g., it has a mutagenized or deleted Fc receptor binding region).

[0136] Also, an antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil, melphalan, carmustine (BCNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0137] Antibody conjugates can be used for modifying a given biological response. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, gamma-interferon, alpha-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors. Also, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, for example.

[0138] An antibody (e.g., monoclonal antibody) can be used to isolate target polypeptides by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, an antibody can be used to detect a target polypeptide (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor polypeptide levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance (i.e., antibody labeling). Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials

include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I, ^{131}I, ^{35}S or ^{3}H. Also, an antibody can be utilized as a test molecule for determining whether it can treat osteoarthritis, and as a therapeutic for administration to a subject for treating osteoarthritis.

[0139] An antibody can be made by immunizing with a purified antigen, or a fragment thereof, e.g., a fragment described herein, a membrane associated antigen, tissues, e.g., crude tissue preparations, whole cells, preferably living cells, lysed cells, or cell fractions.

[0140] Included herein are antibodies which bind only a native polypeptide, only denatured or otherwise non-native polypeptide, or which bind both, as well as those having linear or conformational epitopes. Conformational epitopes sometimes can be identified by selecting antibodies that bind to native but not denatured polypeptide. Also featured are antibodies that specifically bind to a polypeptide variant associated with osteoarthritis.

Methods for Identifying Candidate Therapeutics for Treating Osteoarthritis

[0141] Current therapies for the treatment of osteoarthritis have limited efficacy, limited tolerability and significant mechanism-based side effects, and few of the available therapies adequately address underlying defects. Current therapeutic approaches were largely developed in the absence of defined molecular targets or even a solid understanding of disease pathogenesis. Therefore, provided are methods of identifying candidate therapeutics that target biochemical pathways related to the development of osteoarthritis.

[0142] Thus, featured herein are methods for identifying a candidate therapeutic for treating osteoarthritis. The methods comprise contacting a test molecule with a target molecule in a system. A "target molecule" as used herein refers to a *ADAMTS2* nucleic acid, a substantially identical nucleic acid thereof, or a fragment thereof, and an encoded polypeptide of the foregoing. The methods also comprise determining the presence or absence of an interaction between the test molecule and the target molecule, where the presence of an interaction between the test molecule and the nucleic acid or polypeptide identifies the test molecule as a candidate osteoarthritis therapeutic. The interaction between the test molecule and the target molecule may be quantified.

[0143] Test molecules and candidate therapeutics include, but are not limited to, compounds, antisense nucleic acids, siRNA molecules, ribozymes, polypeptides or proteins encoded by a *ADAMTS2* nucleotide sequence, or a substantially identical sequence or fragment thereof, and immunotherapeutics (e.g., antibodies and HLA-presented polypeptide fragments). A test molecule or candidate therapeutic may act as a modulator of target molecule concentration or target molecule function in a system. A

"modulator" may agonize (i.e., up-regulates) or antagonize (i.e., down-regulates) a target molecule concentration partially or completely in a system by affecting such cellular functions as DNA replication and/or DNA processing (e.g., DNA methylation or DNA repair), RNA transcription and/or RNA processing (e.g., removal of intronic sequences and/or translocation of spliced mRNA from the nucleus), polypeptide production (e.g., translation of the polypeptide from mRNA), and/or polypeptide post-translational modification (e.g., glycosylation, phosphorylation, and proteolysis of pro-polypeptides). A modulator may also agonize or antagonize a biological function of a target molecule partially or completely, where the function may include adopting a certain structural conformation, interacting with one or more binding partners, ligand binding, catalysis (e.g., phosphorylation, dephosphorylation, hydrolysis, methylation, and isomerization), and an effect upon a cellular event (*e.g.*, effecting progression of osteoarthritis).

[0144] As used herein, the term "system" refers to a cell free *in vitro* environment and a cell-based environment such as a collection of cells, a tissue, an organ, or an organism. A system is "contacted" with a test molecule in a variety of manners, including adding molecules in solution and allowing them to interact with one another by diffusion, cell injection, and any administration routes in an animal. As used herein, the term "interaction" refers to an effect of a test molecule on test molecule, where the effect sometimes is binding between the test molecule and the target molecule, and sometimes is an observable change in cells, tissue, or organism.

[0145] There are many standard methods for detecting the presence or absence of interaction between a test molecule and a target molecule. For example, titrametric, acidimetric, radiometric, NMR, monolayer, polarographic, spectrophotometric, fluorescent, and ESR assays probative of a target molecule interaction may be utilized.

[0146] *ADAMTS2* activity and/or *ADAMTS2* interactions can be detected and quantified using assays known in the art. For example, an immunoprecipitation assay or a kinase activity assay that employs a kinase-inactivated MEK can be utilized. Kinase inactivated MEKs are known in the art, such as a MEK that includes the mutation K97M. In these assays, mammalian cells (e.g., COS or NIH-3T3) are transiently transfected with constructs expressing *ADAMTS2*, and in addition, the cells are co-transfected with oncogenic RAS or SRC or both. Oncogenic RAS or SRC activates ADAMTS2 kinase activity. *ADAMTS2* is immunoprecipitated from cell extracts using a monoclonal antibody (e.g., 9E10) or a polyclonal antibody (e.g., from rabbit) specific for a unique peptide from *ADAMTS2*. *ADAMTS2* is then resuspended in assay buffer containing GST-Mek1 or GST-Mek2 and/or GST-ERK2. In addition, [gamma ^{32}P] ATP can be added to detect and/or quantify phosphorylation activity. Samples are incubated for 5-30 minutes at 30°C, and then the reaction is terminated by addition of EDTA. The samples are centrifuged and the supernatant fractions are collected. Phosphorylation activity is detected using one of two methods: (i) activity of GST-ERK2 kinase can be measured using MBP (myelin basic

protein, a substrate for ERK) as substrate, or (ii) following incubation of immunoprecipitated *ADAMTS2* in reaction buffer containing GST-ERK and [gamma ^{32}P] ATP, transfer of labeled ATP to kinase-dead ERK can be quantified by a phosphor-imager or densitometer following PAGE separation of polypeptide products (phosphorylated and non-phosphorylated forms). These types of assays are described in Weber et al., Oncogene 19: 169-176 (2000); Mason et al., EMBO J. 18: 2137-2148 (1999); Marais et al., J. Biol. Chem. 272: 4378-4383 (1997); Marais et al., EMBO J. 14: 3136-3145 (1995).

[0147] As noted above, *ADAMTS2* includes a domain having metalloprotease activity, and modulators of such activity are known. Examples of such modulators are set forth in WO03063762A2; WO-09937625; WO-09918076; WO-09838163; WO-09837877; WO9947550A1; WO0177092A1; WO0040577A1; WO9942436A1; WO9838163A1; WO9837877A1; WO04014379A1; WO03106381A2; WO03014098A1; WO03014092A1 and WO02096426A1.

[0148] Test molecule/target molecule interactions can be detected and/or quantified using assays known in the art. For example, an interaction can be determined by labeling the test molecule and/or the target molecule, where the label is covalently or non-covalently attached to the test molecule or target molecule. The label is sometimes a radioactive molecule such as ^{125}I, ^{131}I, ^{35}S or ^{3}H, which can be detected by direct counting of radioemission or by scintillation counting. Also, enzymatic labels such as horseradish peroxidase, alkaline phosphatase, or luciferase may be utilized where the enzymatic label can be detected by determining conversion of an appropriate substrate to product. In addition, presence or absence of an interaction can be determined without labeling. For example, a microphysiometer (*e.g.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indication of an interaction between a test molecule and target molecule (McConnell, H. M. *et al., Science 257:* 1906-1912 (1992)).

[0149] In cell-based systems, cells typically include a *ADAMTS2* nucleic acid, an encoded polypeptide, or substantially identical nucleic acid or polypeptide thereof, and are often of mammalian origin, although the cell can be of any origin. Whole cells, cell homogenates, and cell fractions (*e.g.*, cell membrane fractions) can be subjected to analysis. Where interactions between a test molecule with a target polypeptide are monitored, soluble and/or membrane bound forms of the polypeptide may be utilized. Where membrane-bound forms of the polypeptide are used, it may be desirable to utilize a solubilizing agent. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)$_n$, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-

cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.

[0150] An interaction between a test molecule and target molecule also can be detected by monitoring fluorescence energy transfer (FET) (*see, e.g.*, Lakowicz *et al.*, U.S. Patent No. 5,631,169; Stavrianopoulos *et al.* U.S. Patent No. 4,868,103). A fluorophore label on a first, "donor" molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, "acceptor" molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the "donor" polypeptide molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the "acceptor" molecule label may be differentiated from that of the "donor". Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the "acceptor" molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (*e.g.*, using a fluorimeter).

[0151] In another embodiment, determining the presence or absence of an interaction between a test molecule and a target molecule can be effected by monitoring surface plasmon resonance (*see, e.g.*, Sjolander & Urbaniczk, *Anal. Chem. 63:* 2338-2345 (1991) and Szabo *et al., Curr. Opin. Struct. Biol. 5:* 699-705 (1995)). "Surface plasmon resonance" or "biomolecular interaction analysis (BIA)" can be utilized to detect biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

[0152] In another embodiment, the target molecule or test molecules are anchored to a solid phase, facilitating the detection of target molecule/test molecule complexes and separation of the complexes from free, uncomplexed molecules. The target molecule or test molecule is immobilized to the solid support. In an embodiment, the target molecule is anchored to a solid surface, and the test molecule, which is not anchored, can be labeled, either directly or indirectly, with detectable labels discussed herein.

[0153] It may be desirable to immobilize a target molecule, an anti-target molecule antibody, and/or test molecules to facilitate separation of target molecule/test molecule complexes from uncomplexed forms, as well as to accommodate automation of the assay. The attachment between a test molecule and/or target molecule and the solid support may be covalent or non-covalent (*see, e.g.*, U.S. Patent No. 6,022,688 for non-covalent attachments). The solid support may be one or more surfaces of the system, such as one or more surfaces in each well of a microtiter plate, a surface of a silicon wafer, a surface of a

bead (*see, e.g.*, Lam, *Nature 354:* 82-84 (1991)) that is optionally linked to another solid support, or a channel in a microfluidic device, for example. Types of solid supports, linker molecules for covalent and non-covalent attachments to solid supports, and methods for immobilizing nucleic acids and other molecules to solid supports are well known (*see, e.g.*, U.S. Patent Nos. 6,261,776; 5,900,481; 6,133,436; and 6,022,688; and WIPO publication WO 01/18234).

[0154] In an embodiment, target molecule may be immobilized to surfaces via biotin and streptavidin. For example, biotinylated target polypeptide can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In another embodiment, a target polypeptide can be prepared as a fusion polypeptide. For example, glutathione-S-transferase/target polypeptide fusion can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivitized microtiter plates, which are then combined with a test molecule under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, or the matrix is immobilized in the case of beads, and complex formation is determined directly or indirectly as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of target molecule binding or activity is determined using standard techniques.

[0155] In an embodiment, the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (*e.g.*, by washing) under conditions such that a significant percentage of complexes formed will remain immobilized to the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of manners. Where the previously non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface, *e.g.*, by adding a labeled antibody specific for the immobilized component, where the antibody, in turn, can be directly labeled or indirectly labeled with, *e.g.*, a labeled anti-Ig antibody.

[0156] In another embodiment, an assay is performed utilizing antibodies that specifically bind target molecule or test molecule but do not interfere with binding of the target molecule to the test molecule. Such antibodies can be derivitized to a solid support, and unbound target molecule may be immobilized by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

[0157] Cell free assays also can be conducted in a liquid phase. In such an assay, reaction products are separated from unreacted components, by any of a number of standard techniques, including but not limited to: differential centrifugation (*see, e.g.*, Rivas, G., and Minton, *Trends Biochem Sci Aug;18(8):* 284-7 (1993)); chromatography (gel filtration chromatography, ion-exchange chromatography); electrophoresis (*see, e.g.*, Ausubel *et al., eds. Current Protocols in Molecular Biology , J. Wiley:* New York (1999)); and immunoprecipitation (*see, e.g.*, Ausubel *et al., eds., supra*). Media and chromatographic techniques are known to one skilled in the art (*see, e.g.*, Heegaard, *J Mol. Recognit. Winter; 11(1-6):* 141-8 (1998); Hage & Tweed, *J. Chromatogr. B Biomed. Sci. Appl. Oct 10; 699 (1-2): 499-525* (1997)). Further, fluorescence energy transfer may also be conveniently utilized, as described herein, to detect binding without further purification of the complex from solution.

[0158] In another embodiment, modulators of target molecule expression are identified. For example, a cell or cell free mixture is contacted with a candidate compound and the expression of target mRNA or target polypeptide is evaluated relative to the level of expression of target mRNA or target polypeptide in the absence of the candidate compound. When expression of target mRNA or target polypeptide is greater in the presence of the candidate compound than in its absence, the candidate compound is identified as an agonist of target mRNA or target polypeptide expression. Alternatively, when expression of target mRNA or target polypeptide is less (*e.g.*, less with statistical significance) in the presence of the candidate compound than in its absence, the candidate compound is identified as an antagonist or inhibitor of target mRNA or target polypeptide expression. The level of target mRNA or target polypeptide expression can be determined by methods described herein.

[0159] In another embodiment, binding partners that interact with a target molecule are detected. The target molecules can interact with one or more cellular or extracellular macromolecules, such as polypeptides *in vivo*, and these interacting molecules are referred to herein as "binding partners." Binding partners can agonize or antagonize target molecule biological activity. Also, test molecules that agonize or antagonize interactions between target molecules and binding partners can be useful as therapeutic molecules as they can up-regulate or down-regulated target molecule activity *in vivo* and thereby treat osteoarthritis.

[0160] Binding partners of target molecules can be identified by methods known in the art. For example, binding partners may be identified by lysing cells and analyzing cell lysates by electrophoretic techniques. Alternatively, a two-hybrid assay or three-hybrid assay can be utilized (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos *et al., Cell 72:223-232* (1993); Madura *et al., J. Biol. Chem. 268:* 12046-12054 (1993); Bartel *et al., Biotechniques 14:* 920-924 (1993); Iwabuchi *et al., Oncogene 8:* 1693-1696 (1993); and Brent WO94/10300). A two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. The assay often utilizes two different DNA constructs. In one construct, a *ADAMTS2* nucleic acid (sometimes referred to as the

"bait") is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In another construct, a DNA sequence from a library of DNA sequences that encodes a potential binding partner (sometimes referred to as the "prey") is fused to a gene that encodes an activation domain of the known transcription factor. Sometimes, a *ADAMTS2* nucleic acid can be fused to the activation domain. If the "bait" and the "prey" molecules interact *in vivo*, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to identify the potential binding partner.

[0161] In an embodiment for identifying test molecules that antagonize or agonize complex formation between target molecules and binding partners, a reaction mixture containing the target molecule and the binding partner is prepared, under conditions and for a time sufficient to allow complex formation. The reaction mixture often is provided in the presence or absence of the test molecule. The test molecule can be included initially in the reaction mixture, or can be added at a time subsequent to the addition of the target molecule and its binding partner. Control reaction mixtures are incubated without the test molecule or with a placebo. Formation of any complexes between the target molecule and the binding partner then is detected. Decreased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule antagonizes target molecule/binding partner complex formation. Alternatively, increased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule agonizes target molecule/binding partner complex formation. In another embodiment, complex formation of target molecule/binding partner can be compared to complex formation of mutant target molecule/binding partner (*e.g.*, amino acid modifications in a target polypeptide). Such a comparison can be important in those cases where it is desirable to identify test molecules that modulate interactions of mutant but not non-mutated target gene products.

[0162] The assays can be conducted in a heterogeneous or homogeneous format. In heterogeneous assays, target molecule and/or the binding partner are immobilized to a solid phase, and complexes are detected on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the molecules being tested. For example, test compounds that agonize target molecule/binding partner interactions can be identified by conducting the reaction in the presence of the test molecule in a competition format. Alternatively, test molecules that agonize preformed complexes, *e.g.*, molecules with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed.

[0163] In a heterogeneous assay embodiment, the target molecule or the binding partner is anchored onto a solid surface (*e.g.*, a microtiter plate), while the non-anchored species is labeled, either directly or indirectly. The anchored molecule can be immobilized by non-covalent or covalent attachments. Alternatively, an immobilized antibody specific for the molecule to be anchored can be used to anchor the molecule to the solid surface. The partner of the immobilized species is exposed to the coated surface with or without the test molecule. After the reaction is complete, unreacted components are removed (*e.g.*, by washing) such that a significant portion of any complexes formed will remain immobilized on the solid surface. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface is indicative of complex. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored to the surface; *e.g.*, by using a labeled antibody specific for the initially non-immobilized species. Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

[0164] In another embodiment, the reaction can be conducted in a liquid phase in the presence or absence of test molecule, where the reaction products are separated from unreacted components, and the complexes are detected (*e.g.*, using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes). Again, depending upon the order of addition of reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

[0165] In an alternate embodiment, a homogeneous assay can be utilized. For example, a preformed complex of the target gene product and the interactive cellular or extracellular binding partner product is prepared. One or both of the target molecule or binding partner is labeled, and the signal generated by the label(s) is quenched upon complex formation (*e.g.*, U.S. Patent No. 4,109,496 that utilizes this approach for immunoassays). Addition of a test molecule that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances that disrupt target molecule/binding partner complexes can be identified.

[0166] Candidate therapeutics for treating osteoarthritis are identified from a group of test molecules that interact with a target molecule. Test molecules are normally ranked according to the degree with which they modulate (*e.g.*, agonize or antagonize) a function associated with the target molecule (*e.g.*, DNA replication and/or processing, RNA transcription and/or processing, polypeptide production and/or processing, and/or biological function/activity), and then top ranking modulators are selected. Also, pharmacogenomic information described herein can determine the rank of a modulator. The top 10% of ranked test molecules often are selected for further testing as candidate therapeutics, and sometimes the top 15%, 20%, or 25% of ranked test molecules are selected for further testing as candidate therapeutics. Candidate therapeutics typically are formulated for administration to a subject.

Therapeutic Formulations

[0167] Formulations and pharmaceutical compositions typically include in combination with a pharmaceutically acceptable carrier one or more target molecule modulators. The modulator often is a test molecule identified as having an interaction with a target molecule by a screening method described above. The modulator may be a compound, an antisense nucleic acid, a ribozyme, an antibody, or a binding partner. Also, formulations may comprise a target polypeptide or fragment thereof in combination with a pharmaceutically acceptable carrier.

[0168] Formulations or pharmaceutical compositions typically include in combination with a pharmaceutically acceptable carrier, a compound, an antisense nucleic acid, a ribozyme, an antibody, a binding partner that interacts with an *ADAMTS2* polypeptide, a *ADAMTS2* nucleic acid, or a fragment thereof. The formulated molecule may be one that is identified by a screening method described above. Also, formulations may comprise a *ADAMTS2* polypeptide or fragment thereof, where the *ADAMTS2* polypeptide contains an isoleucine at position 245 of SEQ ID NO: 4, and a pharmaceutically acceptable carrier. Also, formulations may comprise an active *ADAMTS2* polypeptide or fragment thereof, where *ADAMTS2* polypeptide fragments having activity are selected from amino acids 252-1211, 253-1211, 254-1211, 255-1211, 256-1211, 257-1211, 258-1211, 259-1211 or 260-1211 of SEQ ID NO: 4, where it is understood that the active form of *ADAMTS2* does not contain the propeptide domain. As used herein, the term "pharmaceutically acceptable carrier" includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.

[0169] As used herein, the term "pharmaceutically acceptable carrier" includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions. Pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0170] A pharmaceutical composition typically is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with

acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0171] Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, *e.g.*, gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0172] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0173] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which

yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0174] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

[0175] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. Molecules can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0176] In one embodiment, active molecules are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0177] It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

[0178] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD_{50} (the dose lethal to 50% of the population) and the ED_{50} (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD_{50}/ED_{50}. Molecules which exhibit high therapeutic indices are preferred. While molecules that exhibit toxic side effects may be used, care should be taken to design a delivery system

that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0179] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such molecules lies preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any molecules used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC_{50} (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0180] As defined herein, a therapeutically effective amount of protein or polypeptide (*i.e.*, an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, sometimes about 0.01 to 25 mg/kg body weight, often about 0.1 to 20 mg/kg body weight, and more often about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The protein or polypeptide can be administered one time per week for between about 1 to 10 weeks, sometimes between 2 to 8 weeks, often between about 3 to 7 weeks, and more often for about 4, 5, or 6 weeks. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.

[0181] With regard to polypeptide formulations, featured herein is a method for treating osteoarthritis in a subject, which comprises contacting one or more cells in the subject with a first polypeptide, where the subject comprises a second polypeptide having one or more polymorphic variations associated with cancer, and where the first polypeptide comprises fewer polymorphic variations associated with cancer than the second polypeptide. The first and second polypeptides are encoded by a nucleic acid which comprises a nucleotide sequence in SEQ ID NO: 1-3; a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence referenced in SEQ ID NO: 1-3; a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3 and a nucleotide sequence 90% or more identical to a nucleotide sequence in SEQ ID NO: 1-3. The subject often is a human.

[0182] For antibodies, a dosage of 0.1 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg) is often utilized. If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is often appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (*e.g.*, into the brain). A method for lipidation of antibodies is described by Cruikshank *et al., J. Acquired Immune Deficiency Syndromes and Human Retrovirology 14:*193 (1997).

[0183] Antibody conjugates can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors. Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

[0184] For compounds, exemplary doses include milligram or microgram amounts of the compound per kilogram of subject or sample weight, for example, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. When one or more of these small molecules is to be administered to an animal (*e.g.*, a human) in order to modulate expression or activity of a polypeptide or nucleic acid described herein, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

[0185] With regard to nucleic acid formulations, gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.,* U.S. Patent 5,328,470) or by stereotactic injection (*see e.g.*, Chen *et al.,* (1994) *Proc. Natl. Acad. Sci. USA 91:*3054-3057). Pharmaceutical preparations of gene therapy vectors can include a gene therapy vector in an acceptable

diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells (*e.g.*, retroviral vectors) the pharmaceutical preparation can include one or more cells which produce the gene delivery system. Examples of gene delivery vectors are described herein.

Therapeutic Methods

[0186] A therapeutic formulation described above can be administered to a subject in need of a therapeutic for inducing a desired biological response.. Therapeutic formulations can be administered by any of the paths described herein. With regard to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from pharmacogenomic analyses described herein.

[0187] As used herein, the term "treatment" is defined as the application or administration of a therapeutic formulation to a subject, or application or administration of a therapeutic agent to an isolated tissue or cell line from a subject with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect osteoarthritis, symptoms of osteoarthritis or a predisposition towards osteoarthritis. A therapeutic formulation includes, but is not limited to, small molecules, peptides, antibodies, ribozymes and antisense oligonucleotides. Administration of a therapeutic formulation can occur prior to the manifestation of symptoms characteristic of osteoarthritis, such that osteoarthritis is prevented or delayed in its progression. The appropriate therapeutic composition can be determined based on screening assays described herein.

[0188] As discussed, successful treatment of osteoarthritis can be brought about by techniques that serve to agonize target molecule expression or function, or alternatively, antagonize target molecule expression or function. These techniques include administration of modulators that include, but are not limited to, small organic or inorganic molecules; antibodies (including, for example, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, $F(ab')_2$ and Fab expression library fragments, scFV molecules, and epitope-binding fragments thereof); and peptides, phosphopeptides, or polypeptides.

[0189] Further, antisense and ribozyme molecules that inhibit expression of the target gene can also be used to reduce the level of target gene expression, thus effectively reducing the level of target gene activity. Still further, triple helix molecules can be utilized in reducing the level of target gene activity. Antisense, ribozyme and triple helix molecules are discussed above. It is possible that the use of antisense, ribozyme, and/or triple helix molecules to reduce or inhibit mutant gene expression can also reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles, such that the concentration of normal target gene product present can be lower than is necessary for a normal phenotype. In such cases, nucleic acid molecules that encode

and express target gene polypeptides exhibiting normal target gene activity can be introduced into cells via gene therapy method. Alternatively, in instances in that the target gene encodes an extracellular polypeptide, it can be preferable to co-administer normal target gene polypeptide into the cell or tissue in order to maintain the requisite level of cellular or tissue target gene activity.

[0190] Another method by which nucleic acid molecules may be utilized in treating or preventing osteoarthritis is use of aptamer molecules specific for target molecules. Aptamers are nucleic acid molecules having a tertiary structure which permits them to specifically bind to ligands (*see, e.g.*, Osborne, *et al., Curr. Opin. Chem. Biol.1(1):* 5-9 (1997); and Patel, D. J., *Curr. Opin. Chem. Biol. Jun;1(1):* 32-46 (1997)).

[0191] Yet another method of utilizing nucleic acid molecules for osteoarthritis treatment is gene therapy, which can also be referred to as allele therapy. Provided herein is a gene therapy method for treating osteoarthritis in a subject, which comprises contacting one or more cells in the subject or from the subject with a nucleic acid having a first nucleotide sequence (e.g., the first nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1-3). Genomic DNA in the subject comprises a second nucleotide sequence having one or more polymorphic variations associated with osteoarthritis (e.g., the second nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1). The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer polymorphic variations associated with osteoarthritis than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human. Allele therapy methods often are utilized in conjunction with a method of first determining whether a subject has genomic DNA that includes polymorphic variants associated with osteoarthritis.

[0192] In another allele therapy embodiment, provided herein is a method which comprises contacting one or more cells in the subject or from the subject with a polypeptide encoded by a nucleic acid having a first nucleotide sequence (e.g., the first nucleotide sequence is identical to or substantially identical to the nucleotide sequence of SEQ ID NO: 1-3). Genomic DNA in the subject comprises a second nucleotide sequence having one or more polymorphic variations associated with osteoarthritis (e.g., the second nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1). The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer polymorphic variations associated with osteoarthritis than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human. The method often comprises supplementing arthritis-associated *ADAMTS2* polypeptide with a non-arthritis-associated *ADAMTS2* polypeptide or fragment thereof, where the non-arthritis-associated form of

ADAMTS2 contains an isoleucine at position 245 of SEQ ID NO: 4 having enzymatic activity. The arthritis-associated *ADAMTS2* polypeptide sometimes contains a valine at position 245 of SEQ ID NO: 4 having an altered enzymatic activity varying from the non-arthritis-associated polypeptide.

[0193] In an embodiment, provided is a method of increasing the synthesis of procollagen II comprising providing or administering to individuals in need of increasing levels of type II collagen the pharmaceutical or physiologically acceptable composition comprising active human *ADAMTS2* protein or fragment thereof, where *ADAMTS2* polypeptide fragments having activity are selected from amino acids 252-1211, 253-1211, 254-1211, 255-1211, 256-1211, 257-1211, 258-1211, 259-1211 or 260-1211 of SEQ ID NO: 4, where it is understood that the active form of *ADAMTS2* does not contain the propeptide domain.

[0194] In another embodiment, provided herein is a method of increasing the synthesis of procollagen II comprising providing or administering to individuals in need of increasing levels of type II collagen the pharmaceutical or physiologically acceptable composition comprising an enzyme or molecule capable of cleaving *ADAMTS2* propeptide, e.g., a furin-type endopeptidase or N-ethylmaleimide described herein

[0195] For antibody-based therapies, antibodies can be generated that are both specific for target molecules and that reduce target molecule activity. Such antibodies may be administered in instances where antagonizing a target molecule function is appropriate for the treatment of osteoarthritis.

[0196] In circumstances where stimulating antibody production in an animal or a human subject by injection with a target molecule is harmful to the subject, it is possible to generate an immune response against the target molecule by use of anti-idiotypic antibodies (*see, e.g.*, Herlyn, *Ann. Med.;31(1):* 66-78 (1999); and Bhattacharya-Chatterjee & Foon, *Cancer Treat. Res.; 94:* 51-68 (1998)). Introducing an anti-idiotypic antibody to a mammal or human subject often stimulates production of anti-anti-idiotypic antibodies, which typically are specific to the target molecule. Vaccines directed to osteoarthritis also may be generated in this fashion.

[0197] In instances where the target molecule is intracellular and whole antibodies are used, internalizing antibodies may be preferred. Lipofectin or liposomes can be used to deliver the antibody or a fragment of the Fab region that binds to the target antigen into cells. Where fragments of the antibody are used, the smallest inhibitory fragment that binds to the target antigen is preferred. For example, peptides having an amino acid sequence corresponding to the Fv region of the antibody can be used. Alternatively, single chain neutralizing antibodies that bind to intracellular target antigens can also be administered. Such single chain antibodies can be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population (*see, e.g.*, Marasco *et al., Proc. Natl. Acad. Sci. USA 90:* 7889-7893 (1993)).

[0198] Modulators can be administered to a patient at therapeutically effective doses to treat osteoarthritis. A therapeutically effective dose refers to an amount of the modulator sufficient to result in amelioration of symptoms of osteoarthritis. Toxicity and therapeutic efficacy of modulators can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD_{50} (the dose lethal to 50% of the population) and the ED_{50} (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD_{50}/ED_{50}. Modulators that exhibit large therapeutic indices are preferred. While modulators that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such molecules to the site of affected tissue in order to minimize potential damage to uninfected cells, thereby reducing side effects.

[0199] Data obtained from cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC_{50} (*i.e.*, the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

[0200] Another example of effective dose determination for an individual is the ability to directly assay levels of "free" and "bound" compound in the serum of the test subject. Such assays may utilize antibody mimics and/or "biosensors" that have been created through molecular imprinting techniques. Molecules that modulate target molecule activity are used as a template, or "imprinting molecule", to spatially organize polymerizable monomers prior to their polymerization with catalytic reagents. The subsequent removal of the imprinted molecule leaves a polymer matrix which contains a repeated "negative image" of the compound and is able to selectively rebind the molecule under biological assay conditions. A detailed review of this technique can be seen in Ansell *et al., Current Opinion in Biotechnology 7:* 89-94 (1996) and in Shea, *Trends in Polymer Science 2:* 166-173 (1994). Such "imprinted" affinity matrixes are amenable to ligand-binding assays, whereby the immobilized monoclonal antibody component is replaced by an appropriately imprinted matrix. An example of the use of such matrixes in this way can be seen in Vlatakis, *et al., Nature 361:* 645-647 (1993). Through the use of isotope-labeling, the "free" concentration of compound which modulates target molecule expression or activity readily can be monitored and used in calculations of IC_{50}. Such "imprinted" affinity matrixes can also be designed to include fluorescent groups whose photon-emitting properties

measurably change upon local and selective binding of target compound. These changes readily can be assayed in real time using appropriate fiberoptic devices, in turn allowing the dose in a test subject to be quickly optimized based on its individual IC_{50}. An example of such a "biosensor" is discussed in Kriz *et al., Analytical Chemistry 67:* 2142-2144 (1995).

[0201] The examples set forth below are intended to illustrate but not limit the invention.

Examples

[0202] In the following studies a group of subjects was selected according to specific parameters relating to osteoarthritis. Nucleic acid samples obtained from individuals in the study group were subjected to genetic analysis, which identified associations between osteoarthritis and a polymorphism in the *ADAMTS2* gene on chromosome five. The polymorphism was genotyped again in two replication cohorts consisting of individuals selected for OA. In addition, SNPs proximal to the incident polymorphism were identified and allelotyped in OA case and control pools. Methods are described for producing *ADAMTS2* polypeptide and *ADAMTS2* polypeptide variants *in vitro* or *in vivo*, *ADAMTS2* nucleic acids or polypeptides and variants thereof are utilized for screening test molecules for those that interact with *ADAMTS2* molecules. Test molecules identified as interactors with *ADAMTS2* molecules and *ADAMTS2* variants are further screened *in vivo* to determine whether they treat osteoarthritis.

Example 1
Samples and Pooling Strategies

Sample Selection

[0203] Blood samples were collected from individuals diagnosed with knee osteoarthritis, which were referred to as case samples. Also, blood samples were collected from individuals not diagnosed with knee osteoarthritis as gender and age-matched controls. A database was created that listed all phenotypic trait information gathered from individuals for each case and control sample. Genomic DNA was extracted from each of the blood samples for genetic analyses.

DNA Extraction from Blood Samples

[0204] Six to ten milliliters of whole blood was transferred to a 50 ml tube containing 27 ml of red cell lysis solution (RCL). The tube was inverted until the contents were mixed. Each tube was incubated for 10 minutes at room temperature and inverted once during the incubation. The tubes were then centrifuged for 20 minutes at 3000 x g and the supernatant was carefully poured off. 100-200 µl of residual liquid was left in the tube and was pipetted repeatedly to resuspend the pellet in the residual supernatant. White cell lysis solution (WCL) was added to the tube and pipetted repeatedly until

completely mixed. While no incubation was normally required, the solution was incubated at 37°C or room temperature if cell clumps were visible after mixing until the solution was homogeneous. 2 ml of protein precipitation was added to the cell lysate. The mixtures were vortexed vigorously at high speed for 20 sec to mix the protein precipitation solution uniformly with the cell lysate, and then centrifuged for 10 minutes at 3000 x g. The supernatant containing the DNA was then poured into a clean 15 ml tube, which contained 7 ml of 100% isopropanol. The samples were mixed by inverting the tubes gently until white threads of DNA were visible. Samples were centrifuged for 3 minutes at 2000 x g and the DNA was visible as a small white pellet. The supernatant was decanted and 5 ml of 70% ethanol was added to each tube. Each tube was inverted several times to wash the DNA pellet, and then centrifuged for 1 minute at 2000 x g. The ethanol was decanted and each tube was drained on clean absorbent paper. The DNA was dried in the tube by inversion for 10 minutes, and then 1000 µl of 1X TE was added. The size of each sample was estimated, and less TE buffer was added during the following DNA hydration step if the sample was smaller. The DNA was allowed to rehydrate overnight at room temperature, and DNA samples were stored at 2-8°C.

[0205] DNA was quantified by placing samples on a hematology mixer for at least 1 hour. DNA was serially diluted (typically 1:80, 1:160, 1:320, and 1:640 dilutions) so that it would be within the measurable range of standards. 125 µl of diluted DNA was transferred to a clear U-bottom microtitre plate, and 125 µl of 1X TE buffer was transferred into each well using a multichannel pipette. The DNA and 1X TE were mixed by repeated pipetting at least 15 times, and then the plates were sealed. 50 µl of diluted DNA was added to wells A5-H12 of a black flat bottom microtitre plate. Standards were inverted six times to mix them, and then 50 µl of 1X TE buffer was pipetted into well A1, 1000 ng/ml of standard was pipetted into well A2, 500 ng/ml of standard was pipetted into well A3, and 250 ng/ml of standard was pipetted into well A4. PicoGreen (Molecular Probes, Eugene, Oregon) was thawed and freshly diluted 1:200 according to the number of plates that were being measured. PicoGreen was vortexed and then 50µl was pipetted into all wells of the black plate with the diluted DNA. DNA and PicoGreen were mixed by pipetting repeatedly at least 10 times with the multichannel pipette. The plate was placed into a Fluoroskan Ascent Machine (microplate fluorometer produced by Labsystems) and the samples were allowed to incubate for 3 minutes before the machine was run using filter pairs 485 nm excitation and 538 nm emission wavelengths. Samples having measured DNA concentrations of greater than 450 ng/µl were re-measured for conformation. Samples having measured DNA concentrations of 20 ng/µl or less were re-measured for confirmation.

Pooling Strategies – Discovery Cohort

[0206] Samples were derived from the Nottingham knee OA family study (UK) where index cases were identified through a knee replacement registry. Siblings were approached and assessed with knee x-rays and assigned status as affected or unaffected. In all 1,157 individuals were available. In order to create same-sex pools of appropriate sizes, 335 unrelated female individuals with OA from the Nottingham OA sample were selected for the case pool. The control pool was made up of unrelated female individuals from the St. Thomas twin study (England) with normal knee x-rays and without other indications of OA, regardless of anatomical location, as well as lacking family history of OA. The St. Thomas twin study consists of Caucasian, female participants from the St. Thomas' Hospital, London, adult-twin registry, which is a voluntary registry of >4,000 twin pairs ranging from 18 to 76 years of age. The female case samples and female control samples are described further in Table 1 below.

[0207] A select set of samples from each group were utilized to generate pools, and one pool was created for each group. Each individual sample in a pool was represented by an equal amount of genomic DNA. For example, where 25 ng of genomic DNA was utilized in each PCR reaction and there were 200 individuals in each pool, each individual would provide 125 pg of genomic DNA. Inclusion or exclusion of samples for a pool was based upon the following criteria: the sample was derived from an individual characterized as Caucasian; the sample was derived from an individual of British paternal and maternal descent; case samples were derived from individuals diagnosed with specific knee osteoarthritis (OA) and were recruited from an OA knee replacement clinic. Control samples were derived from individuals free of OA, family history of OA, and rheumatoid arthritis. Also, sufficient genomic DNA was extracted from each blood sample for all allelotyping and genotyping reactions performed during the study. Phenotype information from each individual was collected and included age of the individual, gender, family history of OA, general medical information (e.g., height, weight, thyroid disease, diabetes, psoriasis, hysterectomy), joint history (previous and current symptoms, joint-related operations, age at onset of symptoms, date of primary diagnosis, age of individual as of primary diagnosis and order of involvement), and knee-related findings (crepitus, restricted passive movement, bony swelling/deformity). Additional knee information included knee history, current symptoms, any major knee injury, menisectomy, knee replacement surgery, age of surgery, and treatment history (including hormone replace therapy (HRT)). Samples that met these criteria were added to appropriate pools based on disease status.

[0208] The selection process yielded the pools set forth in Table 1, which were used in the studies that follow:

TABLE 1

	Female case	**Female control**
Pool size (Number)	335	335
Pool Criteria (ex: case/control)	control	case
Mean Age (ex: years)	57.21	69.95

Example 2

Association of Polymorphic Variants with Osteoarthritis

[0209] A whole-genome screen was performed to identify particular SNPs associated with occurrence of osteoarthritis. As described in Example 1, two sets of samples were utilized, which included samples from female individuals having knee osteoarthritis (osteoarthritis cases), and samples from female individuals not having knee osteoarthritis (female controls). The initial screen of each pool was performed in an allelotyping study, in which certain samples in each group were pooled. By pooling DNA from each group, an allele frequency for each SNP in each group was calculated. These allele frequencies were then compared to one another. Particular SNPs were considered as being associated with osteoarthritis when allele frequency differences calculated between case and control pools were statistically significant. SNP disease association results obtained from the allelotyping study were then validated by genotyping each associated SNP across all samples from each pool. The results of the genotyping then were analyzed, allele frequencies for each group were calculated from the individual genotyping results, and a p-value was calculated to determine whether the case and control groups had statistically significant differences in allele frequencies for a particular SNP. When the genotyping results agreed with the original allelotyping results, the SNP disease association was considered validated at the genetic level.

SNP Panel Used for Genetic Analyses

[0210] A whole-genome SNP screen began with an initial screen of approximately 25,000 SNPs over each set of disease and control samples using a pooling approach. The pools studied in the screen are described in Example 1. The SNPs analyzed in this study were part of a set of 25,488 SNPs confirmed as being statistically polymorphic as each is characterized as having a minor allele frequency of greater than 10%. The SNPs in the set reside in genes or in close proximity to genes, and many reside

in gene exons. Specifically, SNPs in the set are located in exons, introns, and within 5,000 base-pairs upstream of a transcription start site of a gene. In addition, SNPs were selected according to the following criteria: they are located in ESTs; they are located in Locuslink or Ensembl genes; and they are located in Genomatix promoter predictions. SNPs in the set were also selected on the basis of even spacing across the genome, as depicted in Table 2.

[0211] A case-control study design using a whole genome association strategy involving approximately 28,000 single nucleotide polymorphisms (SNPs) was employed. Approximately 25,000 SNPs were evenly spaced in gene-based regions of the human genome with a median inter-marker distance of about 40,000 base pairs. Additionally, approximately 3,000 SNPs causing amino acid substitutions in genes described in the literature as candidates for various diseases were used. The case-control study samples were of female Caucasian origin (British paternal and maternal descent) 670 individuals were equally distributed in two groups: female controls and female cases. The whole genome association approach was first conducted on 2 DNA pools representing the 2 groups. Significant markers were confirmed by individual genotyping.

TABLE 2

General Statistics		Spacing Statistics	
Total # of SNPs	25,488	Median	37,058 bp
# of Exonic SNPs	>4,335 (17%)	Minimum*	1,000 bp
# SNPs with refSNP ID	20,776 (81%)	Maximum*	3,000,000 bp
Gene Coverage	>10,000	Mean	122,412 bp
Chromosome Coverage	All	Std Deviation	373,325 bp
		Excludes outliers	

Allelotyping and Genotyping Results

[0212] The genetic studies summarized above and described in more detail below identified an allelic variant in the ADAMTS2 gene that is associated with osteoarthritis.

Assay for Verifying, Allelotyping, and Genotyping SNPs

[0213] A MassARRAY™ system (Sequenom, Inc.) was utilized to perform SNP genotyping in a high-throughput fashion. This genotyping platform was complemented by a homogeneous, single-tube assay method (hME™ or homogeneous MassEXTEND™ (Sequenom, Inc.)) in which two genotyping primers anneal to and amplify a genomic target surrounding a polymorphic site of interest. A third primer (the MassEXTEND™ primer), which is complementary to the amplified target up to but not

including the polymorphism, was then enzymatically extended one or a few bases through the polymorphic site and then terminated.

[0214] For each polymorphism, SpectroDESIGNER™ software (Sequenom, Inc.) was used to generate a set of PCR primers and a MassEXTEND™ primer which where used to genotype the polymorphism. Other primer design software could be used or one of ordinary skill in the art could manually design primers based on his or her knowledge of the relevant factors and considerations in designing such primers. Table 3 shows PCR primers and Table 4 shows extension primers used for analyzing polymorphisms. The initial PCR amplification reaction was performed in a 5 μl total volume containing 1X PCR buffer with 1.5 mM $MgCl_2$ (Qiagen), 200 μM each of dATP, dGTP, dCTP, dTTP (Gibco-BRL), 2.5 ng of genomic DNA, 0.1 units of HotStar DNA polymerase (Qiagen), and 200 nM each of forward and reverse PCR primers specific for the polymorphic region of interest.

TABLE 3: PCR Primers

SNP Reference	Forward PCR primer	Reverse PCR primer
rs398829	ACGTTGGATGTAGTCATCGTCCGCAGCATG	ACGTTGGATGAAGACGGTGTCCTCTCCTTG

[0215] Samples were incubated at 95°C for 15 minutes, followed by 45 cycles of 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute, finishing with a 3 minute final extension at 72°C. Following amplification, shrimp alkaline phosphatase (SAP) (0.3 units in a 2 μl volume) (Amersham Pharmacia) was added to each reaction (total reaction volume was 7 μl) to remove any residual dNTPs that were not consumed in the PCR step. Samples were incubated for 20 minutes at 37°C, followed by 5 minutes at 85°C to denature the SAP.

[0216] Once the SAP reaction was complete, a primer extension reaction was initiated by adding a polymorphism-specific MassEXTEND™ primer cocktail to each sample. Each MassEXTEND™ cocktail included a specific combination of dideoxynucleotides (ddNTPs) and deoxynucleotides (dNTPs) used to distinguish polymorphic alleles from one another. Methods for verifying, allelotyping and genotyping SNPs are disclosed, for example, in U.S. Pat. No. 6,258,538, the content of which is hereby incorporated by reference. In Table 4, ddNTPs are shown and the fourth nucleotide not shown is the dNTP.

TABLE 4: Extension Primers

SNP Reference	Extend Probe	Termination Mix
rs398829	TGGCGTGCTCCTCTAGGA	ACG

[0217] The MassEXTEND™ reaction was performed in a total volume of 9 µl, with the addition of 1X ThermoSequenase buffer, 0.576 units of ThermoSequenase (Amersham Pharmacia), 600 nM MassEXTEND™ primer, 2 mM of ddATP and/or ddCTP and/or ddGTP and/or ddTTP, and 2 mM of dATP or dCTP or dGTP or dTTP. The deoxy nucleotide (dNTP) used in the assay normally was complementary to the nucleotide at the polymorphic site in the amplicon. Samples were incubated at 94°C for 2 minutes, followed by 55 cycles of 5 seconds at 94°C, 5 seconds at 52°C, and 5 seconds at 72°C.

[0218] Following incubation, samples were desalted by adding 16 µl of water (total reaction volume was 25 µl), 3 mg of SpectroCLEAN™ sample cleaning beads (Sequenom, Inc.) and allowed to incubate for 3 minutes with rotation. Samples were then robotically dispensed using a piezoelectric dispensing device (SpectroJET™ (Sequenom, Inc.)) onto either 96-spot or 384-spot silicon chips containing a matrix that crystallized each sample (SpectroCHIP™ (Sequenom, Inc.)). Subsequently, MALDI-TOF mass spectrometry (Biflex and Autoflex MALDI-TOF mass spectrometers (Bruker Daltonics) can be used) and SpectroTYPER RT™ software (Sequenom, Inc.) were used to analyze and interpret the SNP genotype for each sample.

Genetic Analysis

[0219] Minor allelic frequencies for the polymorphisms set forth in Table A were verified as being 10% or greater using the extension assay described above in a group of samples isolated from 92 individuals originating from the state of Utah in the United States, Venezuela and France (Coriell cell repositories).

[0220] Genotyping results are shown for female pools in Table 5. In Table 5, "AF" refers to allelic frequency; and "F case" and "F control" refer to female case and female control groups, respectively.

TABLE 5: Genotyping Results

SNP Reference	AF F case	AF F control	p-value
rs398829	G = 0.740 A = 0.260	G = 0.652 A = 0.348	0.0002

[0221] All of the single marker alleles set forth in Table A were considered validated, since the genotyping data agreed with the allelotyping data and each SNP significantly associated with osteoarthritis. Particularly significant associations with osteoarthritis are indicated by a calculated p-value of less than 0.05 for genotype results.

Example 3

Association of Polymorphic Variants with Osteoarthritis in Replication Cohorts

[0222] The single marker polymorphism set forth in Table A was genotyped again in two replication cohorts consisting of individuals selected for OA.

Sample Selection and Pooling Strategies – Replication Sample 1

[0223] A second case control sample (replication sample #1) was created by using 100 Caucasian female cases from Chingford, UK, and 148 unrelated female cases from the St. Thomas twin study. Cases were defined as having Kellgren-Lawrence (KL) scores of at least 2 in at least one knee x-ray. In addition, 199 male knee replacement cases from Nottingham were included. (For a cohort description, see the Nottingham description provided in Example 1). The control pool was made up of unrelated female individuals from the St. Thomas twin study (England) with normal knee x-rays and without other indications of OA, regardless of anatomical location, as well as lacking family history of OA. The St. Thomas twin study consists of Caucasian, female participants from the St. Thomas' Hospital, London, adult-twin registry, which is a voluntary registry of >4,000 twin pairs ranging from 18 to 76 years of age. The replication sample 1 cohort was used to replicate the initial results. Table 6 below summarizes the selected phenotype data collected from the case and control individuals.

TABLE 6

Phenotype	**Female cases (n=248):** median (range)/ (n,%)	**Male cases (n=199):** median (range)/ (n,%)	**Female controls (n=313):** mean (range)/ (n,%)
Age	59 (39- 73)	66 (45- 73)	55 (50- 72)
Height (cm)	162 (141- 178)	175 (152- 198)	162 (141- 176)
Weight (kg)	68 (51- 123)	86 (62- 127)	64 (40- 111)
Body mass index (kg/m^2)	26 (18- 44)	29 (21- 41)	24 (18- 46)
Kellgren-Lawrence* left knee	0 (63, 26%), 1 (20, 8%), 2 (105, 43%), 3 (58, 23%), 4 (1, 0%)	NA	NA
Kellgren-Lawrence* right knee	0 (43, 7%), 1 (18, 7%), 2 (127, 52%), 3 (57, 23%), 4 (1, 0%)	NA	NA
KL* >2 both knees	No (145, 59%), Yes (101, 41%)	NA	NA
KL* >2 either knee	No (0, 0%), Yes (248, 100%)	NA	NA

* 0: normal, 1: doubtful, 2: definite osteophyte (bony protuberance), 3: joint space narrowing (with or without osteophyte), 4: joint deformity

Sample Selection and Pooling Strategies – Replication Sample 2

[0224] A third case control sample (replication sample #2) was created by using individuals with symptoms of OA from Newfoundland, Canada. These individuals were recruited and examined by rheumatologists. Affected joints were x-rayed and a final diagnosis of definite or probable OA was made according to American College of Rheumatology criteria by a single rheumatologist to avoid any inter-examiner diagnosis variability. Controls were recruited from volunteers without any symptoms from the musculoskeletal system based on a normal joint exam performed by a rheumatologist. Only cases with a diagnosis of definite OA were included in the study. Only individuals of Caucasian origin were included. The cases consisted of 228 individuals with definite knee OA, 106 individuals with definite hip OA, and 74 individuals with hip OA.

TABLE 7

Phenotype	Case	Control
Age at Visit	62.7	52.5
Sex (Female/Male)	227/119	174/101
Knee OA Xray: No	35% (120)	80% (16)
Unknown	1% (4)	0% (0)
Yes	64% (221)	20% (4)
Hip OA Xray: No	63% (215)	80% (16)
Unknown	2% (7)	0% (0)
Yes	35% (121)	20% (4)

Assay for Verifying, Allelotyping, and Genotyping SNPs

[0225] Genotyping of the replication cohorts described in Tables 6 and 7 was performed using the same methods used for the original genotyping, as described herein. A MassARRAY™ system (Sequenom, Inc.) was utilized to perform SNP genotyping in a high-throughput fashion. This genotyping platform was complemented by a homogeneous, single-tube assay method (hME™ or homogeneous MassEXTEND™ (Sequenom, Inc.)) in which two genotyping primers anneal to and amplify a genomic target surrounding a polymorphic site of interest. A third primer (the MassEXTEND™ primer), which is complementary to the amplified target up to but not including the polymorphism, was then enzymatically extended one or a few bases through the polymorphic site and then terminated.

[0226] For each polymorphism, SpectroDESIGNER™ software (Sequenom, Inc.) was used to generate a set of PCR primers and a MassEXTEND™ primer which where used to genotype the polymorphism. Other primer design software could be used or one of ordinary skill in the art could

manually design primers based on his or her knowledge of the relevant factors and considerations in designing such primers. Table 3 shows PCR primers and Table 4 shows extension probes used for analyzing (*e.g.*, genotyping) polymorphisms in the replication cohorts. The initial PCR amplification reaction was performed in a 5 μl total volume containing 1X PCR buffer with 1.5 mM $MgCl_2$ (Qiagen), 200 μM each of dATP, dGTP, dCTP, dTTP (Gibco-BRL), 2.5 ng of genomic DNA, 0.1 units of HotStar DNA polymerase (Qiagen), and 200 nM each of forward and reverse PCR primers specific for the polymorphic region of interest.

[0227] Samples were incubated at 95°C for 15 minutes, followed by 45 cycles of 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute, finishing with a 3 minute final extension at 72°C. Following amplification, shrimp alkaline phosphatase (SAP) (0.3 units in a 2 μl volume) (Amersham Pharmacia) was added to each reaction (total reaction volume was 7 μl) to remove any residual dNTPs that were not consumed in the PCR step. Samples were incubated for 20 minutes at 37°C, followed by 5 minutes at 85°C to denature the SAP.

[0228] Once the SAP reaction was complete, a primer extension reaction was initiated by adding a polymorphism-specific MassEXTEND™ primer cocktail to each sample. Each MassEXTEND™ cocktail included a specific combination of dideoxynucleotides (ddNTPs) and deoxynucleotides (dNTPs) used to distinguish polymorphic alleles from one another. Methods for verifying, allelotyping and genotyping SNPs are disclosed, for example, in U.S. Pat. No. 6,258,538, the content of which is hereby incorporated by reference. In Table 7, ddNTPs are shown and the fourth nucleotide not shown is the dNTP.

[0229] The MassEXTEND™ reaction was performed in a total volume of 9 μl, with the addition of 1X ThermoSequenase buffer, 0.576 units of ThermoSequenase (Amersham Pharmacia), 600 nM MassEXTEND™ primer, 2 mM of ddATP and/or ddCTP and/or ddGTP and/or ddTTP, and 2 mM of dATP or dCTP or dGTP or dTTP. The deoxy nucleotide (dNTP) used in the assay normally was complementary to the nucleotide at the polymorphic site in the amplicon. Samples were incubated at 94°C for 2 minutes, followed by 55 cycles of 5 seconds at 94°C, 5 seconds at 52°C, and 5 seconds at 72°C.

[0230] Following incubation, samples were desalted by adding 16 μl of water (total reaction volume was 25 μl), 3 mg of SpectroCLEAN™ sample cleaning beads (Sequenom, Inc.) and allowed to incubate for 3 minutes with rotation. Samples were then robotically dispensed using a piezoelectric dispensing device (SpectroJET™ (Sequenom, Inc.)) onto either 96-spot or 384-spot silicon chips containing a matrix that crystallized each sample (SpectroCHIP™ (Sequenom, Inc.)). Subsequently, MALDI-TOF mass spectrometry (Biflex and Autoflex MALDI-TOF mass spectrometers (Bruker Daltonics) can be used) and

SpectroTYPER RT™ software (Sequenom, Inc.) were used to analyze and interpret the SNP genotype for each sample.

Genetic Analysis

[0231] Genotyping results for replication cohorts #1 and #2 are provided in Tables 8 and 9, respectively.

TABLE 8

rsID	Replication #1 (Mixed Male/Female cases and Female controls)				Meta-analysis Disc. + Rep #1
	AF OA Con	AF OA Cas	Delta	P-value	P-value
rs398829	0.30	0.28	0.02	0.307	0.0260

TABLE 9

rsID	Replication #2 (Newfoundland) (Male/Female cases and controls)				Meta-analysis Disc. + Rep #2
	AF OA Con	AF OA Cas	Delta	P-value	Not Done
rs398829	0.27	0.28	-0.013	0.627	

[0232] To combine the evidence for association from multiple sample collections, a meta-analysis procedure was employed. The allele frequencies were compared between cases and controls within the discovery sample, as well as within the replication cohort #1 using the DerSimian-Laird approach (DerSimonian, R. and N. Laird. 1986. Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.)

[0233] The absence of a statistically significant association in one or more of the replication cohorts should not be interpreted as minimizing the value of the original finding. There are many reasons why a biologically derived association identified in a sample from one population would not replicate in a sample from another population. The most important reason is differences in population history. Due to bottlenecks and founder effects, there may be common disease predisposing alleles present in one population that are relatively rare in another, leading to a lack of association in the candidate region. Also, because common diseases such as arthritis-related disorders are the result of susceptibilities in many genes and many environmental risk factors, differences in population-specific genetic and environmental backgrounds could mask the effects of a biologically relevant allele. For these and other reasons, statistically strong results in the original, discovery sample that did not replicate in one or more of the replication samples may be further evaluated in additional replication cohorts and experimental systems.

Example 4

ADAMTS2 Region Proximal SNPs

[0234] It has been discovered that SNP rs398829 in *ADAMTS2* is associated with occurrence of osteoarthritis in subjects. This gene encodes a disintegrin and metalloproteinase with thrombospondin motifs-2 (*ADAMTS2*), which is a member of the *ADAMTS* protein family. Members of the family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. *ADAMTS2* is involved in collagens 1, 2 and 5 N-terminal processing, (type II collagen is the major form in cartilage). Mutations in this gene cause Ehlers-Danlos syndrome type VIIC, a recessively inherited connective-tissue disorder that causes loose joints and fragile skin. Mild loss of function may exacerbate physical joint damage leading to a predisposition to OA and incorrectly processed collagen can act dominantly to inhibit self assembly of fibrils. Alternative splicing of the gene generates 2 transcript variants. The short transcript encodes a protein, which has no significant procollagen N-peptidase activity.

[0235] Two hundred-nine additional allelic variants proximal to rs398829 were identified and subsequently allelotyped in osteoarthritis case and control sample sets as described in Examples 1 and 2. The polymorphic variants are set forth in Table 10. The chromosome positions provided in column four of Table 10 are based on Genome "Build 34" of NCBI's GenBank.

TABLE 10

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs2278221	5	210	178695460	c/t
rs1650358	5	3608	178698858	c/g
rs1643818	5	3609	178698859	c/g
rs3733916	5	4318	178699568	c/t
rs1624933	5	5593	178700843	a/g
rs1624857	5	5629	178700879	c/t
rs1624832	5	5639	178700889	a/g
rs1624829	5	5640	178700890	c/t
rs2161171	5	8943	178704193	a/c
rs1530499	5	17968	178713218	a/g
rs888764	5	19887	178715137	a/g
rs873987	5	21034	178716284	a/g
rs4078699	5	21085	178716335	c/t
rs870311	5	21596	178716846	a/g
rs1643817	5	23379	178718629	a/c
rs1643816	5	23432	178718682	a/c
rs1650355	5	24007	178719257	a/c
rs888763	5	26121	178721371	a/g
rs1862212	5	26273	178721523	a/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs1110514	5	26755	178722005	a/t
rs3797600	5	27411	178722661	c/t
rs3797602	5	27710	178722960	g/t
rs3797603	5	27842	178723092	c/t
rs3776819	5	28379	178723629	c/t
rs252076	5	29603	178724853	c/t
rs252075	5	31232	178726482	c/g
rs252074	5	31504	178726754	a/g
rs252068	5	32583	178727833	c/g
rs252069	5	32794	178728044	a/g
rs194040	5	32840	178728090	c/t
rs252070	5	33044	178728294	c/t
rs3797606	5	33150	178728400	a/c
rs171667	5	33218	178728468	a/g
rs187539	5	33513	178728763	c/t
rs3836834	5	33959	178729209	-/tatcaaactaccatgaaa
rs252071	5	34486	178729736	a/g
rs252072	5	36289	178731539	c/t
rs252073	5	36570	178731820	c/t
rs379589	5	38247	178733497	a/t
rs2052472	5	38477	178733727	a/c
rs2052471	5	38518	178733768	c/t
rs2052470	5	38529	178733779	c/t
rs2052469	5	38667	178733917	a/g
rs3797608	5	39781	178735031	c/t
rs3797609	5	39856	178735106	c/t
rs3822601	5	39927	178735177	c/t
rs153131	5	40506	178735756	a/g
rs751546	5	41869	178737119	c/g
rs2279979	5	42452	178737702	c/t
rs252060	5	44788	178740038	c/t
rs3797610	5	46059	178741309	a/c
rs194039	5	46846	178742096	a/g
rs168773	5	47712	178742962	a/t
rs252061	5	48796	178744046	c/t
rs187537	5	49441	178744691	c/g
rs252062	5	49602	178744852	a/t
rs2431255	5	49723	178744973	a/c
rs3797612	5	50050	178745300	c/t
rs3797613	5	50171	178745421	c/t
rs614114	5	50477	178745727	c/t
rs252063	5	50818	178746068	c/t
rs252064	5	50833	178746083	c/t
rs252065	5	50881	178746131	a/g
rs450502	5	50882	178746132	a/g
rs439252	5	51386	178746636	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs252066	5	51534	178746784	c/t
rs457957	5	52317	178747567	a/g
rs3797614	5	52368	178747618	c/t
rs423552	5	52970	178748220	a/g
rs398829	5	53023	178748273	a/g
rs416646	5	53356	178748606	a/g
rs187450	5	53882	178749132	g/t
rs337807	5	54553	178749803	c/t
rs337806	5	55475	178750725	a/c
rs1396438	5	55530	178750780	a/g
rs1396437	5	55691	178750941	c/t
rs2411811	5	55848	178751098	a/c
rs2898813	5	55879	178751129	c/g
rs189256	5	56316	178751566	a/g
rs173072	5	56911	178752161	a/c
rs337805	5	57320	178752570	a/g
rs191415	5	57391	178752641	c/t
rs180045	5	57437	178752687	c/t
rs189255	5	57478	178752728	c/g
rs652766	5	57500	178752750	c/t
rs466750	5	59111	178754361	g/t
rs442406	5	59333	178754583	a/g
rs662407	5	59715	178754965	a/g
rs592971	5	59804	178755054	a/g
rs457187	5	59851	178755101	a/g
rs459490	5	59929	178755179	c/t
rs459668	5	60052	178755302	c/t
rs462646	5	60240	178755490	c/t
rs458272	5	60359	178755609	g/t
rs463455	5	60381	178755631	a/g
rs675880	5	60456	178755706	c/t
rs810617	5	60724	178755974	c/g
rs464156	5	60875	178756125	c/t
rs458083	5	60968	178756218	a/g
rs467333	5	60978	178756228	c/g
rs465381	5	60998	178756248	c/t
rs466363	5	61557	178756807	c/t
rs2457099	5	62091	178757341	c/t
rs463901	5	62645	178757895	c/t
rs465621	5	62943	178758193	a/c
rs463724	5	63131	178758381	a/t
rs465242	5	63145	178758395	g/t
rs467419	5	63406	178758656	a/g
rs456135	5	63427	178758677	c/g
rs464536	5	63554	178758804	c/t
rs461898	5	63661	178758911	a/g
rs389558	5	64093	178759343	a/g

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs466752	5	64153	178759403	c/t
rs455655	5	64409	178759659	c/g
rs463435	5	64544	178759794	c/t
rs2174971	5	65257	178760507	c/t
rs1979979	5	65626	178760876	a/g
rs411804	5	65739	178760989	a/g
rs1623885	5	66392	178761642	c/t
rs1643811	5	66720	178761970	c/t
rs434430	5	69177	178764427	a/t
rs187538	5	69336	178764586	g/t
rs252067	5	69636	178764886	a/g
rs459319	5	69823	178765073	a/g
rs467289	5	69928	178765178	c/t
rs462644	5	70547	178765797	c/t
rs458752	5	70633	178765883	c/t
rs708320	5	71805	178767055	a/c
rs457954	5	72181	178767431	c/g
rs2411810	5	72200	178767450	c/t
rs3084687	5	72474	178767724	-/at
rs69638	5	72567	178767817	c/g
rs455452	5	72973	178768223	a/g
rs464850	5	73468	178768718	a/g
rs431472	5	73889	178769139	a/g
rs2411809	5	75730	178770980	c/t
rs2457094	5	75970	178771220	a/g
rs2457095	5	76114	178771364	a/g
rs2261740	5	76342	178771592	c/t
rs1109180	5	76449	178771699	a/g
rs1109179	5	76465	178771715	c/t
rs1109178	5	76791	178772041	a/c
rs456909	5	78042	178773292	a/g
rs469124	5	80758	178776008	a/g
rs468039	5	80778	178776028	c/t
rs467017	5	81356	178776606	a/c
rs469290	5	81576	178776826	a/g
rs469090	5	81689	178776939	c/t
rs469568	5	81759	178777009	g/t
rs468386	5	81950	178777200	c/g
rs469349	5	82562	178777812	a/c
rs469099	5	83591	178778841	c/t
rs456868	5	83700	178778950	a/g
rs465389	5	83821	178779071	c/g
rs463892	5	83842	178779092	c/g
rs468548	5	83923	178779173	g/t
rs654612	5	83929	178779179	a/c
rs468542	5	84021	178779271	c/g
rs469262	5	84175	178779425	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs708323	5	84417	178779667	a/g
rs469089	5	84747	178779997	c/g
rs469396	5	85746	178780996	c/g
rs468723	5	86129	178781379	c/t
rs467604	5	86335	178781585	a/g
rs338874	5	87315	178782565	c/g
rs338875	5	87648	178782898	a/g
rs1385803	5	87764	178783014	a/c
rs1385804	5	87770	178783020	c/g
rs338876	5	88221	178783471	c/t
rs189803	5	90474	178785724	a/c
rs452215	5	91148	178786398	g/t
rs641170	5	91150	178786400	g/t
rs584398	5	91160	178786410	g/t
rs385330	5	91733	178786983	c/t
rs429538	5	91772	178787022	a/c
rs371229	5	91785	178787035	c/t
rs460874	5	93140	178788390	a/t
rs646121	5	93148	178788398	a/t
rs468262	5	96080	178791330	a/g
rs467863	5	96157	178791407	c/g
rs191434	5	96313	178791563	a/c
rs2054782	5	96759	178792009	c/t
rs468499	5	97026	178792276	a/c
rs180287	5	97320	178792570	c/g
rs338877	5	97732	178792982	a/t
rs650665	5	98713	178793963	c/g
rs193419	5	99707	178794957	a/c
rs180288	5	99959	178795209	c/g
rs186834	5	100009	178795259	a/g
rs189266	5	100020	178795270	c/g
rs189267	5	100065	178795315	a/c
rs170937	5	100086	178795336	c/g
rs463263	5	101270	178796520	c/g
rs463262	5	101276	178796526	g/t
rs460454	5	101371	178796621	c/t
rs460455	5	101376	178796626	c/g
rs460505	5	101439	178796689	c/t
rs931316	5	101820	178797070	c/t
rs463431	5	102392	178797642	c/g
rs461542	5	102602	178797852	a/g
rs463557	5	102604	178797854	a/c
rs191453	5	102896	178798146	c/t
rs2271212	5	189104	178884354	c/t
rs462009	5	189134	178884384	c/t
rs2271211	5	189205	178884455	a/g
rs396474	5	Not mapped	Not mapped	a/c

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs428901	5	Not mapped	Not mapped	a/t
rs452300	5	Not mapped	Not mapped	g/t
rs670256	5	Not mapped	Not mapped	g/t

Assay for Verifying and Allelotyping SNPs

[0236] The methods used to verify and allelotype the 209 proximal SNPs of Table 10 are the same methods described in Examples 1 and 2 herein. The primers and probes used in these assays are provided in Table 11 and Table 12, respectively.

TABLE 11

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs2278221	ACGTTGGATGTCTCATGGGCCACCACAAAC	ACGTTGGATGTATGCTCCTGTCACCGGCAT
rs1650358	ACGTTGGATGTGGATGGCTCCATGTTCTTG	ACGTTGGATGAAGTGCTGGGATTACAGGTG
rs1643818	ACGTTGGATGCTGGGATTACAGGTGTGAAC	ACGTTGGATGTGGATGGCTCCATGTTCTTG
rs3733916	ACGTTGGATGCCGAGCAGGCTGTAGTGTTG	ACGTTGGATGCTTTGTACCACCTGGAACAG
rs1624933	ACGTTGGATGAGGCTGGTCTCAAACTCCTG	ACGTTGGATGTAACAAAAAGTTGGCCGTGC
rs1624857	ACGTTGGATGTGAGGTCAGGAGTTTGAGAC	ACGTTGGATGGCCACCAAGCCAGACTAAGT
rs1624832	ACGTTGGATGTGAGGTCAGGAGTTTGAGAC	ACGTTGGATGGCCACCAAGCCAGACTAAGT
rs1624829	ACGTTGGATGTGAGGTCAGGAGTTTGAGAC	ACGTTGGATGGCCACCAAGCCAGACTAAGT
rs2161171	ACGTTGGATGCCCGTCACCACTTTATTTCC	ACGTTGGATGAGAGTGGATCCAGTCTGCAG
rs1530499	ACGTTGGATGACTCCAAGATTTCCCATTTC	ACGTTGGATGTTCTGTGTTCCACCCTATGG
rs888764	ACGTTGGATGTAGTTGAATGTTGTATTGGC	ACGTTGGATGACCGTGATAAACACAGAATG
rs873987	ACGTTGGATGGCTGTTAATCATGTGTCGGG	ACGTTGGATGATTTGGCCACATCACCAGAC
rs4078699	ACGTTGGATGGTACCGTGGATTCTTTTAGG	ACGTTGGATGGTATTGGAAAAGAGCAGAGAC
rs870311	ACGTTGGATGTCAGGGCTCCAGTGTTGAAG	ACGTTGGATGAAAAGGAGGAGTGCCCTGTG
rs1643817	ACGTTGGATGATGGGAAACTCCTGGTCCTG	ACGTTGGATGAAAATGCAAGCCGCCACCTG
rs1643816	ACGTTGGATGTTTTCTCCCCTTTCTAGCCC	ACGTTGGATGTTGGCATGAGAGATGGACAG
rs1650355	ACGTTGGATGTCAACAGCAACAAAACCAAA	ACGTTGGATGTTAAATAGGTCAGAGGGTTG
rs888763	ACGTTGGATGAAGAGGAAGAGACATACCAG	ACGTTGGATGAACAACATGGACTCAGGCTG
rs1862212	ACGTTGGATGGGCCACATTTTAAAACAAGGG	ACGTTGGATGTCCCCTGAGGTTCCTATAAG
rs1110514	ACGTTGGATGTGCCCACGTTCCATGTTCAG	ACGTTGGATGATCACTGTAGCCCCTTCCTG
rs3797600	ACGTTGGATGCCTTCCTGTCACCTCCTTTG	ACGTTGGATGGGAAGTGACTGCTGAGCTG
rs3797602	ACGTTGGATGAGAAACAGGGACTGGCTGTGT	ACGTTGGATGAGCAGGCTCCGGGAAGTATG
rs3797603	ACGTTGGATGCACCCATCCATCATGATGTC	ACGTTGGATGTGCTACCTCAAAACAGTGGG
rs3776819	ACGTTGGATGCAAGCACCATTCCATTGCAC	ACGTTGGATGAAATGAGGATTGCAGTCCCC
rs252076	ACGTTGGATGACTTCTGACTTCAGGTGATC	ACGTTGGATGTATAGGAACGAAAGAAAGCC
rs252075	ACGTTGGATGTGGGAGCATTTGCAGGCATG	ACGTTGGATGAAGCCTCAGATGGTTCGGAG
rs252074	ACGTTGGATGTTGCGATGGCCTCCTGGCT	ACGTTGGATGAAGTTGAGGGCTCCGGAGCA
rs252068	ACGTTGGATGGGGTAGGAAGGGTTTAAGC	ACGTTGGATGGCAGCCCCTCAATTCTTTAG
rs252069	ACGTTGGATGTGCCCATTTCCTGTTATTCC	ACGTTGGATGTTTGGACTTGCCGTGCAACT
rs194040	ACGTTGGATGTGCCCATTTCCTGTTATTCC	ACGTTGGATGTTTGGACTTGCCGTGCAACT
rs252070	ACGTTGGATGCTCAAGGACATTGTCCCTGG	ACGTTGGATGGGAGAAGCAGCTCTCCTTTC

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs3797606	ACGTTGGATGGTTTCCCCAAACAAGAGAGC	ACGTTGGATGGGAAATGTTCAAAGCCGCAG
rs171667	ACGTTGGATGGGGAAACACATTGTAATGCG	ACGTTGGATGCCTTCCTCATTGTCTATTCC
rs187539	ACGTTGGATGAGCCACCCCAACCTTCAGGA	ACGTTGGATGTTGCTCCTGGACATGGTTTT
rs3836834	ACGTTGGATGAAGAAACGTGACTCTTGCTC	ACGTTGGATGTAGTAATTCTGATCCTGGCC
rs252071	ACGTTGGATGGCTTCAACCTGAAACAACCC	ACGTTGGATGGGGATATTCCCACTCTGAG
rs252072	ACGTTGGATGTTGTTTCCCCAAAGGCGACG	ACGTTGGATGTGTGTTTTCCAGAGCTGGAG
rs252073	ACGTTGGATGGGGAAAGGCCGAGAAAAGTC	ACGTTGGATGACAAGCTCAGCAGAGTTCCA
rs379589	ACGTTGGATGAAACACGGGAGTACTGAGCA	ACGTTGGATGTTGTTAGCTGTCTGTCCGTC
rs2052472	ACGTTGGATGAACCAGCTCAAGGATCACCC	ACGTTGGATGAAAGGAGACGGTCAGCTGTC
rs2052471	ACGTTGGATGACAGCTGACCGTCTCCTTTG	ACGTTGGATGCCCGTCCTGGACAAGCTTTT
rs2052470	ACGTTGGATGACAGCTGACCGTCTCCTTTG	ACGTTGGATGCCCGTCCTGGACAAGCTTTT
rs2052469	ACGTTGGATGAGGGAAAGATATCGCACGCG	ACGTTGGATGAGTGAACAACTGCTCGCCTC
rs3797608	ACGTTGGATGTGCTTTGCCTTGGCTTCTGC	ACGTTGGATGTGCACTAAGGGAGTGAGTGG
rs3797609	ACGTTGGATGTGCAGAAGCCAAGGCAAAGC	ACGTTGGATGACAGCATTTGGAGTCCCCTG
rs3822601	ACGTTGGATGAGGTCAGTGAGGCCTGAGAT	ACGTTGGATGTGTCTGGCCTGAAGATCGAG
rs153131	ACGTTGGATGTAATCACGTGTCCTGATCCC	ACGTTGGATGAGCTGTCCTCAGTCATGTTC
rs751546	ACGTTGGATGTCCTGCTCTGCCGTTCTACA	ACGTTGGATGATCAGCTCAAAGGACCGGTG
rs2279979	ACGTTGGATGTATTGCTACCAGGAACACGTA	ACGTTGGATGAAAAAGGGGCCACTTCAGGG
rs252060	ACGTTGGATGTGGCCAGAGCCCGTGTTTC	ACGTTGGATGCGGCCAATCCCATCTCTATG
rs3797610	ACGTTGGATGAAAAGCTTCTCCCTTGGGTG	ACGTTGGATGCAAGTAGGGCAGAAACTCAG
rs194039	ACGTTGGATGAAAGTGCTGGGATTACAGGC	ACGTTGGATGTGCTGGGAGAAGACATTCAC
rs168773	ACGTTGGATGTGGTGCACTGGAGATATCAC	ACGTTGGATGGATCCCTATCCTACCTCTTC
rs252061	ACGTTGGATGTGTCACACTCCTCTTGTAAG	ACGTTGGATGCTGTCCTTCCATGCTTTTGC
rs187537	ACGTTGGATGCGAGGATGTCATGCTAAGTG	ACGTTGGATGGTACCTCGCATAAGTGGATC
rs252062	ACGTTGGATGAAGCACATTCATGTGGCTGG	ACGTTGGATGCTGAAACTCAATGGGCACAG
rs2431255	ACGTTGGATGGGTGAAGACGGTGACTTATG	ACGTTGGATGCTGGTGTCCTTGAAGAACTG
rs3797612	ACGTTGGATGAGTGAGGACGCAGGGCATTC	ACGTTGGATGAGCGTGGGCGAGGGAGATAA
rs3797613	ACGTTGGATGATCAGAGGCAGAGACCCCCC	ACGTTGGATGGGGTGTCCTGCAGAGGCGG
rs614114	ACGTTGGATGGGTTGGAGGATGTCTAGAAC	ACGTTGGATGGGCTGGATCACTAGGGTTTG
rs252063	ACGTTGGATGTTGGAATTACAGTCCGATGG	ACGTTGGATGCTGAGAGACTGAAAAGCACA
rs252064	ACGTTGGATGCTGAGAGACTGAAAAGCACA	ACGTTGGATGTTGGAATTACAGTCCGATGG
rs252065	ACGTTGGATGAAAACTAAGGCTCAGAGGAC	ACGTTGGATGTGGGCTTGGAATTACAGTCC
rs450502	ACGTTGGATGATGAGAAAACCAAGGCTCAG	ACGTTGGATGCTGGGCTTGGAATTACAGTC
rs439252	ACGTTGGATGATCTCCTGACCTCGTGATCC	ACGTTGGATGTCATAATAACGGCCGGGTGC
rs252066	ACGTTGGATGTTTCCTCTTGACCGGTCTTG	ACGTTGGATGTAAAACGAATTCTGCCGATG
rs457957	ACGTTGGATGTTCACGTGCATTAGAGCGAG	ACGTTGGATGAATTCCCTCCCCAATTCCTC
rs3797614	ACGTTGGATGACTGCGAGCTTTAAGGAGGG	ACGTTGGATGCCAAACAGAAGCCCCTTTTC
rs423552	ACGTTGGATGGCAGGACCTCGATGTTGTAG	ACGTTGGATGATCCTAGAGGAGCACGCCAAC
rs398829	ACGTTGGATGTAGTCATCGTCCGCAGCATG	ACGTTGGATGAAGACGGTGTCCTCTCCTTG
rs416646	ACGTTGGATGGCTGGGTCTCTCACAGTCTC	ACGTTGGATGAGACAGGCACCTCTGTGACTT
rs187450	ACGTTGGATGAGAAGGCAGGGACGATATCC	ACGTTGGATGACCAAGATGAACCCCTCTGT
rs337807	ACGTTGGATGTCACCCAGTGCTGACAGCAG	ACGTTGGATGATGCTGGGATGCCATGGGTC
rs337806	ACGTTGGATGAATTAAGAGATGGGGCCACC	ACGTTGGATGGCCCTGTGTGTTTTGTCTCC
rs1396438	ACGTTGGATGTACCTTCTGGTGCCAGAATG	ACGTTGGATGCCTGGAGACAAAACACACAG
rs1396437	ACGTTGGATGTAAAAACTCTGCCTGCTCGG	ACGTTGGATGTCCAGACATTCCCCGTAGGA
rs2411811	ACGTTGGATGGAGGGATGCTCTAGAACATA	ACGTTGGATGCTGAATTTCACCTGAAATGG
rs2898813	ACGTTGGATGTCCTCACCCACTTTGCCTTT	ACGTTGGATGATCGTGATAATTTTGGGGTG

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs189256	ACGTTGGATGCTCCCTATAGCAAGGCTCTA	ACGTTGGATGTTAACCCAGGCCATGAAGAG
rs173072	ACGTTGGATGAGCTGGAGATCTCTTTGCTC	ACGTTGGATGCTAAAACAGGATGGCTCTGG
rs337805	ACGTTGGATGGAAACAAACCAAGGAGCAGG	ACGTTGGATGATGTGGACAACGTTGGACTC
rs191415	ACGTTGGATGAATTACATGACTCGGACAAG	ACGTTGGATGTGCTGGTGAAGTACAGAAGG
rs180045	ACGTTGGATGGTCCCAGGTTTTCTGTTCTC	ACGTTGGATGTGTACTTCACCAGCACTGAG
rs189255	ACGTTGGATGAGGTTGCAGACTCAGTCCCA	ACGTTGGATGGGGTGATTTGCGGGAATGAG
rs652766	ACGTTGGATGGGGTGATTTGCGGGAATGAG	ACGTTGGATGACCATCCCACGATGCTCCC
rs466750	ACGTTGGATGTATCTCCTTAAATGCCTTGG	ACGTTGGATGTGACCAGGAGGAGTTAAAAC
rs442406	ACGTTGGATGTGACAAGGTCACGTGTTCTG	ACGTTGGATGCCAGACAAGTCTGATACAGC
rs662407	ACGTTGGATGCCACAGTCACCATTACTGAG	ACGTTGGATGCTTGAGCCATGAGTGGAATG
rs592971	ACGTTGGATGGGAAGCATTTCTTTGACTGC	ACGTTGGATGATTCCATCTCATGGCTCAAG
rs457187	ACGTTGGATGTGTGAGATGAGGAGTATCTG	ACGTTGGATGGCAGTCAAAGAAATGCTTCC
rs459490	ACGTTGGATGACAGATACTCCTCATCTCAC	ACGTTGGATGGGGAGTTTTGCTGTTATAGC
rs459668	ACGTTGGATGGCTTCATTTACTGAGGTCTTC	ACGTTGGATGTGAATGTTCAACGACTACAC
rs462646	ACGTTGGATGCAATTATTCGACGGAGATTA	ACGTTGGATGCTCCTCCAAATGAATCAAGAA
rs458272	ACGTTGGATGATGCCTCCTCATTGTCATTC	ACGTTGGATGCCCAACAAAGTGATTCCAAC
rs463455	ACGTTGGATGATGCCTCCTCATTGTCATTC	ACGTTGGATGCCCAACAAAGTGATTCCAAC
rs675880	ACGTTGGATGCAGCTCCATTGATCTGTTTC	ACGTTGGATGAAGAATGACAATGAGGAGGC
rs810617	ACGTTGGATGTGATCTCAGCTTACCACAGC	ACGTTGGATGATGCCTGTAATCCCAGCTAC
rs464156	ACGTTGGATGCAGATCCAAGAATATGTGGG	ACGTTGGATGTTCTAGAAAGGAGCCAAATC
rs458083	ACGTTGGATGTGTTGTTTCTTCCCCTCCTG	ACGTTGGATGTGGCTCCTTTCTAGAATCCC
rs467333	ACGTTGGATGCTTGTTATTTCTTCCCCTCC	ACGTTGGATGTTGGCTCCTTTCTAGAATCC
rs465381	ACGTTGGATGACTTGCCCATCTGTTTCCAG	ACGTTGGATGACAAGCCTCTAAGGATAGGG
rs466363	ACGTTGGATGAAGTGACCCTGAGGTGATGG	ACGTTGGATGTGAAGACAGTTCACCCCGTG
rs2457099	ACGTTGGATGTCTCCTTACACTGCCAGCGT	ACGTTGGATGCACTGTATTGCTACTTGAGC
rs463901	ACGTTGGATGAGAGTGCCAAGTGCAAAAGG	ACGTTGGATGTGTCTTGCGTCTGTGTATCC
rs465621	ACGTTGGATGGGAAGTCATGGAAGTGCTAG	ACGTTGGATGAAAGAGCCCTAGGCTTGGAA
rs463724	ACGTTGGATGAGTGTGCCTGTCTGCCCTCA	ACGTTGGATGAAGGGCAGATGGCACACTTG
rs465242	ACGTTGGATGAGTGTGCCTGTCTGCCCTCA	ACGTTGGATGAAGGGCAGATGGCACACTTG
rs467419	ACGTTGGATGAGTCCCCAAAACGTAAGTCC	ACGTTGGATGAGTCTAATTCCCTGAGCCTC
rs456135	ACGTTGGATGAGTCTAATTCCCTGAGCCTC	ACGTTGGATGACGTAAGTCCTAATGACCGC
rs464536	ACGTTGGATGTGCTCCAGGCTTTGGTCCTC	ACGTTGGATGAATTAGACTAAGGCCATGATG
rs461898	ACGTTGGATGGGGAATACACAGCCACAGAG	ACGTTGGATGAGGTCAACGGGAACAAGGTC
rs389558	ACGTTGGATGGCAGTCCTGACAGTTCTCTA	ACGTTGGATGTTTTTCTCCCTGAAGCATGG
rs466752	ACGTTGGATGGGCCTTCTCTCCTTTAGTGC	ACGTTGGATGAGTCCTGACAGTTCTCTAAA
rs455655	ACGTTGGATGCTATTTGCACCCCATATGGC	ACGTTGGATGAACACACAGCATCAGGTTCC
rs463435	ACGTTGGATGTTCAGCCATAGCTGGATTTG	ACGTTGGATGCTCTGCTGGGAAAATGTGAC
rs2174971	ACGTTGGATGAACACAACTTCCCCTTCGTC	ACGTTGGATGTGAATCCTTGGAGGTGAGTG
rs1979979	ACGTTGGATGTGGCTGTCAGCACCCCACTT	ACGTTGGATGCCCAAAGGAAGGGAGAATTC
rs411804	ACGTTGGATGCAGATGACAGGCGGAAAATC	ACGTTGGATGAGGCTTCCAGATGATGTCCA
rs1623885	ACGTTGGATGAATCAGCTAGGAAGAGCCTG	ACGTTGGATGTTCCTGACCCCTCTAGGTCAG
rs1643811	ACGTTGGATGCAGGGCCCTGGTACTTTCAG	ACGTTGGATGCATGGTGGTGATTGCACCTG
rs434430	ACGTTGGATGTCCAGGAGTTCACTGTAGAG	ACGTTGGATGCACATGCATACATTCATCAC
rs187538	ACGTTGGATGACATGGGGCTTGGCAAAATG	ACGTTGGATGCACCTGCTCAGAAGTAGCAT
rs252067	ACGTTGGATGAGAATTGCTGTGGTGTGAGG	ACGTTGGATGTTTTTCTTGGGAGCTGTCGC
rs459319	ACGTTGGATGCCATCTCTCTGACCTAGACA	ACGTTGGATGGCTCCAAGGAAAATTGGGAG
rs467289	ACGTTGGATGGGCCCTCTTGGCTTGTCTTT	ACGTTGGATGAGGCAGTGTGCCCTCTCATC

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs462644	ACGTTGGATGATGATGTGGGTGAGCCCTTG	ACGTTGGATGTAACACTCAGCACGCACCAG
rs458752	ACGTTGGATGCACCCACATCATGTGCGCTT	ACGTTGGATGCCCTTCTCTACCCAGCACTT
rs708320	ACGTTGGATGAAACCAGCCTGGCTAACATG	ACGTTGGATGACAGGTGCCTGCTATCATAC
rs457954	ACGTTGGATGAACCAGACCTTGACTGATGG	ACGTTGGATGCCTCATACAAGTAGCCAAGG
rs2411810	ACGTTGGATGGCTTAACCAGACCTTGACTG	ACGTTGGATGAGTGTAAGGATATCCACGGC
rs3084687	ACGTTGGATGATCCCTTGAGCCAGAGATTC	ACGTTGGATGATGTCCTGTGCACACACAAG
rs69638	ACGTTGGATGTGCTCATTGCTGTCCTCATC	ACGTTGGATGAGAAGAAAGGTGTGCAGTGG
rs455452	ACGTTGGATGAGTGATGATGAGCCTGCTGG	ACGTTGGATGTCAGGTTCCCTCTCTGTGTC
rs464850	ACGTTGGATGTCTCTCTGTGCTCCAGACCA	ACGTTGGATGTGGGCTGAGATTTCTGTGGG
rs431472	ACGTTGGATGAACCAGTGTGGGTGTGAAGC	ACGTTGGATGAGAGACTGCATCAGGCAGGA
rs2411809	ACGTTGGATGAGCGCATAAGTGACCACCAG	ACGTTGGATGGCACTCACAGGGCATTGATG
rs2457094	ACGTTGGATGTTACTGTCACCTTGGGTCTC	ACGTTGGATGGGAAGTCTGTATAGACGCAG
rs2457095	ACGTTGGATGTTATCAAGGCCTGCGCAGTG	ACGTTGGATGACTCCTGACCTCAGGCAATC
rs2261740	ACGTTGGATGATCGTGCCACTGCACTCCAG	ACGTTGGATGTCATCTTTTGGTAGCCCCCC
rs1109180	ACGTTGGATGCCAGGCCTGTATTGCACATC	ACGTTGGATGAGAATGCGTGTGCATGTGGG
rs1109179	ACGTTGGATGTGTAATGGTATGCAGACCCC	ACGTTGGATGGAGTGCCGTATTTGTCCTTC
rs1109178	ACGTTGGATGGCAAACAACAACAGCAACAG	ACGTTGGATGAAGTGTGGATTTGTGCAGAC
rs456909	ACGTTGGATGTAGCTGCTTCATCTGTAAAG	ACGTTGGATGGGCACTTTACCGATCTACTC
rs469124	ACGTTGGATGACTTGGACACACATAGGCTG	ACGTTGGATGTGAAATGCTCAGGGTGTGTG
rs468039	ACGTTGGATGTGAAATGCTCAGGGTGTGTG	ACGTTGGATGAGGACTTGGACACACATAGG
rs467017	ACGTTGGATGGTCTAGCTGCCACTAAACAG	ACGTTGGATGATGTGCCAAGAGGCTTTGAG
rs469290	ACGTTGGATGTGCCCTTTGTGTGCTCAGAG	ACGTTGGATGTCCCTCTGTGCTGTGTTTGG
rs469090	ACGTTGGATGACTTGTCTTCAGGTGCTTGG	ACGTTGGATGGATGGTTAGTCTCCTGGTTC
rs469568	ACGTTGGATGAGCACCTCTGGCTTTCATTG	ACGTTGGATGATTCACCAGGAAATCCCAAC
rs468386	ACGTTGGATGTAATCCCAGCCCTTTGGAAG	ACGTTGGATGTATGGAGACAGGGTTTTACC
rs469349	ACGTTGGATGTTAGAGACAGAGTCTCACTC	ACGTTGGATGTTGATCCCAGGAGTTCAAGG
rs469099	ACGTTGGATGTTGGAGCTGCTCTAGTTCTC	ACGTTGGATGTGAAAACCGGGACTCAGCTC
rs456868	ACGTTGGATGACAGAGCAGGGAGCTGCGGT	ACGTTGGATGATTCACCCCCAGCTACTGTG
rs465389	ACGTTGGATGAGGCTTTGTAGACAGCTCCC	ACGTTGGATGTGCCAGTGCTCTGAGTATGC
rs463892	ACGTTGGATGAGGCTTTGTAGACAGCTCCC	ACGTTGGATGTGCCAGTGCTCTGAGTATGC
rs468548	ACGTTGGATGACTGGAAGGGAACATGCAAG	ACGTTGGATGCCTGGATGCCCTTTATAGAC
rs654612	ACGTTGGATGACTGGAAGGGAACATGCAAG	ACGTTGGATGTGGATGCCCTTTCTAGACAC
rs468542	ACGTTGGATGGCCTCCATTTTCCTTCTCAC	ACGTTGGATGTGTCTAGAAAGGGCATCCAG
rs469262	ACGTTGGATGTTCTGAGCTGAACGAAGCAG	ACGTTGGATGGGTCAGGGATCCTTTGATGC
rs708323	ACGTTGGATGCACATACTATACAGGTCACC	ACGTTGGATGGAGGGAGAAGATGTTGTGAA
rs469089	ACGTTGGATGTTTGGAAGTACCACCTCAGC	ACGTTGGATGAATGGAAGGAAGGATCAGCC
rs469396	ACGTTGGATGAGTGACTCCAATGAGGGAAC	ACGTTGGATGTCTCACACCACTGATCCTTC
rs468723	ACGTTGGATGTGTGGATCTTGCTGTTTGGG	ACGTTGGATGTATTGGCATCGCGTATCAGG
rs467604	ACGTTGGATGACTCCTGCCATTAAACTCTC	ACGTTGGATGCTTGGCTTAACTTACAAGGG
rs338874	ACGTTGGATGCCCCACCACAGCCACTGGG	ACGTTGGATGAAGGGCCTTGCCCCACCCAA
rs338875	ACGTTGGATGTGCTGTCTTGCTCGCGTGTG	ACGTTGGATGACACTGGATATGTCAGGGTC
rs1385803	ACGTTGGATGTCACCACCATTCCAGAAGTG	ACGTTGGATGACCTTCCTTATTGCTGTGGC
rs1385804	ACGTTGGATGTCACCACCATTCCAGAAGTG	ACGTTGGATGACCTTCCTTATTGCTGTGGC
rs338876	ACGTTGGATGTTAGGGCTGGGTGGAGGAAG	ACGTTGGATGTCCAACTCCCAGTGACAGAG
rs189803	ACGTTGGATGCCTCCAGTTTCTCTCTTCTG	ACGTTGGATGATCCTGGATTAGCCAGATGG
rs452215	ACGTTGGATGTAGCTCTATTCTTCCACCCC	ACGTTGGATGAGCGAGACTCCGTCTCAAAA
rs641170	ACGTTGGATGATAGCTCTATTCTTCCACCC	ACGTTGGATGAGCGAGACTCCGTCTCAAAA

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs584398	ACGTTGGATGTTCCTGTGAGCTATAGAAAC	ACGTTGGATGCGAGACTCCGTCTCAAAAAAA
rs385330	ACGTTGGATGTTGCCCCAACTATTGTCCTG	ACGTTGGATGGGTTTCCCAGACAGTGTTTG
rs429538	ACGTTGGATGTATTATCTGCAGACACCTGG	ACGTTGGATGATCTCATTCCCACCCTCTTC
rs371229	ACGTTGGATGTATTATCTGCAGACACCTGG	ACGTTGGATGATCTCATTCCCACCCTCTTC
rs460874	ACGTTGGATGGTCCTGCGGCTAAAAATTCC	ACGTTGGATGGGGCAGGTCAACTAGAAAAC
rs646121	ACGTTGGATGGGGCAGGTCAACTAGAAAAC	ACGTTGGATGGTCCTGCGGCTAAAAATTCC
rs468262	ACGTTGGATGGCCAGGTTTCGAAAGTTAGG	ACGTTGGATGTGGGTTGGTCATGCGGTAAC
rs467863	ACGTTGGATGTTTCGAAACCTGGCTGATGG	ACGTTGGATGTGCCACTGTCAGAAGACAAG
rs191434	ACGTTGGATGCCAGCTGAAACACTAGACAG	ACGTTGGATGAGCTGAAGAGGTCTTTCTCC
rs2054782	ACGTTGGATGAAAAAAGCAGGCCTCAGACC	ACGTTGGATGTCTGACTCTCATCTGCAGAC
rs468499	ACGTTGGATGCTCCAGGAGGGACACTACGT	ACGTTGGATGTGGCCAGCTTCTCCTCGATG
rs180287	ACGTTGGATGTTGTCTGCAGAATTACCTAT	ACGTTGGATGGAAAAAGAAAAAAAAATCAG
rs338877	ACGTTGGATGCGTGGATGGAAATTTACATT	ACGTTGGATGTTCTTTGGATCAATGTTGCC
rs650665	ACGTTGGATGCCCATCTTACTCTATGATCTC	ACGTTGGATGAAAGTGCTGGGATTATAGGC
rs193419	ACGTTGGATGGCAAATCCAAAGACACAGGG	ACGTTGGATGATGTTTTCATCACCCCAGTG
rs180288	ACGTTGGATGTGTGACCTGGTAGCTTAGAG	ACGTTGGATGTTGTAGGAGGTCAGAAGAGG
rs186834	ACGTTGGATGTAAGCTACCAGGTCACACAC	ACGTTGGATGAGTTGATAGGAGAGTCAGGC
rs189266	ACGTTGGATGTAAGCTACCAGGTCACACAC	ACGTTGGATGAGTTGATAGGAGAGTCAGGC
rs189267	ACGTTGGATGCCTCATTGTGCCCTGTTGTG	ACGTTGGATGCTCTGCCTGACTCTCCTATC
rs170937	ACGTTGGATGCCTATCAACTGTTGATGGCG	ACGTTGGATGTTCCTCATTGTGCCCTGTTG
rs463263	ACGTTGGATGTACTGGACCCCTTTGCACAG	ACGTTGGATGTGCCCATGCTCATGTGTTGG
rs463262	ACGTTGGATGTGCCCATGCTCATGTGTTGG	ACGTTGGATGACCCCTTTGCACAGATGCTG
rs460454	ACGTTGGATGAAGAAGGACCGTGTCAGAGA	ACGTTGGATGACATGAGCATGGGCAGGTAC
rs460455	ACGTTGGATGACATGAGCATGGGCAGGTAC	ACGTTGGATGAAGAAGGACCGTGTCAGAGA
rs460505	ACGTTGGATGACCGTGGACAGCGTCTCTGA	ACGTTGGATGTGCTCTGAGGGCAGAACAAG
rs931316	ACGTTGGATGATGCACACACCCATGGTCAG	ACGTTGGATGCGGTTCACTCCAGCATTTCC
rs463431	ACGTTGGATGTCACCACAGCCCATGGGGA	ACGTTGGATGTTTGAAACTCACAATGTGGG
rs461542	ACGTTGGATGTGATGAAGGCCAAGAATGCT	ACGTTGGATGTGTGTCCAGAACGTCAGGTG
rs463557	ACGTTGGATGTGATGAAGGCCAAGAATGCT	ACGTTGGATGTGTGTCCAGAACGTCAGGTG
rs191453	ACGTTGGATGCATCCAACAGCTCTGTCTGC	ACGTTGGATGACCCATCTGTAGCGCATCAG
rs2271212	ACGTTGGATGAGCTTCCCCGGAGGCAACGA	ACGTTGGATGTGCAGGTCTCGGCCAAAGAC
rs462009	ACGTTGGATGCAGGCTCCTCCTCGTTGCC	ACGTTGGATGTTGGTGTCCCACGTGGTGT
rs2271211	ACGTTGGATGTCGTACCCCTGCTCTGGACG	ACGTTGGATGACTGACGCCCAGGGCCGCTT
rs396474	ACGTTGGATGTGGGAGTTGGAGATGATGAG	ACGTTGGATGTTCCTCAGATCCCAGTCAAG
rs428901	ACGTTGGATGTCAGTGACAGAGCGAGACTC	ACGTTGGATGGGGCTCGATAATGTAGCCAT
rs452300	ACGTTGGATGAGCACAAGCTGAAGAGGTCT	ACGTTGGATGAGGAGAGAAGTGCACAGATC
rs670256	ACGTTGGATGTAGCTCTATTCTTCCACCCC	ACGTTGGATGAGCGAGACTCCGTCTCAAAA

TABLE 12

dbSNP rs#	Extend Primer	Term Mix
rs2278221	CAAACGCTGAGGAGAAGCC	ACT
rs1650358	AAGAGACAAAAGGCCGGGC	ACT
rs1643818	TACAGGTGTGAACCACCGC	ACT
rs3733916	AGGCTGTAGTGTTGACAGAC	ACG

dbSNP rs#	Extend Primer	Term Mix
rs1624933	GTCTCAAACTCCTGACCTCA	ACT
rs1624857	AGACCAGCCTGGCCAACAT	ACT
rs1624832	GGCCAACATGGTGAAACCC	ACG
rs1624829	TGGCCAACATGGTGAAACCCT	ACT
rs2161171	TGGAATAAGAGCCCTGCAGTGG	ACT
rs1530499	CCCCTGCCCCAGCCACAGGAA	ACT
rs888764	ATGTTGTATTGGCTATATTTGTCA	ACG
rs873987	AAAACCTAAAAGAATCCACGGTA	ACG
rs4078699	GACACATGATTAACAGCAAACAAT	ACT
rs870311	AAGGGCGTGACGGCCCC	ACT
rs1643817	GAAAGGGGAGAAAAGATTATCCC	CGT
rs1643816	AGGACCAGGAGTTTCCCATTTT	ACT
rs1650355	GAATCAATGAAGAAGAGAGCTT	ACT
rs888763	GGTCAGGAGGCAGAGGGA	ACT
rs1862212	GGGGTGAAAGGGAGCAGGG	CGT
rs1110514	CAGGCCCCAGGTGAGGAA	CGT
rs3797600	CTTTGTTGGTTAACCAAACCC	ACG
rs3797602	GCTGACAGCTCCGGACATG	ACT
rs3797603	TGTCATTCTCCTTGTGAACCCTC	ACT
rs3776819	CCATTCCATTGCACCTGCATG	ACT
rs252076	CAAAGTGCTGGGATTGCAGG	ACG
rs252075	GAGCATTTGCAGGCATGCCCTCT	ACT
rs252074	CTGGGTGGCTGCTGGGC	ACG
rs252068	GGAAGGGTTTAAGCAAGGAG	ACT
rs252069	TGAGCACCTACTATGGGCTAG	ACT
rs194040	ATTCCATATCTTCAAAGTGATTCA	ACG
rs252070	CCTGGGCTTCCCCTCCC	ACG
rs3797606	AGCCCTTGGCCTCTCTCC	ACT
rs171667	CGCCTTTTGCTTATGCAAAGA	ACG
rs187539	AACCTTCAGGAAAGTTCCCAT	ACT
rs3836834	TCAAAATATCAAACTACCATGAAA	ACG
rs252071	ACCCTGAGACACAGGGACT	ACT
rs252072	GCTGGGTCACACTCGCGGA	ACG
rs252073	GCCGAGAAAAGTCAGGGATTCT	ACT
rs379589	CGGGAGTACTGAGCACCCAGG	CGT
rs2052472	CCCCACTGTGACTATCTCCAC	ACT
rs2052471	GTCTCCTTTGGCTGCCAAG	ACT
rs2052470	TGCCAAGGCCCTGTCCTC	ACT
rs2052469	CGCGGGGAAGTACTCGGC	ACT
rs3797608	GTCCTCCTGTTCTGAGGCCC	ACT
rs3797609	GGCAGAGCGGATGGCCTG	ACG
rs3822601	GTGAGGCCTGAGATGAGAACC	ACG
rs153131	TCCCCATACTCCTGTGCTC	ACG
rs751546	CCGTTCTACAGCGGTTAAGA	ACT

dbSNP rs#	Extend Primer	Term Mix
rs2279979	GGCCACCAGACAGATGTAAG	ACT
rs252060	CGTGTTTCGGCAGAGGTGA	ACT
rs3797610	CTTCTCCCTTGGGTGATGTGTT	ACT
rs194039	CCACCGTGCCGGGACATTTTTTTT	ACT
rs168773	ACTGGAGATATCACGGGAGC	CGT
rs252061	CCAGCTGGTCACAGGGCTCCC	ACG
rs187537	TCATGCTAAGTGAAATAAGCCA	ACT
rs252062	GCCACCACCGTCCACAGA	CGT
rs2431255	CTGTATATTTCACCGCAATTAAAA	ACT
rs3797612	GGCATTCATCGTCAGGGCAA	ACG
rs3797613	CCGCCGCCGGTCTCCCA	ACG
rs614114	GAACGTTCTCTCACTTTTGCC	ACT
rs252063	CTCCCGTCCTCTGAGCCTT	ACT
rs252064	GAAAACTAAGGCTCAGAGGAC	ACT
rs252065	TGGAAAAGGCGAGGCCTGGAGT	ACG
rs450502	GGAAAAGGCGAGGCCTGGAGTT	ACT
rs439252	GCCTCCCAAAGTGCTGGGATTA	ACG
rs252066	TAGCCCTCTGGAGCCCAG	ACG
rs457957	GGGCCCCTCCTTAAAGCTC	ACT
rs3797614	TGGCCCTCGCTCTAATGCA	ACG
rs423552	CTCGATGTTGTAGTCATCGTC	ACG
rs398829	TGGCGTGCTCCTCTAGGA	ACG
rs416646	CTCAGCAGGTCTGATCCATC	ACT
rs187450	GGGCAGACTCCCCAGGAT	ACT
rs337807	GCAGGCCACTCGGTGGAC	ACT
rs337806	CCACCCCAGGGGTAGCCC	ACT
rs1396438	GGCAGGCAGGTGGCCTG	ACT
rs1396437	CGGCAGAAGCAGCCTCAAGA	ACG
rs2411811	ACATAATTTCCAAATTTCACCCC	CGT
rs2898813	GGTCCTGGGTGGAGGGAT	ACT
rs189256	AGCAAGGCTCTATTTGGGGA	ACT
rs173072	CTTTGCTCACATCGTGGCCAAA	ACT
rs337805	GGAGCAGGAAAATTACATGACT	ACG
rs191415	GAGTCCAACGTTGTCCACAT	ACT
rs180045	ACTTGTTTCTACAATTCTCATTC	ACG
rs189255	GACTCAGTCCCAGGTTTTCT	ACT
rs652766	AGAAAACCTGGGACTGAGTCT	ACT
rs466750	TCCTTAAATGCCTTGGTTGGCAAT	ACT
rs442406	TTCTGGCTGTTGGGTTTGAAC	ACT
rs662407	AAACATCTGAAATTAAAAGCACC	ACT
rs592971	AGCATTTCTTTGACTGCTCTTTCA	ACT
rs457187	GGAGTATCTGTTCCTTGTGG	ACT
rs459490	TTGAACATAGGAATAACCCGC	ACT
rs459668	GTCTTCTTTTGTGTTTTTGGAGA	ACG

dbSNP rs#	Extend Primer	Term Mix
rs462646	ATTATTCGACGGAGATTATTTGAC	ACT
rs458272	ATTATTTTTCTGTCTGGTGTGG	ACT
rs463455	CCTCCTCATTGTCATTCTTTTTC	ACT
rs675880	CTTTCATGACATTGACACAACTAC	ACT
rs810617	CCACAGCCTCCGCCTCCC	ACT
rs464156	GGGTTTCCAGGTTAAAATGGC	ACT
rs458083	CTCCTGCTCTGCCTATCCTT	ACT
rs467333	ATTTCTTCCCCTCCTGCTCT	ACT
rs465381	GCCTCCCACAGTTCCCTTGTT	ACT
rs466363	GTGATGGCTCTGCACCAGA	ACG
rs2457099	AGCGTGTGCCAGCTCTCC	ACT
rs463901	GACACAATTCAGAGCGACTTAC	ACT
rs465621	AAGTGCTAGAAGAAAATGTAGC	ACT
rs463724	CCTTGCGCCATCCCCTAG	CGT
rs465242	TGTGCCCATCCCCCCCTT	ACT
rs467419	AACGTAAGTCCTAATGACCGCCC	ACG
rs456135	CCCTCTCCTCTTCTGGGCA	ACT
rs464536	GCTTTGGTCCTCCTGAGCC	ACG
rs461898	CACAGAGCGACTCTCTCTTGGTT	ACT
rs389558	CTGACAGTTCTCTAAACTCCCA	ACG
rs466752	TTCCTTTTTCTCCCTGAAGCA	ACG
rs455655	CACCCCATATGGCTCATGGG	ACT
rs463435	GGGAAGGAGGTACTTAGCAG	ACG
rs2174971	GTGCCACTCTCCAGCGGCC	ACG
rs1979979	TTGCCGGCCCCCACCTC	ACG
rs411804	GAAAATCCCTGTCACCAGTC	ACG
rs1623885	CTTGGCTGCAGCACCCCA	ACT
rs1643811	GCCCTGGTACTTTCAGCTCCCT	ACG
rs434430	GTGTGCATGTGTGTGCCTG	CGT
rs187538	TAAACGGGCCAAAAACGCCTAT	ACT
rs252067	GCGCCTACGGATGTCAGG	ACT
rs459319	CATGTTGAACAGAGAGAAACGGTC	ACG
rs467289	TCACTGAGAAATATTTTGCTCCC	ACT
rs462644	GGTGAGCCCTTGGCTGTG	ACG
rs458752	TAAAGCGCTCTTACAAATCAACA	ACT
rs708320	TGGTGAAATCCTGTCTCTACTAAA	CGT
rs457954	CACCGTTTCTTATAATGCAGCC	ACT
rs2411810	GGGGACGTTACTTCTTTTCAC	ACG
rs3084687	ATTTATATATGTGTGTGTACACAT	ACT
rs69638	CCCATTGGCTGTCCTGGAA	ACT
rs455452	CCTCAACCCCAGATGCCCTC	ACG
rs464850	ACTCCTGCCTGAGTGTCTC	ACT
rs431472	GTGAAGCGGAAGGAGACTC	ACG
rs2411809	CTGCACACCCTCTGCACAG	ACG

dbSNP rs#	Extend Primer	Term Mix
rs2457094	TGGCTGGCACCACTGCACTGC	ACT
rs2457095	TGGCTCATGCTTCTAATCCCA	ACT
rs2261740	CTGCACTCCAGCCTGGGC	ACT
rs1109180	ACATCAGTGACAGTGTAATGGTA	ACG
rs1109179	TATGCAGACCCCCTCCCC	ACT
rs1109178	AACAACAGCAACAGAAATGAAG	ACT
rs456909	CGATTCCCACGCGTGTCTG	ACG
rs469124	CCTGGCTCCATTGGTGTGAA	ACT
rs468039	CCTTCACACCAATGGAGCCAG	ACT
rs467017	CTGCCACTAAACAGATGAGAA	ACT
rs469290	ATTTCTGGGCCCAAAGTCCA	ACT
rs469090	CCAATTGTTCCAGCCACTCCC	ACT
rs469568	TGATATTGCTTGCTTGGGTCTTAG	ACT
rs468386	GGTCAAGAATTCAAGAGCAGC	ACT
rs469349	GTGCAGTGGCACGATCCTA	ACT
rs469099	GCAGGTGGAACCGCAGAC	ACT
rs456868	GGAGCTGCGGTGACTCCC	ACT
rs465389	CCCTGGCACTCGCAGACC	ACT
rs463892	AGCTCCCCCCGCACCAC	ACT
rs468548	AAGGGAACATGCAAGCAAAGACTC	ACT
rs654612	TGCAAGCAAAGACTCGAATGA	ACT
rs468542	TCACTCACTTGATTCCTGCCATC	ACT
rs469262	CACTGTGGGATTTCCAGCAGA	ACT
rs708323	TATACAGGTCACCCATTTAAAGT	ACT
rs469089	CCTCGGCCTTCCCCAGCT	ACT
rs469396	AATGAGGGAACCTGCAGTTTAAGA	ACT
rs468723	CAGACCCCATGCCTTGCC	ACT
rs467604	GAGTTTCCTCCTCTTTCACAA	ACT
rs338874	CACAGCCACTGGGGAGTAG	ACT
rs338875	TTGCTCGCGTGTGCCAGCAAAT	ACG
rs1385803	AAGTGGAATTCTCATGGCAGAT	ACT
rs1385804	CATTCCAGAAGTGGAATTCTCATG	ACT
rs338876	AGGAAGGTGCTCCGGCCT	ACG
rs189803	TGCTTCCCCCTTCCCCCT	CGT
rs452215	TCTATTCTTCCACCCCCATCTTT	ACT
rs641170	CTATTCTTCCACCCCCATCT	ACT
rs584398	CTCTTATATAGCTCTATTCTTCC	CGT
rs385330	AGGTGTCTGCAGATAATACATT	ACG
rs429538	CCTGGGGCACAGGACAATA	ACT
rs371229	GACAATAGTTGGGGCAAGAC	ACT
rs460874	ACAAAACTATCCTTCAAAAATACA	CGT
rs646121	GTTTTTGTTTCTCTGAAAGTGTCT	CGT
rs468262	CACCCAACTACTTGCTCCC	ACG
rs467863	GCTGATGGGAGGCCAATGT	ACT

dbSNP rs#	Extend Primer	Term Mix
rs191434	GTCCAGAGATCCTGCTCACT	CGT
rs2054782	CCCCCTCCATCACCTCCC	ACG
rs468499	GTGAGCCAGCAATTCTCCTA	ACT
rs180287	CAATGATCAGAACTCAGAGGTTTT	ACT
rs338877	AGAGATAAATTTCCAGTGTGAG	CGT
rs650665	AGACATCCCGGCCGGGC	ACT
rs193419	CCAAAGACACAGGGAGTAGATTA	ACT
rs180288	GAGAATATTCTTGTGGGCTTAAT	ACT
rs186834	CCAGGTCACACACACACTC	ACG
rs189266	CACACACTCCCTCTCACTGT	ACT
rs189267	TTCTGTGCATCTTTGACGCCATC	CGT
rs170937	GATGGCGTCAAAGATGCACA	ACT
rs463263	CCCCTTTGCACAGATGCTG	ACT
rs463262	GGGGAGCAGCCAGTTCCTA	ACT
rs460454	AGAGGCTGGGGACAGAGAA	ACT
rs460455	GGTACCCACCAGTCTCCTTCT	ACT
rs460505	CAGCGTCTCTGACACGGTC	ACG
rs931316	GGTCAGAGCAGACACATCCACAT	ACG
rs463431	CCCATGGGGAGCACCAAG	ACT
rs461542	TGGGAGCTCCCGGGATATTGCC	ACG
rs463557	GCTCCCGGGATATTGCCCA	ACT
rs191453	CTGGGCTGGGGCCCTGC	ACT
rs2271212	CGAGGAGGAGCCTGGCAG	ACG
rs462009	CTCCTCGTTGCCTCCGGG	ACT
rs2271211	GACGTAGCTGCCGACACCA	ACG
rs396474	CTGGTGGCCCATCTATCCTGG	ACT
rs428901	GAGCGAGACTCCGTCTCAA	CGT
rs452300	CTGAAGAGGTCTTTCTCCTTCC	CGT
rs670256	TTCTTCCACCCCCATCTTTG	ACT

Genetic Analysis

[0237] Allelotyping results from the discovery cohort are shown for cases and controls in Table 13. The allele frequency for the A2 allele is noted in the fifth and sixth columns for osteoarthritis case pools and control pools, respectively, where "AF" is allele frequency. The allele frequency for the A1 allele can be easily calculated by subtracting the A2 allele frequency from 1 (A1 AF = 1-A2 AF). For example, the SNP rs2278221 has the following case and control allele frequencies: case A1 (C) = 0.36; case A2 (T) = 0.64; control A1 (C) = 0.37; and control A2 (T) = 0.63, where the nucleotide is provided in paranthesis. Some SNPs are labeled "untyped" because of failed assays.

TABLE 13

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs2278221	210	178695460	C/T	0.64	0.63	0.770
rs1650358	3608	178698858	C/G			
rs1643818	3609	178698859	C/G			
rs3733916	4318	178699568	C/T			
rs1624933	5593	178700843	A/G	0.69	0.71	0.255
rs1624857	5629	178700879	C/T	0.79	0.81	0.574
rs1624832	5639	178700889	A/G	0.41	0.44	0.203
rs1624829	5640	178700890	C/T	0.89	0.93	**0.044**
rs2161171	8943	178704193	A/C			
rs1530499	17968	178713218	A/G	0.39	0.39	0.861
rs888764	19887	178715137	A/G			
rs873987	21034	178716284	A/G			
rs4078699	21085	178716335	C/T	0.56	0.54	0.374
rs870311	21596	178716846	A/G	0.51	0.50	0.590
rs1643817	23379	178718629	A/C	0.27	NA	NA
rs1643816	23432	178718682	A/C			
rs1650355	24007	178719257	A/C			
rs888763	26121	178721371	A/G	0.40	0.42	0.390
rs1862212	26273	178721523	A/T	0.55	0.54	0.753
rs1110514	26755	178722005	A/T	0.29	0.28	0.572
rs3797600	27411	178722661	C/T	0.56	0.57	0.738
rs3797602	27710	178722960	G/T	0.65	0.64	0.564
rs3797603	27842	178723092	C/T			
rs3776819	28379	178723629	C/T	0.46	0.46	0.850
rs252076	29603	178724853	C/T	0.46	0.48	0.519
rs252075	31232	178726482	C/G	0.35	0.36	0.859
rs252074	31504	178726754	A/G	0.35	0.34	0.816
rs252068	32583	178727833	C/G	0.47	0.48	0.656
rs252069	32794	178728044	A/G	0.28	0.27	0.626
rs194040	32840	178728090	C/T	0.31	0.32	0.665
rs252070	33044	178728294	C/T	0.58	0.57	0.573
rs3797606	33150	178728400	A/C	0.88	0.88	0.684
rs171667	33218	178728468	A/G	0.48	0.51	0.166
rs187539	33513	178728763	C/T	0.33	0.34	0.652
rs3836834	33959	178729209	-/TATCAAACTACCATGAAA			
rs252071	34486	178729736	A/G	0.30	0.31	0.666
rs252072	36289	178731539	C/T	0.49	0.50	0.677
rs252073	36570	178731820	C/T			
rs379589	38247	178733497	A/T	0.59	0.63	0.096
rs2052472	38477	178733727	A/C	0.05	0.06	0.508
rs2052471	38518	178733768	C/T	0.89	0.88	0.459
rs2052470	38529	178733779	C/T	0.83	0.80	0.125
rs2052469	38667	178733917	A/G	0.83	0.80	0.172
rs3797608	39781	178735031	C/T	0.06	0.07	0.578
rs3797609	39856	178735106	C/T	0.05	0.05	0.812
rs3822601	39927	178735177	C/T	0.08	0.08	0.802
rs153131	40506	178735756	A/G	0.76	0.77	0.944
rs751546	41869	178737119	C/G	0.93	0.92	0.585
rs2279979	42452	178737702	C/T	0.93	0.92	0.436
rs252060	44788	178740038	C/T	0.81	0.82	0.760
rs3797610	46059	178741309	A/C	0.17	0.17	0.858

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs194039	46846	178742096	A/G	0.41	0.47	**0.035**
rs168773	47712	178742962	A/T	0.35	0.38	0.266
rs252061	48796	178744046	C/T	0.21	0.19	0.508
rs187537	49441	178744691	C/G			
rs252062	49602	178744852	A/T	0.95	0.95	0.960
rs2431255	49723	178744973	A/C	0.24	0.19	**0.034**
rs3797612	50050	178745300	C/T	0.38	0.43	**0.036**
rs3797613	50171	178745421	C/T	0.21	0.21	0.941
rs614114	50477	178745727	C/T	0.50	0.53	0.387
rs252063	50818	178746068	C/T	0.57	0.55	0.313
rs252064	50833	178746083	C/T	0.52	0.52	0.806
rs252065	50881	178746131	A/G	0.22	0.22	0.857
rs450502	50882	178746132	A/G			
rs439252	51386	178746636	C/T			
rs252066	51534	178746784	C/T	0.19	0.18	0.618
rs457957	52317	178747567	A/G	0.67	0.70	0.172
rs3797614	52368	178747618	C/T			
rs423552	52970	178748220	A/G	0.90	0.92	0.215
rs398829	53023	178748273	A/G			
rs416646	53356	178748606	A/G	0.56	0.57	0.650
rs187450	53882	178749132	G/T			
rs337807	54553	178749803	C/T	0.55	0.59	0.208
rs337806	55475	178750725	A/C	0.11	0.10	0.925
rs1396438	55530	178750780	A/G	0.56	0.54	0.494
rs1396437	55691	178750941	C/T			
rs2411811	55848	178751098	A/C			
rs2898813	55879	178751129	C/G			
rs189256	56316	178751566	A/G	0.19	0.19	0.988
rs173072	56911	178752161	A/C			
rs337805	57320	178752570	A/G	0.25	0.24	0.657
rs191415	57391	178752641	C/T			
rs180045	57437	178752687	C/T	0.51	0.47	0.211
rs189255	57478	178752728	C/G	0.15	0.12	0.273
rs652766	57500	178752750	C/T	0.57	0.61	0.213
rs466750	59111	178754361	G/T	0.35	0.33	0.493
rs442406	59333	178754583	A/G	0.57	0.59	0.420
rs662407	59715	178754965	A/G	0.31	0.27	0.102
rs592971	59804	178755054	A/G			
rs457187	59851	178755101	A/G	0.23	0.24	0.842
rs459490	59929	178755179	C/T	0.21	0.20	0.604
rs459668	60052	178755302	C/T	0.20	0.19	0.648
rs462646	60240	178755490	C/T	0.43	0.43	0.905
rs458272	60359	178755609	G/T	0.22	0.20	0.523
rs463455	60381	178755631	A/G	0.25	0.24	0.644
rs675880	60456	178755706	C/T	0.63	0.65	0.591
rs810617	60724	178755974	C/G			
rs464156	60875	178756125	C/T	0.34	0.34	0.892
rs458083	60968	178756218	A/G	0.80	0.82	0.499
rs467333	60978	178756228	C/G	0.11	0.12	0.369
rs465381	60998	178756248	C/T			
rs466363	61557	178756807	C/T	0.31	0.34	0.358
rs2457099	62091	178757341	C/T	0.44	0.44	0.956
rs463901	62645	178757895	C/T	0.43	0.45	0.395
rs465621	62943	178758193	A/C	0.62	0.63	0.534
rs463724	63131	178758381	A/T	0.09	0.08	0.523
rs465242	63145	178758395	G/T			
rs467419	63406	178758656	A/G	0.65	0.66	0.647

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs456135	63427	178758677	C/G	0.79	0.80	0.686
rs464536	63554	178758804	C/T	0.36	0.34	0.296
rs461898	63661	178758911	A/G	0.30	0.32	0.411
rs389558	64093	178759343	A/G	0.24	0.26	0.325
rs466752	64153	178759403	C/T	0.35	0.37	0.446
rs455655	64409	178759659	C/G	0.87	0.89	0.536
rs463435	64544	178759794	C/T	0.68	0.66	0.428
rs2174971	65257	178760507	C/T	0.52	0.51	0.695
rs1979979	65626	178760876	A/G	0.07	0.06	0.692
rs411804	65739	178760989	A/G	0.78	0.78	0.976
rs1623885	66392	178761642	C/T	0.82	0.80	0.492
rs1643811	66720	178761970	C/T	0.24	0.24	0.924
rs434430	69177	178764427	A/T			
rs187538	69336	178764586	G/T			
rs252067	69636	178764886	A/G	0.21	0.23	0.606
rs459319	69823	178765073	A/G	0.19	0.20	0.640
rs467289	69928	178765178	C/T	0.26	0.26	0.988
rs462644	70547	178765797	C/T	0.59	0.58	0.914
rs458752	70633	178765883	C/T	0.18	0.20	0.513
rs708320	71805	178767055	A/C			
rs457954	72181	178767431	C/G	0.71	0.73	0.327
rs2411810	72200	178767450	C/T	0.28	0.26	0.252
rs3084687	72474	178767724	-/AT	0.13	0.12	0.884
rs69638	72567	178767817	C/G	0.54	0.52	0.449
rs455452	72973	178768223	A/G	0.59	0.60	0.733
rs464850	73468	178768718	A/G	0.11	0.09	0.249
rs431472	73889	178769139	A/G	0.33	0.34	0.713
rs2411809	75730	178770980	C/T			
rs2457094	75970	178771220	A/G	0.71	0.73	0.383
rs2457095	76114	178771364	A/G	0.74	0.76	0.551
rs2261740	76342	178771592	C/T	0.35	0.36	0.702
rs1109180	76449	178771699	A/G			
rs1109179	76465	178771715	C/T			
rs1109178	76791	178772041	A/C	0.46	0.45	0.820
rs456909	78042	178773292	A/G	0.55	0.53	0.444
rs469124	80758	178776008	A/G			
rs468039	80778	178776028	C/T			
rs467017	81356	178776606	A/C	0.33	0.32	0.665
rs469290	81576	178776826	A/G	0.57	0.57	0.871
rs469090	81689	178776939	C/T	0.82	0.83	0.387
rs469568	81759	178777009	G/T	0.38	0.38	0.888
rs468386	81950	178777200	C/G			
rs469349	82562	178777812	A/C			
rs469099	83591	178778841	C/T	0.66	0.63	0.264
rs456868	83700	178778950	A/G			
rs465389	83821	178779071	C/G			
rs463892	83842	178779092	C/G			
rs468548	83923	178779173	G/T			
rs654612	83929	178779179	A/C			
rs468542	84021	178779271	C/G			
rs469262	84175	178779425	C/T	0.45	0.47	0.405
rs708323	84417	178779667	A/G	0.73	0.69	0.138
rs469089	84747	178779997	C/G			
rs469396	85746	178780996	C/G	0.38	0.37	0.817
rs468723	86129	178781379	C/T	0.37	0.38	0.754
rs467604	86335	178781585	A/G	0.34	0.32	0.504
rs338874	87315	178782565	C/G	0.43	0.44	0.879

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs338875	87648	178782898	A/G	0.48	0.50	0.289
rs1385803	87764	178783014	A/C			
rs1385804	87770	178783020	C/G			
rs338876	88221	178783471	C/T	0.39	0.39	0.889
rs189803	90474	178785724	A/C			
rs452215	91148	178786398	G/T			
rs641170	91150	178786400	G/T			
rs584398	91160	178786410	G/T			
rs385330	91733	178786983	C/T			
rs429538	91772	178787022	A/C			
rs371229	91785	178787035	C/T			
rs460874	93140	178788390	A/T	0.74	0.71	0.351
rs646121	93148	178788398	A/T	0.93	0.94	0.687
rs468262	96080	178791330	A/G			
rs467863	96157	178791407	C/G			
rs191434	96313	178791563	A/C			
rs2054782	96759	178792009	C/T	0.44	0.42	0.353
rs468499	97026	178792276	A/C			
rs180287	97320	178792570	C/G			
rs338877	97732	178792982	A/T	0.04	0.04	0.863
rs650665	98713	178793963	C/G			
rs193419	99707	178794957	A/C			
rs180288	99959	178795209	C/G			
rs186834	100009	178795259	A/G			
rs189266	100020	178795270	C/G			
rs189267	100065	178795315	A/C			
rs170937	100086	178795336	C/G			
rs463263	101270	178796520	C/G			
rs463262	101276	178796526	G/T			
rs460454	101371	178796621	C/T			
rs460455	101376	178796626	C/G			
rs460505	101439	178796689	C/T			
rs931316	101820	178797070	C/T			
rs463431	102392	178797642	C/G			
rs461542	102602	178797852	A/G			
rs463557	102604	178797854	A/C			
rs191453	102896	178798146	C/T	0.11	0.14	0.123
rs2271212	189104	178884354	C/T	0.65	0.57	**0.003**
rs462009	189134	178884384	C/T			
rs2271211	189205	178884455	A/G			
rs396474	Not mapped	Not mapped	A/C			
rs428901	Not mapped	Not mapped	A/T	0.64	0.72	**0.015**
rs452300	Not mapped	Not mapped	G/T			
rs670256	Not mapped	Not mapped	G/T			

[0238] The *ADAMTS2* proximal SNPs were also allelotyped in the replication cohorts using the methods described herein and the primers provided in Tables 11 and 12. The replication allelotyping results for replication cohort #1 and replication cohort #2 are provided in Tables 14 and 15, respectively.

TABLE 14

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs2278221	210	178695460	C/T	0.64	0.62	0.624
rs1650358	3608	178698858	C/G			
rs1643818	3609	178698859	C/G			
rs3733916	4318	178699568	C/T			
rs1624933	5593	178700843	A/G	0.65	0.69	0.322
rs1624857	5629	178700879	C/T	0.81	untyped	NA
rs1624832	5639	178700889	A/G	0.38	0.42	0.265
rs1624829	5640	178700890	C/T	0.87	untyped	NA
rs2161171	8943	178704193	A/C			
rs1530499	17968	178713218	A/G	0.39	0.40	0.765
rs888764	19887	178715137	A/G			
rs873987	21034	178716284	A/G			
rs4078699	21085	178716335	C/T	0.55	0.54	0.733
rs870311	21596	178716846	A/G	0.50	0.50	0.828
rs1643817	23379	178718629	A/C	0.27	untyped	
rs1643816	23432	178718682	A/C			
rs1650355	24007	178719257	A/C			
rs888763	26121	178721371	A/G	0.40	0.40	0.816
rs1862212	26273	178721523	A/T	0.55	0.55	0.936
rs1110514	26755	178722005	A/T	0.29	0.29	0.997
rs3797600	27411	178722661	C/T	0.57	0.58	0.604
rs3797602	27710	178722960	G/T	0.64	0.63	0.879
rs3797603	27842	178723092	C/T			
rs3776819	28379	178723629	C/T	0.47	0.46	0.889
rs252076	29603	178724853	C/T	0.46	0.49	0.410
rs252075	31232	178726482	C/G	0.35	0.37	0.572
rs252074	31504	178726754	A/G	0.35	0.35	0.914
rs252068	32583	178727833	C/G	0.48	0.48	0.853
rs252069	32794	178728044	A/G	0.29	0.28	0.765
rs194040	32840	178728090	C/T	0.31	0.33	0.450
rs252070	33044	178728294	C/T	0.57	0.58	0.609
rs3797606	33150	178728400	A/C	0.87	0.91	0.119
rs171667	33218	178728468	A/G	0.45	0.50	0.125
rs187539	33513	178728763	C/T	0.33	0.34	0.709
rs3836834	33959	178729209	-/TATCAAACTACCATGAAA			
rs252071	34486	178729736	A/G	0.30	0.32	0.566
rs252072	36289	178731539	C/T	0.48	0.51	0.400
rs252073	36570	178731820	C/T			
rs379589	38247	178733497	A/T	0.59	0.65	**0.035**
rs2052472	38477	178733727	A/C	0.04	0.06	0.493
rs2052471	38518	178733768	C/T	0.87	0.88	0.697
rs2052470	38529	178733779	C/T	0.84	0.78	**0.036**
rs2052469	38667	178733917	A/G	0.84	0.79	0.086
rs3797608	39781	178735031	C/T	0.06	0.07	0.530
rs3797609	39856	178735106	C/T	0.04	0.05	0.841
rs3822601	39927	178735177	C/T	0.08	0.08	0.904
rs153131	40506	178735756	A/G	0.77	0.77	0.964
rs751546	41869	178737119	C/G	0.94	0.92	0.265
rs2279979	42452	178737702	C/T	0.94	0.92	0.238
rs252060	44788	178740038	C/T	0.82	0.80	0.553
rs3797610	46059	178741309	A/C	0.16	0.18	0.459

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs194039	46846	178742096	A/G	0.43	0.45	0.589
rs168773	47712	178742962	A/T	0.34	0.35	0.845
rs252061	48796	178744046	C/T	0.23	0.22	0.884
rs187537	49441	178744691	C/G			
rs252062	49602	178744852	A/T	0.98	0.96	0.310
rs2431255	49723	178744973	A/C	0.24	0.19	0.108
rs3797612	50050	178745300	C/T	0.42	0.46	0.254
rs3797613	50171	178745421	C/T	0.19	0.21	0.576
rs614114	50477	178745727	C/T	0.52	0.54	0.717
rs252063	50818	178746068	C/T	0.55	0.57	0.537
rs252064	50833	178746083	C/T	0.52	0.50	0.609
rs252065	50881	178746131	A/G	0.21	0.25	0.234
rs450502	50882	178746132	A/G			
rs439252	51386	178746636	C/T			
rs252066	51534	178746784	C/T	0.20	0.20	0.883
rs457957	52317	178747567	A/G	0.66	0.71	0.162
rs3797614	52368	178747618	C/T			
rs423552	52970	178748220	A/G	0.90	0.92	0.380
rs398829	53023	178748273	A/G			
rs416646	53356	178748606	A/G	0.58	0.59	0.915
rs187450	53882	178749132	G/T			
rs337807	54553	178749803	C/T	0.60	NA	NA
rs337806	55475	178750725	A/C	0.10	0.10	0.997
rs1396438	55530	178750780	A/G	0.52	0.57	0.188
rs1396437	55691	178750941	C/T			
rs2411811	55848	178751098	A/C			
rs2898813	55879	178751129	C/G			
rs189256	56316	178751566	A/G	0.21	0.20	0.852
rs173072	56911	178752161	A/C			
rs337805	57320	178752570	A/G	0.24	0.24	0.950
rs191415	57391	178752641	C/T			
rs180045	57437	178752687	C/T	0.47	0.46	0.918
rs189255	57478	178752728	C/G	0.14	0.13	0.764
rs652766	57500	178752750	C/T	0.59	0.61	0.570
rs466750	59111	178754361	G/T	0.38	0.37	0.606
rs442406	59333	178754583	A/G	0.56	0.57	0.882
rs662407	59715	178754965	A/G	0.32	0.27	0.134
rs592971	59804	178755054	A/G			
rs457187	59851	178755101	A/G	0.23	0.25	0.451
rs459490	59929	178755179	C/T	0.22	0.21	0.671
rs459668	60052	178755302	C/T	0.20	0.19	0.712
rs462646	60240	178755490	C/T	0.42	0.44	0.439
rs458272	60359	178755609	G/T	0.21	0.21	0.755
rs463455	60381	178755631	A/G	0.25	0.25	0.783
rs675880	60456	178755706	C/T	0.62	0.63	0.741
rs810617	60724	178755974	C/G			
rs464156	60875	178756125	C/T	0.32	0.34	0.541
rs458083	60968	178756218	A/G	0.80	0.82	0.499
rs467333	60978	178756228	C/G	0.10	0.13	0.243
rs465381	60998	178756248	C/T			
rs466363	61557	178756807	C/T	0.31	0.34	0.494
rs2457099	62091	178757341	C/T	0.45	0.45	0.997
rs463901	62645	178757895	C/T	0.46	0.46	0.852
rs465621	62943	178758193	A/C	0.64	0.63	0.853
rs463724	63131	178758381	A/T	0.09	0.08	0.737
rs465242	63145	178758395	G/T			
rs467419	63406	178758656	A/G	0.64	0.65	0.694

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs456135	63427	178758677	C/G	0.79	0.76	0.339
rs464536	63554	178758804	C/T	0.36	0.34	0.553
rs461898	63661	178758911	A/G	0.31	0.33	0.727
rs389558	64093	178759343	A/G	0.27	0.28	0.762
rs466752	64153	178759403	C/T	0.34	0.38	0.223
rs455655	64409	178759659	C/G	0.87	untyped	NA
rs463435	64544	178759794	C/T	0.65	0.65	0.973
rs2174971	65257	178760507	C/T	0.49	0.51	0.476
rs1979979	65626	178760876	A/G	0.08	0.07	0.579
rs411804	65739	178760989	A/G	0.77	0.79	0.420
rs1623885	66392	178761642	C/T	0.81	0.78	0.451
rs1643811	66720	178761970	C/T	0.26	0.25	0.715
rs434430	69177	178764427	A/T			
rs187538	69336	178764586	G/T			
rs252067	69636	178764886	A/G	0.22	0.22	0.978
rs459319	69823	178765073	A/G	0.19	0.22	0.245
rs467289	69928	178765178	C/T	0.26	0.29	0.377
rs462644	70547	178765797	C/T	0.58	0.56	0.637
rs458752	70633	178765883	C/T	0.18	0.23	0.129
rs708320	71805	178767055	A/C			
rs457954	72181	178767431	C/G	0.69	0.73	0.143
rs2411810	72200	178767450	C/T	0.28	0.23	0.083
rs3084687	72474	178767724	-/AT	0.12	0.13	0.767
rs69638	72567	178767817	C/G	0.53	0.49	0.157
rs455452	72973	178768223	A/G	0.58	0.61	0.313
rs464850	73468	178768718	A/G	0.13	0.10	0.171
rs431472	73889	178769139	A/G	0.32	0.39	**0.048**
rs2411809	75730	178770980	C/T			
rs2457094	75970	178771220	A/G	0.70	0.75	0.157
rs2457095	76114	178771364	A/G	0.74	0.75	0.707
rs2261740	76342	178771592	C/T	0.34	untyped	NA
rs1109180	76449	178771699	A/G			
rs1109179	76465	178771715	C/T			
rs1109178	76791	178772041	A/C	0.47	0.48	0.715
rs456909	78042	178773292	A/G	0.56	0.54	0.537
rs469124	80758	178776008	A/G			
rs468039	80778	178776028	C/T			
rs467017	81356	178776606	A/C	0.33	0.31	0.480
rs469290	81576	178776826	A/G	0.63	0.66	0.427
rs469090	81689	178776939	C/T	0.80	0.83	0.300
rs469568	81759	178777009	G/T	0.39	0.43	0.234
rs468386	81950	178777200	C/G			
rs469349	82562	178777812	A/C			
rs469099	83591	178778841	C/T	0.66	0.60	0.066
rs456868	83700	178778950	A/G			
rs465389	83821	178779071	C/G			
rs463892	83842	178779092	C/G			
rs468548	83923	178779173	G/T			
rs654612	83929	178779179	A/C			
rs468542	84021	178779271	C/G			
rs469262	84175	178779425	C/T	0.46	0.50	0.232
rs708323	84417	178779667	A/G	0.72	0.66	0.071
rs469089	84747	178779997	C/G			
rs469396	85746	178780996	C/G	0.37	0.35	0.522
rs468723	86129	178781379	C/T	0.39	0.41	0.495
rs467604	86335	178781585	A/G	0.33	0.30	0.303
rs338874	87315	178782565	C/G	0.44	0.46	0.628

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs338875	87648	178782898	A/G	0.49	0.54	0.106
rs1385803	87764	178783014	A/C			
rs1385804	87770	178783020	C/G			
rs338876	88221	178783471	C/T	0.38	0.36	0.609
rs189803	90474	178785724	A/C			
rs452215	91148	178786398	G/T			
rs641170	91150	178786400	G/T			
rs584398	91160	178786410	G/T			
rs385330	91733	178786983	C/T			
rs429538	91772	178787022	A/C			
rs371229	91785	178787035	C/T			
rs460874	93140	178788390	A/T	0.74	0.69	0.118
rs646121	93148	178788398	A/T	0.93	0.95	0.477
rs468262	96080	178791330	A/G			
rs467863	96157	178791407	C/G			
rs191434	96313	178791563	A/C			
rs2054782	96759	178792009	C/T	0.45	0.42	0.514
rs468499	97026	178792276	A/C			
rs180287	97320	178792570	C/G			
rs338877	97732	178792982	A/T	0.04	0.04	0.781
rs650665	98713	178793963	C/G			
rs193419	99707	178794957	A/C			
rs180288	99959	178795209	C/G			
rs186834	100009	178795259	A/G			
rs189266	100020	178795270	C/G			
rs189267	100065	178795315	A/C			
rs170937	100086	178795336	C/G			
rs463263	101270	178796520	C/G			
rs463262	101276	178796526	G/T			
rs460454	101371	178796621	C/T			
rs460455	101376	178796626	C/G			
rs460505	101439	178796689	C/T			
rs931316	101820	178797070	C/T			
rs463431	102392	178797642	C/G			
rs461542	102602	178797852	A/G			
rs463557	102604	178797854	A/C			
rs191453	102896	178798146	C/T	0.15	0.19	0.139
rs2271212	189104	178884354	C/T	0.64	0.58	0.072
rs462009	189134	178884384	C/T			
rs2271211	189205	178884455	A/G			
rs396474	Not mapped	Not mapped	A/C			
rs428901	Not mapped	Not mapped	A/T	0.66	untyped	NA
rs452300	Not mapped	Not mapped	G/T			
rs670256	Not mapped	Not mapped	G/T			

TABLE 15

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs2278221	210	178695460	C/T	0.64	0.64	0.837
rs1650358	3608	178698858	C/G			
rs1643818	3609	178698859	C/G			
rs3733916	4318	178699568	C/T			
rs1624933	5593	178700843	A/G	0.73	0.75	0.447
rs1624857	5629	178700879	C/T	0.78	0.81	0.289

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs1624832	5639	178700889	A/G	0.44	0.47	0.423
rs1624829	5640	178700890	C/T	0.90	0.93	0.294
rs2161171	8943	178704193	A/C			
rs1530499	17968	178713218	A/G	0.39	0.36	0.499
rs888764	19887	178715137	A/G			
rs873987	21034	178716284	A/G			
rs4078699	21085	178716335	C/T	0.57	0.54	0.316
rs870311	21596	178716846	A/G	0.52	0.50	0.579
rs1643817	23379	178718629	A/C			
rs1643816	23432	178718682	A/C			
rs1650355	24007	178719257	A/C			
rs888763	26121	178721371	A/G	0.40	0.44	0.264
rs1862212	26273	178721523	A/T	0.56	0.53	0.529
rs1110514	26755	178722005	A/T	0.30	0.27	0.381
rs3797600	27411	178722661	C/T	0.55	0.54	0.840
rs3797602	27710	178722960	G/T	0.68	0.65	0.534
rs3797603	27842	178723092	C/T			
rs3776819	28379	178723629	C/T	0.45	0.47	0.662
rs252076	29603	178724853	C/T	0.46	0.46	0.986
rs252075	31232	178726482	C/G	0.36	0.34	0.666
rs252074	31504	178726754	A/G	0.35	0.33	0.604
rs252068	32583	178727833	C/G	0.47	0.48	0.648
rs252069	32794	178728044	A/G	0.27	0.26	0.640
rs194040	32840	178728090	C/T	0.31	0.30	0.734
rs252070	33044	178728294	C/T	0.61	0.55	0.157
rs3797606	33150	178728400	A/C	0.91	0.83	**0.005**
rs171667	33218	178728468	A/G	0.51	0.52	0.674
rs187539	33513	178728763	C/T	0.32	0.33	0.836
rs3836834	33959	178729209	-/TATCAAACTACCATGAAA			
rs252071	34486	178729736	A/G	0.30	0.30	0.942
rs252072	36289	178731539	C/T	0.50	0.49	0.684
rs252073	36570	178731820	C/T			
rs379589	38247	178733497	A/T	0.60	0.61	0.981
rs2052472	38477	178733727	A/C	0.06	0.06	0.856
rs2052471	38518	178733768	C/T	0.91	0.86	0.079
rs2052470	38529	178733779	C/T	0.82	0.83	0.828
rs2052469	38667	178733917	A/G	0.82	0.82	0.983
rs3797608	39781	178735031	C/T	0.06	0.06	0.969
rs3797609	39856	178735106	C/T	0.05	0.05	0.879
rs3822601	39927	178735177	C/T	0.07	0.08	0.838
rs153131	40506	178735756	A/G	0.76	0.76	0.981
rs751546	41869	178737119	C/G	0.91	0.92	0.526
rs2279979	42452	178737702	C/T	0.92	0.92	0.906
rs252060	44788	178740038	C/T	0.81	0.85	0.157
rs3797610	46059	178741309	A/C	0.18	0.16	0.593
rs194039	46846	178742096	A/G	0.39	0.49	**0.005**
rs168773	47712	178742962	A/T	0.37	0.43	0.098
rs252061	48796	178744046	C/T	0.19	0.15	0.164
rs187537	49441	178744691	C/G			
rs252062	49602	178744852	A/T	0.93	0.95	0.290
rs2431255	49723	178744973	A/C	0.23	0.19	0.201
rs3797612	50050	178745300	C/T	0.32	0.38	0.102
rs3797613	50171	178745421	C/T	0.23	NA	

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs614114	50477	178745727	C/T	0.48	0.51	0.423
rs252063	50818	178746068	C/T	0.60	0.51	**0.011**
rs252064	50833	178746083	C/T	0.51	0.56	0.265
rs252065	50881	178746131	A/G	0.22	0.18	0.175
rs450502	50882	178746132	A/G			
rs439252	51386	178746636	C/T			
rs252066	51534	178746784	C/T	0.18	0.16	0.451
rs457957	52317	178747567	A/G	0.67	0.68	0.728
rs3797614	52368	178747618	C/T			
rs423552	52970	178748220	A/G	0.89	0.91	0.398
rs398829	53023	178748273	A/G			
rs416646	53356	178748606	A/G	0.54	0.55	0.643
rs187450	53882	178749132	G/T			
rs337807	54553	178749803	C/T	0.49	0.59	**0.009**
rs337806	55475	178750725	A/C	0.11	0.10	0.889
rs1396438	55530	178750780	A/G	0.61	0.50	**0.007**
rs1396437	55691	178750941	C/T			
rs2411811	55848	178751098	A/C			
rs2898813	55879	178751129	C/G			
rs189256	56316	178751566	A/G	0.17	0.17	0.923
rs173072	56911	178752161	A/C			
rs337805	57320	178752570	A/G	0.27	0.25	0.582
rs191415	57391	178752641	C/T			
rs180045	57437	178752687	C/T	0.56	0.48	0.115
rs189255	57478	178752728	C/G	0.16	0.12	0.168
rs652766	57500	178752750	C/T	0.55	0.61	0.231
rs466750	59111	178754361	G/T	0.31	0.28	0.473
rs442406	59333	178754583	A/G	0.58	0.63	0.209
rs662407	59715	178754965	A/G	0.30	0.28	0.449
rs592971	59804	178755054	A/G			
rs457187	59851	178755101	A/G	0.23	0.21	0.402
rs459490	59929	178755179	C/T	0.20	0.19	0.708
rs459668	60052	178755302	C/T	0.21	0.20	0.821
rs462646	60240	178755490	C/T	0.44	0.41	0.460
rs458272	60359	178755609	G/T	0.22	0.20	0.524
rs463455	60381	178755631	A/G	0.23	0.22	0.629
rs675880	60456	178755706	C/T	0.65	0.67	0.564
rs810617	60724	178755974	C/G			
rs464156	60875	178756125	C/T	0.37	0.34	0.439
rs458083	60968	178756218	A/G			
rs467333	60978	178756228	C/G	0.11	0.11	0.902
rs465381	60998	178756248	C/T			
rs466363	61557	178756807	C/T	0.32	0.34	0.547
rs2457099	62091	178757341	C/T	0.43	0.43	0.974
rs463901	62645	178757895	C/T	0.39	0.43	0.342
rs465621	62943	178758193	A/C	0.59	0.64	0.195
rs463724	63131	178758381	A/T	0.09	0.07	0.539
rs465242	63145	178758395	G/T			
rs467419	63406	178758656	A/G	0.66	0.67	0.752
rs456135	63427	178758677	C/G	0.79	0.85	**0.029**
rs464536	63554	178758804	C/T	0.36	0.32	0.332
rs461898	63661	178758911	A/G	0.28	0.31	0.423
rs389558	64093	178759343	A/G	0.20	0.23	0.311
rs466752	64153	178759403	C/T	0.36	0.35	0.781
rs455655	64409	178759659	C/G	NA	0.72	NA
rs463435	64544	178759794	C/T	0.72	0.68	0.230
rs2174971	65257	178760507	C/T	0.56	0.51	0.142

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs1979979	65626	178760876	A/G	0.05	0.05	0.993
rs411804	65739	178760989	A/G	0.80	0.77	0.343
rs1623885	66392	178761642	C/T	0.84	0.84	0.819
rs1643811	66720	178761970	C/T	0.22	0.23	0.847
rs434430	69177	178764427	A/T			
rs187538	69336	178764586	G/T			
rs252067	69636	178764886	A/G	0.21	0.24	0.369
rs459319	69823	178765073	A/G	0.18	0.15	0.353
rs467289	69928	178765178	C/T	0.27	0.22	0.179
rs462644	70547	178765797	C/T	0.60	0.61	0.609
rs458752	70633	178765883	C/T	0.18	0.15	0.271
rs708320	71805	178767055	A/C			
rs457954	72181	178767431	C/G	0.72	0.72	0.882
rs2411810	72200	178767450	C/T	0.29	0.30	0.630
rs3084687	72474	178767724	-/AT	0.13	0.11	0.509
rs69638	72567	178767817	C/G	0.54	0.57	0.440
rs455452	72973	178768223	A/G	0.60	0.58	0.499
rs464850	73468	178768718	A/G	0.10	0.09	0.839
rs431472	73889	178769139	A/G	0.35	0.27	**0.025**
rs2411809	75730	178770980	C/T			
rs2457094	75970	178771220	A/G	0.71	0.70	0.792
rs2457095	76114	178771364	A/G	0.75	0.76	0.602
rs2261740	76342	178771592	C/T	0.36	0.36	0.924
rs1109180	76449	178771699	A/G			
rs1109179	76465	178771715	C/T			
rs1109178	76791	178772041	A/C	0.45	0.42	0.420
rs456909	78042	178773292	A/G	0.53	0.51	0.598
rs469124	80758	178776008	A/G			
rs468039	80778	178776028	C/T			
rs467017	81356	178776606	A/C	0.34	0.35	0.762
rs469290	81576	178776826	A/G	0.49	0.44	0.223
rs469090	81689	178776939	C/T	0.83	0.84	0.883
rs469568	81759	178777009	G/T	0.36	0.30	0.115
rs468386	81950	178777200	C/G			
rs469349	82562	178777812	A/C			
rs469099	83591	178778841	C/T	0.65	0.67	0.560
rs456868	83700	178778950	A/G			
rs465389	83821	178779071	C/G			
rs463892	83842	178779092	C/G			
rs468548	83923	178779173	G/T			
rs654612	83929	178779179	A/C			
rs468542	84021	178779271	C/G			
rs469262	84175	178779425	C/T	0.45	0.43	0.762
rs708323	84417	178779667	A/G	0.74	0.74	0.899
rs469089	84747	178779997	C/G			
rs469396	85746	178780996	C/G	0.39	0.42	0.569
rs468723	86129	178781379	C/T	0.36	0.34	0.573
rs467604	86335	178781585	A/G	0.35	0.36	0.763
rs338874	87315	178782565	C/G	0.42	0.40	0.564
rs338875	87648	178782898	A/G	0.46	0.45	0.701
rs1385803	87764	178783014	A/C			
rs1385804	87770	178783020	C/G			
rs338876	88221	178783471	C/T	0.41	0.44	0.580
rs189803	90474	178785724	A/C			
rs452215	91148	178786398	G/T			
rs641170	91150	178786400	G/T			
rs584398	91160	178786410	G/T			

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p-Value
rs385330	91733	178786983	C/T			
rs429538	91772	178787022	A/C			
rs371229	91785	178787035	C/T			
rs460874	93140	178788390	A/T	0.73	0.75	0.550
rs646121	93148	178788398	A/T	0.93	0.92	0.697
rs468262	96080	178791330	A/G			
rs467863	96157	178791407	C/G			
rs191434	96313	178791563	A/C			
rs2054782	96759	178792009	C/T	0.43	0.40	0.473
rs468499	97026	178792276	A/C			
rs180287	97320	178792570	C/G			
rs338877	97732	178792982	A/T	0.04	0.04	0.928
rs650665	98713	178793963	C/G			
rs193419	99707	178794957	A/C			
rs180288	99959	178795209	C/G			
rs186834	100009	178795259	A/G			
rs189266	100020	178795270	C/G			
rs189267	100065	178795315	A/C			
rs170937	100086	178795336	C/G			
rs463263	101270	178796520	C/G			
rs463262	101276	178796526	G/T			
rs460454	101371	178796621	C/T			
rs460455	101376	178796626	C/G			
rs460505	101439	178796689	C/T			
rs931316	101820	178797070	C/T			
rs463431	102392	178797642	C/G			
rs461542	102602	178797852	A/G			
rs463557	102604	178797854	A/C			
rs191453	102896	178798146	C/T	0.06	0.06	0.929
rs2271212	189104	178884354	C/T	0.66	0.56	**0.012**
rs462009	189134	178884384	C/T			
rs2271211	189205	178884455	A/G			
rs396474	Not mapped	Not mapped	A/C			
rs428901	Not mapped	Not mapped	A/T	0.61	0.72	**0.002**
rs452300	Not mapped	Not mapped	G/T			
rs670256	Not mapped	Not mapped	G/T			

[0239] Allelotyping results were considered particularly significant with a calculated p-value of less than or equal to 0.05 for allelotype results. These values are indicated in bold. The allelotyping p-values were plotted in Figure 1 for the discovery cohort. The position of each SNP on the chromosome is presented on the x-axis. The y-axis gives the negative logarithm (base 10) of the p-value comparing the estimated allele in the case group to that of the control group. The minor allele frequency of the control group for each SNP designated by an X or other symbol on the graphs in Figure 1 can be determined by consulting Table 13. For example, the left-most X on the left graph is at position 178695460. By proceeding down the Table from top to bottom and across the graphs from left to right the allele frequency associated with each symbol shown can be determined.

[0240] To aid the interpretation, multiple lines have been added to the graph. The broken horizontal lines are drawn at two common significance levels, 0.05 and 0.01. The vertical broken lines are drawn

every 20kb to assist in the interpretation of distances between SNPs. Two other lines are drawn to expose linear trends in the association of SNPs to the disease. The light gray line (or generally bottom-most curve) is a nonlinear smoother through the data points on the graph using a local polynomial regression method (W.S. Cleveland, E. Grosse and W.M. Shyu (1992) Local regression models. Chapter 8 of Statistical Models in S eds J.M. Chambers and T.J. Hastie, Wadsworth & Brooks/Cole.). The black line provides a local test for excess statistical significance to identify regions of association. This was created by use of a 10kb sliding window with 1kb step sizes. Within each window, a chi-square goodness of fit test was applied to compare the proportion of SNPs that were significant at a test wise level of 0.01, to the proportion that would be expected by chance alone (0.05 for the methods used here). Resulting p-values that were less than 10^{-8} were truncated at that value.

[0241] Finally, the exons and introns of the genes in the covered region are plotted below each graph at the appropriate chromosomal positions. The gene boundary is indicated by the broken horizontal line. The exon positions are shown as thick, unbroken bars. An arrow is place at the 3' end of each gene to show the direction of transcription.

Example 5
Effect of *ADAMTS2* Polypeptides on Biosynthesis of Type II Collagen in Patients with OA

[0242] To investigate the effect of *ADAMTS2* polypeptides on Type II collagen biosynthesis and processing, human articular cartilage from OA patients undergoing joint replacement is harvested, dissected and maintained as described by Nelson *et al.* (1998) *supra*. Type II procollagen levels in osteoarthritic patients and autopsy controls is determined by radioimmunoassay (RIA) as previously described. Allelic variations (*e.g.*, rs398829) are determined for the OA patients and controls by genotyping (See Examples 1 and 2). As type II procollagen is processed by *ADAMTS2*, increased levels of Type II procollagen in individuals with the allelic variation associated with OA demonstrates that this variation leads to reduced procollagen processing activity and ultimately to OA.

Example 6
Effect of ADAMTS2 Polypeptides on Type II Collagen Processing Activity

[0243] To investigate the effect of ADAMTS2 polypeptide variants on ADAMTS2 collagen processing activity, recombinant polypeptides encompassing the ADAMTS2 variation of SEQ ID NO: 2 at position 733 and a wild-type ADAMTS2 polypeptide are expressed in cell lines such as chondrocytes. Since the allelic variation of ADAMTS2 at position 733 of SEQ ID: NO: 2 will prevent the conversion of the ADAMTS2 pro-enzyme to the catalytically active enzyme, processing of ADAMTS2 pro-enzyme is monitored by SDS-PAGE analysis followed by Western Blotting using antibodies to ADAMTS2 and

methods common to someone skilled in the art. Reduced levels of pro-enzyme cleavage are apparent by the increased levels of immunopositive protein of higher molecular weight than of the cleaved active protein.

Example 7

In Vitro Production of Target Polypeptides

[0244] cDNA is cloned into a pIVEX 2.3-MCS vector (Roche Biochem) using a directional cloning method. A cDNA insert is prepared using PCR with forward and reverse primers having 5' restriction site tags (in frame) and 5-6 additional nucleotides in addition to 3' gene-specific portions, the latter of which is typically about twenty to about twenty-five base pairs in length. A Sal I restriction site is introduced by the forward primer and a Sma I restriction site is introduced by the reverse primer. The ends of PCR products are cut with the corresponding restriction enzymes (*i.e.*, Sal I and Sma I) and the products are gel-purified. The pIVEX 2.3-MCS vector is linearized using the same restriction enzymes, and the fragment with the correct sized fragment is isolated by gel-purification. Purified PCR product is ligated into the linearized pIVEX 2.3-MCS vector and *E. coli* cells transformed for plasmid amplification. The newly constructed expression vector is verified by restriction mapping and used for protein production.

[0245] *E. coli* lysate is reconstituted with 0.25 ml of Reconstitution Buffer, the Reaction Mix is reconstituted with 0.8 ml of Reconstitution Buffer; the Feeding Mix is reconstituted with 10.5 ml of Reconstitution Buffer; and the Energy Mix is reconstituted with 0.6 ml of Reconstitution Buffer. 0.5 ml of the Energy Mix was added to the Feeding Mix to obtain the Feeding Solution. 0.75 ml of Reaction Mix, 50 μl of Energy Mix, and 10 μg of the template DNA is added to the *E. coli* lysate.

[0246] Using the reaction device (Roche Biochem), 1 ml of the Reaction Solution is loaded into the reaction compartment. The reaction device is turned upside-down and 10 ml of the Feeding Solution is loaded into the feeding compartment. All lids are closed and the reaction device is loaded into the RTS500 instrument. The instrument is run at 30°C for 24 hours with a stir bar speed of 150 rpm. The pIVEX 2.3 MCS vector includes a nucleotide sequence that encodes six consecutive histidine amino acids on the C-terminal end of the target polypeptide for the purpose of protein purification. Target polypeptide is purified by contacting the contents of reaction device with resin modified with Ni^{2+} ions. Target polypeptide is eluted from the resin with a solution containing free Ni^{2+} ions.

Example 8

Cellular Production of Target Polypeptides

[0247] Nucleic acids are cloned into DNA plasmids having phage recombination cites and target polypeptides are expressed therefrom in a variety of host cells. Alpha phage genomic DNA contains short sequences known as attP sites, and *E. coli* genomic DNA contains unique, short sequences known as attB sites. These regions share homology, allowing for integration of phage DNA into *E. coli* via directional, site-specific recombination using the phage protein Int and the *E. coli* protein IHF. Integration produces two new att sites, L and R, which flank the inserted prophage DNA. Phage excision from *E. coli* genomic DNA can also be accomplished using these two proteins with the addition of a second phage protein, Xis. DNA vectors have been produced where the integration/excision process is modified to allow for the directional integration or excision of a target DNA fragment into a backbone vector in a rapid *in vitro* reaction (Gateway™ Technology (Invitrogen, Inc.)).

[0248] A first step is to transfer the nucleic acid insert into a shuttle vector that contains attL sites surrounding the negative selection gene, ccdB (*e.g.* pENTER vector, Invitrogen, Inc.). This transfer process is accomplished by digesting the nucleic acid from a DNA vector used for sequencing, and to ligate it into the multicloning site of the shuttle vector, which will place it between the two attL sites while removing the negative selection gene ccdB. A second method is to amplify the nucleic acid by the polymerase chain reaction (PCR) with primers containing attB sites. The amplified fragment then is integrated into the shuttle vector using Int and IHF. A third method is to utilize a topoisomerase-mediated process, in which the nucleic acid is amplified via PCR using gene-specific primers with the 5' upstream primer containing an additional CACC sequence (*e.g.*, TOPO® expression kit (Invitrogen, Inc.)). In conjunction with Topoisomerase I, the PCR amplified fragment can be cloned into the shuttle vector via the attL sites in the correct orientation.

[0249] Once the nucleic acid is transferred into the shuttle vector, it can be cloned into an expression vector having attR sites. Several vectors containing attR sites for expression of target polypeptide as a native polypeptide, N-fusion polypeptide, and C-fusion polypeptides are commercially available (*e.g.*, pDEST (Invitrogen, Inc.)), and any vector can be converted into an expression vector for receiving a nucleic acid from the shuttle vector by introducing an insert having an attR site flanked by an antibiotic resistant gene for selection using the standard methods described above. Transfer of the nucleic acid from the shuttle vector is accomplished by directional recombination using Int, IHF, and Xis (LR clonase). Then the desired sequence can be transferred to an expression vector by carrying out a one hour incubation at room temperature with Int, IHF, and Xis, a ten minute incubation at 37°C with proteinase K, transforming bacteria and allowing expression for one hour, and then plating on selective media. Generally, 90% cloning efficiency is achieved by this method. Examples of expression vectors

are pDEST 14 bacterial expression vector with att7 promoter, pDEST 15 bacterial expression vector with a T7 promoter and a N-terminal GST tag, pDEST 17 bacterial vector with a T7 promoter and a N-terminal polyhistidine affinity tag, and pDEST 12.2 mammalian expression vector with a CMV promoter and neo resistance gene. These expression vectors or others like them are transformed or transfected into cells for expression of the target polypeptide or polypeptide variants. These expression vectors are often transfected, for example, into murine-transformed a adipocyte cell line 3T3-L1, (ATCC), human embryonic kidney cell line 293, and rat cardiomyocyte cell line H9C2.

[0250] Modifications may be made to the foregoing without departing from the basic aspects of the invention. Although the invention has been described in substantial detail with reference to one or more specific embodiments, those of skill in the art will recognize that changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the invention, as set forth in the claims which follow. All publications or patent documents cited in this specification are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference.

[0251] Citation of the above publications or documents is not intended as an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents. U.S. patents and other publications referenced herein are hereby incorporated by reference.

Nucleotide and Amino Acid Sequence Embodiments

[0252] Table A includes information pertaining to the incident polymorphic variant associated with osteoarthritis identified herein. Public information pertaining to the polymorphism and the genomic sequence that includes the polymorphism are indicated. The genomic sequences identified in Table A may be accessed at the http address www.ncbi.nih.gov/entrez/query.fcgi, for example, by using the publicly available SNP reference number (*e.g.*, rs398829). The chromosome position refers to the position of the SNP within NCBI's Genome Build 34, which may be accessed at the following http address: www.ncbi.nlm.nih.gov/mapview/map_search.cgi?chr=hum_chr.inf&query=. The "Contig Position" provided in Table A corresponds to a nucleotide position set forth in the contig sequence (see "Contig Accession No."), and designates the polymorphic site corresponding to the SNP reference number. The sequence containing the polymorphisms also may be referenced by the "Nucleotide Accession No." set forth in Table A. The "Sequence Identification" corresponds to cDNA sequence that encodes associated target polypeptides (*e.g.*, ADAMTS2). The position of the SNP within the cDNA sequence is provided in the "Sequence Position" column of Table A. If the SNP falls within an exon, the corresponding amino acid position (and amino acid change, if applicable) is provided as well. Also, the

allelic variation at the polymorphic site and the allelic variant identified as associated with osteoarthritis is specified in Table A. All nucleotide and polypeptide sequences referenced and accessed by the parameters set forth in Table A are incorporated herein by reference.

Table A

RS_ID	Chrom--osome	Chrom Position	Contig Accession No. [1]	Contig Position	Nucleotide Accession No. [2]	Sequence Position	Amino Acid Position	Locus	Locus ID	A [3]	Allelic Vari-ability	OA Assoc. Allele
rs398829	5	178748273	Hs5_77500_34:3	1729878	NM_014244	coding-nonsynon	V245I	ADAMTS2	9509	R	[G/A]	G

[1] Contig Accession Number which can be found in the NCBI Database:
http address: www.ncbi.nih.gov/entrez/query.fcgi

[2] Sequence Identification or Nucleotide Accession Number which can be found in the NCBI Database:
http address: www.ncbi.nih.gov/entrez/query.fcgi

[3] "A" column is the sequence orientation ("F" is forward, "R" is reverse).

[0253] The following is a genomic nucleotide sequence for an *ADAMTS2* region. The following nucleotide representations are used throughout: "A" or "a" is adenosine, adenine, or adenylic acid; "C" or "c" is cytidine, cytosine, or cytidylic acid; "G" or "g" is guanosine, guanine, or guanylic acid; "T" or "t" is thymidine, thymine, or thymidylic acid; and "I" or "i" is inosine, hypoxanthine, or inosinic acid. Exons are indicated in italicized lower case type, introns are depicted in normal text lower case type, and polymorphic sites are depicted in bold upper case type. SNPs are designated by the following convention: "R" represents A or G, "M" represents A or C; "W" represents A or T; "Y" represents C or T; "S" represents C or G; "K" represents G or T; "V" represents A, C or G; "H" represents A, C, or T; "D" represents A, G, or T; "B" represents C, G, or T; and "N" represents A, G, C, or T.

ADAMTS2 Genomic Sequence (SEQ ID NO. 1)

```
>5:178695251-178884700
1       gggcctcggg ccagcactgc ccagcgctgg gaagacagga gaccacaccc caagtggctt
61      tgacacaggg cgtgtccctc ttaaggcaca gaggagaagt gggcagccag ggctggggat
121     cctagggtgg cccctctgtg ccccaccctt ccccaggcca cttacacgtg gccagtctca
181     tgggccacca caaacgctga ggagaagccR tcctcatggt tcagggtgca gctgcggacc
241     ggatggcaca tgccggtgac aggagcatag cctgggagga gacaagaggc ggctccagat
301     gctgccatag cctggccggg aaggtgaggc ctggcctaac tcccaggcgc tgcttctcct
361     caaggcccca atgccctctc taccacaggc aactgccccc ggctggcaca gctcagaaga
421     caccacagca gacagctcat agcctgtgac atctggctga cagcaggccc ccagcccgtc
481     accacacaag ccccgtggcc gttctgcctg taacagccac actgcagctg gggccctctg
541     cttagtcaga tgtcacctgc tatggcttgt ctgacacctg actttcctgc ctgccgttct
601     ctttcacgcc acctgcctct gccccctgcc tgcctcactg agtggccccc gagcagcacc
661     tgcttccaca cctctctctg ctagaggcat cctgcccctc gtctgcctgg tatcacaccc
721     tccaagccca cctcctctgg ggggcgtttc ttgggtctcc ccgtgtttct ctggggtcct
781     tgagacccta gctagacctg tttccataat gccgcagaag gctgcaaagc tgttcagccg
```

```
841    atgggccaca ctaccctgca gaatatccca gcaggggct ggctggtgcg gactgggagg
901    tcagagccgc cgtagaagat gaggccagtg gcctacgaca gcccagggcc agggggaggg
961    tggcagaagt tcatgacgca gagaccccac gtcaaactga ggaagatgga taatgagacc
1021   tattcacttc cccagctcct gtctcagcag agggaggcgg cttggaaaga tagggaagtg
1081   cctacagggc tatgggtgcc acacgaggtc tctgcttgta cccctgggag tcttcctaga
1141   ggcctgccaa gcatggagcc ctgactttca gaaccccaac ctgccctcac tcctgccatg
1201   ccccactgag agaccctgag gccacgcgtt ccacagagaa gggaaggagg gccactggga
1261   ccccgggtga gctggcggtg tacgcgccta aaaatagaag catcgtgatc taacccttgt
1321   cttttcccgt tgtaataaac aggaaaatct gcatttttg ctctgcagat tttgagacga
1381   gcgtggagtc tgtgtgcctg agtggaacgt tgccatctcc tctttgccct ttgtatgcca
1441   ggcttgcaga tgcatctgcc tccgtgggag gctttccatt catcctactc agcattacag
1501   gagcctgcga gatctgaaag cgcatcttta tgtttttctt tgttttcttc cctcttattt
1561   tactttgtgg ctgttttctc tctccggaat cttattagat agagtgtgcc tcctcgatgg
1621   agggtctgtc tcctaacttt tctctcatgt taatcttttt gtcttttgct cccattggga
1681   gatggccttg acttttttatt tcagctttcg attttttttt ttttttttg agatggagtc
1741   tcactctgcc gtccaggctg gagtgcagtg gtgtgatctc ggctcactgc aacctccgcc
1801   tcctgggttc agtccattct actgcctcag cctcctgagt agctgggact acaggcaccc
1861   gccaccatgc tcagctaatt tttgtatttt tactagagac gggatttcac catgttagcc
1921   aggatggtct ccatctcctg acctcgtgac ctgcccgcct cggcctccca cagtgctggg
1981   attacaggcg tgagccaccg cgccccgtct acctttcgaa ttttttactt cccccatcct
2041   atccataatt ttatacaaat ggtttgttgt tctctaattt ttcatagaaa actcttaggg
2101   tttatggatg tattttctca aacattctgg gaatactact tttaaaaaca tgcttttctt
2161   gtctctaaat tatctctatt ttctcttaga gccagttttc aaacttttg ttttgtttta
2221   catcttggtc catctttttc atgctgtaag gatttcttgt gttttggttt ttttaaaata
2281   tctggtaacc cttggctgtc ctttcatttt ttctttttttt ttttttttt tttgagacag
2341   agtcttgctc tgttgcccag gctggagtgc agtggcacaa tctcggctca ctgcaacctc
2401   tgcctccggg gttctagtga ttttcctgcc tcagcctcct gagtagctgg gattacaggc
2461   acctgccact acactggcta atttttgtgt ttttagtaga gatgttggcc aggctggtca
2521   cgaactcctg acctcaagtg atccgcccgc cttggcctcc caaagtgctg ggattacagg
2581   agtgagccac cacacccagc caatttcaca tttttaaatg agggatcagg tcacttaata
2641   taaaagctgt gtcggtttcc cctcctaggg gatagctctg ctccccatta gtgccctccc
2701   caagacaaaa cagccaacag cactctcatc acatggtcag ggcaacacct ggctgcgctg
2761   tgtttgaggg gagctatcca ctcctcaccc agacatggta gtttcagtct ttttaaccta
2821   gctatgctat taggtgcgtc ttgatatttc attgtgtttt taaattttcc ttttttttt
2881   ttcttgtaag acaaggcctc gctctgtcac ccaggctgga gtgcagtggt gtgatcatag
2941   ctcacttcct gggctcaaac aatcctccca cctcaggttc ccgagtggct gggactacag
3001   gcatccacca ccatgcccag cctcattgtt ttaattgcat ttttccaatg tctagtgagg
3061   ttgagtgcct tttcatatgt ttattgctca ttcatatttt gtcaagagcc tgataagagt
3121   ctcctgccca ttatctgact ggattgtctt tattatcctt attatgattt gtaggcgttc
3181   ttcacatact tcagatataa atccttttt ataaatattt cccccagtgg attagcgtgc
3241   ctttaatgca caaacttttg aaatgtgcta ctatttatca gttttttcca ttgagttcat
3301   ggtttgtttg gttttttttg tctctttttt ttttgagaca gagtctcgca ctgtctccca
3361   ggctggagca aagtggtgcg atctcgactc attgcaaact ccgcctcccg ggttcacacc
3421   attctcctgc ctcagcctcc cgggtagctg ggactacagg cgcccgccac catgccctgc
3481   taatttttt gtatttttat tagagacggg gtttcaccat gttagccaag atggtctcga
3541   tctcctgacc tcgtgatcta cctgcctccg actcccaaag tgctgggatt acaggtgtga
3601   accaccgSSc ccggcctttt gtctcttttt aaagaaaaca tctcttactc caagaacatg
3661   gagccatcca cctacgttat cttctttcat tattttgcgt ttcttattta gacctaaaat
3721   ccatgtgaga tgctctctgt ctatagagtg agtggaggtg acaggcctcc tttctttcca
3781   aattggcccc acaccatttg ttaggctgtt ttcctcctct tctctgaaat gtcacttttg
3841   tgacacatta gcgtccctat acacataggt ccaattcagg acactggatt ctcttctaat
3901   gatgtatttg tccatcagtg cactgcccca caccctcacc cagctaaggt ggccacggcc
3961   ttccctgccc tgacactctt ccctgggctg ggccaaggct cccggggccc cttgcatggc
4021   caggggctca tttccagctt cacgcctctg tggccctgca tgggtgaggc tcaccttgca
4081   tgccggaagg cccaaagtcc tgccgtgtga ggaagatggc gtgatcgtgg tattcatcgt
4141   ggcccgtgtc tggcttctgc tggaggtagg cccagcggca gacattctcc aggctctgag
4201   aggggttccc gatctcgatg aggctcatgg actgcagggg gatggagaga aatggaagag
4261   agaggttggc gcctggtggc ccagtggggg gccgagcagg ctgtagtgtt gacagacYcc
4321   atccactggg aatctgttcc aggtggtaca aaggccctgc ccggtcactc tcaggacctg
4381   ctcccactgg gctccagtct ttgacaggga agaaaagttt ccccagtcac actcacctgc
4441   gtgagtttcc acacaaagtc accgcagttt tcaggtgaga tgcagaagcc aagctctacg
4501   tcatctaagg cctcgcatag tcccaccgtc taccccattt ccagaagtcc ctgtgtttgt
4561   tctatgaggc acctgttccg tgcaaggcct ccacagaagg caaatgtcat gtggacctca
4621   ccccaaagag ctcacagttt tgggagggtc cgtggcaggg gaggcggaaa ttccagtgtg
```

```
4681  gtgtgcaagg ccagaggaag cagatcacct tatacgttcc ccccgtgtga aggtacttgc
4741  agaaaccaac acaatggagg aaaagaaaca gcaactgaca tatttggtgg gtgcaaaagt
4801  aatcgcagta ttgccatgaa aagtaatggc aaagactttg gcatcaacct aatagaaaaa
4861  cagccatatc aagaacaagg gcatacacag atgattccca caggaactat gcatgggaag
4921  cccccgggaa ccatcccatt ccattttgta tcatgacgca cacctgacag ctagggtggc
4981  ctcgggaccg ctcgtcttgc acactctctc tgcaccatga catcagcagg cactcccatt
5041  tagacttcag gactaagaag cctgtcttgg acaggaaact gagactcaga gaagttaaga
5101  agcttgccca ggtcatgaaa ctaggaagta ggagaattga gatcggatcc caagaaggct
5161  gaaaccaaaa tctagattca actcactgcc ctaaacttcc tccttaaata agacatacac
5221  aatatcattt caaaagcaag gcttctgtga gcggcaccct tccttttttc ctccacaatc
5281  ctcacagcag gcattttggt ttctgttctc accatagact ccaaacaccg aagtagttcc
5341  ctccaagaga accgagagcc cctctgagtc ctgggcatgt tcttttcccc tttaaggatt
5401  tatctggcca taaaatagag atgtgcattc cttggaagct acgtatgcag gtgtttttc
5461  tcttgcataa atgtatccac aaagtagagc cacgtatttc tctttgtgtc tataaataac
5521  aaaaagttgg ccgtgcgcgg tggctcacac ctgtaatccc agcactttgg gaggctgagg
5581  caggtggatc acYtgaggtc aggagtttga gaccagcctg gccaacatRg tgaaacccYR
5641  tctctactaa aaatgcaaaa cttagtctgg cttggtggcg taatcccagc aacctgggag
5701  gctgaggaag gagaatcgct tgaacccggg aggtggaggt tgcagtgagc tgagatcacg
5761  ccactgcact ccagcctagg cgacagagtg agactccgtc tcaaaacaaa acaaaacaaa
5821  caacaaaggg tattgttagc aagccagtta gttccagaag aagggagcac aattcaaggc
5881  taggtaagac aagtcgttcc caggggtccc agtcaatgac tgacaagatg gcagaccaat
5941  tcccaagtcc caagcacaga gttaattgta aagactttat ttcctgctcc tgggagataa
6001  gataactcat tctaacaagg tttccatgag tcccgatgaa ataagtcata aatcagagtg
6061  tgatgtcctg tgactaagac ttgtgggaca ttggcataga agtggacaga ccagaggaag
6121  ctggaggagg gcaaggggag gtgcacttcc tgttcccatc atgaccagga agagcatgtg
6181  actagctctg gccaatgagc tgtgagcaaa agtggggcat gtctcttttc ggttggagca
6241  tctaatttcc cattgagacc cttcagagag ctctcctttc tggcacgaga tctggcaaca
6301  taaagacagt ggctgctctg tcacctagga cctgagtgac gatgagaccc gaatcctccg
6361  ccaacccaca ttgaacatac agcgtgagca ggaaatcttg gtcgttttaa gccactggga
6421  tgcaaagtgt gtttgtttct gtagcataac ctcacctact ataattgata caggaggaag
6481  ggagtgggta tctgcatcac atccaagcct gacccctgca gctcatctcg agtccctgcc
6541  aggtagtatc cgcctctggg tagccttgag aggtcacagt tctgaaggag gaatcgggcg
6601  aaagaatgtc ccttctcact gtctccagct agggggtgag cttgggatgg cacaagaagg
6661  aagggaaact cggggtggat gtgattcggt gctagagcgt gggccttgtg gttggttgta
6721  ctcgctgaac ttaagattgg cagcccagat atggatgagc ctgggggacc ttatgctaaa
6781  tgaaataagc caggctcaga aagacaaata ctgcacgctc tcactcatac gtggaagcta
6841  aaacagttga tgtcacagaa atagagagta gttcctggag agtggggggc agcgggctgg
6901  ggattgccaa ggctggttaa catatccaaa agtgcggcaa gatgggggaa taagcgttag
6961  tgccctatag tgccggaaag cgcctggaat ccgtaagaat gtattgtgca ttttcaaata
7021  gctagaagag tggactttga atgttcccaa cacaaagaaa tgataatgtt tgaggtgaca
7081  gatatgctaa ttaccctgat gtaatcatta cacattgcat acacgtgtct aaatatcaca
7141  ccctacccca gaaatatgta caattattac atgccaatta aaaataacag taagagcaaa
7201  atcaaaaacc aaacaagaat gacttttaa catacatttt ttaaaaattg ccagtccaaa
7261  tccaaatcag agggtcagca caaaggtcac taataagcgc ttttgctagg gtggtggcag
7321  ggcccctgct gcagtgtgag tgtctccatc caggacaccc agcacagctc ggtagccttg
7381  ctgggctcca gggaaagggg ccttgcttcc tccagggcac gtctcccagc atcagtgtca
7441  agggagtcct gtccaagatg aactcacctg ccctcagggt cctaagcccc atgtagtggg
7501  acggtccctt ccgatgccct ggtgggttgc ggtgacttct gcctgccctt gtttcccttt
7561  cgtgaaactt cccctccttt aatctgagtc agaccccagg cttcaggggc aggcaggcct
7621  ggccaatccc agcaccacgc cttcctggcc accatgaagg atcagggtga acatacaacc
7681  aaagcgggcc aaggagtagg caaggtgtga ggtgggggggc ctgcagcggc tggagccccc
7741  ctgcactaca ggagaccccc caccaaggat taaaggagga tgagaccact gtcgagctaa
7801  gactggggct gcagtctcat ctgaaggctg taccggaggc gggtcagctc ccaggctcat
7861  tcaggtggtc acggcgggcc ccagctgagc tgttgcacac cataccgtat gggcccctcc
7921  tggggccgtc acccatgtca gctttacccc acacggtcgc ccctgctcga gggacccaag
7981  agacaacaag agaaggcacc tcccctacag aagccacagt ctgcttttga tagaatctca
8041  gtcccgccta ccgcagggca tggacattaa gagactgggt cactggcggc catcacgaag
8101  gctgcctgcc actgacgggt gtcatttatg cctgaagaag ttcctctcct tgtgaaagcc
8161  aattctgagt tgtgctcttg tcacttgcag cgaagagaat ctgagccacg tgcttcctcc
8221  tttgggggac cacagggacc ccagtcagga cactcgctgg cccatgaaag atggcgtctg
8281  atctgggggc agctgatatg ttctgggggc agtttatatg cttctcagtg ggagaagggc
8341  cctggccaag tctttgagga ggagtcaaga gtccagccag aaagacatgc cccaatatca
8401  ggaccagagg caggaatgag gctagtgtgt aggacagagc tgcgggagga gccaggctga
8461  ggcaggctgg gggtgtgcag ggaggtccgc tatcctagtg tgtgggcttg tggggagtac
```

```
8521   cgggaggatg ctagaaaccc aagcgcctac aggagcaagg caggtgacaa gtcaatgagg
8581   caggctggtt gcacgaaaag taagtccatc ttgtgttttc ccagttttga aggagaaagg
8641   gtacagagga atatttccct attagaatag agtgggggtc ggtgataagg agtggcgagg
8701   actgtggcaa acccaggtgc ccaggcacag ctgaagggag caacatccgc ccagtgctgg
8761   caggaacaga ggcccagagc tgctggatca gatttctcag gtcaatcgtg aaatctggat
8821   tctacagaca cctacctaat agtaaacact ggctcaaatt gaaatcagtt atgcagacaa
8881   aacaacgcat cctccccgtc accactttat tccagaaccc tggaataaga gccctgcagt
8941   ggKcagcccc ttctccacgt cctgcagact ggatccactc tggccgatca cctctctcct
9001   cccagatgct ggcttctgtg gttcagcctg ggttcccagc ccgtcttagc agccaaagtg
9061   atcttgctgc tgcggcaaga caatttattg aaatattgat ttgtgttttt gttcttgcct
9121   cgctttgttc tcggcccagt ccaagaaggc agcctgccac tttcgttctc caaccccaag
9181   gaggttgtgc tgcagggtcc agagctaaag gggtctatga cccccttctg gctttggggt
9241   tctgaggaga ctccctgagg agggggcaga ggggagggct ggggtgcatg ggcacaggga
9301   ggggaagctg cactggggcc aggggagccc tgggaggcag gacttcagga gacatgagag
9361   tgtgctagac cctgggagcc tgggtcccag cagggggtac cccaagaagt agaggagagg
9421   gttacctcag tgtccgggca ccccaggact caacctgcca ctgggagctt aactgacaag
9481   ccacagagct gcttgtgctt cctctctctc tctgccaacg tcccaacatc tccaaggtcc
9541   cagcctatct ctgacgggca cagaggagcc caggggcaga gatcttgtcc ttgctgggtc
9601   tggagcattc aagggctatg gggtacccat gaggcccaga cattgacctt gtgcccagag
9661   gccagggcaa ggtctgtgtg cattcttaaa acagcccttt gggtcagtga ggaaggagtg
9721   gggatagaag gggacagtgt ggcactgaga tgcatgcagg tgtggctggt gccacgtcag
9781   gagggtcagg acctggtggc aggagctgag aggcatcagg gctgcagggc gggagcaatg
9841   aggcagagac ggcaccagtg tctggctttg gggattggta gcaaggcaga agaggcggcg
9901   cgggaagggg acggcaagtg ccagaggaag agcgtggggt ccgcagtgca ggaaacatgg
9961   tcacggcaat gtctttcctg gccagcttgc tcgttgggaa gagctgggct gttttgcttt
10021  gggagctctc ccacttctgg gggtgcagcc cttgtgggtg atcagtccca agccgtagct
10081  gggacccatg ttaggcccat ggagcacagg ttcgaaagga ctgaaaactg gctgaagtgg
10141  gtttgcctgg tggcagcacc caaaacaacc atccgcaaac tcaggctcat gcaccccaga
10201  gccccctttc ctccacccac tcctcccact ccatgagagc tacaggcagc cttgggttct
10261  gcatgcctct aaggactcct cacagaaaga aactgatgtc caggcagaga catcggggca
10321  gctggacagg tctgcggccc aggagggaag tctgggctgg ccgtggacag ggcaaggccc
10381  tcgctactgg aggcagtcgg aacccaaggg aagagccaag ctcaggtctc tccgctgaga
10441  cctccagcca aggatactgt cctgacatgc agtgaactcc cctgtgggtc acttgggctc
10501  cagcgggacc acctgctggg atgcgacctc ctttgctcct ctgccacctg gcctgcatgc
10561  aggaggccag atgggtccct gctgcctggg gcaccccagc ccccaccatc ctgtgccctt
10621  gctatgtatc aagcctggga actgtgcttc ccctgagcga gaagaagaca catttctcat
10681  atatggatct cctccagaag tgagggaggc tgcactgctt gtttccactg aggagtcttt
10741  caccagctcg ccctggtcat ctacgtccct cccagtcctg aatgcacctg acttccagct
10801  gcctgctcgg ctctgcacgg ctcctctagg aaagtctgtc tgtgtgactc cacctgttcc
10861  tagctgtgct gaggggggga ccaggagtga gccgtagcac cctgggctct gcaaaggggg
10921  tggctgcagg accagccagg gactttacag ggcagccagt ccctcccagg ggcagccgcg
10981  ggcacccagc ctccagagca gggggcggta gatggtgctg tatgaccggg gatggacatt
11041  tcgaggccct ggggctgcat ggtagctgca gggtccacct cctgagtgag gcagggcctc
11101  tgagggcaga ctcttcacag cggcagcagc tcccagaact cccaggtcca gcctagggcc
11161  ccagaagagc caggcgggag aagcctgcag tagggctgtg gatgaagtcc aggggcccat
11221  ccagcccagg atgcaggagg agtcctgagt gggctgaccc tagctcagag cacgggaaca
11281  gatgagcttc caagaggctg atcggatcct ctacaggggc cccaggacag tcgtcacccc
11341  tcatggaggg ctctgccacc cctgtttgga ggtgacatcg accactgcag acatgggctc
11401  ccaactgggc tccactgccc gagtgctctg gggccctgga ccaggctggc tcttccagag
11461  tgcagggtcc tccttggcca tcatgagtgc ccacctatgt ccacatggag accctccttg
11521  ctatgctggt tcacagagct gcccagatgc aggaggcaga cactcgtcca ggcccctggg
11581  gccctcccac agcagcaccg ggagcctggt cccaagaagg atggtgtttc ctccgggttc
11641  agcctgtttg gctcccctgg cccgggctgg aaagggtctg aggacatgcc tgaaagaccc
11701  agggatccca ccatgaggtg gagagggcag atctgagggc cttagggagg caagagcttg
11761  atggccctca ccttgggtca gaaggtcact ttgctgaatg ctccccaggg ctgtcaggag
11821  gcttggccag ggcaagggtg aggaaacact gcgggcccct gaacctcagg cccagcctgc
11881  aggggtctgg gtaaccccac gggcctcagg gaacagccag gagcttaggg ggcccgtggg
11941  ccttgggtgg acgagtaggc tgcgtccagc tccaagtccc agccccatcc tggccgcggg
12001  accctggctc tgagctgccc gccgggtccc tcctcctgcg tgcgatcggt cacctgccag
12061  atggggcacc tactggggat gtgcctgttg ctgtcgctgg cctctgagtc actaaagcct
12121  aagctccttg agggccgggt ggttgctggg cccgagtctg tgccccagcc ctggcccacg
12181  cctgccctca gtagccccac tcctcccttc acggagcaat cccggcttct gctctccatg
12241  ccaggatgag gcagcgaacg cggccagagg accccggctg ctgggcgctc agtgatgaag
12301  gaatgaacac gagcaccctc aggagccagg ctgggcaggg agggaggcgc cggctgcggg
```

```
12361  gacgttctcg ggaggcctgg ggaagtgagc ccaaagggcc gccccggcag atgctgaccc
12421  cagcaggaag tcaccgtccg caaggagcgc cccgctaggc tcaggcttgg cacacgacac
12481  ctcgcttcca cttcattttc ctaccttccg gatgacgaac tgcgtctcag acaactgaaa
12541  ggactcgcct gagtcccaca gccggaaaga ggtcgggggtg ctgccccccg cgcggggcgg
12601  gcagaggaag ggccgggccc gagcggccac caggtggcgc tgctgccgcg agaacagcgg
12661  cccgggccgg ggacgcaccc ggcgcccaga ctccgcggcc gcacccgggc tcccggggcc
12721  ccagcggccc caagacagcc tctgggcctc accctaaata catcaattat gacctgagca
12781  aaaagttctg ttccaatcgt tgctctccga catttccatt gtttgctctg gaaggagctg
12841  aattatctat gctcttccct ccttcagtca aggagacgtg ggaggaaacc gggatgggga
12901  tcagcagcct ggaggccgcc tccgctggaa ccgcgcccgc cccgccagga ggctctgcct
12961  gctgggcaag gcgcactcag ccagccccgc aggccgccac gcgaccgagg ctcaccaagt
13021  ccactgcagg tggcaggtga ggtcacctgg gcagctctag gcccggccga aatatctcat
13081  ctgctctgtt cttgggcaag ttaccttact tgtccccacc tgcaaaatgg gcacaactgc
13141  agctccgagc ttggagctgg ggggcttccg cccatgacag ttcaggcagg gtgcagtcag
13201  cgcccacaaa tgtcccttgt ccttgtctct gccgtgctgt tgatactgat ggagtataac
13261  accagtccct ggggactggc ctacccgctg gggctggctc atgcccccaa ggggatgcgg
13321  cttcagcaaa gcttctcaac cgtccccatc ccagaggggc cctcctgcct cagaccagcc
13381  tcctaaacag gtgcaggata ggacagcagg gaggttgggt tctggtgagc agaccacatt
13441  tctcaacctc agcactccag atatttgggg ccagataatt cctgttgggt gaggcgggca
13501  ccctgttcat ggcaggatgt tgagcacacc cctgggcact ccttgccaga acccagtgga
13561  accctccccc tagtcgtgac aaccaaaagt ctctccagac actgccaaat gtcccccggg
13621  tgggggggagg ggtggcaaag tcactcttgg ttgggagcaa ctgaccctca ggggaccagg
13681  acaaggagcc tgaagctggt gctcctgacc agccgggatc acagagtcca gcccctcctc
13741  ccagagcaga gtggctccac cagcgtgtgg ccccgggcag gccgctcgcc ccctggagcc
13801  agggtcctca ctgtcaaatg gggatgatca cagcgcctac tccacagggt tgctgtgggg
13861  gtgagggcat aaagtcacat aaagggcttc agacggtgcc tgtcccagaa gaagctctac
13921  aaacagtcac ttgcacgaac gcctttatga ttgtcgtcat tcctgttgtg tgctggggtt
13981  tcacagacct cctcttatgg gggaaactaa ggccccatga tgttaaattg ctcaccaaag
14041  gtcccacgag tatggacaaa gccagaatga atggcaggga caaggtccca ccatccctgc
14101  tctgtgagca catgttctac cgtgcccccc agctgagtgc aaagtgggct cccccaaggc
14161  tggaggtctc ttgttccagg cagggcttac agatcaaatc tcatcacgac agagaaccac
14221  gagagctggg gcaggaggcg tgcacctcat ttctctgcca gaactcccat atcgttccag
14281  cattttgttt ccagccatct tccccaaagc ctgggaagct attcccagag agagccaagc
14341  tgccagaaca ggattctcaa cttgagcctt cccaggcatg agccagtgca ggcctgtggg
14401  gaggcagaag aggggcctcc tgctagaatc tgaatgttgt gtcccccaca tttgaaaggt
14461  tgaaagctga gaaccaatgt tatggtatta ggaagtgtgg tctttgagag gtcattaggt
14521  catgagggtg gagtctccat aaatgagatt agcaccctta caaaagaagc ctgagggagc
14581  ctgttcaccc ttccatcatg cgagggcaca gctagaaggt gccctctagg aggaatgggt
14641  ccttacgaca catcagttct gctggcgtcc tgctcttgga cttcccagcc cccagaacag
14701  tgagtaacac aattccattg gttataaatt actcagtcta aggtatttct gttattgcag
14761  cccaaacaga ctaaggcacc tcccaagggc agtgtccagc cttagtgcct cctagttctc
14821  tggacccagg taggtctggg tgaggaggtg gatggaggat gatgtgggtg ggccatcatg
14881  ccttgcaccc ctatcaggtt gggggttggg acccagatgc tcaggaggac agggggctgt
14941  ccctggggtg aggcatgggg tgtgtttccc acctcatccc ctgtcccaga tccccagggc
15001  ccttgatata tcctccccag accttcactt cctggccttc ctgcaccatg gctgggccac
15061  tctaaatcct ctaccctata ggtgggtggg tgggcacacc aagcccccac ccccagcacc
15121  tctcttctcg tgctttccac taagagactc acatgcagaa tttctcagac ctttcacctc
15181  caatgctgaa aaattccagc aagcattcca cactttgtct tgacctggtt ttttataaca
15241  agacacttta tgtccttctc tgatgctccc caagtctctg atttccattt gctttgattt
15301  tcatcatcct aggaaatatt taaaatgaga acagttgagt agctttggta ccttctcaaa
15361  aaatcaattg aaaagccagt tgctatgcaa cctcaagtgt tgccgatgct ctgctccctg
15421  gctggtggta tattgtataa aataagatca tctcttttct tctgcttttt tttaagaaat
15481  ggagaaaaat gttgttttag gaaaaacttg agataactca gaggcttctc ataagctaga
15541  agacaaacat gtcactcaaa caagtgctac caattttatc cccactggag cctggtgagg
15601  cctgggggac aggcaatggg ggagcggcag gtggggagct ggtctatttc tgtcacaatt
15661  tgggatgaat aacaggaacc gagtatctgg gccactttct gcccaagtct gggtcatggt
15721  ctcacatccc ccagagtctg tccccaccgt gggggggaca gctcagcccc ctcctgactg
15781  ccatcgcctt ggttttgcca tgctaaaatt cttctagaga cgggggcctc attccttgac
15841  gggaagcctg tggttccttg aagagcagct catcagaatt catccccacc atgtgccaaa
15901  ctttgtcccc agagccccat cgagaatccc tggctgtgct tctctgtgag caaaaggggt
15961  ctgttccctt ggacacagga gctaggcctt ttgcccccag atcttggctg ggaagtcccc
16021  atcctggctg ctccatccat ggtcccctat tgcctgccac cctgctgtat tccttgccgg
16081  tgctcaccac tctgtcgctg tcttgtctgc tgctactgcc tggacacagg gctcctctcc
16141  cctcctcgtt catgcacctc cctgggatta aacagcagct gctcgggaag ccagaggctc
```

```
16201  tgggctggcc ggatgctttg ggggcacaag gatacatctc ctcccacgtt catcagacac
16261  ctcagagacc tgaaaacagg gcctccccca gtgctatgca aagtgaagtc tgtgcctggt
16321  ggacacaaac tgttccagtc cacagtgaga taagtacaga aactagaaac ttttatagca
16381  attggacggg ttgagtttat gtccacagaa tttaataata aaaatccaga cctagagttt
16441  ttggatacct cggtttttgt cacatttgct tttcccagta attcatttat aacgtatggt
16501  acggaagtat tggtctgtga tgggtttgaa ataggaaaaa gaaaacagcc aggtctttgg
16561  cattgaggtg cactgtgtac tgctgctccc aggatggcct ctcccctggc cacctgggga
16621  tggcagatgg ctcctccggt cccacagacg ctgctcccaa gccctgtggc ccacagcaca
16681  ttcgctaagt cagccagggc ccatgaccag aacccatttt cctagccgct gtgccctcta
16741  ccccaagcct tcagcccagc ccctagcagt gccacctcct ctgctctact atttcctgca
16801  cttttgcagt aggtccaacc taaagcaacg aggactcata gcctcggctc acttcccctc
16861  tcacagccca gaaccccccа gagaagggca cagcagcggg caggcccggc tcttctggca
16921  gtctacactc agctgatcaa ctcaggagat ccccgggatg gagcggaccc catgggcact
16981  ggcgtcccct acccccatca ctgcctcctg tgcttgatct gggaggcttc taggaggaag
17041  gcggggtagg gccaggcaga aaaaggtggg cagagtatgg ggtgagcttt gctgagcccc
17101  actctgggca ggcatgagtt aggagcagaa aaaaaggccc agaatgctgg aatgttccag
17161  aacattccag gaggccaatc atccctgaat tcccggggtc tgacagaggg accggctgtg
17221  tgttgtcctc caagctaggc tgaggggcct gggaacaggc actggggtgt cctgggtccc
17281  acacccctca caacccagca ctgcctctcc cctgcctcct cagctgcggg tccactgagc
17341  cctcggggcc gggggtaagc tggttccatc tggagttagc tctggaagcg tgcgtccagc
17401  ttccggttct gtcttccaat ccctcaccac catcagttct caagcccctt cccagcagga
17461  ggcggaagca aggccagcct cagttcacct atgtcctctc tgttctcttt gtacctgggt
17521  cgcagaagtt gcccggtgcc caccacaggc atgagctgcc ctggtttgct ggctatggat
17581  ctcagcaccc ccagggcctg cacatgtccc catgttgtcc ctgggaagag caggctgcac
17641  ctgacaaccg gtcccctgcc cactgcccca ttcccaactc tgccaaaagt ggaagtgggg
17701  ccccagcatg gccccagtga agcagagctt ctgcaggtgc atgaggggtg ggggtcccag
17761  caaagcagaa cttctgcagg caaggcgcat gaggggcagg ggccaaggag gccctggcca
17821  ggagggtggt gcctgctaac ccaggggcgt gggcttctca tgcaggggag accacgtacc
17881  tatggcagcc tgcgtcctca ctccaagatt tcccatttcc ttcaggtgga cccgctgcag
17941  gtggaccccc tgccccagcc acaggaaRcg tgagctagcg cccatagggt ggaacacaga
18001  aacctcatta ctcctcccca gcccactgca gagatgacgt gccaagggaa agcatgaatt
18061  ctctttgatg tcttcattga aatcagaaat aaaggactga gcgtgacaga gccctgtggc
18121  atgccaccgg agacctttct ccagagtgct gaattcagtc aaacggcatc atttggatcc
18181  taccattttt aaatgatttt ttaaaaaatc atttaaaaaa tttaaatttc acaaatttaa
18241  aatgcagtgt tttgtttata aaagaaacat gctggtccag gctcagctgc tcacacctgt
18301  aatcccagtg ctatgggagg cagaggcagg agaatcattt gagcctggga gttcaagacc
18361  agcctgggca acagagtgag accctgtctc tacaaaaaaa aaaagaaaaa aaaattagtc
18421  gagtgtggtg gtgcgtgcct gtagtccaag ctacttggga ggccgagatg agaggatccc
18481  ttgagcccaa gagatggagg ctgcagtgag ttatgatcac accactccac tctagtctgg
18541  gcaacagagc tagaccccat ctcttaataa taataataat aataataata ataataataa
18601  aaaccatgct catcatattg aatttaaaaa attcagtaaa gtacaaagaa gaaaatgaaa
18661  attaattagc ctactgccca cagagaaatc ctgttcacat ttgatgtgtt ccttccagtc
18721  tttttggtaa atatatttgt acaccaaatt gagatcatac ggaaaactga gatcctgctt
18781  ttcaaacaac aaacagcttt agactgtaac catttcccaa tgccattaaa catgtttcga
18841  aaatgcaatt ttgtggcagc ctaatactct accacatagg tttatcatta cttaactaga
18901  ccactattat tggacaatat aggttgtttg ctgttgttca catgagagat aatgccatga
18961  cccttgtctt gttcctaaaa cttggcccac agctgggatc actgctttgg aacagagttg
19021  tagaaatgaa tgtctggggt cacagaaatg aatgtctggg ggcaaacatc aagaacattt
19081  taaaggccaa atgcggtggc tcgcgcccca taaccccagc actttgggag gccgaggcgg
19141  atcacctgag gtcaggagtt caagaccagc ctggccaacc tggtgaaacc ccatctctac
19201  taaaaataca aaaaattagc tgggtgtggt ggcaggtgcc tgtaatccca gctacttggg
19261  aggctgaggc aggagaatca cttgaaccca ggtggcagag gttgcagtga gctgaggtcg
19321  cgccactgca ctccagcctg ggcaacagag caagactcca tctcaaaaaa aaaaaaaaaa
19381  agaaagaaaa aaagaacatt tttaagggca gtgataaata ttgctacatt tccttagaat
19441  atctgtactc atactcaaag tgtgcctgct tcattcaccc agccataaat ccctcttcat
19501  cttaacaggg ttgatgcttt ataaatggtg tattatttat ttctttaaca gtagagttag
19561  atatttttcc atatgggctt tctcttagcc acttggattt ttttctttgt ttccttccat
19621  tgacaatttt gtttccttat gatttagagg aggttttata tattaagata tatttatcac
19681  attgcaaatg tttttcctgc ttgtcatttg ccttttcatt gtgttttttg acagaagttt
19741  ggtattatac ttatccaaat atatccatat tccccctttac aattccttca attggattta
19801  tgcttagaaa gctcttgaca accaatattt tcttcttgat ttgtgtgatt taaatagttg
19861  aatgttgtat tggcttatat ttgtcaYatg ataatttaat ttcctattta ttaaatttat
19921  gttatatatt tatttataac acaataagca ttctgtgttt atcacggtag gttatttgta
19981  agaggggtat tttcaactat tttattcaac tgaactgtct atgaaagttt atgcacatat
```

```
20041  ggcactattt taattatctt cactttacaa gatgtttgga ggaagtctct tacttgcttg
20101  ggtcccacag ctgtctcggc cattcttgac cgttcatgtt cctttggagg aagtctcttc
20161  cttgcttggg ttccgcagct gtctcagcca ttcttgacca ttcatgttcc tttggaggaa
20221  gtctcttcct tgcttgggtt ccgcagctgt ctcagccatt cttgaccatt catgttcctt
20281  tggaggaagt ctcttccttg cttgggctcc gcagctgtct cagccattct tgaccgttca
20341  tgttcctttg gaggaagtct cttccttgct tgggttccgc agctgtctca gccattcttg
20401  accgttcatg ttcctttgga ggaagtctct tccttgcttg ggttccgcag ctgtctcagc
20461  cattcttgac tgttcatgtt cctttggagg aagtctcttc cttgcttggg ttccgcagct
20521  gtctcagcca ttcttgaccg tccatgttgc tttggaggaa gtctcttcct tgcttgggtt
20581  ccgcagctgt ctcagccatg cttgaccgtt catgttcctt tggaggatgt ctcttccttg
20641  cttgggttcc gcagctgtct cagccattct tgaccgttcg tgttcctaga tggtgcttag
20701  aatcacttca taacatttcc aactatgaat ctgggaaagg ccaacctctc gattataccc
20761  agcttcccat gaggacagca tttgtgtctt catttgtgat cactttcttc ctatcattaa
20821  tcaggtacaa tttccttcca atgggtccat tgtcttgtca ggactattcc aggtattcta
20881  catttttggt tactaccata atggaaattt tctctccctg ttttccccac taccaaggct
20941  gttgtttttg gttcacacag aagctactga ttttttaaac aatggtctga tatttggcca
21001  catcaccaga ctcctctcct aactctacaa gttRtaccgt ggattctttt aggttttccc
21061  gacacatgat taacagcaaa caatRagaat ttgtctctgc tcttttccaa tactagtttc
21121  atgtcacata caagtatcta ggattttcag aaccacagta actagtttat gggtcttttt
21181  tgtttgtttg tttccaagac tatctccagg gcagtgctcc ccagagcagg ttcagcaggc
21241  tgcggatctg ctgagcaaga agcttccgtg gagaaagttt tcagagacca cctgtactgc
21301  tcggactctc ggaggtacac catgcacagc tccacaggaa agtctccggg aaatttcacc
21361  cccaggaatg cccattttcc tttgtttgac cagcattttc cagacttctt tgaccttggg
21421  acccctctat agtcctctgt aacatctact catatcctaa gaattcgctg tgcagaacac
21481  ttttagggaa atgtgcttct ttttccgcct ttaaatacaa tcttggttgt cctgttgccc
21541  tctgttacta gttttctggg gatctggaaa aggaggagtg ccctgtgagg ggctaYgggg
21601  ccgtcacgcc cttgccctgc cagaggcttc aacactggag ccctgaggcc tctctcccag
21661  gctcccccta ggcagcaagc tcctcatgcc tgcagttgct tctgctaccc ccagctccag
21721  accccgcagg gctccagacc cacatccaca tcttcttggc ctcctccgct gggatggcac
21781  caggtacctc taactgcaca tctcagctga cctcttcagc ttcctcctg tgctccccaa
21841  tctcaggggt tgataccatc atctacccag ctgagagtct ctccgccttc acccacctag
21901  tgccacatcc tctcgaagtg gcctcctctg tcctcctgtc tgtatccctg gacccaggcc
21961  tggtcccagt ccagctgcca gcatcccccа tttgatggca gtgactgtct cctaagccac
22021  tgctcccacc tgccccttct gcacacagga gccagtgatc ttcttagaaa tgcacatggg
22081  atcgtgtcac tgcttaaagc tgccctcatg ggcaagccaa acccccttggc gggagacgca
22141  ggtctgctct gctccttgcg atcggctcct tccgacgtct ttggcattgg gtctgctgtt
22201  cctgtccctg tgctcgtccc tctgggttca gctgccctcc ctcccctccc agcctatgaa
22261  ctcagagcat ctctatgctg gtgacttcac tggaccatct tcaggtgtgg gtggaacggt
22321  cacttcctcc cgttgctttt cctgaccttg taaggaaaga ctgcctgacc cgcgtctcct
22381  ccatccagcc ctgagccctg gtacaattgt ttccttgtct agatctgcct tctggaagcg
22441  gtcccctgag gacagagact atgccagtga atattcccag cacagcactt cccacacaga
22501  agcccttcaa acagtatttg ttagaggatg agttttgtca tttggaaact gatgtgatga
22561  actgtatgaa tagatttcct gatattaaac aatctccaca ttcctaggat aagccctaga
22621  tgatcacggt agaagtttct ctttatacat tattcaatta aactcttaat gccttgggat
22681  ttttacttct atttttagaa gtgagacagg tctgtacttt gtcctgacgg gctacctttg
22741  gcatctttgg gtataagggt cccattgact acgaaagaca cattgggtag atttcagaat
22801  acatgagttt acagggtatt gtattagtct tgcctgataa atgcttgcaa atgagtatga
22861  atgcactggc aaaactttgg aaaaggtgaa gaacttgagt tccctccatg gttatgggac
22921  ttatggcata ttctccattt tttggagtca gctttgaaat attcacatcc caggaaatcc
22981  tcaatttccc caggatctcc gtgtccctgg catagagatc ctcaaattct caccttcagg
23041  gtttgactct cttctgcaaa tgttctgact gtgatcacat actccttcta cctacctgag
23101  gcagttaagg aaaaaaaaag aaaaagaaaa agaaaaggct tagggtcggg ataatttagc
23161  atagagcctg ctaaggagta attaataaag gaggctttat tccatcaagt actcaagact
23221  gggaaagagc agacactttt caggccaaat aagatccaaa gctttgccag cactggtaag
23281  caattaaccc tagtcaatta caaaattctt ctttttaaac aatgtaggag caacctgggg
23341  gaaaatgcaa gccgccacct ggcacccaga ccaatcaaKg ggataatctt ttctcccctt
23401  tctagcccca ggaccaggag tttcccattt tKggaaactt ccaaaagagg atataactct
23461  gtccatctct catgccaaag gcttgagaat tcctaaaaca ccagaggatc ctggccagga
23521  agggacaggc tggaaagacc cggcttgggg aaggccggaa cagggaactc cactggaggc
23581  aggcagccag ccacatggga tagtccaaag atccccccg cacctccccg cctgtgaatg
23641  gagagctgga accggattgc tgggctgggg cccaccccca ggctctgcat ctgtgtggtc
23701  caaagccccc tgccacaaac ctgggataga gggctcagcg agcctctctc tgccctccta
23761  gccagcattc actggcagag gatgccctgc acatccctcc tccactgatc atccctggac
23821  ctccgaagtg gccggctgca gagagcctcc caacagcttc ctagtgggca gatggccctg
```

```
23881  catgctttcc tttctgccag gagaagtatc tttttgtagt cacattacat atactctttc
23941  tgatctttta gtttgtgcct tctctctttt tttctagatt aaataggtca gagggttgct
24001  ttttccMaag ctctcttctt cattgattct atgtgtttct tccattttct aatttattga
24061  tttctgcttt ttctgaacta tttccttatt tttgctttcc ttaagttttt ggttttgttg
24121  ctgttgaaat tcattcaaat gtactgagtt gaaggcaggg ctaatgtgtg tcgaacatat
24181  cacccaagga agaagctttt ggaaaacatc tgtgaatttg cctctgaata cagctttaac
24241  cacattccaa aagatttgac agtagtgctc ttgtttttat tagtgttcca aatagtctgt
24301  actgcagtcc taatattctc tttccttgct ctgttaccca ggctggagcg cagtggtgtg
24361  atctcagctc actgcaacct ctgcctcccg ggttcaagca attcgcccac ctcagcctcc
24421  caaatagttg ggactacagg cacatgccac cacacccggc taatttttgt atttttttgg
24481  tagagacagg gtttcaccac gttagctagg ctggtctcaa actcctgacc tcaagtgatc
24541  tacccacctt ggcctcccaa agtgctagga ttacaggtgt gagcgaccat gcctggcccc
24601  tagtaggttt ttttttttt taatgttttc aaatgaattg gatttttta ggtttataaa
24661  ttctgctgcc cccacccta cttttaggca tttcatcagc gaagatggac aaaatcgttt
24721  tagctgtata aaattcacaa tattttcttt atgacccaaa acacttctgt aatttttaag
24781  tgttctatga ttcctcgaaa agaaggttca tctttctttt tttctgtagg gcaagggaaa
24841  cagtgatata actactaatt tagctttact cattgtgtca ttcaaaaatt ctatgcctta
24901  ttagcatcta atctgtgaaa ggcttttaaa agtgtattag agactctcat agttaggttt
24961  ttgccaattt ccccttttgtt ccaaggattt gttttgggat gttttgtgtt ctcttggggt
25021  acacgaaggc ctgcaactgg catccgccct gtgggtgcct tcggtcactg tggaatgagg
25081  tgcttggtgg gtgtagggaa gtggccccaa atctacttag tattcctggg atcccttctg
25141  ccaccggagt ccttcgtcat cattttaca tcgtgtgcct tataagttgt atgcagtttg
25201  attttatttt ttgagactga gattctcttt gaacagagtt caacttttat ataattatct
25261  gatgtatttg atcctattat gatttgattt tctatgcaca gccagaccac aggctcgaat
25321  tctgctgtct gggtaagaag cctgactcct cgggtgctgg atggccctgg ctgcttacct
25381  gggcatgtca ctaagtcaca ttaagcctcg gtgttcttat ctgtgaaatg ggcagagtca
25441  cagtgtgcac ccctccatct gccctgtaga ttaagggcat tcatccatac aaagtgcttc
25501  ccacacggct ggtacaggca ctttgcagtc tacacgggcc gtaccgtggg gctcctctct
25561  tcctctgtct gcacagcatc ccgtgttgcc atcccaggtc actgtccctg gcggctacac
25621  acccatgcac accgccagga aaggacgtcc caggtttggc tgcaagagga agtgggacgg
25681  gcaagagagc ccagctggga cagcagccga ggccagagga gaggaggcca cagatttaat
25741  acgggggcag aagtccaagg gagggtcgtg ttaaccacgt gtttctgatg ctttgacatc
25801  cgagccttgc tgactctgga gggactgccc cgctaagtgg taaccaatct ttagagacag
25861  gaaacaactc atccatgagc acatttttca gatacaaacc aaccaatcca gcgcccatgt
25921  ccccagccac ctcctttatc agacttcaca ctctgagcca ctatcccccc gccctcatta
25981  cccagaaaac taactcagga ccgctccact ccccagagcc cactggaatt attcaaactg
26041  gccaacctta agccagctca ccctgtcccc atcggtcctt cctgcagaaa caacatggac
26101  tcaggctgct gtttacccaa Ytccctctgc ctcctgacca cccctggtgc ctcccctgtgt
26161  ggcccccgtg gcctggtatg tctcttcctc ttgggatctg ggagtaacag actcttttca
26221  gtgaacaata gtaatggcca cattttaaaa caaggggtga aagggagcag ggWtcttgtt
26281  tcttatagga acctcagggg agccagggag aggcagggtg gttctggcaa acgcacacac
26341  tctccaagga ggcccatgcc tcactcccag gcccctcact ccgagggggt ggaggcaggc
26401  ccggctggcc acagtgcact caccttтcca tagctcagga ggatgatccg caccaggacc
26461  acgttgatgt gggcacccaa ggactcgtca tggtagattt cattgacctg aaagaaacag
26521  ggaggcatca gcgggaacca caggccctag gactggctct ggctctgcca atgggatgac
26581  ccccacctgc tccttcttct tcccatgctt tccacccagg cgtcaccatc aactaggagc
26641  caccttgtga cccctccctc attgcccccc gccctctgcc tctccaggct gccaccacca
26701  cctgctggga tcactgtagc cccttcctga gcaaccccac ccaccagccc agggWttcct
26761  cacctggggc ctgaacatgg aacgtgggca gggaaagcag ccctacgctt gctgtagcct
26821  ccagctgaaa cacaaccttc ccttcaacag tgaacgtggg tgatggaccc ccgcggcaca
26881  ggcagggctg ggaccggccc tggcagaagt cactccaagc tatagctggt gggtgtgggg
26941  attacctacc tgcatcgcta cttggaaatg ggggcggttc taggcccacc accaggtata
27001  atgttttaac gtgttaataa aaagctcata ttactgcatc cccaatgtgc tctccctgtt
27061  ctgttttgat ggctggagct cctgcagtcg ccgtctctgt atttatcaca atcatattct
27121  tacacgtgtt tcattcttca catttaaaac cattattctg agcaggtgcc aatgggcttc
27181  agcagatatc aaagggaccc gtggcacaaa aacaggggg tgaactcccc ttctacagaa
27241  cacagccagc aagaccctcc agaaacatag gtcaggttat cccgggctcg aggctgtcag
27301  gggcttcctt cgcactgagc ccccaccctc cagcttccca ccgcacacac ccagggccct
27361  ccctagcgca gccccccttcc tgtcacctcc tttgttggtt aaccaaaccc Yactcctcct
27421  cgaggccagc tcagcagtca cttcccccctg gaaggccccc cgcaggcctg agccgccccct
27481  catcaagcac aaggtgtgtt atttctggag ccctctgtgt gcccctgtgg gctgggcagc
27541  cacctgcatc ctccctgctt gcatgcccag agccaggcta agcagcacct ggcaggcact
27601  cagggatacc cgctgaaagg ctgaagccat tggcaccatc aagaagtgga gaaacaggga
27661  ctggctgtgt gcagaccgag cccaggggct gctgacagct ccggacatgK ccaagacata
```

```
27721  cttcccggag cctgctgcca cgtcaggcca gcacacactc cctgcactcc aatctgtaga
27781  gcctgcatct gagcaacagt gattgctacc tcaaaacagt gggaaggcac ctcaggaaac
27841  cYgagggttc acaaggagaa tgacatcatg atggatgggt ggacaggcat acagggcgtg
27901  caagacaagg atcccgaggc ccgctggcat cggtgctggg aacaaagatg gcaccgatcg
27961  tggggcagag ttcatgacat gtggaccctg ctgagggtac catccagccc aaacgcagct
28021  cctcttggca actgctgccc agcaaatcta catctgattg taaatgggct ccccacaact
28081  cccacctctc tttcctatag gcaagggaca actcatcaga cccacgggag cgtggctggt
28141  caccgtggct ccgggctgta ggcgtctggg gagggtgggt cagcaacccc tgtaggcgct
28201  gagggttatc ctctagaccc ccagtgaccc atctcgcccc tgtggctgac aagatggagc
28261  tccgaggagg gcacccaggt ccccaggaag ccttgccatt tggtcatcgc cctccgtttc
28321  ctctgtaaaa tgaggattgc agtcccccca tcacaaagct gttgtgggga tgaaaccgYc
28381  atgcaggtgc aatggaatgg tgcttgtgca aacaatgaaa cggtttttca ttgctggtaa
28441  accatagtgc cctgcagctc cctgtgaggt cctgggggta gggtatgcac ccctaaacca
28501  cagaagtcct tgcccagctt tgagggtcag actagattgt ttagtccacg ctggcacagt
28561  agccttaaaa gccagttttt cttaagagag aaggggtttc tgtaattgtc cacagtattg
28621  ctttctctat cacgacaaag cttggccagc ttggctcatg gagtctgacc gagggaaggt
28681  cccactgcag ctgaagggag cagaatagga gagaggagaa aggccaggga tgaggggcca
28741  ggcttctcct catcctcaac cccaacctca caggtcatac agaacagtcc tgacatctga
28801  gaaggaagga aatgcaaaag agcttgatcc tggctgctgc ctgggacctg agaggggaca
28861  ggttcctagc agtaggagtg gcttccaggg cccaactggt ggcccagcct gctcaggcct
28921  gagagggtgg cccagctccc agctgtgtgt agcagatgcc agggtcccct gcaccccaga
28981  gacacatggg caagatagtt ggggactggc ttgcaggttt acctggctct agggggcacc
29041  accaggcttc agggcaagcc caggggggca ctggcctaca ggagaggagg gcaggcctgc
29101  ttgcaaggct actgcagagg ggactcatcc ctactgcccc ccaccaggcc tctgcctgca
29161  aatggggctt ttgggaggta attaggggta gatgagttca tgggggtggg accctcatga
29221  tagggttagt gtcctatagg aacagacacc agagagcctg catcctctct ctctgccgtg
29281  ggaggaccca gcaagaaggc ggctgtctgc aaaccaggaa gagaatcctc actggggaat
29341  gacccagctg gcaacatgat cttgaaattc ccagtcttca gaactgtggg aaatgaattc
29401  ctgtgattta aacccctggg tctatggcat tttgttatac cagcccaagc ggaatgagac
29461  aaaggcttta tggggaagag actgagccac ctcccacagg ccagactgca gccttccttc
29521  tatcctgggg ctgagtgccc gagatgaggg cagcaccaga tataggaacg aaagaaagcc
29581  ctggccaggc gcagtggctc acRcctgcaa tcccagcact ttgggaggcc aaggcggtgg
29641  atcacctgaa gtcagaagtt caagaccagc ctggccaaca cggtgaaacc ctctctctac
29701  taaaaataca aaattagcca ggcatggtgg cgagcgcttg taatcccagc tgctcaggag
29761  gctgaggcag gagaatcact tgaacccagg aggcggaggt tgcagtgagc cgagatcgcg
29821  tcattgcact ccagcctggg agacagagca agactctgtc taaaaaaaaa aaaaaaaaaa
29881  aaagaatgaa agaaagttgc atttttcccc acgtttgagc ctaagcgtgt aaatgttgac
29941  ctcaccgtcc acacagaccc tcagcacagc cacgggcccc tcacaggctc tcaatgggac
30001  ttctcaaact aaactgaccc tggcctcttg tgcagcccac cacaccctgg gacccagaat
30061  ggcctgggcg agcctgacct ggtctctcct tccccactgg gctgaggctg gcacccagca
30121  gacccagcag aaccactgcc tcaccatgaa ttgtggctct gagtagatca gagccagccc
30181  tcctgccagg aggcggagag ggacactcag atgctacgag accagctcca ggatcaccgg
30241  cctcgaggga aaggcaggga accagaggat atattagtgg gaatctgccc actggggcct
30301  ggaaggacgt ggcatgtcat gagacctgag aaacagaaca gggtagctca gcaaagcagg
30361  gatggcgctc ctggcagagg aggcagccca tgcaaacctc ccagggttgg aagcagcgag
30421  gcaccttcca agcacagagg ggatgtggaa gggatgcccc agcagaggag gtgggagggg
30481  agcactgagg ccagaccacg aagtcaggag aaggattcca aatcctctct aagagcagtg
30541  ggaggacatg gaggaaggat gatggcgggg catttaagaa gcttactcca ggtgccttac
30601  ggaaagtaga tggaaggggt caagatgtgg gaatgtgggg ttcagctttg gggatgagtg
30661  cagagaaggg acggatgtga gggatgatgt ggattggaat aggggtcatc tgccccgcct
30721  gagcagggag aggctggggc tctggaaggg cattccggca gctcccacag ggcggaggga
30781  ggagatgcgg ggctggccct ctcctggctc ctggccaggc cctgcccctc aggacgcaag
30841  atcttcccac tctcctagcc ctacccctgg ggccgaaggt ggcagctctc atctcaagaa
30901  ggaatcttgt gtccttctga acattgagca gatctaatcc tgctccctga tttgggacag
30961  gaggtgacca accactccaa aagccccgtc gctgggcatg gaactccctg ggatagaccg
31021  tcagcctcac attctgcttg gaggtggggt cgaggcagct gagccctggg gtgtcaggct
31081  gctaggcgtg ggcccctggc tggggagctc cactgtgggc tgtccgccag cagccagctc
31141  ccacctcctg cgctgggtgc cctgaccctg gcctctggaa gcctcagatg gttcggagat
31201  taactggggc tccctggctg ctgaggagct aSagagggca tgcctgcaaa tgctcccagc
31261  aggtagccag ggagaaggag gccaggccgc agccaaggcc ccctcagccc tccctccctg
31321  gtagccttca actgtggtgc gctctccctg atcctctccc caggaaacct ctgtcccttc
31381  ctcccttcca caccagcaca gcacatagtt ccccaggcat gcccactctc tgggaggcag
31441  gcctgagcaa ggccgtggtg gggcttgcga tggcctcctg gctcctctgg gtggctgctg
31501  ggcYtgggat cctgctccgg agccctcaac ttggcccccc cccaggccag gtctcagcag
```

```
31561  cccctcccag cagtcaggaa ccccatgggg cactgtggcc cagagaccac tgaccactgg
31621  cctgggtggt tctcctgccc ctgcgtgtgc tatggcaaag tccaacccac agtccggggc
31681  cgggctcctt ctgctgtcca gcctctcagt ccccgtaggt taatatgata catcaggaac
31741  agacatgggg ggcaggcagg gtttgtgggg catgtgagag gcaggggtgc tccacagtgt
31801  ccttgtcctc cgtgggcctg aggagtgagc cccgtcctgc cccctctacc atcccagggc
31861  tctacctgct tttcaggagg ctgcaaaatt gccaaaattt cctgcccagc cctggccaga
31921  ggcctgcagg gcccacctgg gcatgggaac cactgggagt aatcagtgta attcccgaca
31981  aaacactggc gtcctcagta aggacacagc ggcaacattt ctgcagagca gagagtcgac
32041  tgatgtggca aaaagagcaa ctgaagacag aaggcgacct ccacatgcct gcctcctgca
32101  catccccctc ctccccccggc cccacccact ttctctgcca gacaggagac aggcggtagg
32161  gctccccaac ggtccccctc gtgtcctccc caccccccca cccacacaca ccattcttca
32221  ctacgatcac caagcggaat agatctcacc ttccccttcc actgtctaaa accctcaacg
32281  gctctccagt gccttcggaa gcagggccca gcccctcgcc tggcattcgg agccctctcc
32341  acgctggccc tggctggctt ctccatgcgt cacttcagat acctccccac atggcaccct
32401  tgctcctgac agcccagcca gccttcccca gagccggctg ccctctcctg ctgcctgtgc
32461  tttggttcag gcctggaatc ctcactctcc ctgtgcagcc cctcaattct ttagatatct
32521  caggagcatt tgaaaaaaaa gactcatcct aaaaaatata tctcaaagga aagaggcagt
32581  gaSctccttg cttaaaccct tcctacccca aggcatgaga ccgcagttcc tggcgtgacc
32641  tccaggccag gagggtctgg ccctgctgag tcttctcggg ctgccctggc cctgctccct
32701  gtgctccagc ggctagcccg gctgctcctt gcacaggcag cctgtctcca cctcaggaac
32761  tttggacttg ccgtgcaact gctcccagca gtgYctagcc catagtaggt gctcagtaaa
32821  catttgctga atgaatggaR tgaatcactt tgaagatatg gaataacagg aaatgggcaa
32881  aatgtatgac ccagcgtagg cctgtgaccc ctctcatggg gaggccccca gctaagggcc
32941  tcccctcccc tccccccagc agccctgggg gcctcctccg catccaccct acccaaggcc
33001  tgcgtgtgct ggggagaagc agctctcctt tcccaggttg cagRgggagg ggaagcccag
33061  ggacaatgtc cttgagtact gtctgagaaa ttgatcctgg aatctttaaa ccttgggggg
33121  aaatgttcaa agccgcagcc atctctgtgM ggagagaggc caagggctct cttgtttggg
33181  gaaacacatt gtaatgcgcc ttttgcttat gcaaagaYgc agccaagttt ctgttctgga
33241  atagacaatg aggaaggagc ggctctgcat ggcaatgtaa agtttgcctc actggtggca
33301  gagttccacc caggggatgg tgagccctgg gaggtggcct gcggctgctg ggcagaggtg
33361  actttgtcct ctgccaaggt gggggagggg tgcagaaagg ggggaaccgg tgcaggctcc
33421  ctactgggga ggcctactgg cctgccagcc acagaggaga caggcagggg ccctggaaca
33481  gcagccaccc caaccttcag gaaagttccc atRtccttcg ctcagctgag ctttgggcca
33541  ccagaggcag cctgtggccc acctggcaaa accatgtcca ggagcaagcc aggcctgaaa
33601  agtctgtcag aggcctgggg gagggggccc tgctgctctg tggcttctct gggacccccc
33661  gaaataagtg aggagaaggc tgttctctct gtgccccttc ggaggccagg cttggaccac
33721  caggatggag gcagagaaga gagtgcagcc aggagcaggg gacagaggtc tgctggcctc
33781  cgtggaggaa gagtttaggc attgcatggt gcctaaacgg ggctgccaga gcctgggctt
33841  atcatgagaa tcaacgttcc cattgcagat cttcttcacc ctcggctcct cagcagatgc
33901  ttcagaggga atgctagaag aaacgtgact cttgctcaaa atatcaaact accatgaaNc
33961  ggaaatggcc aggatcagaa ttactaggct cagttcatac atcaaaaagt gaggtggtca
34021  gagtcccctc cttcaatacc cagcgcagga acactctgcc caaggccacc ccctcactcc
34081  tcaggcgacg tctcctgtgc ctgtccacac tctgctgata cctctgcaga tgcctcaggg
34141  tggggacggg gctcctccac ttccaggcca gctcatcaat gcacagagcc cagcagggtc
34201  tcaagagatg tgctgcaccc ctcagtgtgg cactccagca ggcacgttga gaagacaggt
34261  cgcattacaa accttcccgg gtttgtacta acgacggcaa gaggctgccc ctccccctct
34321  cctgaatttg gggggttagc agagtgtggg ggggatattc ccactctgag gtcagatttc
34381  atgggtgcca gcatgggctc tgccacaatc ctgctgcgtg acttggggcc agttacttaa
34441  cctgtctggg cctcagtttc tttatctata aaatggagat aataaYagtc cctgtgtctc
34501  agggttgttt caggttgaag caacaatgaa aattatcacg tgcgtccatg tgaagagatc
34561  accaaacagg ctttgtgtga gcaataaagc tttttaatca cctgggtgca ggtgggctga
34621  gtccaaaaag agagtcagca aagggtggtg ggactaccat tcgttggtat aggtttggga
34681  tagacggtgg agttaggagc aatttttttt ttttttgag acggagtctc tctctgttgc
34741  ccaggttgga gtgcagtggc atgatctcag ctcactgcca gctccacctc ccaggttcat
34801  gccattctct tgcctcagcc tcccgagtag ctggggctac aggcgcccgc cagtgcgcct
34861  ggtttttttt ttttttttttt ttttttttt agtagaggca gggtttcaca atgttagcca
34921  ggatggtctt gatctcctga cttcatgatc tgcccgcctc ggcctcccaa agtgctggga
34981  ttacaggcgt gagccaccgc gcccggccag gagcaatttt ttgtgggctg gggacggatt
35041  ttacaaagta cattctcaag ggcggaagaa tattacaaaa tatcttctta aggtaggggg
35101  ggacaatatt acaaagtatc ttcttaagga tgggggtggg gaagaatatt actaagtatc
35161  ttcttaagtt ggggggagag aatattacaa agtatcttct caagggtggg gagggtgtat
35221  catacaaagt agattcacaa gggcgggtcc ggcgggggcg ggtggcaata tcacaaagta
35281  cattacccca agggcggaga gggtgtattg ttcacaaatt caattgattg atcagctagg
35341  gtggggcagg aacagatcac aatggtggaa tgccatcagt taaggcagga actatctatt
```

```
35401  ttcacttctt ttgtggatct tcagttgttt caggccatct ggatgtatat gtgcaggtca
35461  caggggatat gatggcttag cttgggctca gaggcctgac attcctgtct tcttatatta
35521  ataagaaaaa caaaatgaaa tagtggtgaa gtgttggggt ggtgaaaatt tttgggggtg
35581  atatggagag ataatgggtg atgcttctca gggctgcttc gagcaggatt aggggcagca
35641  tggaaaccta gagtgggaga gattaagctg aaggaagatt ttggggtaac aggtgatatt
35701  atggggttgt tagaaggagc atttgtcgta tagaatgatt ggtgatggcc tggatgcagt
35761  ttggtatgaa ttgagaaact aaacggaaga cacagcgtcc gaataaaagg agaaaaacag
35821  gtattaaagg actaagaatt gggaggaccc aggacatcca attagagagt gcccaagggg
35881  gttcagcata attatttgct tggttggcga gtttttgggc tctatccttg agtttatgtt
35941  gtcatacacc aggccagact gatttaggta aaaacaacac ctaggtgatt caaaagcttt
36001  attgctcaca caaagcctgg tggtggtctc ttcacacgga catgcgtgac aaaagtgaaa
36061  tccccagcac ctagtacagg ctgaatgaaa ctgtcatcaa attacaggag ggtccaacag
36121  cccaagctgt ttccctggga ccccatgcac agaatggtcc acctgggctt cgcccttaca
36181  cccaccctgg ctctcctcct ggccatcacc atcgggagag gtctgagtga acagcttgca
36241  catgcccctg tgttttccag agctggaggg gctgctgtgc ccaggcacRt ccgcgagtgt
36301  gacccagccc tggagctctc cccgctggct gcgtcgcctt tggggaaaca acagccatgc
36361  caccacttag ggactgacct tcccacccgc tgaccggatg cctcatcaga aagggaaatg
36421  ctgcagaacg gggaaggacc agtgctgctg aggctgcagg acgcagaagg acacggccga
36481  ggcctcaggc cagagcccag tgtcccccag gggcctctcg gccactgcga gccactgaca
36541  gggaaaggcc gagaaaagtc agggattctR attcttgcta gcagtggctg caggacggcc
36601  ctgcctccct ggaactctgc tgagcttgtc ggctgtccct ggccacagag ccctgggggg
36661  ctcagtgagg agtttccttt caaagagggg ccctaagtgg ccagggctcg tgccaccccc
36721  ggccctggca tccccccaca cgcccgtctc agaggctgtg tggcccggcc catcccgtga
36781  ctgagctcgg tcacctgggt ccgtttgagc accaccatgt aatttgagaa caatgcattt
36841  ttattccccc acacatcata ttctgccgct gctctgtcac cagtgtgacc taaggaaaga
36901  gggaaggaaa atgccgctat gggaggagag agctgtggca tcaggggaca ggaacggtgt
36961  gggggagggg gcagcaagca gctgccgggg tgggggcgg gctgctgagc ccacaccagg
37021  cttggagccg gagccctatc cctaccgctg cccccgcctt agggtgagat gcagatagtc
37081  cccggggttc tgggctccac ttcccactga gatgagaccc tctgctgagg gtggaggcca
37141  acccacatgg tggccaagca ggtggttaga atggagaggg atctcatgtt aatgaatggg
37201  cctcaggcag cacatggatg cccctcgctc cagaaggggg tgtgtgggat gcagcagctc
37261  ctgctggcga gggccagggc gtgggtagct ggcactggct ggcagaggct gtagagtgga
37321  cacccatcaa ggcatagggc ttggactggg caggggtcca gcatgcctaa gtggcccagg
37381  cgtcagaccc gaccacctca gagcaaagct gaggaggact caggccagcc tccctactcc
37441  ccaggcatcc atgcatgatg aggaagaagg gagaggccct ggcagagcag gtatgaaccc
37501  ctcagagact gagaaggcat gacagagggc tgcaggccat caccttgcac tgtgcccctc
37561  gacctgggca ggggccccca aggcactcag agcgcagggc aagagtaagg tgaaggctgc
37621  aagaagggtc ctgcattaca agctcacggc aagggtcgtc tgctgccagc gtatccctcc
37681  ctgaaagcgc agtcatgcag ggtgctttcc aacacccaga gcagatgttc cagcgcctct
37741  tgggcttggc gggaaacggc tttgcccttc tgtgcagcag gtcacaatcc ccctgcacca
37801  ccagagtctg tttatgtggc ttagctccct tgccagactc tggcagatgg aaagatagat
37861  gaaatcctgc ccaccgctac acaggaaacc cagaaccaaa ggaagagggg ccgaattatt
37921  ggaagcacaa gggtccgtga tcacttctgc tcaggatcag aagggccagc atgggcagcc
37981  cccaggccag gctccctgcc aggcgcgggt gggaggtctt gcaggctgca gccaggtttc
38041  cttcctcctg tctggctgca gggaagtttc ccttgctctg aagtttcctc actctgtgaa
38101  cattcccacg gggcacccta tgctgcctcg ggtgctgtcc catcctggta acttcctggc
38161  accatcgtga tctccagtcg ccttcgtttg ttagctgtct gtccgtctcc actaggcagg
38221  gactgttctg cattcttgct gatgcaWcct gggtgctcag tactcccgtg tttccccagg
38281  cttcaggacc aaggccaagc tcagccgcac gcgccttctc ccaccccagc gggctcccag
38341  ggtggccgag ggctggcacc tcttttgcac aaggggctcc tctgtgtgga atgatgccct
38401  cccactttcc acttgggaga caccaactct gtgaccaaaa ccagctcaag gatcacccca
38461  ctgtgactat ctccacKacc aggtggagac agctgaccgt ctcctttggc tgccaagRcc
38521  ctgtcctcRc tgtgccaagg caagcaggtg gcccccatga gaaaaaagct tgtccaggac
38581  gggagctggc tggggctctt cccagacatc atgggccgag tgaacaactg ctcgcctcgc
38641  tggtcggctc tgatcttctc cgcctaYgcc gagtacttcc ccgcgtgcga tatctttccc
38701  ttcccacacc ctgcgagtga gtgttatccc cgctgtgcca gtgaggaagc cgaggcacag
38761  agagattgag aggctcacat aagtgggcat gggagtcagt acagaggctc tgaggagcaa
38821  tttggcaaac ctgctgcaac tagaaactgt atcccgggac ctggccattc agacgtcagc
38881  atggacgatg gagacacagc ctctgtcata gaagcgaagg cataaggaca cccagccacg
38941  aggagttcca cacccacaga tagagttcat ttttatggga gtctctgaga tcacagtcgc
39001  tttatgggaa ttcatttagt cacttattca ttcaaaagag atttactgag cacctactac
39061  gtgccaggcc ttttccaggt actcagtgaa aaatcaggtg ggcagaccct ctctgggtcc
39121  gatacaaagt caccttttgtg ggagtcccta accctgctga gacacaccac caaggagacc
39181  cctggactgg ggaggaagac ccaggattgc ttgactgcaa ctcagctcca ggggcagcct
```

```
39241  gggaggggcc tcagggagtg agagcccacg ccaggtcagc ccgacagccc ggcgtggcac
39301  atcatcgcct ctgttcttgt ggttcagctg tcacctcctt gctggagcct gcacaagaca
39361  agctccgagg ctgcctcaag ctgtcatccg ggtgtgtgga tggctggccc tcctcgtcca
39421  cagggactct aactcccatt ctgacaacca tcagttcccc gcgggaggcc aaggacagga
39481  tgctgggagg cttccacatc agctatcagg aggtctgcgg aggagggagg agggaggagg
39541  tggggagatg tccactggtg gggagggtgc tgcacatttc aggaggaagc agaggtgaga
39601  tccacccaca agacccctgt tcgagtgttc cccacctgct caccatcact ggtctgtcgg
39661  cctccccagc cctgctggaa catgtgctcc ctgcggtctg gatcccgtgc tcaccacgac
39721  atccccagca cctagggctg ctctatccgg gtgcactaag ggagtgagtg ggcaggcggg
39781  Ygggcctcag aacaggagga cacagtagat ctatgcagaa gccaaggcaa agcaagaggc
39841  agagcggatg gcctgYgggg agaggcgggt gtggccaggg gactccaaat gctgtgggga
39901  ggtcagtgag gcctgagatg agaaccYgcg gagcatgcta ggggatttgg gagctctcga
39961  tcttcaggcc agacagtagg ggaggaccag cacaggggcc accttcccac aggtatgtga
40021  ctccatctgc cgtgctctgg ccatgtctct ctcagtctca gtgacctgat gcaggcaagg
40081  gaacctcaca gggccactgg ggcaaggtag tgaggtcaca ggtgtgcctc cttgcacagg
40141  gccagcacgt gcaaaaccag caaatgtgag ttcccctcct caggtgggga ggggtgtttc
40201  caaggataga aagcataagc cccaaacctc ctaagagaga ggagtctatc tttgtagacc
40261  acaaatcaac ctcgctcccg ctctccaagc cccacaagct ccagcagggc ccaatctgcg
40321  cactgcgatt cacgatgcgg ccaggccttt gcgcgcgctg tgccaccacc aggagtcctc
40381  attagaggca actgcggtgg cccttgtccg aggagccttc cctgaccagc cgccccaggc
40441  acccttccct gatgaaccaa ggtgtaatca cgtgtcctga tcccgctccc catactcctg
40501  tgctcYgagc tcccccagtg cagggatgcg gaggccagga gtccagggag tgccgaacat
40561  gactgaggac agctcccaat cccagcatgc tcctcccaca cccgtgctct actgagcact
40621  ttcctggtgt tcaactcgag tggtgctccc aacagccccg ggagttggca ctgaccagca
40681  cagggcgcag caggacaggc agtcgcctcc ttccttctag gctggaaaga acactcaggc
40741  cacccacaca ccagacttgt cctgcagccg tgttctgctt cacctgtgca gtgtggcttc
40801  ttaatttcaa tctgtggccc acattgaaaa ataattagat ttcccaaaaa aagtagattt
40861  ccagcttctc atggaagagc gagctggcag cagtggtctg cttattccta cagaaacaca
40921  agcgagtgga accacgagga gctctgcagg ggggcgtggc ctctccggtc gcccgagtcc
40981  ccaccactcc caacagcctt cagccacctg ggcccctcgg gcctggctac tgtgagcacg
41041  tgagggcact gccctcttct gagccttgcg tgcagcctcg cacacaccac tggccctcat
41101  ggctgtgtct cctggtggca cacagggcca ggctgtaagg ccagcgggac aagcgtgagg
41161  aacagaaaca gtgccagcaa cacccccagg gccacagcac cactagcaga ccctgaaccc
41221  cgcttgcctc cccccactta agggacccgt gtttcgtgtc cagtttcaga gatgttcttc
41281  tctttcccag gaaccagagc cagcgactcg tgaactatga cttggggcga cgccttccgc
41341  ctggctggtt tgcatctctg cggccagttt acgagatttc caccacgacc agctgaaaac
41401  actcctgtcc gaccactgcc ttccccaccg ccaccatgcg gtctcagcac tcgtgaaagt
41461  tggtgagaaa ttgagcccat atgccttcgg attgtttgca aaccctggca aggctctggt
41521  aagtccaggc caatttctgg attaaattag aaatgaaaag aggaaaaata tctgaatcct
41581  ggcatagaga gaaatcattc attcaaaaaa aacggtcgta gaacatactg tacagagaat
41641  gttctcgtgc tgggaggggt caaaggttat agccgcgact gaaggcgcag aagatccttg
41701  gattccacgt tctccatagg cctaggagcg tgtctgccct cagcagaaga gatgctttgg
41761  gggctcaggc attctcccag aacataagca gttaacacag ctgggagaga ctattctgca
41821  tgcccggaaa cctgctcctc ctgctctgcc gttctacagc ggttaagaSc agttcattct
41881  atcctttaaa aagaatcccc gaagtagcct caccggtcct ttgagctgat aaggctagtg
41941  tgggggtggg ctggggtctg agcagcccac tgtgctcagt acttccctaa tacgtacacc
42001  cacgtgcact gatgtagtga aaggcacatg ctcactttgg aggcctgggg ccatcacagc
42061  tcaaggcagg cactaagcaa gtacatttct gcacagcctg gtagcaaaaa ttcctttagc
42121  acctcatagt gaatgttctc agctttgtgg gccatatggt ttctgttgca actacccaac
42181  ccactgttgt agcacaaaaa tggccacagg caattcataa atcaataggc gtggctgtgt
42241  tccaataaaa ctttatttac aaaaacaggt gaagggccag gtggccctgg ggccagagtt
42301  tgccaacaca gctttagaat ctccagttta ccttgacaaa ttcacgtgaa ttttgctttc
42361  atgcaagtaa tacgtccaaa tttactttaa tgtaaaactg atgttttaaa atgcttacca
42421  tccaaaaaag gggccacttc agggggagat gYcttacatc tgtctggtgg cctctggcag
42481  gcctgagagt acgtgttcct ggtagcaata ggttgagcgc tggccttgct gcaggctggg
42541  tatcacccac tgcaatggtc tgcctcctgt ctacaaggag tgcggtggga ccaggggctc
42601  acaaagacag ttcaaggtct ttgtagatcc tgatatttaa gcaacacatt gaggccttag
42661  gcttctcggg aagagtagga ttgaaattag cgctttagtg aaatgcttga agccacaaag
42721  gaagcttcag ccttgggccc aagctttata tttcttgaag tcttggcaca gatagatttt
42781  acttttaaaa atgtatctgt agccaggcgt ggtggctcgt gcctgtgatc ccagctactc
42841  aggaagctga gacagcagga tcacttaagc ccaggtgatt gagtccacca tgcagcatag
42901  catgaacctg tctctaaaac aaatctttaa aaaatgagtc aggcatggtg gtgtgtgcct
42961  gtagtcccag ctgcttggga ggctgaagtt tgaggctgca gtgagctatg attgcagcac
43021  tacgctccag cctgggtgac tgagtgagac cctgtctcaa aaaagaaaaa aatgcatata
```

```
43081  taaacatatt acttccacaa cggctctgat cttccaaggc attcatccct gcctcccatt
43141  tacctgagcc tgcagaagag tccctgtctg tacctgggga cgaaacttga ggtgccacac
43201  acatctgagc tgcctcctag catggcagcc tcgcctgtca ggcccaagcc cactctttag
43261  gggtgcccag gcccacacac atggccacag catctggttt gtgagcagag actagcccag
43321  gcgctggcag agcaagtttt tgaaaatgtg agaaatacca aagccccagg gtcagtatca
43381  ggcatgttca gcaatgtcac ctgtgtccca gcctggcagc acccagtact tcagggagta
43441  tgtttcccaa gcaggaaagg tcaaacatga cagtggtctc ccaatgccct cgggggcggg
43501  gggcgggcct gggcagagga gagcccctta tcctcccggc tgggcccagg ggaggcagca
43561  acgcaaggtg gaggctgcag gctgagccag agtagaaagc tgggaggagc aggagcagaa
43621  tgaaggcaga gggaatagaa gtcactctgc cagtgacggg gctggggggc cagcaaagct
43681  ggatgggcca cacatctgcc cacggctctc actccatcct cctagcctca cagtgcttgg
43741  aagggagacc cctctgccct tagacggggg aatgtgggca tccccaaggg gcctcagcat
43801  ctctgaccag gctaagggcc gctgagcctc aggagaccag actcatccca gggttgccag
43861  cagccaggag ggctacagct gcgtgtgctc aaactccagt gtaggccggg agcagtggct
43921  catgcctgtg atcccagcac tttgggaggc tgaggcgggt ggatcacctg aggtcaagag
43981  ttctagacca gcctggccaa catggtgaaa ccccgtctct actaaaaata taaaaattag
44041  ccaggcatgg cggcacgtgc cagtagtccc aggtacttgg gaggctgagg caggagaatt
44101  gcttgaacct gagaggtggc ggttgcagtg agccgagatc atgccattgc actccagccc
44161  gggcgacaga gcaagactct atctcaagga aaaaaaaaaa aaaacaaaac tcactgcaga
44221  gagcctctgt ggacaagggc ccgccccctg cctgccacag gctcagcaca cacccagtgc
44281  cctcttagca cggctggctt cgcctgggcc tcagaggtgt gtggacatgc ccaagcagag
44341  gctggggaaa ggccacagag aacgggagtc tgaggtggca tccagggggc acatgcaggg
44401  cagcaggtgt tccctcaggc tatggggtct gagcgcaggg ctcaggtttc tgggctcgcc
44461  ctagggacag gctgacttca tagatgacca gggcctatcc tcagaaggcc ccgaccttgg
44521  ggcttgaccc tctgcagctc tgtcttgaag ttcttcgtca tctcaccctt gcatgtgtgt
44581  tttgtaagtg aaggctcctg gggcaatgca gcatggtccc atctccccag gacaggcttt
44641  cagctgcccc cagcaggggc aggatcaggc atgtattccc cacggcatct cagggcaggc
44701  gtggtggtgg ccatcccgcc cacggctggc aggaaagggg catgtctggt ggatggctgg
44761  ccagagcccg tgtttcggca gaggtgaRcc tcccgtgagt gacacctgca tagagatggg
44821  attggccgtg gccatacgct ctgggctgga gcagtgcacc agtaggaagg gggcgtgcct
44881  ggctctactt ccccagacgc cctggccagg gcacagccaa tgtgttcttc caggggtggc
44941  aggaagctct cagaccccag tgggtgtgcc cttcctgctg ggggtgcact cactctgcta
45001  ggaccccgta cctgaggagc ctcccctcgg caggattcca ctctgtgaaa tcctctcttc
45061  ttcctcccag cctccctgag tctggctgtg cctgtcataa acttctggtc agcctgaggc
45121  acccatcagg gatcagccac aaaatacaca tttgtttaat ttcagtgacc ccacatagaa
45181  gctaaatgct ctaatatttg catttaaaat agccatcgca caatttaaag atgaataaga
45241  aattcatgct aataattcaa ggttccaatt tttgttcact tagaacaata ttaaaaagca
45301  aataaaaaga acagcgagtt gagagacaga gagacagaga ctaaggaaga aaggaagtgg
45361  cttaatagtc cctttgtatg gcaccttcct ctgctctttg aacaagcgat cccacatttt
45421  cattgtgcgt tggggcctgg gagttactac tggctctgcc tttaggccag tgttccccac
45481  tggtaatatc ctgacgagtt ttgcagcagc cagatattga ggggaaataa gaatgcattg
45541  catgtaatac attggctcct ttgaattctc tatctccccg ccacaccttt ctttcctttt
45601  ttttttttt ttttttttga gagagaatct cactctgtcg cccagactgg agtgcagtgg
45661  cgtcacctca gctcaccgca acctccgcct cccaggttca agccattctc ctgcctcagc
45721  ctcccgagta gctgggatta caggcacgtg ccaccacact cggcttattt ttgtattttt
45781  agtagagatg aggttttgtc atgttggcca ggctcgtctc gaactcttga cctcaagtga
45841  tccgcccgcc ttggcctccc aaagtcctag gattacaggt gtgagccact gcactaagcc
45901  tatctttcct cttactttgg gagaaattca ggtggagggc tgctatggct aaacccaaga
45961  acagtcagcg gttggtgagg aactggagct tgggaagtac agctgccaag tagggcagaa
46021  actcagaaga ttaacttctg gggagggcag gaggcatcMa acacatcacc caagggagaa
46081  gcttttcccc tgggaaggga aagactgcag gatctttccc tgtggtcaca cacacaaaaa
46141  tgtaggacat caaaaactat cccaggcgga ataaaacaaa aggtcaacaa caggactggg
46201  ggaaatattt cccacacatg tgacagacaa aaagtttatc tacttaagta cacagactct
46261  tcagatgaat aaaacacccc caaatcccag cagaatcaag ggcatgaata ggccaagcaa
46321  aaaaataaaa taatctctgt ttacaaatac acgtatattt ttaaatgcag gctcattaac
46381  atcaaggaaa taacaactta caacaaaaaa acttatctcc gttgtaatta aattaccact
46441  gctcaaaagg actcagtggt gtgaggaggt ggggagacag tcatttgctc aatgaagcgg
46501  gaatagatga aaccataaca gagaacattc cagtgtagaa agcttaaaaa atgggcatat
46561  ctgttggcca gagacttcgc tttcagcaac tcagcttaag gaaataagta agcacgagcg
46621  atagattcaa ctctatgaac gtgatacagt tagtggcatg tctgacctct aatggagaaa
46681  taagttttgc tatgtgaata tgtcatataa ataataagtt aggtaaaaag tgtgtgacag
46741  tcatatggtg cgatgttatg caatcattaa aacaacgtag tagacaatta actgctggga
46801  gaagacattc acatacctac aggaatttat gctaatttta catagYaaaa aaaatgtccc
46861  ggcacggtgg ctcacgcctg taatcccagc actttggaag gccaaggtgg gtggtcacct
```

```
46921  gaggtcagga gttcaagacc agcctggcca acatggtgaa accactgtct ttactaaaaa
46981  tacaaaaaaa aaaaaaaaaa aaaattagac ggccgtggtg gtgcatgcct gtaatcccag
47041  ctactcagga ggctgaggca ggagaatcgt ttgaactcgg gaggaagagg ttgcagtgag
47101  ccaagatcac accactgtac tccagcctgg gcgacagagt gagactctgt ctcacaataa
47161  ataaataaat aaaataaatc atctgtgtta aatatggact atttcaataa accaaaaaac
47221  atgcttttct agatgtaagg aggaagataa gaaaactgga cccagcaggg gctgctggag
47281  tgggcaggtg ggtggttgcc taaaccaaag agccccttc tgtgcccagg tggcctcatg
47341  aagtgctcca tttccaagcc gcttcccttc tggcaagtct gagatgaaaa gggcagcttc
47401  atctttccca tagaaaaggg aatatcacgt cttgtcttta acatagacag gaagcagccc
47461  ctccagtgat ttccactgct cccggagcca caggcggctc ccctccacct ctggaagact
47521  gcggcggccg gccttgccgg ccccgacttc ccctacctgt gccccctgct tgacaggcca
47581  ggctgcctcc attcttccag ccggccccat tcctgcctca gggccttggc gccgcctgcc
47641  ccctccccca aacctggaac aggcgatccc tatcctacct cttcccacat ccttccgttg
47701  tcgtgagcct cWgctcccgt gatatctcca gtgcaccagc ccctgagctg tagaaagtgg
47761  cctgccttcc cctacccttc ttccttctcc atctcctaac tattttattt ctttcattgc
47821  atttgtcatt atttgaaatg atcctgtttg tttttcactt cagtatcgtc tgtgcctccc
47881  ttcccagaat gcaaggtagc agggttacgt cctgtcatgc tcacagctgc acccccttgcc
47941  tgacatataa tagacgcccc ataaacaccg gcccccgtat gaacggcagc caggggcacc
48001  agacagagga ggatggctat gccgagaatc caccccatct cagcagctga acacaataca
48061  ccgcacaccg tgtttccttа ctcacaccat ggcgcggggt gggtcgggag ggcccgagcc
48121  tatgttgcag ctgtacctac tgggacacat ggcttccaag gtttccgtgg caggggagac
48181  agagatggag gggactccaa gctcttacca gccttggtcc acaggtgacc caggtcactt
48241  cctttcacac aggccactag gcaaaactgg ccatgcagct ccacaccagc tacaagggag
48301  actggggagg ggagcacagg ggtgatcgat gaggctgaac tgcctgtgcc acccctggac
48361  cccatatccc agcccaggct ctgccacaaa gagatcccaa agggagctct gcaggcagaa
48421  gtcaccccaa atgatgaggg aaactgaggc agtgcagggc tgccagggtg gagctgtgcc
48481  tgcactcagc ctgccaccac ctcacctcct cctcagagcc tgcattccct gggtccccac
48541  catcagggcc cccaccagct cctcctccca gggctcgacg gcctttccca gggcacaggc
48601  tgtgccacca ttctctgcat ccagttcagt gggcagctca ttgcccaggg ctggcccccа
48661  gaccccgggc tctggatgtg ccgttgccca gccccacctg ctctacagct ccagacaaac
48721  acctcactgg gagcccagtc ccagccggct gctgccacgt ctgtccttcc atgcttttgc
48781  tttcgctcca gccacRggga gccctgtgac cagctgggac ttacaagagg agtgtgacaa
48841  gccactggcc aggccttaga gggccacttg gggttgtggt tcgaggcccc catagcaccc
48901  aagttcagag acagggcacg gtaggcagat cctctgtgca caggcccaac cctgccctgt
48961  tcagcacagc agctgccagc cacactgcgg cttccatcca ggtgaaaatt aatccaaaca
49021  aagtactctt cggggtggct accgtaaaaa agaaaaaaaa gacaagagtt ggtgacaatt
49081  tggagagact agaatccctg tacactgttg gtgggggga aaatggcaca gccactgtgg
49141  gaaacagcgt ggaaactcct caaaaaatta aagaaagaat taccctgtgt cccgcaattc
49201  tacttatggg catatagtca agagaacgga aaacagagtc tggaacaccc acgttcacgg
49261  cagcactatt cacagtagcc catgaggggg ccaccggagt gcccatggat ggctggataa
49321  acaaaatgtg gccgatccac ccacacacgg gatactggtc ctccctgaaa aggaaggaca
49381  ttcttacaca tgctgcaatg tggatggccc cgaggatgtc atgctaagtg aaataagcca
49441  Sacacaaaag gacaattatt gtttgatcca cttatgcgag gtacccagag tagtcaaatt
49501  ctcagaaaca gaaagtggag tggtgggtgc caggagtcgg ggggagggga ggaaagggct
49561  gaaactcaat gggcacagtt tcaattttac aagatgaaga gWtctgtgga cggtggtggc
49621  gatggtggcc cagccacatg aatgtgctta cgccaccgaa tcgcacgctt aaaaatggtg
49681  aagacggtga cttatgttct gtatatttca ccgcaattaa aaKtttttaa attaaaattc
49741  tcttggaaca aataagaagt taaattaaaa attcagttct tcaaggacac cagccacact
49801  tcaagtgctc cagagccccg gtggctactg ccccagaaag ggcgagacga gcatctcccc
49861  agcaccgcgg gaagctctgt cgcacagcag ggctctggaa ggtcaccctt tctcagaagc
49921  tcccacttgc tcaatgcccc tcctccccaa gaccaccaaa gggtccgaca tagcttagat
49981  ctgtcctcag gactctccgg gcatgcagag gctctcagtg aggacgcagg gcattcatcg
50041  tcagggcaaY gccatgctcc aggcacggcc gcgccttatc tccctcgccc acgctgcgct
50101  cttgcagtgg gagctggggc tcagatcaga ggcagagacc ccccgctgac cctccgccgc
50161  cggtctccca Ygccccggga ctctctgcca cgccccgccg cctctgcagg acacccccac
50221  tgtgcccatg acaagcacac tgtcaacacg tttgctgaat gaatcagtgc tcacttctgt
50281  gcaacagggg acaacagaca cggcccaaat actttctcaa cttctgagac ttgtctccta
50341  aaacggtttc tctgttgtga taaaactcat ctcaatttaa gaatttttaa atttctcatg
50401  cttttctaga aacgaacctt cccattattc aaaatagggg gtacggctgg atcactaggg
50461  tttgaataaa gttggaYggc aaaagtgaga gaacgttcta gacatcctcc aaccagctgt
50521  tgtgacagag agaccctggg caccaggaga aaggttgatc tgcctctgcc agcctcatga
50581  aggactcacc acgggcccca catttggtca gcgcccttgg tgggctatca gaagtgaccc
50641  ctcctggact gtcactaaac agtgccactg tcatgataac aaaaccacat tttatgtgga
50701  aactgaaaac gtgttcaccc tactgagaga ctgaaaagca cattcactga cattatctca
```

```
50761  tgtaatcaca tcaaccccca cgatgaaaac actggcccat tttacagatg agaaaacYaa
50821  ggctcagagg acRggagcag cgttcccaac gacgcgcctg gaaaaggcga ggcctggagt
50881  YRccatcgga ctgtaattcc aagcccagtc ctttccccgc tgggttggaa ggcgacataa
50941  tgctagggga agaactcata ttgtgaaggc agccaagatt ttatacctgc cagtctcaca
51001  gacctagcat gaggacttcc caagataatt tagcatggca agtgcccagc atgggcccgg
51061  cacagtcaca tagtaggggc tcgataatgt agccattatg gttttattgt tattattatt
51121  attattatta ttattatttt tgagacggag tctcgctctg tcactgaggc tagagtgcag
51181  tggtgcgatc tcagctcact gcaagctccg cctcccaggt tcacgccatt ctcctgcctc
51241  agcctcctga gtagctggga ctacaggcgc ccgccaccac gcccggctaa ttttttgtat
51301  ttttagtaga gacggggttt caccgtggtc tcgatctcct gacctcgtga tccgcccacc
51361  tcggcctccc aaagtgctgg gattaYaggc gtgagccacc gcacccggcc gttattatga
51421  ttattgcatt aaaggtacgt ttcaaaaata agatgagggt aagtgtgaca acgctctccc
51481  aaataaaacg aattctgccg atgcagcgga cttcggcccc ctgtacggat aagRctgggc
51541  tccagagggc tagctgactc acccaagacc ggtcaagagg aaagtgagca tgaaggtggt
51601  gtctctgtcc agtgttcagc tcactcacat cccctcctgc ccctgaggta tcttttcacc
51661  agggccctgg ggactctgac ccatgtgtca gcttggctcc tggaggggct caccctggt
51721  ccgaaaagca gagctgggca gcagatcctg agcagacctg cacaccctgc tgcctgcctc
51781  tagcccggcc ccagaggacc tcattcatcc acaggtgtgg acacgcagca cggggttcta
51841  gaacttccca cctgcccggc ttccacacca cctccagccc tccctaagcc ccggcttcct
51901  cccacaaata ccccctgcc cctagggccc cactggcagc atctcacatt ccaggccgtg
51961  ccctggtcct ccttctcacc cccttctttt ccctgcagga ctcagccaag ccagtctgct
52021  cccctgggag cctgcatttt gaagactgga cgcccctcat ccccacagtg gctctgacca
52081  catgaggcag agagaggaaa ggtctgcaca gcctccaccc acacacggtt cagcatcctg
52141  gcacctcctg cttaggttgt tgggggtatg gaatgagggg gaggtggttc tttaatctct
52201  tagtgttagg cagaccatgg gcaggtgccc agaagacgaa ggtggcacat agacaccccc
52261  ttcaatagcc cagactcaca gggagaaagg aattccctcc ccaattcctc ccactgYgag
52321  ctttaaggag gggccctggg ttggtgtctg gccctcgctc taatgcaYgt gaatctctac
52381  tttaaacaga aaaggggctt ctgtttggag cgagaagaag gcagggctat ccagctgggg
52441  ctgaataacg tcactttatg tcttactatt atattagctt ttcaggtaaa ataaggttgc
52501  ctttttaaat gattttagtt ttaaaagtgg caaacatcaa gaaaacatat ttttcaaatg
52561  acgggacatt gaatgacatt gtcattcaaa cgactggagt ttgcacaaac ccgccttagc
52621  ctgtgaagag cctcaccaag ttaccatcac ccacgatgtg cagacgagag aactgaggtc
52681  agggatggtc aacttgtctc acctggggac ccagcaagcc tccctgagac tgtgtcactc
52741  acctccggct aacaaggaaa tcggcagagc ctcaggggac ctggcccagc tgggcctctc
52801  tggcctgccc agcccctggt tgaccctccc cgccccaccc tgccccctca gccaccccac
52861  tcacaatgtt catgagtgtc agcaggtact tctgtacgtg ctccttcccg tggaactgca
52921  ccacagagtc atccacgccc agcaggacct cgatgttgta gtcatcgtcY gcagcatgcc
52981  tgcgtgccct ccgcctcgag ctgttggcgt gctcctctag gaYgcccagg gcgcggctga
53041  ggctgtccag gctgtccagg gaggcccctg caaggagagg acaccgtctt cagcggcagg
53101  gcaaacccac ccggacacaa acctaccagg cgccagcttg gccatcctct catttaaaac
53161  tcatagcacc ctgaaccgag ggtattattc cattttacag aggaaagcga ggtgcagagg
53221  aagatggcag agacttgcca agctgtctca gacacagcag ggcccagaca ggcacctctg
53281  tgacttccag gaccgctcgt tccccagccc ctggtggcaa ccccagccac agcaggggcc
53341  acagtggcct ccacaYgatg gatcagacct gctgagactg tgagagaccc agcccagcat
53401  caccgtctgc cttatggagc ccagggctgg cattcagcca tggagaggtc gggaacctca
53461  gcccgcactg cctgacgctg gagtgggcag agccaccctt tgcccacact gcccgatgct
53521  ggagtgggta gagccacctc ttctcccccg aagggctgcc aggtgccaaa ggactggtgt
53581  cccaggtgtc atcgccagct gttatgactg gggaaaccga ggcccatcct gggctgtgca
53641  tgttccccag tgtctccttg ggcccctccc agaactttct gctaagtcct ccactgaagc
53701  gaggccccac atctctgggc caggtcccgg gccccctccc caggtgaacg gtaccgcctc
53761  tggcctgatt gaattgtgca gagaccaaga tgaacccctc tgtggcagct ccgctgcagt
53821  cggccctggg caggcactga cctcctgccc ccagggtgtg cccctggcca cttggggctg
53881  cMatcctggg gagtctgccc cggatatcgt ccctgccttc tgtgcagtgc tgtctctgct
53941  gtgttctgtg tcctgcgggc ctggagacca ccctggacca ggcttcagtt cccagccctc
54001  cactgcccgt ctgaaggcca cagcaaggct ggccaggctg acctgcagca tcgatggcag
54061  ccccagacca cactgcccac cgcccccaa gccccagtgt cctggaagcc ccctttccct
54121  tgcactggtc tctgtgtcta agccaggtcc cagccccagg gtctccatgg cattccccag
54181  gcaggtcctc agagactcct ggcccgggac agacccaggg ctgcaggtca tcgtgacatc
54241  actgacccac agggcggtgg ccaggccccg aggcccctgc agctgaggga gaccagcgtc
54301  cctgctgcac cacctctcta caaagagtct tccagaacaa cactttcac ccccaacgcc
54361  tctctcctgc tgcctcttcc aggcagggac aggcactccc tccctgtgag ggtggcccag
54421  gacaggccct ggaggcagaa caaggcccct gcaggcggca cggccactcg gacagtgagg
54481  cagcctggta ccaggccctc atcccggcac acgcttcctc acccagtgct gacagcaggc
54541  cactcggtgg acRtggccat ttccgtttta cagatgggga gacccatggc atcccagcat
```

```
54601  ggccgactct cggccagaag ctctctcctt gcaccctgca gcctggctca gacaagacag
54661  actgaacatg aagtttcagg cacaaacctg cagcccggct gtgggcaaga ccaagacaga
54721  cagtggaggt gcgaggcgga gggtgagggc tgggaaagag aagaggagta agtggggcca
54781  gggctgagca gctgctgggg ttccagtacc ttcgggggtc cttgtgccac ccccagctcc
54841  acagttctgt gtcccctcgg cgcacacaca catgcacaca cacacacatg cacacacatg
54901  tacacacaca caagcacaca catgcacaca catgtacaca cacaggcaca cacacatgca
54961  tgtacacagc aaggactttc cagggccact ccagggacag gggtggggcc ggcaggcctg
55021  cgggcagggc tgtggggagc cgagcagtcc acttagctgc ctggatgact cagggccatc
55081  catgccgttc ccagaggaag cgccagcaac tcaagcctga caggggggtt gaggaatcgc
55141  cactctattt ttgtacattt atttctttgc atttccaacg aacagagaca gctcaccttc
55201  agaatcacct tgggaaggag agtgatggca atttccatag gaaaactctt cctccctggg
55261  gaacaggccg ggcgttaccc tctgcccttg tcaaactagg ggtcacacac gggcggtgcc
55321  ctcggcaaaa ccagaccaca gaggcactcg ttgaggtcac gtggtgccat ctggttgata
55381  gtatttgaaa actgggagat ttcatgtttt aaaaatctag aacatccagc ttctcttgag
55441  gaattaagag atggggccac cccaggggta gcccKggtct gtgaattgag gggccacacc
55501  tggagacaaa acacacaggg cttggctcaY caggccacct gcctgccact gtcaatgtca
55561  ttctggcacc agaaggtatc acagtatgtc ctcctggccc taaccccaga gtccccatgc
55621  agggacccct ccagacattc cccgtaggag ggcatgggtg ccgcatcggg acagagctgg
55681  gctggggcac Rtcttgaggc tgcttctgcc gagcaggcag agtttttaac taaactgtgt
55741  gttgcaagcc cattaaaaac agcaaaggtt tctaaagatt tagaatctga atttcacctg
55801  aaatggaatt attattgttg ccatcattat tttaatcgtg ataatttKgg ggtgaaattt
55861  ggaaattatg ttctagagSa tccctccacc caggaccagt gcctagagag acggcccaag
55921  gcccaaaggc aaagtgggtg aggagaggaa gacaggggcc tgggccacct ggcaggtgac
55981  agccacgccc tgcgtctggc ccctggaagc ctcagtggtg ctcaggctgg acaggacaag
56041  gggagaagcc ctaagagcag ggggatctgc aatgccctca gacctggggc aacaggagct
56101  ctggcccagc ccccctcctg tcctcctctg tcccaacaag acccggcagt caggctgaag
56161  ccccagcttg tcaatcacga gtgccacctc agttttcccc acaataagat tgaccctgac
56221  cctgtcaatc acgagtgcca cctcagtttt tcccacattg ggcttaaccc aggccatgaa
56281  gagactctga ccacatgctg gcccttgcag acctgYtccc caaatagagc cttgctatag
56341  ggagctctgg ccagtgggcc tggcgtggtc ctgagtcgtc ttcctagtga tccctttgaa
56401  gtcaaccttg gccttgggcc tgcccacctg cactggttgc ctacctggtc taacagcccc
56461  tgttccactt ggtcctcca aggcagaaga gggctatttg ctgctctccc ctcctccct
56521  gggagctccc tgtgtagccc agccctgctg agctgtggtg actgggagct cacacagcct
56581  ctgctgtatc cctcggcact caccccgcct ggatgagtga tcagcgcacc catctcctgc
56641  agaggcagga ggatgacact gcccttggcc ttcctttcct ctgtgtgcag ccttccccac
56701  aagaaggcac tgggcccct ggggtgctg attgaccaag ccccagaagt catacccagg
56761  tgggctgcag ctaccctgaa gggaggtgtc tgtggcagga tcccatcttt taaataggta
56821  acacagagct ttcgagttcc tggcattccc tgtgctcagg gcccctttg gatggcagct
56881  ggagatctct ttgctcacat cgtggccaaa Kaatgacact gtgggaagca ctccagagcc
56941  atcctgtttt agagtctcta gaatggaaca aaaagactct atcgaagagt caatcaataa
57001  acagggagag gatggaatga ggggaggcag cagttctgtc cagggaattc catcagggga
57061  acgggtgggt cacagtagcc acgggctcat ccacagtgcc acagtgcaca gggcacgtgg
57121  gcaagggctg caactgccag catcctaggc acaccccgag tctccaggca ggggtgtgtg
57181  cacagccctt cacagtggca gctccatacc cccagcagcc atccaatccc ctcgccaagg
57241  tggaggcgtg tcaccatcag catatcgtcc tatttcagca tcagggaaac aaaccaagga
57301  gcaggaaaat tacatgactY ggacaagcca caccaccaga gaggaggagt gggcacgcgc
57361  ccaggcctct gagtccaacg ttgtccacat Rcccggagcc cttctgtact tcaccagcac
57421  tgaggggtga tttgcgRgaa tgagaattgt agaaacaagt atgattagac tagagaaSag
57481  aaaacctggg actgagtctR caacctcggg agcatcgtgg gatggtgcgg gctctgaggg
57541  tgggtacagt gggcaggtgt gggatctgtg ggcaggtgca gtgggcaggc acgggctctg
57601  tgggcaggtg tgggctctga aggcaggtgc agtgagcagg cgtgggccct gaaggcaggt
57661  gcagtgagca ggtgtgggcc ctgagggtgg gttcagtggg cacgtgtggg ccctgagggc
57721  gggtgcagtg ggcaggcatg ggctctgtgg gcaggtgtgg gctctgaagg caggtgcagt
57781  gggcaggcgt gggccctgag ggtgggttca gtgggcacgt gtgggccctg agggcgggtg
57841  cagtgggcag gcacgggctt tgtgggcagg tgtgggctcc gaaggcaggt gcagtgagca
57901  ggcgtgggtc ctgagggcag gtgcagtggg caggcgtggg ccctgagggt gggttcagtg
57961  ggcaggtgtg ggccctgagg gcgggtgcag tgggcaggtg tgggccctga gggcgggtgc
58021  agtgggcagg tgtgggccct gagggcgggt gcagtgggca ggtgtgggcc ctgagggcgg
58081  gtgcagtggg caggtgtggg cctgagggcg ggtgcagtgg gcaggtgtgg gctgagggca
58141  agtgcagtgg gcaggtgtgg gctctgaggt caggcagggg ctttgcagtg ctaagggtgg
58201  ctgggtgttc gctgtcccct gtgcgaagct cagtcctatg ccttttctgg gctggcctct
58261  tcacctgcga tgccctttt gctgctgccg ctgtgctggc caaatttagg ccccctgaaa
58321  gacccagaag gaagggagcc cgctgcctcc catgggactc agagctcttg aaagacagga
58381  gcatgttctg cccccatctg cctcctgcac agccacactg cgtgccacta ggggacgaca
```

```
58441  gggacagggg ccggggcagg gatgcttaaa acctgaggac cacactgttc agtgacacgg
58501  ccgactgctg tccccctctcc atgggatggc cgccccctca ttgctctctt ccttcaggtg
58561  tctgctgaaa tgtcagctcc taagggagaa ctttccttat ttcatcccaa attgaaatca
58621  gccctcccct gatttctccc gacagcaccc cgtgctcttc cttcctgtga cactccactg
58681  caggcaggtc ttgtctcatt tgtgaatttg cctgggcatt aactgacttt ccctctcaga
58741  tagagaaccc tgggggatgg agaccatggg gtctggtgtg cctcagtgtc cccagtgccc
58801  cacaggtaac cgcagggctg tgaggggcct ggagccatgg cagagaggtg ctctgggaac
58861  agagggccca gcagaggcga gctgggggcc tctggggagt tgggaactgg gatagaagga
58921  gaggcaggtg cagcagggcc ggaggggcca cactgggggt ggggagccga gaacaggagc
58981  aaaagtgtgg tggcagttgg agaagcatga gatggaacaa aatccagcta caaattactt
59041  gcatatggca taaccaagtc caaatgacca ggaggagtta aaacaagtgg ggcaaagaaa
59101  cgtaccatgt Mattgccaac caaggcattt aaggagataa actgataaaa caaacaactc
59161  atggaaaaaa atacaaaaga tacgaaactt tatgctccta aagcttcaac ctggtgcaag
59221  gaaggagaga caaggccaca gtgataggag cactgtaata catttattcc agacaagtct
59281  gatacagcat taggtaggga tagaaactat ttgaattaat aggaaaacct aaYgttcaaa
59341  cccaacagcc agaacacgtg accttgtcaa gcacacacgg gagaagttcc acatttttacc
59401  acattaggac acaactcaaa aactcaaaag ccgtgcccac agtcaccatt actgagacac
59461  attaggacac aactcaaaag ccgtgcccac agtcaccatt actgagacac attaggacac
59521  aactcaaaaa tcgtgctcac agtcaccatt actgagacac attaggacac aactcaaaaa
59581  tcgtgcccac agtcaccatt actgagacac attaggacac aactcaaaag ccgtgcccac
59641  aatcaccatt actgagacaa aatcagagat aacaataaaa ccctaaaccc taaacatctg
59701  aaattaaaag caccRttcta ataggcctag actaaataga aaatatacat tccactcatg
59761  gctcaagtag aaaacctgaa gaaaccaata acctcagaag aaaYtgaaag agcagtcaaa
59821  gaaatgcttc catagaagag tttaaccaaa Yccacaagga acagatactc ctcatctcac
59881  ataaaataat gcaaagatca agacttcttg aacataggaa taacccgcRa gaaagcagag
59941  tggaaaaaag agcttatcag ctataacagc aaaactccca agtatctaag aacaaacaaa
60001  aactaatgaa tgttcaacga ctacacaaaa agtagtataa tatagtctaa gRtctccaaa
60061  aacacaaaag aagacctcag taaatgaagc tacatggaca taatcctgga ctggaagttg
60121  gtcctcctcc aaatgaatca agaaatttgg cataatctcc atcaaataat tgttaaaata
60181  attgttaaaa ttattctccg tcaaataatc tccgtcgaat aattgttaaa attattctcY
60241  gtcaaataat ctccgtcgaa taattgttaa aataattgtt aaaattattc tccgccaaat
60301  aatctccatc aaataattgt taaaacccaa caaagtgatt ccaacattca tccggaagMc
60361  cacaccagac agaaaaataa Ygaaaaagaa tgacaatgag gaggcatatt tttttcaaat
60421  taatgcagtg tattataaaa taatattaat gaaaaYgtag ttgtgtcaat gtcatgaaag
60481  aaacagatca atggagctga ataaaacttc caaaaacagg ctgggtgcag tggctcacgc
60541  ctgtaattcc agtactttgg gaggccgagg cgggtggatc acctgaggtt gggagtttga
60601  gaccagcctg accaatatgg agaaacccta tctctactaa aaatacaaaa ttagctgggc
60661  atggtggtgc atgcctgtaa tcccagctac tcgggaggct gaggcaggag aatcgcttga
60721  accSgggagg cggaggctgt ggtaagctga gatcacgcca ttgcactcca gcctgagcaa
60781  caagagtgaa actccgtctc aaaaacacaa aacaaaacaa aaaaacttcc aaaaacagat
60841  ccaagaatat gtggggtttc caggttaaaa tggcRgattg aacacagata tctgatttgg
60901  ctcctttcta gaatcccatt aaaagttcag taaagaaatt taaaaaaaat ttaaagtcac
60961  aagcctcYaa ggataggSag agcaggaggg gaagaaaYaa caagggaact gtgggaggct
61021  ggaaacagat gggcaagtgg taacagactt ggtacatcaa gaaagctgaa tcccaggctg
61081  gccatgaaga cagccacatt ctacaaagtc tcccggagaa taagaagggg gaaaatcagg
61141  ttacaggaga ggtcatagac aaagaattgg aatcagaatg actcagagtt ctcaaaagca
61201  gcattcgatg caggaaaaca gtggaggaaa gccttcagaa ttctgaagga aaatgattgt
61261  ccaactggaa ttctgcatcc agacacattc cccatcaagt atgaaagtgg aataaggaca
61321  tttctagaca tgtcagttct caaaagattt atgtgacaag cactcctctc aagaagctac
61381  tgaaaggtgt gcaccatcaa aaacaaaaaa ggcaacaaag aaagagtaag acacagatat
61441  agaaaacgga agcccaacac agatagagaa aacgggagcc caacacagaa gacatggcct
61501  gggaggccca tggagggtgg cgagaagtga ccctgaggtg atggctctgc accagaYgtg
61561  gagagcgact gagccatact gagcagcgtg acccacgggg tgaactgtct tcaccaagac
61621  cccacctcca tcaggccatc tgtagcccgg ggacaaaatg cccaggagag cctggcctag
61681  gttcttggca gtacttggct tggccatgtg ccgatgaggg gcgctcccct cctctgctga
61741  ggacgcacaa cattcacaga agtttccagc tttcccccca ccgagagctg gaggcaggcc
61801  gtggcgagct tagaagcagg acgtacaggt cagccccctc cctctgaccg tatttccgct
61861  gcaggtccag cgcgtggtcc ccacctgggc cctaccaggt gcctgactgt gctgagccca
61921  agacttcctc gagaccttgc tcacgacttc cccaggaggg gccttgtcag ttcccggaga
61981  agcagaagtc agaccacgac ctggagactg atctgctcac ctccgggagc ctccatccag
62041  cgggggcagt gccgccctct ccttacactg ccagcgtgtg ccagctctcc Rctttaatat
62101  taatcgtctt tgatattcat ttgcatgtaa ttataaatag ttgctcaagt agcaatacag
62161  tgaataaaat tagtaaatga tacaggtagc aaacggtgct aggaaacggc ggaggtggag
62221  caggagggga caacctggca gtctggcact actgagggga tcatgaggaa gagcaccatg
```

```
62281  cggctcatat cctaaagata caggatgtct atcggatagc ccagtgccct ccttggactg
62341  acccttggcc catgggccat tgttcggccc catggactgg cttgcagatg ggcaaacttg
62401  cacaggtctg taaggaggca atggggagct gccccttgca gcattgcttg ggtggagtga
62461  ggggagctgg aaacaacacg ggggtcatca gtgggtgaga ggagaagcaa atgtggtggg
62521  ggcatcccac aaagtgctac caaggttaga agtttgatat ctacatagat ggatggatct
62581  taaaaacaga gtgccaagtg caaaaggtaa gaaacagaat gagacacaat tcagagcgac
62641  ttacRtaaat tatggataca cagacgcaag acagcaacac tcatgttgca aaaatgtaca
62701  ctaaggaaag gatacggttt gatcacctga aatggttgct cactgcagga gaaaatcaga
62761  aggaagagag caggctgggg agataaatgg cttttgtttc tttctttgtt ttaatgatgt
62821  taggacaact ggttagaggg aggaaaaggt caaattttga cctcatgcct taagcaaaaa
62881  cagattccaa gtggatgaga tgatcaaaag gaagtcatgg aagtgctaga agaaaatgta
62941  gcKaggcacc tttttatcat cttgctgttg ggcgggcttt gggttccaag cctagggctc
63001  tttcccagcc ctctccttag ctgccccatc ccctgtgagc agtttcccac tctgctggac
63061  tctgctggct gaatgcaagg gcagatggca cacttgctag gggatggtgt gaggggggat
63121  gggcacactc Wctaggggat ggcgMaaggg ggggatgggc acactcacta ggggatggcc
63181  tgagggcaga caggcacact cactaggtag gggatggcct gagggcagac ggcacactca
63241  ctaggtaggg gatggcctga gggcagacgg cacactcact gaggcacctg cacacagaca
63301  gaggtgctgt gctactgcct caacctgcca accatgtgga tgggaacaag tcatcctttt
63361  tccagtgctt aggagtcccc aaaacgtaag tcctaatgac cgcccYgcag agccagaact
63421  gccacaStgc ccagaagagg agagggaggc tcagggaatt agactaaggc catgatgttg
63481  gcaaatggcc aggccagaat gccagcccag ttcctgcaca caagcactgc cagggcctgc
63541  aggggccacc accRggctca ggaggaccaa agcctggagc accagcagcc tctcctccaa
63601  catgaggagc cccacccagg ggaggtcaac gggaacaagg tcatcccctc catttcttac
63661  Yaaccaagag agagtcgctc tgtggctgtg tattccccta aagataatca ttaagatgaa
63721  atatgtttat gtggaagtgt aatcaggaca cagcagaaag ccctgcttgg aagcaggcag
63781  gctctttgga ggctctggga agcagaaggc aggctcagcc ccacgggggc catcagcaca
63841  gagccccact ggtgtacttt attaaaagat gctcattagg attattacat cccagccctt
63901  tataacttta ttactgactt tgaattaatt tttgcaactt caacagacac agctcatcca
63961  atgccatttt tatgacctga ggtggatcgg agggtgggga ggggctcctg gggccggcct
64021  ggccatcagg agcgcatcag gaaccgctgt gccgaatctc aggggcagtc ctgacagttc
64081  tctaaactcc caYgggatgg gctgccccgc ggacagatgg acgctccagc ccaggcctgc
64141  tcagcctcag ccRtgcttca gggagaaaaa ggaagcacta aaggagagaa ggcctctccg
64201  ggccagtcct cagaacatac ccccgcacag cagaggacaa aggacacccc tcagtggtgg
64261  acacagaagg tcctggcctg cccagcacct gcacaccctc acagagccac ctggggttgc
64321  acagcacggt ggcctgccct gtctggccat tacacctttt ctgctagtaa accaccctcc
64381  cctatttgca ccccatatgg ctcatgggSa gccaatccca ctgcacccca gctccaggag
64441  tgcccaaggg gtcctgttag gccactggaa cctgatgctg tgtgttggtg tgcacaggaa
64501  gactcccgtg ctttcctctc tgctgggaaa atgtgactct gggRctgcta agtacctcct
64561  tcccccagga gcagcagagg cgagagatga gggcagcccc gtgtgctgct gacactgttc
64621  aggtccccaa atccagctat ggctgaaggt gatgcacccc tggacatcct aattcttcag
64681  gtcaattcat ttagctctct gtctcttgca accacgagag tcctgtgtgc ccttacaaac
64741  acagacacag ccaaatgtgc tggcctgaga gagacaccat ggtttggctt tgcagccaca
64801  gctctcttga acgattgagg catcagacca ggccactctc ttctgccctg tgcctgcacc
64861  tcccagtgtg gggcgaggag aaggtctgca gtatttaagg tctatgacca gaaaaggggc
64921  caggctctgg tccggctccc agatacgtgt ccttgggaaa tggtgcccag cagaggtgtg
64981  aggctgctga ggttgagccc aagccagcag ggccatgctg agtgaccagc agctgtgcga
65041  gcccctctga ggtgtcctgc agcagggctg gggcttcctg tctacagccc tcacagaggt
65101  tcccaaacac aacttccccc tcttcacccc agggctgggg cctcctgtct acagccccca
65161  cagaggttcc caaacacaac ttccccttcg tccccccagc acccgccgaa ctaccgaggc
65221  tcctctgcac ctgccccgtg ccactctcca gcggccYctg cagcccactc acctccaagg
65281  attcacgggg gtctcggggc cttcagaggc tggggcgggt gacaagagcc agcaagccct
65341  gcccctgcct agcatctgct taagccaggg agggtcccca ggactcacca cagcccccag
65401  ggctccaagc cttccctctg ctgggcagtt ggcccaggga aggggagctg gcctgggtaa
65461  tgtcacgggg gcaccgcagc acgcggcagc caagtggtgg gggccgatgg agaggccggc
65521  aggtctttta ttgaaaatat tcactgtgaa cttcagaaca aaacgaagat ccccacgggt
65581  cccaaaggaa gggagaattc ccaggggttg tgttctgaac gcagaRgagg tgggggccgg
65641  caagtggggt gctgacagcc agtgccacgg gacccatgtg gccggaggct tggccagtgg
65701  ctcagcagat gacaggcgga aaatccctgt caccagtcYg gtacatgctc cagagccccc
65761  gatttggaca tcatctggaa gcctggcatt gctccccgga aggcctcagg tacctcacac
65821  tcagaaggtc cagggcctgc tgcctcctct gcccgcacgt gcacctccgg ctgcactgcc
65881  agctgcatcg tccacctagg gagtggggcc cgcatgcagc caggtccatg ccaggagcag
65941  aacctgcctc tccccctccc tcaaaggcag ctccctcctc actcctcagg gtctctggaa
66001  cctacccctc cacgctctat gccctctgta ctgcccacgc tcctgactcc agcagcatct
66061  gcgcctcccc catctctgca ctcttcaaat ccaagttcca aggcatttct ttacctgcca
```

```
66121  acctcagttt cccttgttgt ggccttcacg tcctttgatg ttgagccctg cgttcatgca
66181  gggtgggcgt gggccctgca ggggtgaggt cctggtcccc tgggaagagc ttgcagccaa
66241  cacaagcggg aggtctcaga tgctgcccga ccctgtgcaa atgaggccct ctcctacccg
66301  gccatgagcc acgtgcaggg actcagcacc tgcctctgct ccctcctcct tcctgacccc
66361  tctaggtcag gagtccaggc acacagcagt gYtggggtgc tgcagccaag cacaggctct
66421  tcctagctga ttgtgggacc tggggcagcc ctgcacggtg ggccacactg tgccaccaag
66481  ctgccttcct aggaggaaga gttcctcaga tgcccaggca ccagggactt cacacacctc
66541  ctgtttcttc ttcatggtag ccggtggagt gggcacggga cctctcttac gcaaatgagg
66601  gaacaagccc tgggcccagg caacaggcac ccctgcgtga ccccagcatc tggctctgtc
66661  ccccgcatcc cgagcttcca atggcccatg gtggtgattg cacctggtcc agcagccaaR
66721  agggagctga aagtaccagg gccctggccc agctgaggac cttgctgcca tcacccacca
66781  tgacccttgg gcacaaagac cccccacttt cagtcgtggc accaagcaca gtccatgtct
66841  gaccaggacc tgctcaagga gcaggagtga ccgaggacaa ccccggggac caccccagcc
66901  ctcccccatg ctgggggtgg aagggtggtg aggcctgggg cctcttgatg ctcccatgcc
66961  ctgatgtccc atcctccagg acgctcccat gcccctgcgc ctcctgaggg ggcagggaaa
67021  ccccatgtgg gcgggcagca gccaggctcc ctggatctgc ccagagaaga gccccccgca
67081  gaggtgatgc aatgctcacc acgcccccct cagctcaaga ccctggaact tgccagaccc
67141  tcagccctct ctcccagtga gtgtcaggga cctccctttc ccctcaggct gctgggcccc
67201  caaaccacat gtcctccttc cctctgctcc agccccccat ggggctgagg agcaggcctg
67261  cccaaccttt gtttctggtc tctcctgtcc ttcacgcctg gctgtgggat cttctctcag
67321  acctgcctct cccacgggta aatcccaagg tgcagactca gagacagcac cgagaggccc
67381  ccagtgcagc cgccactctg agcccagagg ccaggccatc caaccctgca gggacggggg
67441  ttcctcccat ttgtcttcct gtgtgaactc cgtgggtcca gaagcctgag tttgggggtg
67501  gtgacaattg gccctggtgg accccacaca ctcctgtccc atgatgcttc ctgccctaga
67561  atatcccagc tgcagttgag gagggaaggg gctcctcata ctccccacac agcacccaga
67621  ccacggtgtt gacgaggctt aatttgatca gccctatttc gagaagggag gaaatcagaa
67681  atcagagtga gtgctgagtc ctgaaaattt aatccccaag gcagcctcac agggcctttc
67741  ctccccaacc ggggcaggtg gcagggatgc actacaagcc cagatcccag ggccaccctg
67801  agaaccagga ggggagggag ggccaccctg cctgcagaga ggatggcaaa ggccctgctt
67861  gccgggcccc agctgccctc aacactgcaa gggctcagaa gactggacca gcagctggcc
67921  gggcagaaac tatagaaatc atcctaattc tactttaaaa ggctggggtt tcctcttctt
67981  gcttaaaagc tggtgtgacc cttccaggta gcagccagcg gcaggcctgt ggctcactga
68041  gatgggctgg gtgggtggcc ctctggcctg tgctcccaac cagctgccca tgtgctcctg
68101  cctgccctgc agaggtgacg tggctgccat cacagcattg catgttgtga actgactcct
68161  gccaagccct gagagggcat caagtctggc agcagcccct gcagggccca gctgcctccg
68221  aacctccagc atgcttctcc cagggcagga gcaccctccc cagagcaccc agtcctgttg
68281  ccactttctg ccaggcaacc cctccccctg cttccaggtc cagcctgact ttcctcctgt
68341  ttgcaacagt tcctacctgc ctgccctggg cccatgccct ccaccaggac aagtcactgt
68401  ctccttctct ggctcccaaa accttcattt tcattcattt gttcattgtt cattcactcg
68461  tcaagtattt tgctaactac catttgccag ccttgcgtgg caccacctct aggagagcgc
68521  tctggggtgt caccatcaca ggctggcctg ctcagtgatc actcctcaga cacatgcaca
68581  cacacacatg cacgcagtca catacacaca tgcacactca cacgaatgca ctcatacaca
68641  cacacacgaa cgcactcaca tacacacatg cacactcaca caaatgcact catatacaca
68701  cgaatgcact cagacactca caaacacgca cacacgaatg cactcacaca cacgcatgca
68761  gtcacataca cacatgcact cacacgaacg cactcacaca cgcacactca cacacgaatg
68821  cactcacaca caaatggact cacactcaca tgcacactca tacgaatgca ctcacacaca
68881  tgcactcaca ctcacacgaa tgcactcaca cacacgcgaa tgcactcgca cacgcatgca
68941  ctcacgcgtg aatgcactcg catactcaca tgcacactca catgaatgca cacacacata
69001  cactcacaga cgcacactca cacatgaatg cactcacaca cacgaatgct cttacatgca
69061  cacaaacgca catgcataca ttcatcacat gtgagtgtat gtgagtgcat gtgcgtgtat
69121  gtgagtctat ggatgtgtgt gcatgtcaca cgtgtgtgca tatgtgacat gcacacWcag
69181  gcacacacat gcacacacac aaacgtgcac atgcacacac aggctctaca gtgaactcct
69241  ggaagactga ggtggccctt gacccctctc taagtcccca ggtacccaca tggggcttgg
69301  caaaatgaat aaataaacgg gccaaaaacg cctatKggat aaatggaaaa cttagttatc
69361  cttatgctac ttctgagcag gtggagacag gacagggtag gacgaggcgc agcgtggatg
69421  cgggcggatt gtctgtatct ccttggtggg agcagttggc cgtggagtct acatcggttt
69481  ccttcctggc cgtcatttac agggagagca tgagggcggc gtgaggtcag cggggcaggt
69541  ggatgctgtg cgcttactgc agccatgcgg tgggtgcacg ctaccaccgt cttctcctct
69601  ttttcttggg agctgtcgcc atggctcccg gcacaYcctg acatccgtag gcgccatcct
69661  gacaacacgc tgccggccgc aggcctcaca ccacagcaat tctcactcgg gcctccctga
69721  ccctcgacct gtgggtccct gctaggctgg gcgtgtttcc cgatgcccca tctctctgac
69781  ctagacatat tttgttcaca tgttgaacag agagaaacgg tcYgcatttc cagaaagaaa
69841  tatactctcc caattttcct tggagcatgc ggccctcttg gcttgtcttt tgcttattcc
69901  ctcttcactg agaaatattt tgctcccRtg agaaaagcca tgtgggcagg gggatgagag
```

```
69961  ggcacactgc ctccagccca aggtggccag tggtgactag gagggtgcag gtccatgttg
70021  ctgggtctta tttttgtaag gaagtgagaa atctggattt gcatgtgaag tctctgatct
70081  ctaaatactg gcaaaaagca atttaagaat aatgtaggtg ctgtgctgct tgtgaaatga
70141  accaaagctg ggtccccagg tctgtctgcc acctcagctc cacgcccaga ccaaagctgt
70201  gtcctcaggt ctgtctgcca cctcggctcc acgccctgag caaccgtttc cctgtatcct
70261  cctccgtctg gcctggagag gttttgagca cagtaggttc tggccaacca gagtgagtcc
70321  acctgcctct gcctcacagt ggctgaagct tcccgggccg cagttcacgc cccacttgtt
70381  tctccacatc cctttcccac cttgaaggac agctcctgat ggatgtgttt tatggtggaa
70441  tcctcacgca ggggcctgag gaacactccc tggttatcca cacggcaact aacactcagc
70501  acgcaccagg ctcctcctcc ctctcatgga ctctcaattc agccccRcac agccaagggc
70561  tcacccacat catgtgcgct tcagacaaag gactaatttc cttaatacat aaagcgctct
70621  tacaaatcaa caRgaaacaa tccagcaatc caaaagggaa atggacaaac ggtattgata
70681  caaaagtgct gggtagagaa gggcatgctc cctttaaatg atatggaagc agggaagtgc
70741  atggtccctg gctaagggct ccaccctcac ggacctatgt gaggacaggc actcttgcct
70801  ttgtgcccaa atgtcacatt tcccaagacc accctggtcc accatgtccc catcctgtgc
70861  ctataaaaac ccgagaccct aacaggcaga cacaggcggc tggacgtcga gaggagcgca
70921  tgaggggagg aacacacagg cggctggacg tcgagaggaa cgcaccaacg agcaccagca
70981  cgctgcaggc caccgaccgg cagaagcaga acgacacgga gtttggccgg ggcagtcaga
71041  ggagagccca ggctgcttag cggcccgact ccagggaaag ccctttgcac cccatcctcc
71101  ttctggcttc ccccatctgc tgagagctac ttccactcaa taaaacctcg cactcattct
71161  ccaagcccac gtgtgatctg attcttccag gacatcaagg aagaacccga gatacagaaa
71221  gccctctgtc cttgcgacaa ggtagagggt ctaactgagc tggttaacac aagccgccta
71281  cagacagcta aagtaaaaga gcacatgcag cacacgccca ctggggcttc aggggctgca
71341  aacattcacc cctagacact gctgtggggt cggagcccca cagcctgccc gtctgtattc
71401  tcccccagag gtttgagcag agggacactg aagaaggaag ccacaccccc atagcacgcc
71461  ctgcgaggag gacaagagaa cttctctcat ttcaatatga ggggacaatt gtcagaaaag
71521  aaaagacagc agcttttctt ttcttcttta tctctttctt tctttccctt ccttctttcc
71581  ttccttcctt ccttttcttc tttcttctct ttcttctttc cttctttctt ttttttttt
71641  gagacagagt ctctgtcacc caggctggag tacagtggcg tgatctcagc tcactgcaac
71701  caccgcctcc cggattcaag cagttttcct gcctcagcct tccaagcagc tgggattaca
71761  ggtgcctgct atcatacctg gttaattttt ttttttttt gtatKtttag tagagacagg
71821  atttcaccat gttagccagg ctggtttcaa actcctgacc tcaggtgatc catccaccct
71881  ggcctcccac agtgttggta ttacgggtat gagccaccga gcagcttttc agtgtatgag
71941  aagacgctcg acctcaccct taattaaaga aacaacctgc atcagattgt ccaaataaaa
72001  atgtacggat caggggtaca tgctgagaga aacggatcca gccaaccatc ctagggttgt
72061  ggtcatcctt atcaaagttg aaaatgcaca aacctttga atccacaatt ctagttatca
72121  aatttaatcc tacaaatgtc ctcatacaag tagccaagga aataagtgta aggatatcca
72181  Sggctgcatt ataagaaacR gtgaaaagaa gtaacgtccc catcagtcaa ggtctggtta
72241  agcaagtgat tcacaggatg gaatgcctga gcaggaggaa tgggcaggtc tggaggggct
72301  gctgtggacg acgtccaaga catgttccct gataatcgca aatgcagggt agcacacggt
72361  gtagtctaca gtgtgcagga aaaagtcaga aaaacgaaaa cacagtatct acaggacaca
72421  aaatcccttg agccagagat tctaatccta ggatttatat atgtgtgtgt acaNatgtgt
72481  atatatatat acttgtgtgt gcacaggaca tcctgaaagg acacagaaga aaggtgtgca
72541  gtggctgccc tgcagaaagg agctgaSttc caggacagcc aatgggaggg ggatgaggac
72601  agcaatgagc atttcatatg gctgcaatcc ttagtccagc caaaaagcaa gccacgcaca
72661  tgcaggagag gccaggactc tcccagcagc tcccccaggg gtcaggggca gagggagccc
72721  ccagcctggc ctgctccctg acgactctac acttggcagc tgaagggggc caccctgaca
72781  gtcaaggccc agctgtgatc tggggtggaa ctggtctggc accgatctgc ttggcctggc
72841  tctgggtgct ggcacggcag tatctggtgg gctgcagggc ccccagctgg ggccctttga
72901  gtgatgatga gcctgctggg ctgggaccac agagtgagca ggaccagcat cccctcaacc
72961  ccagatgccc tcYaggactg cagggcccag acacagagag ggaacctgac gctcatgggg
73021  agggctgaga ggcaggcaga gggggaaggg tgttcctgac cacggcccac aggaccagca
73081  gtgcagaggg cctgggagtg agggaagccc ctgctgtgcc aaggagggag ggccaggaga
73141  ggagagatgg ccgaggccgg gaggagggca gaagtgcaga gagactagag ggggcagggc
73201  agccctggct tggggctgga gagggagcca ggaaggaggg tggaaggcag gggaggcagc
73261  gtgtggacaa agactgagag ggggagtcac agcttgggtg cagaaagtgg ggccagggag
73321  gattccgggt ttctgacctg ggcaaccggt caccctggga agccttccct gcaagggacc
73381  ctcgggagga gccgcgtggg aggaggagaa ggccgtgtgg ggcgtgttgg gctgagattt
73441  ctgtggggac acaaggacag acacccaYga gacactcagg caggagtggt ctggagcaca
73501  gagagagggt gggccggagg ccccaggtgt gggcggcctc caggatgaat cagctgcaga
73561  gcaccgcagt ggcgcacaca gatcagtgtc ctgatctgaa aagtaggcat aacgatgctg
73621  gccacagccc acaagtaaga cacatagaaa acctgaggcc cacagaggtg acaggaacgg
73681  gccaggtgca cggacagggc tgttcctgac tcagctcact ccaccagaac ccagtctggg
73741  caccagcctg ttttcttgtc ctctccagcc agcagggcag aattgggggt ggacttgccc
```

```
73801  cagcctgaag acctccgggg ccctggctcc tccctgctcc acctgccata gcccaaaacc
73861  agtgtgggtg tgaagcggaa ggagactcYg cagcaaggcc cagctcttat gccggccact
73921  gccttgcctc ctgcctgatg cagtctctcg gcagcaaggc aggtgccctg agacctggag
73981  gtgcccccag ccccagaacc caccatgcgc ggctgggccg actgtgcctg cccttaaggc
74041  aggcagaaca ctaaccaaag ccagcggaca tccactgcct gcggagcatc tggggaaggc
74101  tcctgtgggg ctccagaccc ggggcggtgc cttcaccacg gcctcctcat ccagcatcca
74161  caactctgga gctaggaagc ccggtgctcc ttcccagagg agggagccga agctctgcca
74221  gtctgcactg aagtctgtgg tgtgcggtca cctgagaaca gctcagtcag tctggctgga
74281  tcctgagctc ctcccccggc ctgtgcttga gaggtgacag ccagcacgtg agcaagtgcc
74341  ctgggttctg gtcccagcaa agctacctcc agctgtgcac ctcggtcagg cacctccagc
74401  tgtgcacctc ggtcaggcca ccctctctcc gtcagaccct cagtgtcctg atcagtgtcc
74461  acaagtaaga cacatagaaa acctgaggcc cagagaagcc aaggaagtcc ttacaggctt
74521  ctgtcagaga atcggaggaa aggaggggac gccagagaat ctgggcttaa gtgacttggc
74581  cgtgatcaaa acacaggcag agtcacaaac acgagacccc gctgcccact cccgacggag
74641  aggtaattcc acaaacacga gaccccgctg cccactccac aaacatgaga ccccgctgcc
74701  cactcccgac ggagaggtaa ttccacaaac acgagacccc gctgcccact ccacaaacac
74761  gagaccccgc tgcccactcc cgacggagag gtaattccac aaacacgaga ccctgctgcc
74821  cactccacaa acatgagacc ccgctgccca ttcccgacgg agaggtaatt ccaggtcagt
74881  ggcatccagc cttccccggc ccccaggccc ccagctgcca ccaagaaaca ctctttgtag
74941  gggtcctgcc ccactggggt gcagaggtac atcccccaag gcccagcccc gcaggaagcc
75001  cttcctctgc agccattctt gaaatcacct ccaagaaaaa agaaatgctt cagcttccaa
75061  agatatcccc aggcaggaaa tgggccgcag gcagcatgaa tgtttaatta cgttaattgt
75121  ccaagtccag cgcacatcat ccctcctaag taccttatgg gaaatcgtaa ttaggcgtga
75181  aatggctcat tttcacaact ccccttttctc ggggttctcc agggcgcatg cccctgtcag
75241  ctggccggac aggcctctct tgccaaggct taccctcctt ggttctaatt taattttgtg
75301  acctttttctc tcgacatcct gaccccgtac atccctgcgc cttggcacac tgcaccaaag
75361  caccatagaa ttactgagct ataagcctct catggaaatc tgtttttgac tttgttagaa
75421  aacactataa tcaaatccct gagagtcagg agggatgggc ttggcctgcc agaggaaaca
75481  tatcaccgga ttaagtgatt tagcagaggt ggtcccggcg ggaggagggc agggcaggct
75541  gggcagggct gggcgtgagg tgggcaggca gggtgccctc gggggcaagg ggggagggga
75601  tgcgcagagg cagaggatgg gcaatgtggg attaccagaa agtgcggtct ggacatccca
75661  gggcctgcag gcttcctgag tgcctacctg gccctgggca ctcacagggc attgatgccg
75721  agatgctcaR ctgtgcagag ggtgtgcagg tctggtggtc acttatgcgc tccagggcct
75781  gcttctgctg atgccagggc aagacccagc ctcaaacaca catcaaatac atacgcttga
75841  cgttatgccc gggagggctg tgcacacagg cacacagaga cggtgagact tggggatact
75901  tgggtccagt tactgtcacc ttgggtctca cttctgggag cgtggatttg gctggcacca
75961  ctgcactgcR gtgtgtctgc gtctatacag acttcctcca tttcacgcat gtacctaaaa
76021  cataccacca ttcatgtact gtcaggcact ctttcatttt gtaaaacaat agggttatca
76081  aggcctgcgc agtggctcat gcttctaatc ccaRcacttt gggaggccga ggcaggcgga
76141  ttgcctgagg tcaggagttc gagaccaggc tggccaacat ggtgaaaccc catttctact
76201  aaaaatacaa aaattagccg ggcatggtgg tgggcgcctg taattgcagc tactcaggag
76261  gctgaggcag gagaatggct tgaacccggg aggcggaggt tgcagtgagc cgagatcgtg
76321  ccactgcact ccagcctggg cRacagagcg aaactcagtc tcaaaaaaaa aaagccgggg
76381  gggctaccaa aagatgagag ggacccaggc ctgtattgca catccacatc agtgacagtg
76441  taatggtaYg cagacccccc ccccRcatgc acacgcattc tgaaataagc caggcccaga
76501  aggacaaata cggcactcgt ccactcacat gaggatctgt aatcaaacgc atgaaagcag
76561  atgacaccat agaggctgcc agagctgggg gagcgggaaa tggggagttg ctgttcaatg
76621  ggtgtaaagt tttagtgatg ctggacgagt aagtactaga ggtctgctgt acaacgttgt
76681  gcctgtagct gaccatgtgg cactgtgcac ttcgaaattc tctgagaggt ctgagctcac
76741  gttaagtgtt ctttccacaa aagcaaacaa caacagcaac agaaatgaag Kgacagaagg
76801  aaaccgtggg agaagacgag tgtctaccgc ctcgatgtgc tgatggcgtc ccggtgtctg
76861  cacaaatcca cacttgctga actgtaaggg gccggtgacc tctacagtcg cctaccatgg
76921  cgagcataaa cttgcagaga agaggatgag aattctgata ataggacaaa tcaaagctta
76981  acaagtaatt aaaggacaaa ttggtgcata taacaagtcg ttccctgtct cgcagctgac
77041  atggatcaat gtccaaaatt tttatccaaa ttgttataaa tacacatgag agtcttctcg
77101  gtgcagtgaa tagtgaagtc agcagaggca gtggctcacc cctgcagtct cagcacttta
77161  ggaggccgag ggggtaggat cacttgagta ccagagttag aggctgcagt gagccatgat
77221  tgtgccactg cactccagct ggggccacag agcgagaccc tgtctctagg aaaaaaaaaa
77281  agaaaaaaga aaaagaaaaa aaaaaagagg aaattagcca atatcccaga gagtgaaggc
77341  agaacccgta tcagcttttg ccaaaaatga gaactccaca gttgcctccg cattctgtct
77401  tttaaaaagt gtcaatttta cattatgaaa tagagtgcat ctttttaaag taaaatcgat
77461  gctccaggaa gatattccac gtttatcctg gactttggtg ccctctcgac acttggtttt
77521  gattaaatta atccaaactc cagtttgcta agccagtgca cctgtgtgcg gctgttacat
77581  tgcaccaatg ttttatcaaa tctccgacta tgcccaagtg cggcgccatg gaagccacac
```

77641 gggatccctg acagacagaa acatccatac tgctcttaag gtggctcagg cactgttcca
77701 agcacctcgt ctatagttgc ccactgattc ttcgcagcag ctgtgtgagt tagctgtgat
77761 gcttatcttc attctgcaga tggggaaact gagaaaggct atcccaattt cacactgctc
77821 ggaagtgtca gaaccaggat atgaaccctg gcatggctac caagagtctg tgctcttgaa
77881 cgctgtgcta ggccactcct tctggggctg ttacatttta actctgacat gtcaagcaaa
77941 tcactataag tttattgagt catttcttag ctgcttcatc tgtaaagtcg ggtgacaatg
78001 gctgcaggtc ctgccactca gacgattccc acgcgtgtct gYatcaggat gaggatgagt
78061 agatcggtaa agtgccttgt agactgtgat gatcatattt ttgtctttga ttccactgcc
78121 agcacaatac ctttttttt ttaataaagg gctgttgaac tgcaattccc atgtttgtat
78181 acattcttct tctgtttctt tggttaaagt ttcaagattc tcttagggtt caaatgttta
78241 aatttcaaat cctttggctc atctgactaa ttacaagcat aaaatatggc atttccaaca
78301 agtctggaga atggaagcac atgaaattat gcacgaccat gagcatctgt gtcgggaggc
78361 gggaaggcgt tcacccttca aactcaagtg aaaaaggttt gccgtagtta aaggctgctg
78421 acaaataact actgttctga gaaatcacca ctgtttactg ggagaatcgt ttttcagcaa
78481 atatatcaag aaaagtaaat atcaagtata atttgcagag ttgcagataa ctccacattt
78541 tggaataaaa aacttctgtg tctgtgtaca agtgtgcaaa acacagcaga gacatttttc
78601 tttccaatcc tgcctaaata ctgactgaac atcatcagtg ccatctccca tgactgtgac
78661 agtgtatctt gtgtgtatgt gttgtatcat attatctgct ttgttaaatg ctatgcttgt
78721 taaaatgtgt cacattaaaa aacaaaaaca gcccgggcat ggtggctcac gcctgtaatc
78781 ccagcacttt gaaaggctga gggtggggga gggtggatca cgaggtcagg agttcaagac
78841 cagcctggcc aacatggcaa aaccctgtct cctctaaaaa atacaaaaat tagccaggcg
78901 tgttggcagg cacctgtaat cccagctact cgggaggctg gaggcaggag aatcgcttga
78961 acccggaggg agaggttgcg gtgagaggag attgtaccat tgcactccag cctgagtgat
79021 agagtgagac tccgtttcaa aacaaaacaa aatgaacaaa caaacaaaac aaacaaaaac
79081 aaaaaaacag aaacacacac tacactgact acactgaagc cctcaagccg ctgagcagcc
79141 atctccaggt ccccaaggac caggcaccaa ggtctggggg tggcccagca tccattctcc
79201 cctttctcag agcagcagcc cagtgttatt tcctggaatt cctggaaccc tgcatgcaca
79261 cagccctccc caagccaaac atcctctccc tcacagagtg tgggatttga gccgcaggag
79321 ccagaagagg aaaaggtagt ggtgtcacta aacacctggt cacaatggtt aagaccctcc
79381 tgtgtccagg accccgactg ccaggccctt ccacagcccg actccccgtg gactctgcag
79441 gtttcctaat gtcctcccag taactcttcc tggctcaggg cagctggact tcatgcaagc
79501 tctctgccag aagagaccct ctcctgccac aggcgccctc cccatcagat gccagagata
79561 tcaccagccc tcgaggctta acccctgctc tgtgggggat tcctgctgct ctgcctgaat
79621 tcacccaggt gggcagtcct caggtgactt ctccagctct gcatggagaa ggcctcacca
79681 tgcatctcag agagaagtgg aggctgcacc cccacaggaa gtggggccca gtccaccgtg
79741 ccctggacgc tgctcatcca ctaggactgg gcttccgtgt gcagggcttc accctcgctc
79801 tcctctctgc ctgctccaca cctgctgctt tgacctccat gaccatggac ctgctgacag
79861 gtgccccccg acccacctcc agcctgcacc tccccaggct ccagaccccg ccccctgctg
79921 cctgcaactg cccctggggt gtcacaaggc accttcatgc caacaagtcc caaacaaacc
79981 tgtcaccttt ccctacccca acccatcagc cattgctgct gtgcccatct catctccaca
80041 tccaaggagt caccgcatcc tggcaccttc cccatctccc cgtccatgat gagctcagcc
80101 cctccctcta cctggatgca gcagcctcct cccagacctg gccccatccg ctgctgctcc
80161 ctgcccttca ctccctgtag ctcgagtcct cacctgagct tgcccccatt aaaatcctct
80221 gtacctccct cttcccaagc ctagcagacc cgtgcgggag tgcgagcaca ctggctaggg
80281 cctcctgatg ggcctgacct gcctgccaac cctcccaggg acctgctcat gttcccgcaa
80341 cgcccttaca gccatgggtc cgagaaaaca ctgctcactc tgcccagaat gcctgccctg
80401 ccctttctgg cagactccta ttcagtcttc aaaacccagc tcccagctcg ttaggcccgc
80461 aaagagagca agttactctc tctcctagac tcaagcaccc tgtgcttcct tcttttaaac
80521 cactgatcat gcagaagtat aagctcacca gtttccaagt cccctaacca gaccatgagc
80581 tccaggggta aaatcatgca tcagattcat ctctgggtca cctgccttgg ctgagaggag
80641 gctcatgaag gtttggcaca atgggatgaa ggaatagaca aggagcaaga atacgagctc
80701 atcctcatgc ctcagaatag catgaaatgc tcagggtgtg tgggacagaa ctgacgcYtt
80761 cacaccaatg gagccagRtg ccagcctatg tgtgtccaag tcctaccaag tcccaggctg
80821 catggaaatc agagggaccc caaatcgaat gagcgagggg cccttaaaga aactcacctg
80881 gccccttttgt ctcaggtcct aggggttggt gctgccagga actctcatag gagagggcct
80941 tgttcccacc tagtcccaag catctgagca gggccaacga aagtgctggt aggccaggcc
81001 ttgccctgga gaggaagggc agagaggaag gagaggggaa gcggggtgga ccacctctgc
81061 tcagaccaaa ggcagaatcc agtgctgatg gttgccaata gggtcctctc tgttgctggg
81121 cccccatgaa ccatgtgagc cctgcacaga gctcctgcta gatcctgggg gtctccctgc
81181 actgggattg ctccaacagt gcccccaccc tcagggcatg ggttgccctc tgcatctggc
81241 caagtgcctt cccagacacc ctgcagcctc agcctcctgt gaccactcat gtccacctag
81301 cctggtcctg gtcccaggtg ccctcctggt ctagctgcca ctaaacagat gagaaKctcc
81361 ctcccatccc agccctgaaa tatgctcagc ctcaaagcct cttggcacat ctcagcttcc
81421 agatgtcctg tgccttgtga gatattaacc acactctgcc tagccctctg ccatgaggtc

```
81481  agctccgctc ccaggcaggg ggaagagctg ccttgggagc aatgatgggc atcgtccctc
81541  tgtgctgtgt ttggggtctt ccctccctcc aagtcYtgga ctttgggccc agaaatcact
81601  ttccctccct cctctctgag cacacaaagg gcaggacttg tcttcaggtg cttggggaag
81661  agggacgcca attgttccag ccactcccRt aagggtgaac caggagacta accatcaaat
81721  tcaccaggaa atcccaacct ccaggccctg actgaggcMc taagacccaa gcaagcaata
81781  tcaatgaaag ccagaggtgc ttaaggtggg gaacaagaat gagctgtcag aggcctctga
81841  taaagaatcg tttaaaaaga ctttctttgc tgcggctcat gcctgtaatc ccagcccttt
81901  ggaagtctga ggcggtagga tcacttgagg tcaagaattc aagagcagcS tgggcaatat
81961  ggtaaaaccc tgtctccata cacataaaaa aaattagcca aacgtaatgg ggtgcacctg
82021  cagtcccagc tactcgggag gctgaggtgg gaggactgac tgaccctgag aggttgaggc
82081  tgcagtaagc cgagtccatg ctgctgcact tcagcctggg tgacaaagca agacctggtt
82141  tcagaaaaaa gaatttcccc cttcgatgta tgctatggac tgaatatttg tacccccaaa
82201  attcatatgt tgaaacctaa tccccagagg gatgatttta ggaggtgggg cctttggggg
82261  gtaattaggt catgagggtg gggcctcatg aatgggatta gtgcccttat caaagaagcc
82321  ccatggccag gtgcagtggc ttacaccagt aatctcagca ctttgggggg ttgagacggg
82381  aggatagctt gagcacagaa gtacaagacc agcttggtta acacagcaag ccctcatcac
82441  tacaaaaact aaaaataaaa aaaaatatgt tgcatgtggt ggctcacatc tctagcccca
82501  gctacgtgag aggctgaggc aggaggatcg cttgatccca ggagttcaag gacacagtga
82561  gMtaggatcg tgccactgca ctccagccta ggtgatgagt gagactctgt ctctaaacat
82621  ttttttaaat taaaaatgta gaaataacat aaaagaggcc ccagagagct ctcttgcccc
82681  ttgcaatgca tgaagacaaa gtgcaagaag gtgccatgtg tgaaccagaa ggtaggccct
82741  cagcagacac aaaatctgcc agcactttga tcttggactt cccagcctcc agaaccatga
82801  gaaagaaata aacactatgt aagccacctg gtgttggggg tgctttttgt ggtagcagcc
82861  tctactgact aagacagtgt cacttcagct actctcaaga aaggcttcgt cacctggatc
82921  cagtcgcgtc agttaagcgg tgctgcccag ctctgggagg ctgggggaga tgaggcgatg
82981  tgtgattctc aaggtcagca tgttggaaag tctagcaggg tttaatgagg acggaattaa
83041  aggagacggg gcctgatgag gggctctggg cctctctgtg tccctgtctg ctttgtctgg
83101  aaaatggtga aaggaaggag gcatcttgga gcatctgtgt cctctggttt tccttgatcc
83161  ctggattcac caggacacaa aaacccagtg cttcttgtac tgcaaggtgc ttgagaaagg
83221  aagagcaaac ccacaagctg aagagtccca ggcagccatc gctcccgaca cgcacgccgc
83281  agtgtagctg tggctcctga gaacggcggt gttaaaggac agttacttaa ccagaacttg
83341  gggtcccccc gccccgcccc acggaggcct tgaacatcct acaataaaca cacaccgaag
83401  ccatgttctt ggagagactt tggggaggct gtgcactctg gaaacagcca agctgttctg
83461  tggcttggaa gaaacaagca gttccatcca ctctgggctc acagatattc ctcctgagct
83521  tgaaggaagc cacagcggaa cttggagctg ctctagttct ctggaacatg cagcaggtgg
83581  aaccgcagac Rtctctccag ggagctgagt cccggttttc acctgctggg tgtccacgga
83641  ttcaccccca gctactgtgt aggggccagc tcccctcagg gactgctcct gggagaccgY
83701  gggagtcacc gcagctccct gctctgtgga gcggccacgc tagcagaagg aacagagggt
83761  gccagtgctc tgagtatgcc ggagggcagt gagtgctgcg ggaaggggct ggagggcaca
83821  Sggtctgcga gtgccagggc aSgtggtgcg gggggagctg tctacaaagc cttagagcgc
83881  cagggtaggt cccactggaa gggaacatgc aagcaaagac tcKaatgaKg tgggagggtg
83941  agctgagggt gtctagaaag ggcatccagg cggaaggagg accccatgtg gggttttgaa
84001  aagaagggca aggaggccca Sgatggcagg aatcaagtga gtgagaagga aaatggaggc
84061  cacggggtcc cagggcgagg cgctgggtcg tgtggggtct ggtaggtggc ccgggtgctg
84121  ggtgctgact tctgagctga acgaagcagg agccactgtg ggatttccag cagaRgacag
84181  acatgatcca gcagaaggca tcaaaggatc cctgaccacg gaccgcccca ggacccttcc
84241  accatagtgc aggattcctc ttacaggaaa tgccccagta ggcagatcta gagaggcagg
84301  aagtggatga atggttgcct ggaaggtggt gggggaggaa ggacgacagc taaggggtgt
84361  ggggtctttg gggagggaga agatgttgtg aatataataa aaaccattga atcgtaYact
84421  ttaaatgggt gacctgtata gtatgtgaat tatatctcaa taaagctgtt agagaaaaga
84481  atccctgctg ctgtgttgag gacacatggg ggtggggagg cagggaggtc tgctgggggc
84541  tcccaaagtc atcagaagag gacaaaggct tgacgcaagt gacaaccgtg gagatggtga
84601  gaagtgatca gggtcggggt ggattttgaa agaaaaccta aaaagatttc tcaacaggtt
84661  tctcatcagt gtgagaggaa gagaggggtc aaccctaact gcagagcttt ggctgtgcaa
84721  atggaaggaa ggatcagccg tgcacaSagc tggggaaggc cgagggtgga gtgcggagag
84781  ggtgagcgcg agttcagtga ggggcgtgct gaggtggtac ttccaaattg aggttggcaa
84841  gtagagaaat gccttggaac ttggatttga agagtgcaga gacagatgag gtgcagattc
84901  tgctggagtc aggagcgtgg gcaatacaga gagcatggaa ggtggagggg cagttggaat
84961  atgagtcttg ggtgcaggag agagatctgg gctggagacg caaatctggg agccatttca
85021  tggtacataa agcaacaaga ggaatgagat cgcccacaga ggggtgcaga gggagaccaa
85081  ggagcgtcca ggacagagcc ctgggcgcat caaccccaga gggtgcggga agaggaagga
85141  tcagcaaagg aaacggggat gaactgtgag tgctgtgatt agaccaagaa agtgggtgtc
85201  cggtaagcca caccaaggga gcaggaggga ctagcctgcc acgtgctagg gatggcgact
85261  gaggattggc agggagatgc agcagcatga tgacctcggg gagggtgcct ctggcagagt
```

```
85321  ggcacacaca gaggcctggt ccaagtgggg ttaagacaca gtgagaggag aggaatcgaa
85381  gatggcgtct ccacctaggg ggtgctgctg agagagcaaa aagctgggag agtaggtgac
85441  agacgaggga agccgtcagg tgtgaatgcg gatagggagc agatgttgga ggtgttcaga
85501  ggacggaaga tatgaaaagt catctggaag gaggcaaaca gactgagggg agcagtctgg
85561  ctgctagcgg caccttgctg gtgaacatca tcgtaagcaa gagcagaagc agggctgagc
85621  tttgttcagg ggtacccgtg ccagcatgaa gtaggtagaa agtttcattt taccaggact
85681  agggcattgt tcagtagatg ttacaaagca agagtgactc caatgaggga acctgcagtt
85741  taagaSaagg aggctgggta aggggtggag ggaaggatca gtggtgtgag agaccgtgac
85801  aaggcggcag catcaatggc ctgcaggttt gctggagcac aggtcggagc aaaagggaac
85861  cgggaaaata gaaggtcatc agaatgcaac actgcaacgg attatgcagg tataggggcc
85921  gctggcaaaa gaaggtttaa ggtatgacca aggccaaatc cagtggggag tccttttgg
85981  aaaccttgac agctgtggtc atggtcgacc tcatgggaaa ttttgcaaac ttgatcctgt
86041  gtcaaatgag ttcccgtgac gcgtgtcagt gcgtgtggat cttgctgttt gggggagggc
86101  agaaactctg cagaccccat gccttgccRc cctcgaccct gatacgcgat gccaatagac
86161  acactgctgc ggaaaccata aacgtcacca gattcagagc ttgagcccac ctctcccaga
86221  ggttttgtcc ggtaaaggga agaggaacag ggttcaactc tcctggcaga actctatgga
86281  tgccgcagaa gacaacgtta atgagcttgg cttaacttac aagggatttc cggtYttgtg
86341  aaagaggagg aaactcaaat ctcaggagag tttaatggca ggagtgagct tgagtgttgg
86401  tttccctaat agatgggttt agctgcatgg gtgaggtaga ccaaggccct ctgtagaata
86461  tgctggagaa caatgattca agactacaaa gaaactgaag tgtgagcgga agataggagt
86521  gaaccttcga gaaccggagg ccatgccact gccttgtttc gggtggagga acaaagcctt
86581  gtcactgtgt tgccagggac agagtgcaag gtgcctggaa gctcctcggg aacgttagct
86641  gtgtccctca tcgcaggcaa tgggaccctg caccagtggc cagtacctgc tgccccagcc
86701  agcctctgtg aggcacacac tgccagagat gacctcacgc tggtggaaaa cgaggagaca
86761  gcagatcaac ccagccgggc ttccacgtcc agcaaaacga ggcgagttcg ggttgttatt
86821  ctgctctttc atgagtcagg gctttgggcc tcactgcctt ccaaacagag tcaaaatcaa
86881  tttgacgttc aaaacgacat gaaaattgcc atgtcaaagg ccattctgta atttcagtgt
86941  attaaaatca aaagagcaca gccttcttga agaagtttcc tttgggcaga attcaagttt
87001  cctctttctt ttacttgtgc aatttgaatt tatttcactt tttcaggaag tgaccatttt
87061  tgcaggaaaa gtgtagtcaa aagagataat gcacatgaag tttcttttta agttctgagt
87121  atgtcgaaga gatttacagt gcattaaaat aaactatagg caaaatagtg tgtgtaccta
87181  tctctacgca ttttttaaaa ggggcaagtg ggggaccatc ttgttgattt ttcacaccag
87241  tagccccttt ccgccagcgg gaagggcctt gccccaccca atgtgtctct ggtggatggg
87301  taattcatgc ccatSctact ccccagtggc tgtggtgggg gggcacatag cccacacctg
87361  gtactcaatg ccctcagcac agtgattggt ccaggggtg aacacatgac tggagtgaga
87421  ctaatcatgg gtcttccatg agatctgaac attgggagaa aaaaatattc ccttcctggc
87481  tcagtaagct cacagcgtag gcctggggct gcgtatgtga agagccaatc tgagaaggaa
87541  gtctctgcag aagagagcca agtcctagga ggaggagaga cgctgagcct tggcagcctc
87601  gtgtgggcca gcggtgcctg ctgtcttgct cgcgtgtgcc agcaaatYtc cttttcttgg
87661  cttaattgga tttggatctc taattatacc ttgaatgacc ctgacatatc cagtgtcttc
87721  taccttcctt attgctgtgg ccctttaaaa aaagattagg aatMatctgS catgagaatt
87781  ccacttctgg aatggtggtg agaggagccc catggacaca ttcccctcag aacaaccata
87841  actggtgaaa agtattgaaa agtcaccatc aacaacaatt taaagtctct agaaattatc
87901  ctaagagcac acaacaaact aagcaacatc atctattcaa gaaaatcaac caaatcttgg
87961  gaagaaaaat cccagtaaga acagcaagaa tcggtggcac ctgagccatc acttgctctc
88021  tcttccccgc ttctagtcct tccagttcag cttatgggga gttccactct gggggtgtgt
88081  ggccaagaac acagggctcc ctcttccctc agatcccagt caaggaatac agtatttcac
88141  caggatagat gggccaccag cgtttctcat catctccaac tcccagtgac agagggtaac
88201  tccctgctga gtgtgaccga Raggccggag caccttcctc cacccagccc taactcaggg
88261  caggagctcc gtctcaggtg cagcagggcg agagtgctgg gctcctaatc accctaagtc
88321  cagcctgctt gctagaaaaa tattccatgc tagggggagg caaaccaaga agatcagagg
88381  ctacctcctg cccaatacct ggagtggtgg cttcagtgaa gattctggcg gcaagaattt
88441  aagaggaggc tgacagctct atgagaacaa caacctgaac cacagaccag cttatttact
88501  ggaaaaaaaa aaaaaaatca ggagaacaga tcgttatgag gatctcttcc agggggagaa
88561  tgaatttcaa agactggcct caaaatcatc cctacccaaa tttaattgga tcaaactatg
88621  tgacaattta tgtctcagga cattgttgaa aataatagag caatcatccc tcaattagtg
88681  aagcctagta gctgggtgtg ataccaaatg aagcagagag tgtaacagac agatcagaga
88741  aagggacagt catagggagc cctgctgaaa tcactgtcat cccgggatga ccctgcacac
88801  gctcaaggct gtgccctcca acagctgagg cttcccactg tgaagaatac agactttgtg
88861  aaaacagtct aaccaaatca ggaaacaaat aaatacacaa acaactgcaa acagcctcag
88921  agatggggga ggggaatcag tatgcagagc tgccacatga cccaaaatgt ccagtttcac
88981  acaacagaaa cacaaatgac tcattcacag aaaaaaaggc ggcaacagac actgctggta
89041  agaaagccca gatgtcagat gtaacagctg tcagattttg cagcaaagat ttcaaagcag
89101  ccattggaaa tatgtctttg aaaaaaggaa accatgctta tgtaaaggag tgatgatgac
```

```
89161   aatatctcat caaataaaga ctatcaataa agagaaatta taaacaagaa ccaaatggaa
89221   attctggagt tgaaaagcac cataactgag aggcttaaca gtagattgga actggcagaa
89281   gaaagaatct tgaaaacaga tcaatagaca ttatgcaatt tgaaggacac agggaaaaaa
89341   gaatgaagaa aagtaaacgg aacttaagaa aaatgtggaa accataaagg gcatgaacat
89401   atgcacaatg ggagtcccag aaagaggcaa gtgagtataa aggagcagaa aagatggaag
89461   aaacagtggc aaaaagctcc ctaaatttgg tgaaaacatt aacctacgtg tccgagaaac
89521   tcagcaaact tcaaacggga taaatgccaa gagatccaca cccagagaca tcatagtaaa
89581   aatgccgaaa gccaaagaca aagagaaaat tctgaaagca gcaaaagaaa aatgacttgc
89641   cacatatgtg ggaatcccag tgggatttcc agccgacttc taataatgga agccagaagg
89701   cagcagaatg gcatatccaa tgtaaaaaag ctgtcaacca agaatctttc tccagcagaa
89761   ctatttttca aaattaaggt gcaatataga cagtcccaga taagtaaaaa cagagaatta
89821   tgagtagacc cattttatca gacatactaa aggaagttct tcaagctgaa agcaagtgac
89881   ctcagttggt aacttgaatt cacacccaca cacatacagt accagtaaag gtaatcacgc
89941   aactttaaaa gacaatataa atgggtattt cttctctttt cttcccttaa ctggcttaaa
90001   aagcaataat atagaagaag atgtatataa ttgtattatt gggcccatat aatatataaa
90061   tgtaatatat ttgactaaca gcacaaagca ggtgaacaga aacacagcta ctggagtaaa
90121   aaaatgacac cagatgggaa cttgaatcca ccgcaacaaa tgaagagagc cagaaatggt
90181   caacaggaag gcaaactgtt gatatatatg tactctcctc tctttttca gcttctttaa
90241   gcatgaaatt atataaagca ataattacaa caattgttag gtttgtagca tatatagctg
90301   tgtggtaggc agaactgtgg ccctccaaag atgttcacat tctaatcccc agaacctatc
90361   tatctgtaag gttatatgta aaggaaaatt aacattgtaa atcagatgac tttaaaatat
90421   tgaaattatc ctggattagc cagatgggcc cagtgtaatc acaagggtcc ataKaggggg
90481   aaggggaag cagaagagag aaactggagg gatggctgca cgggaaggac ttggcctgat
90541   gttgctggca taaaagacga aggacagaag tcatgagcca aggaatgcag gtggcctcca
90601   gaaactggaa agggcaagga aacagatcct ccccggagga ggacccagaa ggaacaaaac
90661   cctgccaaaa ccctgattta aactcagtga gactcatttc agactctgac ttccaaaact
90721   gcaaaataat accattgcat tatttaagcc actaaatttg tggtaatttg ttaccgcagc
90781   aatcaaaaac caacacaagt tgcacagcaa gaacagtaca aagatggggg tgggccgggc
90841   gcggtggctc acgcctgtaa tcccagcact ttgggaggcc gaggcaggcg gatcacgagg
90901   tcaggagatc gagaccatcc tggctaacac ggtgaaaccc cgtctctact aaaaatacaa
90961   aaaattagcc gggcgtggta gcgggcgcct gtagtcccag ctactcggga ggctgaggca
91021   ggagaatggc gtgaacccgg gaggcggagc ttgcagtgag ccgagatcgc gccactgcac
91081   tccagcctgg gcgacagagc gagactccgt ctcaaaaaaa aaaaaaaaaa aaaaaaaaaa
91141   aaaaaaaMaM agatgggggK ggaagaatag agctatataa gagtaatgtt tctatagctc
91201   acaggaatta agttaatata aatctaaaga ttctgataag atgcatacga caagggagag
91261   gacatcacca aagtgacaga atagaggact ccaaaattct gcccctccac aaaaacagga
91321   aataagctag taaatctcag aatcgacttt tttggaactc cagaatttaa ccagaaacct
91381   acaacaacca gggaatgctt aatgaagaaa gcagctactg aattttggtg acagtgggtt
91441   atggtgtttt aatttacttg cttaccatta tcttattctc caactcagca gtggccatga
91501   agatggcaga ccacattcct ggtgtaggtt gctgatacca acctacacat ccaaggagct
91561   caatgactcc cagtttgaaa actcaaaaga aagaaatatg gaccttatat ccagagaatt
91621   gtggttgtgg gttttaaccc atctgctggc ttgcctttgt ttcaactgtc tcggagcttc
91681   cccaggactg aagtggtttc ccagacagtg tttgtcaaaa gtatttaaag gtRaatgtat
91741   tagctgcaga cacctggggc acaggacaat aKttggggca agacRcacaa taaacatatc
91801   taaaggcttg gggaggaaga gggtagggaa ggagatattt gaggaaataa ggtttttgga
91861   aagctcttgt gcataccaga gaatctagga ttctaccact gacatgtcta gggtgagatg
91921   catgctcaga aaaggtctaa gaagactcaa aagttttcac ctctggctga catttagggt
91981   ctgtacaagt aggaagtgaa ggctaagaca gagttgtaaa cagtctggct aagcatcaaa
92041   ggtgtgctca aacacagaac caatctacaa agacgaggag agtatttctt cctaccctgg
92101   cttttaagaa agtctctgtc aaatcactag ctgaccacta agctaacaaa acagagactt
92161   tggtggccat atataatgaa caatgcagac tttacaaaaa tagtttagaa aaatcactaa
92221   acaaacaagc aacaacacat aaaaaacaac aagccccggg aagtgggggg catctgattt
92281   ccagagtctc cacattcaaa atgtccagtt tccaacaaaa aatacaaagc atgcaaaata
92341   acaagaaagg atggtccact cacaggaaat aaaaaagacc ttccctgagg aagcctagac
92401   acctcatgtg ccagacaaag attttaaata aattgtctta aatgtgttca aagaactaaa
92461   agaaaccatg ggcaaataac gtaagtaaag caagaacata atgtatcaca aaatagagaa
92521   tatcaataaa gaaatagaaa ttataaaaag gaaccacaaa caattttgga gctgaaaagc
92581   ataataactg aaataaaaat ttcaatagat cagttcaata gcagatttga gcaggcaaac
92641   aaagaatcag caaacttaca ttatcagcaa tcatccaatc tgagaagtag aaggaaaaag
92701   aatgaggaaa aaggaacaga acctaagaga tcaagtacac caaaatacaa aaaaatgaga
92761   gttcaagaaa gagaatagag aaacaaaggg gcataaagaa tgtttgaaaa aacaatggct
92821   ccaaattccc caaatttgat aaaaagaaca tgattctaca catccaagga gctcaatgac
92881   tccaagtttg aaaactcaaa gagttacatc aagatacatt gtaatcaaat tgtcaaaaga
92941   caaagacaaa aagagagtct tgaaatccac gagagaggag cagcttgcca catatacaag
```

```
93001   ggctctcaat gagcttaaca actgatttgt catcagaaac aataaaggcc agaaaccaac
93061   gggatgacat atttaaggtg ctgaaaaaaa tactgtcctg cggctaaaaa ttccaacaaa
93121   actatccttc aaaaatacaW gaaaaatWag acactttcag agaaacaaaa actgagagag
93181   tttgttttct agttgacctg ccctccaata agtgttaaag aaagtccttc aggttgaaat
93241   aaaaggacag aagacagtaa ctcaaagcca tatgatgaaa tgaagaatac taataaaggg
93301   aaccccaaaa tcttcgtttg taactcttct ctttttttcct atatgattta gtctatagat
93361   gcgtaaagca ataattataa atctacatta atagacacac atgtatgaaa tgtaacaata
93421   ttataataaa gggtggggaa gacagagctg tataggagca aagcattttg tatactattg
93481   acactaagtt gatatcaatt caaacaaaat tgttatgtgt ttaagataat agctgtaatt
93541   cccaggataa ccaataagac catagctttt aaatatacag caaaataaat gaaaacatga
93601   atcaaaacag tacactaaaa aacaatgtgt taaacacaaa agaaggaaat atttgaggaa
93661   ttgaggaata aagaatatga catatacaaa acaaatagca gatagcagaa ttcagtccct
93721   ccttatcagt aattatttaa atacagatgg actaaatgct gcaattaaaa ttcagagaat
93781   gggagaatgg attaaaaaat cccaagatat aatccaacta tatgcttatc cacaggggac
93841   caaatttaga ttcaaaatac acaaatagtt tgaaaatgaa aagatggata aagaaatgct
93901   atgcaaatag aaaccagaag agacctggga tggccatact aatatcagac aagatagact
93961   tcaagtccaa aaattttaca acaaagaaca gcattatata ttgatgaaag agtcaatcca
94021   ccaagaagat ataacaatta taaacataaa cacacctaac aacagaatcc caaaatctat
94081   gaagcaaaaa ctgacagaat tgaagatgga aatagaccat tttacaataa tagctgaaga
94141   cttcaatatt ccactttcaa aaatggataa aacaaccggc acatgatcag taagaaaata
94201   gaggacatga acaacactgt aaatcaacta gacctgacag acatacatag agcaccccac
94261   tcaacagcgg cagaatgtgt attcttctca tgtatgatga tcattctcca ggataggtca
94321   tatgttaggt cacaaaacaa gtctcaataa ccttaaagag actgaaacca tacaaagcat
94381   cttctccaac cacagtggaa taaaactaga aatcaatgac agaagaaacc ctttaaaaat
94441   tcacaaatat gtagaaattt aacaatattc tcttaaagaa ccattaggtc aggtaatatg
94501   ttacaagata aattagaata tataataaat aataaatctt gagacaaatg aaaataaaaa
94561   cacaacatac ccaaaactta aaggacatac aaaagcagtg cccagaagaa tatttatagc
94621   ttcaaattcc tacattaaaa ataataaaga tctcaaatca ataacctaac tttacacatg
94681   aaggaaccag aagaaaagca acagaaactc aaagctagca gaaaaaagga aataatcaag
94741   attatagtga aggtagacaa aatagagaat tgaaaaacaa taagaagact caatgaaacc
94801   aaaagctggt tctttgaaag atcaacaaaa ctgacaaaca tttagccaaa ctgaccaaga
94861   taaaaagaga gaaggctcca attactaaaa tcacaaacaa aagtggggac attactaccg
94921   accttataga aataaaaatg attataagag aatattatgt acaattgtat acgaacaaat
94981   taaataacct agaagaaatg gacaaattcc tagcaacaca gaaactacca aaattgactc
95041   aaggagaaat ggaaaatttg tacagatcta taacaagtaa agagcttgaa tcagtcatca
95101   aaaactccca ataaagaaaa acctaggacc agatggcttt actgggaatt ctacctatca
95161   cttaaagaat taatatccat ctttctatga ggccagcatt accctgatac cgaaaccaga
95221   caaaaacatc ataagaaaac tacagactaa tgtctcttat aaatataggt gcaaaaatcc
95281   tcaatgatat tctagcaaac caaattcagc agcatattaa aaggcttata tacaatcacc
95341   aagtgggatt tatccgtgga atgcaagagt ggttcaacac acaaaaatca atccatataa
95401   tacactacat tcataaaatg gaggaaaata aaccacacag tcatcttggt tgatgcagag
95461   aaagcattag acagaaccca acacccttg tgatcaaaaa atactcaaga aacaaggact
95521   agaagggaaa ttcctcagca tgataaaggg tatttacgaa aagccaaaag tactcatcat
95581   ggtcaactgt aagactggaa gcctgctctc accacctgta ttcaacatag taccggacat
95641   tctagtcaga gcaattcagc aagaaaaaaa taaataaata aaaggcatcc acattgcaaa
95701   ggaagaagta acacttcttg agggaaaatg gggaatgatg gctcgtgggt acagggtttc
95761   ttttgggagc aatgaaaatg atctaaagtt gactgtggtg atggttgcac agctgagtga
95821   atatagtaaa aattatggaa ttatgcgccc gaaacgctga actacagcat atgtgaatta
95881   cagctcaata aacccaccat aaaggaaaga ttaaacaatg atctactcct tacctctgtt
95941   ctcagagcca tttccagccc agcccaggcc ccaggcaacc ctctgtgggt gacgcagcat
96001   tacctgcttt ctggctgtcc agtgttgtgt agcgcaaggc cctgggaggc cactgggttg
96061   gtcatgcggt aaccaagaaR gggagcaagt agttgggtga caaaccctgt acatctgctc
96121   ctaactttcg aaacctggct gatgggaggc caatgtSacc ctctaacgcc ctcccatagc
96181   agcctcggct tgtcttctga cagtggcact gtccacccac aggcatcacg catcctgccc
96241   gcacattgct tccgccagtg gagccccagc tgaaacacta gacaggagag aagtccagag
96301   atcctgctca ctMtagggaa ggagaaagac ctcttcagct tgtcctgcct cggcaaaggc
96361   aaagcctcat gcatttgctc actcctccct cccagggctc agccggcacc tgaagctagt
96421   gtagcagaaa gagcccaatt ctgcatcagg cgggcctggg ttcaaatccc agatcctcca
96481   ctttctaatt gtgccatctc tgagccttcc atcccttacc tagaaacaga gttctttcca
96541   cccatgccct tgtgagacag cgtaagtgaa aatgacatcc acacggtact ggaagcagag
96601   ctgctagaaa cccagccagg cagggtttga acttgttatc tccaaaaagt ctcaggaatc
96661   gtatttctgc ctgatggtga cctacttcag caaggaccca atgtagaaat tactctgcca
96721   ccaaaaaagc aggcctcaga ccccctccat cacctcccYa atttatgaat taaacaacga
96781   ggccagtgcc tgaggggtct gcagatgaga gtcagaaacc agcagccccc caccccacag
```

```
96841   agacaggtcc ctgctaacta gacacaagaa ttggccttct ggggtgtctc tgcgtgttct
96901   gtgtatggtg acctagcccc ggccctccag gagggacact acgtgcagga cattttggaa
96961   aacagtcttg gtgtttcctc aaaaagtgaa acactgtgtt atcatgtgag ccagcaattc
97021   tcctaKgcat atacctaaga gtaatgaaca tatatgtaca cacaaagact tgtccacaaa
97081   tggccatcga ggagaagctg gccacagaga agatggccca gagaggaggt gctgtgtgca
97141   gaagcagctc tgggaggaaa gacgtgcaca ggccaaattc agattactga cactttttt
97201   ttaatgcaga gattgtctgc agaattacct atttttgact tatcttgaaa aactgaggat
97261   ctggcaacac tgaccccgaa tcttcctaac agcaacaatg atcagaactc agaggttttS
97321   tgtctcactg attttttttt ctttttcttt tctttttttt ttttttttga gatagggtct
97381   gactttgtca cccaggctgg agtgcagtgg tgcactctca gctcactgca acctctacct
97441   cccaggctca agcaattctc ctgcctcagc ctcccaagta gctggttcca caggtgcatg
97501   ccaccacgtg tagctaattt ttagattttt ttggtagaga tggggtttca ccattttgcc
97561   cgggctggtc tcgaacccct gagctcaggt gatccatccg cctcagactc ccaaaatgct
97621   gggattatag gcactttgct gcacctggcc ttgtctcact gatttctgat cttatttgt
97681   attatctttt tccttctatt ttctttggat caatgttgcc tttttctaac tWctcacact
97741   ggaaatttat ctctttaatt tttagacctt tttcttttct aatgtaaatt tccatccacg
97801   ttttgatatt tagtgctttt attatcattg agttgtattt ttgaagttcc actattattt
97861   cttctttgac ccatgaatta tttaaaagta tttttttttа atttccaaat aatggggatt
97921   tttgctttgg gggctattaa tttctctctc acaggcatga tggtcaggga acaagacctg
97981   ctgacactat tcttttagtt tctgtgagat ttgcacttaa ttgaccagtt gttacaagtg
98041   tttcctatgt gcttgagaaa aagaaataac ctctacttgt cagatgcaaa attcatcaat
98101   gtcaagctta ttatttgtgt tatttagaac ttccttatct gtgctgggtt ttttgtctac
98161   ttgatccaac accaattgga aaaaaatggt tggattctct caaaaatgat gataaatttg
98221   tcaatttctc tatttctaac aaagttcacg tcaaatatgt tgaggttatt ttattaagtg
98281   actctacctt tagaactgct ttatcatctt ggggaaatga acctttctc attaaacggt
98341   gacctgtctt tccccagcag cgtctcctgt cttgaggtct gttgagtctg agattgatac
98401   agcaatgtcg gcttgccttt ggcggcctga taggtctgtt tccatacttt actttccact
98461   ttttcttgcc tttacacttt actctggtga tagcgtccag ccagattttg aatttggggt
98521   ttgtctcgtt tgtcagatat gacagcctct gtctttgaat ttgtgagttt aatccattta
98581   catttacctg gattattgat aaatctgggc ttgtttctcc catcttactc tatgatctca
98641   atttgtcttg gtttttctgt ccttttttct cctttataat ttgtcttata aaaaaagaca
98701   tcccggccgg gcScagtggc tcaggcctat aatcccagca ctttgggagg ccaaggtggg
98761   cggatccctt gaggccagga gttcgagacc agcctgacca acagggtgac accccatctc
98821   tacaaaaaat acaaaaaaat tcgggggtg tggtggcaca tgcctgtaat cccagctgct
98881   agggaggctg aggcaggaga atcactggaa cccgagaggc agaggctgca gtgagccgag
98941   atcgagccac tgcactccag cctgggtaac aaagtgagac tccatctcaa aaaaaaaaaa
99001   ggcatccctt tttctctaat ttgtcctgtc accactgtgc tggctgcccc agccaggctg
99061   caaccctggg gacacacatg cccctccagc agtgagttca gacccttctc acccctttggc
99121   ctcaggctcc tcacttcctg ccccctctcc tgagaggtga cacgccatgt ccacaccaac
99181   tccaaatctg atcatcggct ccagtccagt ccctgcacca gctgctcatg ggcctttctc
99241   tctggggtgg ggctgggagc tgtggttcct gctgctgtgt cctgcactac tccacatttc
99301   ccagttcaga ggtgatcgga gccccctcta atatatgcca tcccagggcg gggcagcagg
99361   gcacaaggcc acttcagtgt caacacggat ctcactgcag gaactaggag gggcctccct
99421   taggaagagg cactctggac tgttttaacc acagtcccca cttctccctc ctgtctcaca
99481   gtcccgagct tcatacacac acgctgctgc ctattctgga attatgcagt attattattt
99541   tatattcatg tcgctgggca tatgatgctc ccatgacaag gggccctgga gcttttagat
99601   caatccttag aaggactcca gccagacccc aaaggccaca tattatcaat tgggtttcta
99661   tgaagtatac agaataggca aatccaaaga cacagggagt agattaKtgg tcactatgag
99721   ctgggaaggg gaatggggag tgactgctct gggtgcaggg ttcccactgg ggtgatgaaa
99781   acattttgga actagatggt gatgatggct gcacaacact gccaaaaacc actggattac
99841   acactttcat actcatatgt attatagtcc attgattttt aaaaggtcag aggaagcaac
99901   tcaaatgctt gtaggaggtc agaagaggcc cagatgggtg aagtcggggg ggcgtgcaSa
99961   ttaagcccac aagaatattc tctaagctac caggtcacac acacactcYc tctcactgtS
100021  cctgaagccc atagcccccc ctgcctgact ctcctatcaa ctgtKgatgg cgtcaaagat
100081  gcacaSaaat atattttggc tgaaagaaac acaacagggc acaatgagga agggctgcca
100141  agcagcctat tagcagcatt tgtcatggtt catctgggag tctgcctttt cccccagcca
100201  gactcttcag ggacagagac cagattgttc atactcagtg cccagcaggg cgctggcctg
100261  gggtgcttgc agacactgac tggatgaatg gatggatgga ttgggtggat gaatgagtgt
100321  gtagatgaat ggatgatgaa tgatggatgg atggatggat gatggatgaa tgaatggata
100381  aataattgga tggatggatg ggtagatggg ggatgggtag atggatgagt aagtagatga
100441  atggagatca atgatggatg gatagatgga tggatgaatg agtgggtaga cgaatgaata
100501  cacgatggat gaatgaatgg ataaatgatt ggatagatga atggatggac ggatgacaga
100561  tggataaatg gatgaatgat tggatagatg gatgaatggg tagacagaaa gactctgata
100621  ctggaaagtg aatccttcac atccatggca agtgaaccgg gtaacaaagt cagaggcaag
```

```
100681  accatagcag cgtcatttgt cactgttgcc atttatacac atttttgggg cagaatcggt
100741  catgcttgac cacaggtcat ctctagaggg tgaggattgg gggtcaggaa ctgtggggtg
100801  ggctcagggc tagggctgcc gatgtggcct ttgtgcctgt gagcagactg catttccatc
100861  agcctcatcc ccatcttccc tctctgcctc caccagtgag ttcagatcct tcctacaatt
100921  caatcttggg gtcccctcac tttctgtccc atctcccaag acctggctgg ggcctgactc
100981  agaatggggt cagcaaagcc ctgaggtaga gccgtctccc aagattatgg cctggctggg
101041  gcccgcctca cctccattca aaggacacca tgtggaaaac caatgtgccc ccaagcaggg
101101  gtggcacggc acagacactg atggcacagg ggccacttct tgctccttcc tggtgtcttc
101161  atcctcgggg atcaggggct ctgcagcagc aggcagggct gggcagccct ggagtgtgtg
101221  acacaattcg ggcactgtga ccctactgga ccccttttgca cagatgctgS tgggcMtagg
101281  aactggctgc tccccactgg ctgctctggt aggccctggg gtctgcctac acccccaaca
101341  catgagcatg ggcaggtacc caccagtctc YttctStgtc cccagcctct cccgcagctt
101401  ggccttggtc caccgtggac agcgtctctg acacggtcYt tcttcccaca gggagaccgg
101461  gagggtcttg ttctgccctc agagcagagg ccccaggctc cttcaggtgg gagcacaggt
101521  gcctttcgca cagggcccag cagccagctc agcccacaga acagtaagcc gccaggtccc
101581  aagttgtcat cttgtgaccc gcccctgggg acacgggtgc ccaacaggaa agaggacggg
101641  ggcttattat aaggaaaata gtgtcaggcc tgccatggag ctttgggcct gaggcctcag
101701  ctgaggccaa ggcagcagga ctcatccaga gacaggacag accctgggct cctggtgccc
101761  agctcaggga agctcctggg tgcggctcgg ttcactccag catttcctac atggatgaaR
101821  atgtggatgt gtctgctctg accatgggtg tgtgcatgcc tgcgtgtgtg tgagagagag
101881  agaggagaga gagacggaga gagtttatgt acgtgtaact accaaccaga gtccaggagt
101941  ctcacactcc actgcaaacc aggcaggcgg ggccagcatg agtgggggggg ccaggcacga
102001  atcggcaggg agggaggggt tgtgttcgcc catccagagg aggcacagag cctcccaccc
102061  agtgctgctg gcaggaacac gcccagggtg gccaggcctt ctgaaggaac tgaaaattga
102121  gattttcatg tgaaacctcc tgatttttaa gtgtacactc aacatttctg aagccgttgt
102181  acgagtcaaa taaaacattg cggggtgggg cggcgaggcc gcccaagagc tgcagggctg
102241  aggcctggct ttagtccagc accccgatgt acatacagac gagaagactg aggtcaggcc
102301  agagcaagga ctccgcaggc caggcccaca ctggcggccc cggctgcctg gcccatcact
102361  ggggtcacca cagcccatgg ggagcaccaa gSacaccaag aaagggaggc ccaggcctgg
102421  tccccggggt ctctgtcacc aagggcccac attgtgagtt tcaaaggtgg ccgaggtggt
102481  tcctacaggc ctgtgagtcc ccacactcct tcccagttca aggcctcggg acaaatccaa
102541  gcccagcttt gtcctcgtgg tgatgaaggc caagaatgct gggagctccc gggatattgc
102601  cYaKaacaaa ggagcacagg cacctgacgt tctggacaca agggcagaac cctcttgaga
102661  ccatcatcgg ccgtttgctc tccaggctgc gggggcctgg aggacatcca ggcacgggta
102721  taggtgccgg gagcccgggg aacagaacct cagacccgga actgggcacc agatgcacca
102781  gccgggggtc tgtccgccca gcccggggag tccaggggct gctccgaacc cggcgccacg
102841  cctgctccct cagtgccgca tccaacagct ctgtctgcct gggctggggc cctgcRccct
102901  ccccgctgct ggctcccgct gatgcgctac agatgggctt catcgctgcc tccaagaaca
102961  acaggacgac cgcaggtttc gcctcacaga aacggaaccg ctggaaaggc ctctcttgac
103021  attcccgaaa ggaaaataaa aattcctctg aagtacattt caactccgag gcagccctgg
103081  ccacatccaa gaagctcggt cctgagcgcc gtgggctcca gtgaaggtcc ccagcactga
103141  ggccgcctcc tgacccccat cccggccact gccccgggct gctcaaccct tacacggctt
103201  tcacaaattt tgaattagct gccaacagtt taaaatgaag agattgtaag taaaatcaat
103261  ttccagcttc tcttataaaa ttggaggccc tcctgctgct ggccgacccc gtgtctacct
103321  gggcccagtg atctctgctg gcgtcacctg ccaggccccc atcagtgtgc ccatacgaga
103381  ccactgtcct cagcgaacgc ctgacccccа ggctccaggc aaggttgaga ggacagatgc
103441  tctcatcctg ggggctctgg ccttcctggg gccagtgtta tccagctctg ccctccagag
103501  ccctctgcac acgctggggc tgggactgcc catggctgtg ggctctgatt tgggtgggca
103561  gacctgagca ggccatcatg cttcttattc ccagcctgac acccccagac cgcccccccgc
103621  caacccagac aatgtgtact gaactcctcg tcaacttgac ccctgagctc ctccccgcag
103681  cccaccaggt gctcctgctg tggtttgggc agcacctagt ccttttcgcc ctgctggacg
103741  tcgcctggcc agacttgcag agccatctca gccctttgtt ctcctgactc catccctcca
103801  agcctggcca ccccagcctc ggccccagct cctgccacgt gaattgtcaa aggcagagca
103861  tgaggaggct gaaggcagcc cccatggcac accccacgga gtccctgcag tcgtccaaaa
103921  aaggctcaag cctgggcagc attgctcgca gctaggaatc tgcagctgga ctcaaatatg
103981  tgtccagaat gatctgggaa aggtccttga gaaaagggcc agacacaggg accttcccag
104041  gcccggatcc cacagaggaa atgattctag cgagcgccac ctcgacaggt ctgaggtcca
104101  gacaggggtg gagctgtcac aggcagccgg gtggggctgt gatctgggtc ctcccagcct
104161  cacggtgatt tggaatggga atacggttct gccaggcaag gagtatcccc ctctgaccaa
104221  cctgtggact gcctaccagg actcccaaca cccttcctgc acgatggcgc tgaggggctg
104281  atccggccgc tgctctcatt cccatggcca cctgatccag gccgcagtct ctccctgcac
104341  acaggacagc agcctcctgc cggctccctg cctcttccgt gctcaccctc ctcggaaacc
104401  agaccatgcc acctgctgca tggcacagcc cctcctccac gacggagccc acagaagcca
104461  tcgtgatctg acctccagtc ccctcaggcc ctcaccctgc ccctcctgcc acacccccaa
```

```
104521  acaagccccg tcctcacccc tcaggtactt cgcatctgct gccctggccc cttttcctcc
104581  tggggaactg caacccacac tccaggcctc agcccaacgt ccagtgactg cgggctcact
104641  ctgtggcact tcccaagtct ttcattgtgc aggtatttgt ggactgacta gtgcactgtg
104701  ggctgtatga ggtcagggct gtgcctgtct ggtcccagag cctggcccag tgcccggtcc
104761  tgctgtgcgt gccgggtaaa gatctgttgg atgaatcaag ggagagagga aggggagcag
104821  ccctgggatt ccacaggtgc tttatgtcca gagacaaccg cgcagggaac agtggccaag
104881  gcacgctggg agcagtgctc cagcccgacg gcatccccag ggcagaggct gggattcacg
104941  cattgctgcc ctcaggcacc aaacgggcct gtggcagtca caggggcaca ttcctgatac
105001  cgggtctgtc gttccagcat ggacagggcc atcttcctcg ccatctgcag tctggcatca
105061  gacattccca aataaaggac agacagttaa ctgtcagaaa gtgctggtgc ttgggcctgg
105121  aaggaaggga gcccgtgtct actgggcacc cccaattttg gccactgtgc agtgccctgt
105181  gtcctcaacc tcggggcctg gaccacagct ccatgagacc acagggagga agcagagtca
105241  cagaagaaag agtgatgaac agcactggcc acttgatttg cagggcacag tgcaaaatgg
105301  aaacgcacag tcccttgttc aaaaagtgat tacgacttct aaggcaggaa tgacagagtg
105361  ttaaagtggg catagggccc tgccggatgg gtcacaagcc ggcgaagtca gtcctgctca
105421  agtgtgagga agtgggacta gcaaaggccc agggccaccc aatgtcccat gggcccatgg
105481  gaccagtagc cacccacagc tgccaacctg agtctgcagc cctgacactg tggcaacaac
105541  aggaggcgtc agtgccaagc cctccaatgc ctgcagggag caactgttgc tcccggagtg
105601  agctcctggg cgaccgggct tcctaggcac tatgcttatt ctttcttttc acggatattt
105661  acgcaccaac cgtgtgccag gcattcctca aaatgctgca aattccactg taagcaaaag
105721  attctccccg aagctaacgt gctaagtgac ctggagacac atcctcactc accctcgctg
105781  ggccccagtt tctgcagccg ttaagtggag ttccaggcct tggtgcttgg aaggccctct
105841  gtccaacaaa cagatggggt cacaggctac cgggttttgc cagcccaggc tctgagcggg
105901  gacaggaggg cactgcactg ggtgtcagca gccctgggtt ctaagcctgc tcctccctcc
105961  tgatgcagga gtcaaaaggc ctggctccca ctgtttctac agcttactat ctgtgcaacc
106021  gtcggcacct cagtttcctc atctgtaacg tgggcacagc aaaagcacca acccaccgtg
106081  gggctcatta caagaatcct aggagatgat gtacctgcag cgtgctggca gacgcggtca
106141  acggtaagtg ctccaggaac gcgtcacgtt cttcttgctc cctgctgttc ccgctactgc
106201  ttggacagtg gtagccctgc accttagttt tctctctgct tccaggacta ccgtgcctat
106261  taaatgacac catgaagagt gcccaccttc gcgcaggccc tcggtgaatg ggcatgtcct
106321  tgaacgcaaa cttggctcca acggggcagg agaaggatca ttcagactca gctacagaaa
106381  aacagacttt tgtgcaacta acgctaacaa aactggaaag gaaagaggaa ctacggcctg
106441  gggaaaagct tgtatcgaac atgacagaaa gtcaatatct aaaaagagat aaagggctta
106501  tcccaatata taagacccca ggagataaac aggcaaagga cttaggaata ggagacatgc
106561  agagtaatca aacccaggga agatcactca tcctcgccag taaccaaaga agcgcaaatt
106621  agcgcaaaaa gcaacgccgc tttgctgccg gagcagcaaa atattaaaca ctaaagcccc
106681  cgtgctggtg aggatttgga gaaaccagga gctgctgtgg gagccagtct ggctctgccc
106741  cgagtggtga gtctgttaag cgctgggatt tcctaattca tttagtcact cagtaggtgc
106801  cccctgatgg ctgctcaggg ccagggctcg agcgcgtctg ggctggctca ggccgccatc
106861  tgccgggtca gcaacagata cctatttgca ggaacagaac ctgaggtcag ctcccaggat
106921  gtccccaccc ctgagtttca agagagtttg caccaggagc agggagcatt ccagctgtct
106981  cgggcagctt ttgtgtgggg aacagctggt agcgctgcct gcggcccctt ggggtggaca
107041  ggaaggctct gcctgcaaag gcctagaggc agccacacac cctgccctgc acactcctaa
107101  gtacgtgcag gccacagttc ctgcatccat tcatcccggc cagtctgggg tccctcccca
107161  cagtggcagg caaggggaag ctggaccggt cctgctagac aaacaaggat gcacacacgt
107221  ccatgggacc ccaaacctca cactgtccct gacagcccgc cccacagagc acagcctctg
107281  cctcccggag caagaggagg tggcagtgca tcccagggcc tggctgcctg tggggctgca
107341  ttgggggctc ctgcccccgc cccgtgagtc tgggaacaca tgggtcttgg ccttggcacc
107401  ttctttcctg ggaaaacacc tccctctggg ccagggcagt gcagagcagt ggaagcgggc
107461  agctgtggag tcagagtgat gggtgccaat tctgactcct gcacgtggcc cagaccacct
107521  aacctgccac ccccaccagc acacctgccc ggccaccccc accagcacac ctgcccggcc
107581  agcctcaggc caccagccag cctcccagcc acgtgacctc tcaggggcag gatgtgtcct
107641  tgattccttc cttcacacca cgtcccggaa gctccacctc aaactcatcc tgaacccact
107701  gcctccaccg ccatctgtca ccgggactcc tccctgcttc cacgccgtcc accgaaaacc
107761  ctccaaaggc ctccaccgca cagggaatga attctcaccc cgtaccgtga ccgtcccttc
107821  aaagcgatga gtgccaccca tccctcccgg ccctgcacgc ctcccactcc cccattacgt
107881  cctcagttcc aggtactagc tcttccttct gccccttggt cacgctgcgg taactccagc
107941  ctcagggctc ctgcatgtgc tgttccctct gcctggaaca cccttcccag ggctgggctt
108001  tcccatcatc accaacctgg ggcgcctccc tcccttacct gccttctcac gctgcccttt
108061  caccccgttt tactttgttc acaggattct ccactgtctg cgagcatctg ctcaccaggt
108121  ctcccctgcg gggctgtgag cccagagaac agggactcga tcgggttcct ccgctgctac
108181  agccccagca cccagtcctg tcagacacat ggtggacaca tagcaagaac gtgacgagtg
108241  aatgcaggaa aatacacttg tggcagcagg caaggtgccc tctctgagcc tcagtctccc
108301  cctaagcagt agagctgcta atgctattat tcccccatga tttggggagc agtattattc
```

```
108361  ccccatgatt tggggagcag tattattccc ccatgatttg gggagcagca ttattccccc
108421  atgatttggg gagcagcatt attcccccat gatttgggga gcagcattat tccatgattt
108481  ggggagcagc attattcccc catgatttgg ggagcagcat tattccccca tgatttgggg
108541  agcagcatta ttccccccatg atttggggag cagcattatt cccccatgat ttggggagca
108601  gcattattcc cccatgattt ggggagcagc attattcccc catgatttgg ggagcagcat
108661  tattccccca tgatttgggg agcagtatta ttccccccatg atttggggag cagcattatt
108721  ccatgatttg gggagcagca ttattccccc atgatttggg gagcagcatt attattgagc
108781  attaatgaac ccgcatggca ttcaggtgcc cggccttttc ccaaccagac cagcgcacca
108841  gccacctctc cacacaggcc cagtgcccag gtcacctcct gtcctgtcct gcaggctctc
108901  tctgggtgtg ccgacagttt gggatgggag gcgtgggagg cgtgagctgc gctcctggcc
108961  gggttctcta ccagctgtgc tcgtggcgca gcccacacct cacggcaagc cccagccaaa
109021  gggaccaagt caagagctct gagagacatc ccagccgaag aatccagccc ttgtcccaaa
109081  cgtgtgtatg cacaggcaca cgaaagaagg tgagacagaa ggagagaaaa atgaagccag
109141  agagcaggag agagagaaga cagacgccag cacgcccatc tgactgcgcg acctttcccc
109201  gctcagagct ccttcagggc ccagagcaca gcgctgccta ggattaattt caaagagaaa
109261  cgggtcaaag aaaattggaa atttttatag aaaatatttc aggcttggag ctggctgaag
109321  tgtctgccaa cctgcagaga attctgagag gagatggggc ctgtggtcag aggcctccgg
109381  ctggcacaaa ctggcagagt ttggacctcg gacccaaatg cagtttctga gccaggcctg
109441  tcctcgctgc tgctggggaa gagcttcctg tccccttcag atgtccctac agctgcctct
109501  gcagccctga tgctggtacc caacgcctct cacctgtcgc cccacccctc tctatcccca
109561  agaggcctct gtctagggac ccactatggg atgcagtccc tttgtcccca ttatgcaggg
109621  tgcccatgtc tctttcaccg tcatccatgg ggcagccagg gcatgaagga agcctcacct
109681  gggtcccaag caggtcccac tgctccttgc ccaaacttca ccccagccag caggctccta
109741  catccaaggc acagatgtca cagacatgaa aagatgccct ggacacatgc ctctctccca
109801  gaagcctgcc tctgccatgc tggggacctg aaaagagggg gcatgcccag cccacagttg
109861  ctgatcaaac gccagatgcc cccgtgagca gatcacagct tcacccctga gccgtgtact
109921  gtctgcatgc cagggactgt taccttgtgc aaaacccgaa aagctctttg gaggacattc
109981  ccaacacaga tccaagggaa ggaaagaaag tatcaattca ctgtgtctgt ggaagatggc
110041  gaggcagagg agggaaaggg gacggagagc aagtgtcgca gtgagcactg ggcaggcgcc
110101  ctgtgccctg cgtaattcca gcagcccctg tgccactgca cccaggtaca gtggagatct
110161  cagcacccag gttctgagat cctgaggggc tgggtgagct gctctgggcc ccttagtgag
110221  ccagaacaac agcatgtcgg gtggagctga gcacactgac ccctgcacca acagcagcat
110281  gctgggcgga gctgagcgcg ctgaccccctg caccagcgct gaccctgca ccaacagcag
110341  catgccgggc ggggctgagc acactgaccc ctgcaccaac agcagcatgc cgggtggagc
110401  tgagcacact gacccctgca ccaacagcag catgccgggt ggggctgagc acactgaacc
110461  ctgcaccaaa ctgcccgctg cccaccccac tcacccacct agtgctggaa gcatctgtgg
110521  gagcagccct aatgcagctc ctcagaacca ctggccggtc ttccagaact gtcccctgca
110581  ctcgagttgg ggctgcagcc aagccagggc caaggccacc atcctccggg tcaggcttgt
110641  cacctgccca cggtgctcca ccaaagatcc aggcccttgc cagccacatt tacctggtcg
110701  gctccacccc tgaaccagaa accatgtcgg gaggggagag gtggcggggg aagggcaagc
110761  ctgagactca gggactaaat ttatgtcgga ggcacagggg agttgctgcg cacgtggggg
110821  ctgtcaggcg gagtgccagg cccagacgcc gtggaggggg agcacaccct ggcacgtctc
110881  cactgtggaa taaggggggc ccagccctcg ctggggctgc aagcctcgct tctgccttca
110941  cagcccaggg ggtgggaagc acccacaggg cagcgctctg agcagcagac tccagccaga
111001  gagccagcca ggcccgggag ctggcccctc ctgctctccc cggctgaccc caggcaactc
111061  cagcctcgga gaatgtgcag cctcggcttt cccagcgccg gcccccgccc acccccttccg
111121  cgtgggccac atcaccgcgc tggcatctcc aacagccatc ccaagggccc ggtctgcacg
111181  aggacaggag cgccgcggcg tctgccaagg gtgcgctcag ccctgaagca cgcctcccgg
111241  agccgcctcg ggtttcacaa tcagtgcttc tccctgggtt tcccggggcc tgggctgcag
111301  gctcagctcc agggtggaaa gagaggatga gctgagagga ctccagggat ccagcgccga
111361  ggcgctgaac tcagtgagtc ggcaacagtg gcttggcagg gcccaggctg accagggtat
111421  gagagagagc acctatcacc acgccagagg ccctggcctc aggggtctgg ggagtcactt
111481  gggaagtgcc cggttggaga cacagagaca ggtctgggca caagacgctg gccaggtcca
111541  gggctcaccc tgcaaatcca gccaaagccc tctctccatt ctcccttagg acccaaggtt
111601  caacacttag acatgtcagc tgaatcatga cccccggacg tccatgtcct aatcccccaa
111661  aactcgtgag cattacctta tatggcagaa gagactttgc aaatgtgttt aaatcagggg
111721  tcttgagatg gggaaagtaa cctggatggt cccagcgggc cctaaatgtt atcacaagtg
111781  tccttctaag agggagagct ggctatagaa gaggagaagc cacgtgacca gggaggcaga
111841  gactgcagca atgttgccac aagccaagga acgccaacag cccccaggag ctgggagggg
111901  ccaggaatgg attctgccct ggggcctccc gaaggaacca gccctgccag caccttgatc
111961  ttagccccta aaatcctatt tcagagttct gagctcccga actgtgagga atgcaggtgt
112021  gctgttttaa gccattaagg tgtgggtaac ctggtacagc agccacagga agctgagatg
112081  gacgtcgaca gctacagggc agaaaggctc tctgacctgg cattcagcaa attggcaccc
112141  cccaacaaag cacacggccc tcctgcccca tcctgggccc cccagccccc acctgggcca
```

```
112201  agcctcacat ccgctgtgtc agtggggctg gctatctgct cgccactgaa tggatgagtc
112261  tcgcctgctc cccagtcctg tggtctgaca gaacagagct cctctctctc tcctgtgcca
112321  ttgctccagc ctcccccacc agcctccctc acactgcaac cagtacgagc ttgctgaaac
112381  actcaactct ttgtgagact ggagggcgcc atccccacct tgggtcattc aaggctgctg
112441  cttccatgga ggctgcccca cagctctctg cctccagccc tgggctctgc acacccaggg
112501  ggaactgtca tgcctgaggt ccgcccccac ccccgccgcc cactcttccc ccaggatccc
112561  ctgcggcctg gaaaactcct acccaactca aggcaaagtc acagggtgga gactgtgggt
112621  caggaggggc tcttcctggc ctggtgggga agggctggct gtgggctgca ggtggcagcc
112681  acgctcagcc acatggagga gctgcccagt gccggcgctt gtcctctgtc tcctggaggg
112741  ccttccttgg tgcagcgagg ctgagaggct cccgtggtgg cgtgcctcgt ctgcccgtca
112801  gggaggatgc tgcagcctga cagcagcagg cagaggcttg gcaccggcgg tgtctggggt
112861  ggaggcagcc aaggtcactg gcacgttgct gtctgacttc tcttccttca gcccagcagg
112921  gtgtgtgcac agcagcctgg tagcagttcc ccaggatggg aagcacctgc ccctcctctg
112981  tcccaaggcc aggccggggc gagccccagg agagcagccc acagaggagg gcagaagatg
113041  cttctacctc tgcatcacag aaagcatggg tagccaatgg gggaccgtgt tttgtttggt
113101  ctatatagtg agcacgggag gggaccccag gcatgacagc tcccactggg tgtgcagggc
113161  ccagggctgg aggcagagag ctgatgtgga ggcttctgtg gaaagagggc tttgtctgga
113221  tttgctggct gagccctgga cctggccagc gtccttgtgc caggacctgt ctctgtgtct
113281  ccaaccaggc acttcctgag tgactcccca gacccctgag gcctggtcct ttcgcatggt
113341  gataggggct gtctctcgta cccgggtcgg cctgggccct gccaagccag ctgttgccga
113401  ctcactgagc tcagcgccgt ggctggattc ctggagcctt ctcagttcat cctctcattc
113461  cagaaatttt aagccacatt ttaacatcag gaaagttcac ataaaaagtc tgatgtctgg
113521  attttcttga taggatgttc agctgcacca gacccaactt ctaccaaatt gaggtcaagg
113581  gagttgagga gggtctgtcc ctccttgcag ggcctcccag acgccctgtg cccatggcaa
113641  ggccagggct ggacaccacg tgtggctgca ttcccactgc tgtttctttt tagtggagat
113701  gtattcttgg tctccacgtt tccatcaaaa ggagagaaat gaaagccagg ccaagggtgg
113761  gtgcaattat ctttttttcc tccactgctg tccttgttgg cattgcctgc caggccctgc
113821  aggctctgag tttgcagctc ttgtctttct gcaaatggca ctgtgtgtct gaaacagaga
113881  ccacatgctc aacacgtgac tcggggtctt tctcactgtg tggcaacctt cacagagtcc
113941  caaggtcagt ctctgggaag ctaagacagg ccctcagtgt cagcacaggg ttggcttctc
114001  tgtgcacgtg gtcttggagt cagccgctcc aggtcccttа acgcgggcgg tgggggagga
114061  ctgccaggct gagactggca cttagacatg cagggaagag ctcccacacg acagggtgga
114121  gggtccagtg agggaggcag caggaccagg gcctgcctgg gctgtgcctc tgggctatat
114181  gccctgggga ggcgtaagtg aagcctacag tgctgctcct ccgcgtgacc cagacgggcg
114241  cctcccgggt gtgctgtgca ctgcgtggcc agccttgtac gtgagggcca ttcacatcct
114301  gtagctggct gcgtggtgcc cccaaagatg ctggatcctg atccctgcaa cctgagacgg
114361  gtaccttcta tgggaagaaa gggctttgca gatgtgcttg cagtaaggct cttgagatga
114421  gaagcctgtc ctggattact cgggtgagtc ctaaatgtaa tcaaggcatc cttgcaagag
114481  ggaagcacag ggacacgtca gaagaggagg gggcgacatg atccgggggc agagattggc
114541  atgatgcagc cacaagccaa gggaggctgg cagcccccag gagcggggat gggccagaaa
114601  cagattctcc cctggagcct ctggagggag cacagccctg tccacccttg atcttggctc
114661  agtgagattc atttcagact tctggcccac agagctgtga gagaggcatt tgtattagtc
114721  cgttttcaca atgctgataa agacataccc gagactgggc aacttacaaa agaaagaggt
114781  ttattggact tacagttcca cgtggctggg gaggcctcac atcatggcag aagatgaaag
114841  gcacgtctca catggcagca gccgagagag agagagcttg tgcagggcaa ctcccgtttt
114901  taaaaccctc agatctcgtg agacccactc accatcatga gaacagcatg ggaaagaccc
114961  acccccatga ttcaatcatc tctcactggg tccctcccat aacacatggg aattatggga
115021  gctacaagat gagattcagg tggagacaca gagacaaacc atatcaatgt tcctattgtt
115081  tcaagctccg tgaggactcc ctcctcaaca gtcccacaca ggatgagatg cacacacacc
115141  agagaggaca atgccacagg gtgccctgtc cctgtacccc agcacagtgt ccctggacac
115201  agagctggcc ttgggaaggg cagagaacag ggattggaga tgcctgtcag aatgcctggg
115261  gggacacctc aaccactgct ccccaaaagg ccacccagcc tcagagctcg gcctccggtc
115321  ctggccaggt tcccaggcca gcagcactga gcaggaccct tctgccaagg ccagcatggc
115381  cagggaggag agaaaaggac cctccccgct ccctcacccc ttgcccctcc taataacatc
115441  ctctcccggg tgttgcctaa gctgcccagt gcacacactc atccctggcc tgtctgtgaa
115501  atgctttaaa accgtcattt tctatccgtt tcccccaggc aatctgcaat ccagcaactg
115561  atcttggatg acagagacta ttagtgaaaa tgattccctg aggctccatg agtccccgag
115621  atcaccctga gcagcccgtg ggcttctcgg ggaaaacagg acatcctgaa aaggaggcac
115681  ccctgacgct gcagggatat cctgccaccc agacagatgc ccacccccca ctgggacacc
115741  cagggcaggt gtgtcacctt ccccggcaga acataaatag cagggtgctt cacacccact
115801  tccagacgtt gcttttgggg aggcaggaag aaactgccag ccagcacctc ctgccagctt
115861  ctgccagggc cacactgata tatcagggtt ccctcagaat tcactggaag aaagggtccc
115921  ctatacacac acacacatac acacacaccc gcacccaggt cctggagttg tgtgccaggc
115981  aggctgtgcc cctcactatg cctggccaca ggacacagct tttatgtatc tcccagttgc
```

```
116041  cactctgggc cctgaaaagg cccaggcaga tggaaagctg gacgcctgag gtcaccgtgg
116101  gccctccacc cagctccggc actcactggg cctggtgccc ttccagtcag tgtgtcgatc
116161  tcagcccagg gccacgtggg aacgattagg tgcatggcgt gggagctagc tcactgaagg
116221  cccgagcccc tcatgcaggg tctgctgaca ccagacagga acatcaagca aaggggactt
116281  ggccccagcc ccaagttctg ggatccagac ctatagcccc aggcccacgc tcacatccac
116341  agcctgggcc ccaggcctgg agctaaggct ggacaggctc acctcctccc cgacagccca
116401  ttaccaaacc cccaccttcc agcccagcct cacccctgac ctggcagctg gcctcaccca
116461  gcgtcttcta aggccaatgg tttctgggct tattctgaga ttgaaattcc tttcctgtgt
116521  tctgaatttc aagttctcat taaagatatg tggattgggg gtgggggtgg agggaggatt
116581  cagcagaaga tgccaaacac cagcagaagc ccagaaaata aggcaaggcc ggccaggctg
116641  tgggggaagg gctgccatgt tcaggaagac aagcaccata tggaatctgg gatcagagac
116701  atggccaagg gcacgtggcc agctcacctc acctgagcag aggcccccag aaccaccctg
116761  aatcttccag gagaggccag ccagaagcac caagcccaca gcacaagtga ccagcccctg
116821  agctctcggg gacacagggg ttgctaatgc cactgggctt gcccgacagc agctagctag
116881  caaggagcaa agctggggcc ctgccccggg gtctggagca ctcgctcagc cccttccacg
116941  ctggccctcc tagattactc ctccttcctt ccctgcaaaa tagtccaagg gtggggataa
117001  gtcgaggctg agaccacagc tggaaaaggc tgggcaggca gtacccagtg gcccggctgt
117061  ctgcagcata gcagacgctg atttgtcacc aaggaacaag gggccaccgg ttgcactgat
117121  tggctccaga gtacattggg cttcctgatg gaacaattcc tttgcaaagg tatctgatgc
117181  cgtttcatga aattagaagt atgcctgcca ggctgtaccc aatttttctg tcaagctagg
117241  aagtcagaca gacctacagt aaatgaggcg gggctgctat ggagtgacgg gagtacctta
117301  gtaaatcaca gcacgggggc tggcccagcc caggcccctg gagcactcgc tgtgaacgtg
117361  caggtgtgcc cgatcctggg ccccagactc cagactctcc tcacccaggg gtcctgacca
117421  gaggctgagg gctgagctcg cagcttccca ctctcccagc aagagccaag cacaggccag
117481  gagtccctga ccacacgggg gaccctgaga actatgggcc tgcagaacca catcagacac
117541  caaccctggc ttcaccacaa tccaggacca gagactgggg gatgctggga ggtgtgggct
117601  ggcacagtga ggccagatct gaggcgacag tcatggactg tcaccatggc cgcctggcag
117661  ctcctttcac gtttctgggc ccagggcaca cgtgggttct gagttgaaaa agacagacgc
117721  ccatgagtct gtgcagagac tgctgaggct gctgggagca cctccagagt ccttgtaggg
117781  cacatgcctc cagggatcca gaaagagcat gcagggcctt tctccctgag cagccaggtg
117841  agggttggga cctaccacag gcaccctccc agggaccatg gcagcacaga gcaggagagg
117901  cgctgtctgg ggctctggag gcctcttcac aggcacagac tcagagacgc aggcactgga
117961  ctcaggcctg gccgggggcc cccgccccgc tccacgacac ttgcttgcct ttaggcaaca
118021  gaagatgggc ccttggacag ccttcatagt ccaccatgga ggccccagac atgaaggcag
118081  aggtgtctgg gctgcttgtc acccacatgc acccagaaca gaggccccag ccccagcagc
118141  cctgctacgc cctgccgtca gccaggcagc tggcccattt ctgagccact gagaccgggg
118201  ctcagcctca gcagccaagc tggtctgtgg agagctgcct gagtctctgg gatgctcccc
118261  tggggaccag ggcctcagag ggctctccac acagcctgcc cacctgcagt agcctcacct
118321  gtgtccaggg cctgtggccc cccgagagga ggggacgtgg gtggccggcg atacaccaca
118381  tgcacacggc cttgctcagc ctcctgcgcc gccagcccct tctccaaggg ttcgatgaag
118441  aactcctcct cctccatccg gatcagacca gcctgcggga caaagacaac aggatcagat
118501  ttccagcaca caaaagacca aggaagggga acagcgagga gaccccctca gggagtacct
118561  cccacctgaa gaccctgccc agcaccccag ctggtgctca gcttgaaccc tgggctggcc
118621  ggagggtatg aacatgtggt cccagaggcc gccccccgcc gcccaccctg tctaggaaag
118681  gggcctctgt ctgggtcatc tccaccccta tacaccaacc ctgtctgctt tcagaaaagt
118741  tactgtgttt ataaagtcaa aaccgtccag agaagcaggg agacattcaa gggcagctgt
118801  gggcctgtgc gtgtccccag gagggcatcc accaaagtgc atcaatatgg gccaagtgct
118861  gcccccactc ccaggagccc agagtccaag acaaaggtca aaacagccag ccggggattg
118921  aatctgccca cacacatgtt ccatctgggc caaacaatat ttttaaagct ctgaagctaa
118981  cactcagaat gatgagattt catgtcttga acatggaatc ccagctttcc ttggaaacgc
119041  aggccctgac cacagcgggt cttggatgga acacatgccc ctgcaactgg ctccagtccc
119101  tactgccccc caactgtctc tcctgctctc tgtgtcagcc accagcccag actctacagg
119161  cagctgaact gctgcccctg acccccctagg ccagccagca ccctccctga ctacaaactc
119221  ctcgctgggt cctcatttcc gttgggactc aggctgctct atatgctggc attcaggctc
119281  ttggcctgcc ccaccctccc agaccgcggc ttgcaccacc ccatgcttct cactgggctg
119341  ggtgcaccct gccgagccac ccagcccctg aaccccatgc tgccaactca ggaatcccca
119401  ttctcccacc ccaccacccc atccccagct cggccatctg gtaaacctgt gttcccctt
119461  cgaggcctga ttcagacccc ctcacctctc ctgccctccc ctgccatcca gcctgccctc
119521  ccctgccata ccctgccctc ccctgccata ccctgccatc cagcctgctg gcaccatcag
119581  gtccacccat cccatgacaa ctccagctcc tacactttta tcttctggtc cattatccat
119641  aaaccaaggt ctcacactgg aagtgcacac tgtgtccagc cttcagagtg tttccttcag
119701  atcacaagct tatgacccat gcaggggatt ttaaaagctt gaatttgttg ccaaacttaa
119761  gaaacaggag agttcacata aacgaccaga tttccagact ctcttgaaaa tcagaaaagc
119821  tggcatttcc agcacccatc gacactccag cttagctggc gctggccggg gtcccctgtc
```

```
119881  cagttaggag tgtgccctct ggtgggcagc ccccggcacc tgccatctgg atgtgcggaa
119941  accacacccc ccccaaagta acctcatgat ggcctctgcc atatcatcat cttggttgtg
120001  ggggggcacg gtggcgcacg ggctgcccct ccttctccct gaccccaggt gctcggtgag
120061  ccccatcctg ttgctggctg ggagcctctg cagaccgaga tgcagtcagt gccccccagg
120121  gcctgctggg cggctgcccc tagcctcaag tgtagcgagg gaggctggag atgcctcccg
120181  gcgcactcag cctgggccct cgggaagctg atgtgccagg caggggctgg tggaggtgca
120241  gggcctggag gaacacagag cccagcatca ggcctggctc cagaatgaag gatgcctccg
120301  gcaggaggtg acatctaccc aaacccaccc aatccctttg tgctggccag gcaaagagtc
120361  agagagagga ccagtgctcc atatggggga aaccgcacat gccatggccg gggaggtgga
120421  cggagcacag ctggtgggaa gagctgacca ggtgggtgga caggagcatc aagggcacgg
120481  tgcccggtgg cccatcactc agggggctgg tgagggagat tgtaggcagc ccagggcttc
120541  tgggggggagc cttgatctga ttccagttca gaagcatggt ggctgcggca ggggggaatgg
120601  gctgcggaac aaaaatgggt ctggggtcct ggggagaagg tgttacaggc acctgggaga
120661  ggggtaatgg tccagacggg agcatgagag acaaggacga gtggcaggta tgaaggaggt
120721  gaggagcgaa atggacagga cgtggtaggg tagagccggc tgagatggga gggaggagga
120781  agcacctggt gggcttccag gtctgtggct gaagaaccgg cccccaaagt tacccaggcc
120841  cccatccctg gcagctgtga gggtagtgga catggtggaa agagactctg cgggtgtgat
120901  caggtcagct ctggggctgg ctgggccctg aatgcagtcc ttgcccactt ccttatgccg
120961  gggagtggag ggggattagg cagatgcgca gaggacgagg ccatgggcag acagggagga
121021  tgccagatgc cagctttgga gattgqagcg atgtggcctc aagccaagga atgctggcag
121081  cccccaggag ctggcagagg ccagaaagtg tcctccccca gagtctccag agggagcgca
121141  gccctgccga tgcctggatt tgggtcaggt tataccgact tcggacgtcc ggcctcagaa
121201  ctgtgagaga acgaattcct gctgttttaa gtggttcctt acagcagccg cagaaaagta
121261  attcagggtc ctggtgggtg gccggcaaag tgggtgccat tctccgaggg gcatgagaag
121321  aagggcaagg ggcgcaggac cctctgggct caggcatcct gggcttctgg ggaagaggcc
121381  taggaggcag tggtaaccag agttaccagg gcaagaccga ggtcggagaa ggaggtcagc
121441  agggctgtgg gaggagagcg gaagaggggg tgggaaccct gcaggcccca cgcttctgac
121501  tcatccctgg gtctcagggc tcaaccaggc ctggcgaaga ctcagcagat gcctgtggaa
121561  tgagcgaacc gatgacccca aagctgcagg ccacgtcccc caagggaggc accgagcagg
121621  caggcgggaa gaacacagcc aggcctgtcc actggcacag gggcagtgtg tttaccagtg
121681  caggagttgg gagggtccag cactgatggt cccggtgcgt ggtgtggaga aggctggtgc
121741  ctcaaatcca tcttatgact gaaactcatt ggatgaagtg caggaattaa ccctgggggg
121801  cggcagcggg caagctgtcc tggagcgtga agttctgact tcctggcacc ctttctatct
121861  ggccaggtga cctcaggcaa ggtgtcaagc tccccaagcg tccagtgact cgtctgtaca
121921  tgaggccggt catttcccgt gcacactcac acaggagcac atgcagcctg ggagacactg
121981  agaaccaggc cacgcctcca cccaagtgat ttcatccagc cagcttgctt tccaaatgag
122041  gaaaccgagg cctagatggg cagacaggct gctggggaca cacaggttct agggatcaga
122101  actcacacct acacggaaag ggcatctccc agacaggtcc ctgggccaga ctgggccgat
122161  tgagccaatt agggcaggac actggggcat gaggacccct tatggcagct ccatcttctg
122221  ggggaacttg cagcccaggt cgggagccat cgatgccaca ggcctgaggc cctggggtta
122281  ttctggaggg acctagtgtg acaatgaggc caggctcagc ctggggaagg gcagtactct
122341  ctggccggag taacccgggg gacagtttgg ggtctccctg accagcaggg gtcaggctcc
122401  cctccctggc tgcctccctg aggacaatca ctgggctgag ccaacagcac tagctccatc
122461  tgatgctgcc ctgggccttg cctcctggaa gggcaccccc gcaggcgact cctcggaggg
122521  cacaggagca cactggggtc catctgaagc agggcctggg ctcaggcttc ctcacacagc
122581  cagaagcctc caagcggtgg cattctccaa cacagacgtt caacatgctc ctcacagccc
122641  cgcccgtctc tgttgaccac cgtgcgatgc gcacaacgca tgctggacga tgaacatggt
122701  ggcacctgcc ccgagaccaa aggctgaccc ccccgagacc aaaggctgac ccccccccga
122761  gaccaaaggc tgaccccccg cgagaccaaa ggctgaccgc ccccgagacc aaaggctgac
122821  ccccccccccc gagaccaaag gctgaccccc cacccgagac caaaggctga caccccccag
122881  agaccaaagg ctgacccccc cgagaccaaa ggctgacccc cccgcgagac caaaggctga
122941  ccccccaccc gagaccaaag gctgacaccc cccagagacc aaaggctgac ccccccgaga
123001  ccaaaggctg acacccccca gagaccaaag gctgacaccc ccgagaccaa aggctgaccc
123061  ccccgcgaga ccaaaggctg aacccccccg agaccaaagg ctgacacccc ccgagaccaa
123121  aggctgaccg cccccgagac caaaggctga ccccccccgcg agaccaaagg ctgacccccc
123181  ccgagaccaa aggctgaccc cccgcgagac caaaggctga ccccccccga gaccaaaggc
123241  tgacccccccc ccccgagacc aaaggctgac cccccacccg agaccaaagg ctgacacccc
123301  ccagagacca aaggctgacc cccccgagac caaaggctga ccccccccgag accaaaggct
123361  gaccgccccc gagacaaaag gctgaccacc cccgagacca aaggctgacc ccccgcgaga
123421  ccaaaggctg acccccccga gaccaaaggc tgacccccccc caagaccatc agctgacgtc
123481  ctgccaagac cgctggccag aataatgctc ggggcggggg gcacttcacg gaagaagtgg
123541  agatcatttt attccctgat tttcaaacac ttcagtatat gcatcccagg aatgatctgt
123601  ctaaaacaca cagaagaaaa ttgacaggag agcaaagcac aaaatgtgag ctatgttttg
123661  ctgcatttt ttccgggact ttgattttcc tgctgctagt gtcaagtgta tctgttttta
```

```
123721  catgtaattt ttattaatta gaatcagttt cctctcccca ctcaataaat attaaagaaa
123781  ctccagaagc acactaggct gaaaagcact cagttgggag cctgctggtg gcctgtctgt
123841  ccaaccccac agctgtccag cctggggtct tacagaaagg ttggtacccc gacctggctc
123901  taagtgtgag tcccgctctg ctcttgaagt ctgtggatgt ctggcaaacc cagccaggtt
123961  ctcccctggg ggacagagag aggatcatgg ggagggctct gtccctgacc ttcaggtgcc
124021  accgcagggg cccagagcct ggtagtaccc gggtcatcaa gtcaagttgc cggcattcag
124081  atcctggtga gttacacaac gcctgccctg cctcttcctt ctatagaacc tgctcctttg
124141  cagttggatt gatggtaaag tagttactag aaatggcaac tagatgttaa aaatttataa
124201  agatccaaag gcttaacagc tctcctctat tactctgaat ttttaagtat tcaaccacag
124261  acagcctgga agttaggggt tcacaggaaa cacaagcatg catcctgttt ccttctgcag
124321  agcacccagg ctggctggtt cccactgccc cttcccatgg aagccacagc tgcagccatc
124381  agcagccccc cacctgtgta tgactgggac ctggtctgtc actcaaccct gtcaacctcc
124441  agcataaaca ctgtcaggtg tgtgccaagg ttgcagtggc aacaatcaag catagaaggc
124501  acaaagcata ggaagcacac aggtccatgc acagagggac ccagactttg ccaagggaca
124561  aggctgcaag tccctgttgc cctcaaactc acctccctcc gaaatacaca cacagcacgc
124621  accttgccaa gagtccccca gatgctggca tctgctaaga ttcccattcc tgaaagtatt
124681  ctaactccaa gattctttct ccccatcttc cttttggtaa tgaacctggg agatctgctg
124741  gacaacgggg caatggccag gcagcctccc ctgctgtgac agctgcctgg tggaatgacg
124801  gtctcacagg gagagctgca cagtgcctgc agttcccagg gcgcctcctc tcagagcctg
124861  ctcgggcact ctcttgcctc tcccagctcc ccagggaggt ctctaacaac cttgggagct
124921  ttcagggaag ggggctggac ccctcactac tgaacagtcc caggagtggg aagtgtcatt
124981  gagtgggatt tgagccactc cgtcctcacc actggacagt cccaggagtg ggaagtatcg
125041  agtgggattt gagccactcg gtcctcacca ctgggggctc ctttacagtt cagcatccca
125101  gaggatttca cacactgact tttccacttt tccaaaaggg acgccagcgg gcaggagctg
125161  tccatggggt taggaaacag ctgtcctcac ccgcatctcc accagctcct cctctgtctc
125221  atgggatcct cgccaggtgc cagccactcc cgtccttcct cttggagagc gacccccttgt
125281  ctagggctct gtcttggagc tatggctgga gctgggcctt ccagggttct gctgagcaca
125341  gtgaccacaa cagagttgcc tctgagctcc acagaacctg atgactttgc ttggccactc
125401  taaccttccc tggacctggt ttcaggccct acagaccttt actccagaaa gtctcttttt
125461  tggcctaagc tggccggagc caatttccaa caggaccaag gagccccgac agtcacatgc
125521  ccagcgaggc tctaaggaaa gctagactcc actttgaagg gcagggtggg gggcgaggca
125581  ggcagggaga gtaagcactg gacgctgagc caggggccct ggtttccaat gcggtcatgg
125641  ccagtcctgc ccccttgcag gcccccagtt ccctcatctg caaactgagg agctggacta
125701  cgtaacctat gaattactgc ttatcctgtt tattcatcac cccaaaaaga aaccccgcac
125761  acgttggcag gtaccgatca tccttctaaa actctactag gaccaaggag aaagaaccaa
125821  accaaaaacc agaaacccac tcctgtaaaa taaaggccaa ggccgtccca tggcacgcaa
125881  ggccttccat ggggtcccag cagccctctg tccctgggcg cacccccagt gtcttcctct
125941  ctctccgggc ttctatttgc acctcaaagc ctacaccact gcccttctct cttgttatag
126001  aggtcagtaa gtagcagaga gctggtaaag atctgtcagc accaaactga gactcccctc
126061  gactcaacca gagagtttaa aatgcaactg aaaagggaat catttttcat tataaagttc
126121  aatgcttttt ttcttctttt tttgagacag agtctcgctc tgtcacccag gctggagtgc
126181  agtggcacaa cctcagctca ctgcaaactc tgcctcccat ttttaagcga ttctcctgcc
126241  tcagcctccc aagtaactgg gattactggt acacaccacc acatccagct aatttttgta
126301  tttctagtag agatggggtt tcaccatgtt ggccaggctg gtctcaaact cctgacctca
126361  ggtgatccac ctgcctcggc ctcacaaagt gctgggatta caggcataag ccatggcgcc
126421  cggccagttc aatgcttttt aatatataac agctttatgg tgctgtgatt accattccat
126481  acatctcagc catctaaact atatgctgaa agtgaacaat tcaaccataa ccactattga
126541  ttttagaaca ttttcatcac cccaaaaaga aaccccgtac acattggcag tcactcccca
126601  tgttttcccc aacctctcct ccccaaccca gccctgggca accactaatc tacattctgt
126661  ctctatgaat tggcctattc tggacatttc atatacgtgg aatcacatgc tatgtggcct
126721  tttgtgactg gcttccttca tttagtatgt tttcaaggtt catccatggt gtagcatata
126781  gcagtatttc attcctcttt tattgtcaaa taatacccca tcacatgtat ataccacatt
126841  ttatttatcc atttgccggt tgatggacat gtgggttgtt ggtttttggc tcctatgcat
126901  aatgctgcta tgaacatctg tggacaagtt tttgtgtgga catgtgtttt cattcctctc
126961  aaagtggaat tactgggtca tacagtaact gtgccagact gtcctctaca ggggctggac
127021  cattctcagt gcccccagca gtgtgtgagg gttcaatttc ccctcatccc caccaatact
127081  cattattctt aggctctttg actctagcta tccagcaggt gtgaagtggt gtcccatcat
127141  gcttcggctt gcatttccct gacaactaat gatgctaagc atcttttcat gagcttatag
127201  gtcatttatt taactttgga gaaacatcca ttcagatact ttccctattt ttaataagac
127261  cattttcttt ttattgacct gtaagagctc tttatatatt ctagacacaa atcccttatt
127321  agatatacaa tttatgaata ttttctcttg ttctgtgggc tgtcttttca actttcttat
127381  tagtgtccac tgaagtcatg aaggactttc ttgaagtcca gttcacctat ttttttcttt
127441  tgtccacttg tgcttctggt gtcatatcta agactttgcc taatccaaag taacaaagat
127501  ttactcctac attatttaag agttctatag ttttagctct tacatgtaga tctatgatcc
```

```
127561  atccatttac agttaatatt tgtgtatggt gtgaggaagg ggtccaactt catttttcca
127621  tatgtggata tccaggtgtg ccaacaccat ttgttgaaaa gaccattctt tcccccactg
127681  acttgtcttg gacctttgtc aagaatcaat atgaggatgt atttccaaac tctcagttct
127741  attctaccaa tctatatgtc tatccttctg ccaacaccac acagtcttga ttactacagc
127801  tttgtagtaa gtcttagaat tacaaagcat gagcccttcc tctgttcttc tcctcaatag
127861  cattttggtt agtctggatc ccttgtattt ctgtatgaat tttaggatca gcttgtcaat
127921  ttctgccaca aagctagctg ggatttgata gaattaaatg cattctggag tcatgtttgg
127981  tacccattag ttcacctcct aggccaatgt ttaggaaaca ttggcctaca aagaaactct
128041  gcattagaaa ccaagggctt ggtcaggcat ggtggctcac accctgtaat cccagcactt
128101  tgggaggctg aggcaggcgg atcacgaggt caggagattg agaccatcct ggctaacacg
128161  gtaaaaccat gtcatcttga gatgggagcc ctaagtctat caactaacca ggtgagccac
128221  tgtgagcaac tctgggccct gggagagggt gcacagaggg atggcttcaa ccctgctgct
128281  agagaatgcc ctcgagagcg tctgtctcag ttctgcttgg catccctccc cagcacccc
128341  cacctgccac tttacgcagc ctggacttga ctttaaaact gagacacctg gcaagtgggg
128401  aaatcacagg tcgaaatagc ggaattgccc tctgcatcta tgctacaggg ataatgaggg
128461  ttacaaatca gaagacattt agcatatatt ctggaaaaaa aaagctatgt aatatataaa
128521  ctattcataa tttaacttta ataaatgggg gcaggcaaaa aattgccaaa caagcccaca
128581  acaatcagac aaagagtaga ggaagaaaaa aggaattaca gtttaattgc actcgtttcc
128641  taatcttcag aatcttcagt tagcatcaac agttactggt aagtttctaa aatcagtaga
128701  tacaagctga agaattctac tcaaaattag aaaagtcaca actagtaaaa ctaatgtata
128761  ccttccaaat gactgaaggc agaccatata gaaaatatgg tagactagaa aaacagcaaa
128821  aaaaaaaaaa aaaaaaaaaa tccagaaaaa cagaaaacat aaattagatg acagaagtaa
128881  gaacaaatat ataacaataa atgtaggctg ggcatgatgt gatcccagaa ctctgggagg
128941  ctgaggcagt taggaatttg agaccaggct ggccaacatg gtgaaacccc atctgtccta
129001  aaaatacaaa attagccaga cgtggtggtg cacacctgta atcccagcta ctcaggaggc
129061  tgaggcggga gaatcacttg aacccaggag gcagagttac agtgagccga gatcatgtca
129121  ctgcactcca gcctgggaga cagagacaga ccctgactca aaaaaaccaa aacctaaaac
129181  taaacaaaca aaacaaaaca ataaatggtc agattattat tattattatt attttggaga
129241  ctccagcctg ggagacagag agataccctg tctcaaaaaa acccaaaatc caaccgggcg
129301  cagtggctca cgtccataat cccagcactt tgggaggacg aggcgaatgg atcacaaggc
129361  caggagttca agaccagcct ggccaatatg gtgaaacccc gtctctacta aaaacccaaa
129421  aattagccgg gcttggtggt acgcgcctgt ggtcccagct gcttgggagg ctgaggcagg
129481  agaattgctt gaacccagga ggctgaggtt gcagtgagcc gagattgcat cactgcactc
129541  cattctgggc aacagagtga gactccatct caaaaacaaa caaacaaaca aaaacagaca
129601  acaaaaacaa taaatggtca gattattatt attattattt tggagacagt gtcttgttct
129661  gtcacccagg ctggagtgga gtacagtggc ctgagctcag ttcactgaga cctctgcctc
129721  ccaggttcaa gcaattctcc tgcctcagcc tcccaagtag ctgggattac aggtgcacaa
129781  caccatgcct ggctaatttt tgcatttta gtagagacgg ggtttcgcca tgttggccag
129841  gctggtctcg aactcctgac ctcaggtgat ccgcccacct cggcctccca aagtgctggg
129901  attacaggtg tgaaccaccg ttcccagcca gtcagattat ttcaataaca ctctatgccc
129961  tgcaaaataa ttttacaaaa tttacagatt tatgctaggc taaaagagtt tctcagattt
130021  tttgaccact taaggaacag acacacccat gacatattgg tgaccgaaga aggcggcaag
130081  cccagctgca gcatgacctc cttacgtaaa atcatgtata tctctgtgcc aaacgtcagc
130141  acagtctaat aattaagcat gtggcctccg agtcactctg cctcgattca aatgtttact
130201  tcacctctga ctgagtggcc tctctgtgga cagtgtctgc agggttgaat ggagataata
130261  acagggtttc catggctgat gtgagggcta agcgagatac cgcgtctcta gcactgggca
130321  cagcacgtga taaatcagcc gactggcagc accatcacca tcatgatgat catggcatga
130381  cagctgttag gaaacgcgta acaaagggtc agcagtgtta cgatcggggg tgagtttcac
130441  tttttattaa tattttctgt atttttttg ttttacattt ttacaaaggg catatagcaa
130501  aacagacaat tcatgtgaag acaggagaga cggaaagggg gagagcacag agagaaagat
130561  aaggggggaaa atggaataaa caagatgccg acaagaatgc ctcacggggc cagcgcaggg
130621  gccagccagg cggccttctg ctaaatcaag caacgcttga gtggctccct cgggacctgg
130681  cctgtccaga atgtcccaca ctcagccctc tgcagccagc tcccccatct ccatggctcc
130741  tgcacacacc aatgccgggg tagcctccag gaaacagagc tggccagcca gacccagcca
130801  ggacacagag gtcagtgggt cagacccaga ctctgggact gcaacaggcc tgcctatttg
130861  tgacgagaac tgacactcgt cccggccaga ttctctggct gacatttccc aggtctcgtt
130921  cagcatgaag cccacgtcgg ggaacgtccc cagtcacaaa ttaacattca cataaataac
130981  agggcgctct ctactaaaga agaaaaatga ctcgtgctgc aggaacattt gccaaactat
131041  caaaaagcaa gatttttctt tctgagcttc catgtctcac cagctggacc acagcagatt
131101  gtggccttga gacgtgtggt ggaggagagc tcatggaata aggtccaact tccccattca
131161  agatcctgcc aacaggccgg gcacggtggc tcacgcctat aatcctagca ctttgggagg
131221  ccgaggcagg cggatcacct gaggtcagga gtttgagacc atcctgggca acatggtgaa
131281  accctgtctc taccaaaata caacaaatta gcgggacatg gtggtgggcg tctgtagtcc
131341  cagctactcg ggaggctgag gcatgagaat cgcttgagcc cagaaggcgg aggttgcaat
```

131401 gagctaagat cgcaccgctg cactccagct tgggctacag agtgagagac tcttgtctca
131461 aaaaaaaaaa aaaaaaaaaa agaccctgtc gacaggccct tccctgggct ggcacctgcc
131521 cacaccagct ggaacctaac acctttgcac agctgttccc tgccagcctc cctgcctcct
131581 tggaggtctg cacacaccgc ccctcccttc ctccaaccag cccgggagac cagcacgcct
131641 gagcaccagc actcccagag acagagccgg cacggtgggt ctgtctgctc aggggctgg
131701 ggtggcaggg gcacatgtct gggagttgcc aacatatgct tccttaccag attccccagg
131761 ggacccaccc tggagagcaa ccaaaccctg caaggctgca ctccaagaac tgagggcctg
131821 gggacccagg accgtccccc agcattcaca gcaggctcac ccacatccac caggagatgc
131881 tgcccaggta gactgccagc acccccctcc acaaaaggtc ggggccggcg ccttccctag
131941 gttgctcggg caaccatcac agggcagcac aggccggggc ttgaatagca gaacctattc
132001 tctcacagtc ctggaggcta gagctctaaa attaaggtgt gggcagaggc ggtttctctc
132061 gaggcctctc tccttggctt gtcgacagca tctttcccct gtcctcacat ggccgtcccc
132121 ctgtgtgtac ttctgtccta atcgcttctt cttaggacac cagtcattca tgttgaatca
132181 gtgacttcat tttcagttaa ttatctcttt aaagaccctg cctccaaata cagccaatat
132241 cctgatctac gggagtttag gacctcaaca aaggaactgg gggatctagg gagggcgtca
132301 ctcagcccat aacagcctcc aggcgccaag tccacacaga atcggagcag gctgctggca
132361 gggtccggtg gccagagctg ggcgggctgt tccttgggga gccactctgg acaggccgga
132421 aggtcaatgc caggatcact ccccaggggc cagaaatcca gcatggagga aagctgccac
132481 tccagggaag taggagcccg cccagggctg gccacatggg atgcccatct cacccttcct
132541 tctaaactgg gcattctcac atggggacac ggggcagtga gtgcaggcgc agggagacga
132601 gaatgctgca cagccggtag gtggtggacg ggcctcagga cccctccgcc agcagcaggc
132661 cactctctca cggtccagca ggagccctgc tccagagccc acgactggag ccagctgagg
132721 ctggtgtctc acattcctgc agagaggctg gctaaggctc ccgtgtgggg gcactcccca
132781 tgcccactgc accccagaat tttctgggcg atcccaaggc tgagtctacg cagctgttgg
132841 aagacggggt atgcaattct agatgtgtgg cgtgttttga acagcatcca ataccctttc
132901 tgtggcagct cagcccggag agcaggtccc cagtctcgag gacccaggag gcagggtctg
132961 ctccttccca cagcgggtgc tcctccagga ggggccaggt gctcagaggg aaaccagtgc
133021 ccaccaaggg cccagctgcc tggctggctc ccagcagtgt ggggaagaca cactacccga
133081 cggacgtccc ccttagaagc aggggcagac aggaactccc atggggagag cacaggctgg
133141 gacgcagccc gcccaacgcc agtcccccca ctccactgtg caacaaggat cagcctttcc
133201 tctctcaaag cctcggttcc cccagagggg gctgcagttg agagttgatg gtgagactca
133261 gtggggcatg tcctccatgt ctgcttgtgc aaagctgccc agatcaggca gttttcccag
133321 ccagaggacc ccccctttca ctttccatca caggctgtca tctccccggg tccctgggcc
133381 acaggccccc ctcaggaccc ctccggcctc atgcacacac agagcctgtg cactgcctca
133441 ctcctgcttc ctttgaattg ggcttctttt cctgctgtga tctctggggc ccactgtgct
133501 atccagggca cgctgaccgc cgaccgtcct ctgcccgcct gcccagctgc cactcccggg
133561 cgggcagccc tgccaggccc gaggctgtct gcttcccctt ctgtccagag ttcccaaaac
133621 aaaaatcagg ccataccatc tgacgaagga tcctgtctgg tttatttatg ggaagagcca
133681 gggctctgag ggccaggttg tctgggctgt ggccaggctg ctctgcaggc cttcagacac
133741 tgcccagccc gtgtccccac ccacccaggg tggctccggg ggaggggcgg gggcagggcc
133801 ccagcactgg tgagcccaca ctggtgactc tgggatgtgt atttattcta gagccaggac
133861 agcagccgcc agggccctag gcccctctgt gggtggttgg cccactggag agccggagca
133921 gcgaggccag caatgaccaa aggcgccgta tccagaatgc aggcaggctc aggcgcacct
133981 gccctccctg gatgccacta cagattcggg gagactgaac tcatgggatc aagtgcccca
134041 cagatcctgg tcctcacaag ggacaaggcc accaggtgtc acactgggag acagtggcac
134101 cccagggtat gaaaggccac accaggctta tgtccagtaa ccctgcctgc acagcacagc
134161 acggcacggc atccataccg cagcacagcc ccgccctccg gcagtgccaa gcccgggatc
134221 tcagggcccc caccagaaac cagacaggtg agcaggtggc agctccaggc caggtgctga
134281 ccttgtgcat accaggcctt ccccgagagc aggctgcagc cccccagctg gttctgactg
134341 ccacaggact gcgcccctcc tgcagggctc tgctcacacc cacactccct gctcagagac
134401 ggcctgtccc accgccccgt gtgaaatcac acccaagcac agcggaacga tggaggaggc
134461 agctggaagg tgctttcggt ggtcaaatct ggggcaattt gaacacaata ataaatgata
134521 gtaataggtt agaacccatt gaataaaata aatatccaca gatcagtatt ggtagaaaca
134581 aataactgaa taataaataa gtgggagggg aagggcagct ctttctcaca gggtaattca
134641 actaaaaatg taaaagaaat gatgagatag aaaatcatgg tagtaaaccc catcggcaac
134701 agcacagtca ggactgcggc aggtacgact tatccgtgga ggctacaatt agtgagcaaa
134761 aggataacaa gaaacagaat gctcacatca cgtcacagca gctacccacg ggagatttaa
134821 tcatcgcaat gggaaaaaag agtgaaagag tggtttgctc atcaagccac tcatctgaga
134881 cctgaaaaaa cctcacagtc acagccctag agctcccggg gcatccagtg gaatcccagt
134941 aggtaacacc ttagccaaat gaagaagggc atcactgaca ataggagaca actggacatc
135001 ccaatgtgac agtcccagcg tggtgcccta cggagggcac agtgcttctg tgacagtcct
135061 gccagaaaca cgtaagctca agccagtaca aggcacacca gaaaaaccca tggggatgca
135121 ccgtctacaa aacagctgac cagtcctctt caaaaacatc caggtcatga aacctcagat
135181 gggaggaaac gggagagaca caacaactaa atgccacgtg ggatcctgag ggggagcctg

```
135241  aaccagacaa cggacatgag tcggaagact gacaaaattc agtgcagtct ggagtgctac
135301  ggttagaatg tgactggttt gttcccacca aaactcatct tgacatttgg tccccagtgt
135361  ggcagtgttg gaaggtgggg cctggggtga ggtatctgaa tcatggaggc cgatccctcg
135421  tgagtggctt gatactgttc tcaaggtagc aagggaattc ttgctctgga gaggcttgat
135481  tagttcccga gcctgggttg ttataaaagc aggacactcc ctgggtttcc cttctttgca
135541  cacatgggct ttccctttga ccctctccac cacgttatga cacagcacaa aaaggcctca
135601  ccagaagcca gggccatgct cttgaacttc ccagcctgca gaaccatgag ctaaataagc
135661  ttcttttctt tataaattac ccagtctcag gtattccatt atagcaacac aaaatagact
135721  aaaactaaga cactaagtac caacgcttag tatcaaccta caaagttcct ggtttcagtc
135781  cttgttctac gttgcataca gaggaagctg ggtgaagggc acagaggaaa tctatgctat
135841  ttttgcaact tttcttgcaa tttttccaag acagcataga tctaaagtta tttcaaaatt
135901  aaaactttaa acacataaaa ataaaactgg gccccagcct ccctcagtgc tctctggccg
135961  gtccattctt cacattggct gcctttccct ggagtggagg cgcccactgc atccccagtg
136021  tccagggagc aggtcctgta gaaggtggta ggttccaggg atcggggagc aagtacagag
136081  gccctgagaa ggaagcaagc ctggcgtgtt ccaggaacac cagggagaac cgtgtagccg
136141  gagcaatgct cttgtgcaga gggcctatgc ctgagccgcc ctgtgggccc tgccgttccc
136201  ttcagggcac tctccaaccc tctgccctgt gcatggggcc acggatgccc caggagctct
136261  agggctgttg actatgaggt tgcttcaggt ctcagtgagt ggcttgatga gcgagccacc
136321  ctcactggcc aggaggggac ttccttcaca ggtgtgaatg ggactgagcc accagcatga
136381  tgctgacacg tgggttttga ggattcccac tcacatcaga cagaatgagt gcggggctct
136441  gggatacagc tgcccaagcc tcaagcctga gtggcacttg tgggctcctg catcggctgt
136501  ggggccacct ccgggctctg gtgttcaggg gtgggcagtg gcagcagaca tccttcactc
136561  tgtgcctctg tcactggtgc ccagggcggt ggcccacacc ctcaaaggtt ccgtgtcatt
136621  tccgggcagt cttccagggc tggctgcatc cacctgcttg gagtgctttc agagggaagc
136681  tgttgccctg caatgccacg acccttcccg tgtcctctct tgcctccaag ccgtgctgga
136741  catcatgctc tcctcccagg ctggtctgca gagggatgga atgcctgtca caactgggat
136801  ccctcttctc ttgtcattct gcctgctggt ggcagagtgt ggaaggcggg agtgtgccca
136861  ccattaaacg aggttgaatt ctgggagtgc agaagtaaca gcctcaggac tgatggggaa
136921  gatgaggctg caagatgtgt ggttcttccc ttcgctataa aggtccaaac gatatttatt
136981  tatttattta tttatttaga gacaggatct tactgtgtca cccactgcag tacagtggct
137041  caaacacagc tcactgcagc ctggaccccc tgggctcaag tgatcctccc aactcagcct
137101  cccaagtagc tgggaccaca gacgtgtgcc acaacagcta gctaattaaa agaaaaaaaa
137161  aaatttgtag aaatgaggtc ttgctatgtt gccagggctg atgttgaact cctgggctca
137221  agtaatccta ctgccttggt ctcccaaaat gctgggatta cagatgtgag ccaccacacc
137281  tggcccaaac attaaattta acacgaccag atgaggacgt atggctcaca ttttcttgca
137341  cactctgggc aagatccaca ttggtggtca tcattaatga agcacggtaa ccaccttcaa
137401  gggaacaacg gaagccggca ttcccggggg cagagagaag cggcggagtc aggagaaatg
137461  ccacaaccag cactaaatac atggggctgg ggaatgcggg gcaagaagat atacagcatc
137521  tccacacaaa caggttccaa agagccacac attgtgagcg gtaacagctt tgctattacc
137581  ccccagctgt gggagatata aatatgaaat tagctgggac agcacactcg accataaaga
137641  acaggaagag atagctcctg agcctgagca gtaacgaggg tctctgcaag cactgagcag
137701  acagtgagca aatgtgttcg tgcttctcct ccccgtcccc taaatcttcc ttgatacatc
137761  ttgctattcc ccatgtgggc tcatgaatct tgttataaat tttttaatca aattgtctat
137821  atagacagga gtcctgcagg aaatatatgc ccagggcccc atgtatccta gggacagcca
137881  gccatgcctt tgggaacagc ctagaaggac tgtcaggaag gggcctgggt gggtgggagt
137941  cagcttgccc aaggtgactc tctctccttg caagatacat ctgagagaga agcccattgt
138001  aagcagggcc aatccaagct cccaccccac cctggagtgc agaccactgc ccagacggct
138061  tcctgaggtc ctggctgggg ccctccaagg taccccattt ccaggcctcc agccccagcc
138121  ccccaatagc ctgccttgaa ttgtcttctg cttaagtgag ttgaggtcag ttttgccatc
138181  caaagagaag ccctcctgtt ttcctagagg ttgtcaggag ctacgctggc cggtcccctg
138241  ggcttgggac atcctctgtt gttgggggga gagggtggga agcatctttc ctgcagccat
138301  gacctcacct tggtgacagc cacagcttct cactcacagc actggtgtaa gtgctaacct
138361  gaagccgctc ctccttgtcc acggggaaga cagtctgacc ccacttttcct ctgctccccg
138421  aaaataagga acgttattgg tgttgctttg tcctgacaga ctcacacgtc cttaaaaagt
138481  gctaatcttc acaaaagagg cagcggcctg tgccttcctt gaggaaagtc agattaatta
138541  gctgactccc acatgagcag cctctgattc ttgcaggctt tgtttatgga tcagaaatca
138601  ggcttgaagt gaaaactgac atctcaatgt gaagagtatt ttccctgcta actgcagtga
138661  gtcagagccg tgcgctgagc tagacagata gggaacatgg ccttcccatg tggactggag
138721  tgtgccaacg cctccgggcc acagcccagg acaagcgtgg gacatcagcc tcccattgct
138781  aggccagaac aggccagtgc cccatagatc ccagcccaag acaagcaccg gagttggcat
138841  tccagggtag ggttttgttt gtttgtttgt ttttctcaag atggaatctt gctctgtcgc
138901  ctaggctgga gtgcagtggc atgatctggg ctcaccacaa cctccacctc ctgggttcaa
138961  gtgattctcg tgtctcagcc tcccgagtag ctgtgattac aggcacacgc caccacaccc
139021  agctaaattt ttttttttttt tgtatttttt tagtagaatg gggtttcatc acattggcta
```

```
139081  ggtggtctcg aactcctgac cctgtgatcc gcctgccctg gcttcccaaa atgctgagat
139141  tacaggtgtg agccaccgca cctggccaag gttttttttgt ttttttgttt ttttgtttta
139201  aggtatttgt gcatctcaaa cattccactt aatgactggg aactggggcc tgcaatccca
139261  gcacttttgg gaggccgagg caggaagact gcttgagccc aggagttcca gaccagcata
139321  gtgaggcctc atctctacaa ataatttaaa aattagctgg gtgtggtggt gcatgcctgt
139381  ggtcccagct acttgggagg ctgaggtggg agaatcacct aaaccctgaa ggtccaagct
139441  gcagtgagct aagatgctgc cactgcactc cagcctgggt aacagaaaaa gacactttca
139501  aaaagaaaaa atatgactgg gaaccgggag aaagatgttg atgaaggcac gcagcctaca
139561  gtcagagctg acagcccaga aacacgtcca gccagccaat tatttttaat gaatgccctt
139621  cctttggtga ctcaatccca tgaacaggga agatgggtgc atggctagaa gctctgtcca
139681  ggctccgagg gctgcccagc agacccaccc taggggggtgc caggatcaac ccgacccagg
139741  gatgctgagc acccatgcaa gtctgaccca cccacgtggc ccaaggaggc agcttgtgga
139801  ggtccggaat ggtggtctgg agattgggca cccacagact tggggagtgg aagggccacc
139861  ccaagccctg cccccgcccc cactgcagct tccccgcagg gctgcaccca catccgcagg
139921  gtggcccctg ccccgtgtgc ccagcttcca aggtggcctg cccctgatgc cagagaaact
139981  tcctgctggc caagcggagg ggcttgcttt ctagggtcag caggaaatgt caacattttc
140041  cctgaaaaat ccttcaattc cctcattgag tctccagtag acttaggtca tgtatacact
140101  caacaggaca actcttttcc accccaaatg ctgacagcct ctgaggcagt ctaaagaagg
140161  aaggaagagt cactgtgcag actcctggca tggaggccct cctgtcgctc tcaactactg
140221  cctctaggcg aacgggcctg tggggaactt ggcgggttcc cactggccgc atggatcatt
140281  gtttccactt caaaaccagg ccttgagcac cctactggag gctgctgggt ttgtctgtca
140341  tcctcagagc ctgagagcat ctggcaccag gcctggctga ataaatagat tctggattag
140401  aaaggaaacc tggctttgaa aagacacaga gaagaaccag gtccctgcgt cccttccttc
140461  caggctgatg ttctgggctg gcgggtctct gttgggctcc ccacccttc accttctgcc
140521  ctgtcctaca gcccagtagg cagacctgat ggactggctc ctcctggctc tccctgggtg
140581  aaggggggca ccgacaggaa gccagggctg gggagagaga cagaaggttt tatttctccc
140641  gctgtggtgg cccccagcct ccccgccctg caagctccct cgtcctgccc gcagctctgt
140701  gagttgtgcc tttgtcaact cctttctgtt gatcccttat gtgtcccagg cccctgactg
140761  atccgacatg ccctgtagcc cgaccaggca gccctcactc tcatagtcca ggtgctggtc
140821  ccatctctag ggtttgggat gggacttcca cactccagcc caatttccac cctgaagcac
140881  acgggtgagc cagttccctg caaccaccac agactcagga cacaaagtcc caggctggtc
140941  cagaacattc tgagcagggc agaggagccc cgtccatggc ggctggggca gtcccgcaag
141001  tgagagtcgg ggtgggagga gctggaggct ctggaaggga ttcaggagca gccaccaagg
141061  ccaccttcca cacacgtcct caaaagccct tccatattcc gctgaaacca ctagtggggc
141121  ctgtgctggg agcaagggag gcgtggagac aggtggggct gtggaaggag gctgccatga
141181  ggagggaagg ctcctccaac ccaggacgcc ccactgcagg aggaaatgcc tttctggctg
141241  tggtccagga gactgagggt cctgctcagc cacacagcac gtgccaaggt gcagagccca
141301  ggggaagagc aaaccgagga gctggcggtg cctcggacga tgcagtgatg gtgaagcagg
141361  aggatggggg aggcctgagc cgtggggaca ggagaatgac cacaggatcc acacctctgt
141421  ggtccgtggg acctcagcag acgctttggg tgatgccaga gagccatgga ggaggtggcg
141481  gcaggggctg tgcttctgag aatgctgaca atgatgggac ccgggagcag ccggagctca
141541  agggacgggc aggggcaatg ccggggcctg tctgtgctcg gaggaggggg aggtgggtga
141601  gcaaggaggt gggtgagcag ggagcgggaa ggtcccaagg ggggatgctg cctgcagagg
141661  ccagcagtca ggaatgtcga agtagatcct tcagcgaggc tggggcccct gctcggaggc
141721  aggaaagtaa gggaggaggg atggggctgg acccagcaat tcagcaagga aagcaggagg
141781  cgggagacag tggtacaggc agggagcaag tacagcaaag aggaccagtg gcatccgact
141841  cggataagga aggaccgcga ggcaggtgga gatgggctca gtgggtaagg tccccagggg
141901  cggcctgggc agagggcagg agggagaggc ggcgggcaga gagaggctgc tgcgtgctgt
141961  gggtcaggag ggtggtgcct gggaagacca gctgcctgcc tgctcccagg gtggacaggg
142021  gacaagtcaa gcataaagat gcaaaggtgc aggccgaaaa aaggacgggc cactggtatc
142081  actaacacaa ccatcaatgg gtttaacatt gcagttagag atcaaccaga ctgagatgga
142141  acaaacaagg catgccgtct gtaacacatg cctgaaacat gctaaaagag agacagagaa
142201  aactgcaaac ccagaaagca gggtgtctgt agtatcatca aaatagaact cagagcaagt
142261  actaaatgac tggaaactcc tgttgtattg acaaggcttg gtgaaagcac acagtcacca
142321  agctttacaa accaagggcc gcagcatctg ccatggttag aaacacaagt ggctcaacag
142381  ccctgtcaaa gggaaatgcg aacggccact cccagtgggt gacaggtctc ctagaccaca
142441  gcagaggggc acagactcat tgactcggga aatgggccgg attgatttct ggatggatct
142501  gacgacttac aaccgaaagc aaatgagtat tctttacaag catgggggag catttacaaa
142561  aattgatccc ggcctccccct gcctgcctgg cctgaatccc ccaagcctgt cagccgtagc
142621  ctcccacccc acctgcctgg caatgcagaa acctgagatt gctgcttctc ggcaccaaga
142681  accaagaggt gaagttggta tggggacccc cttctgcccc actccctgct agtactgtcc
142741  agccagaagg ccctccccac agcctgcccc tttctcttga ctgttccctt ccccaatacg
142801  ctgaggcccc atgtctccca ggaccctccc tcaagacccc ggcttccctc tccagggtga
142861  cttgggccct tgcatcatgg ggcataatgc caactcccca cccctactga tgaagtcact
```

```
142921  ggcagagtgc ccccaacgcc ctccactata atcccagagg acggagagct cttgctctga
142981  gccgagacaa cccactgccc accaccagct ccctcagggc tctccacaag tcccttctcg
143041  cctcccctgc tgcgtcttcg gcctcctcct ctctaaagtc ctctctcagc ccaacaacag
143101  aaccgggtct cttcaatcct gaacaagaag actctgcttc ccctccagcc acaggacctc
143161  ccttccctca cagcccttct cagcaggctg gcctctgctg ctcccctcca cgcaccaatg
143221  cccatggcct ctgtccctcc tccccagggc cccggggacc tccacaccct cctgctcagc
143281  ctctctctgg ccgcccccag ctgctccggt ttccacagca ccagaggcca gggtcccctc
143341  gtgccacagt gaccctgcaa cgcagattcc gtgctccctt cagaagccca cctgacattc
143401  atagaagctg agcaaacacc aggagacaga ggcaatttca gaaattcccc gaggctcggg
143461  gaacccaggc tgtccccttc actcctaatc tgtggcaggc ctggccctgc caagcctcca
143521  tggagatgag ctcttcctgt cccaaggtga tggtgtgaag cgggcctttg gaaggtgatg
143581  aggtcatgag ggtggggacc ccgttaatgg gattagtgcc cttatcagag aggcccaggg
143641  agcttgtgca ccctccactg tgtgcaaaca cagcaagaag gccccagcta tgagcgagga
143701  agcagccctc accagacacc aaacccactg gcgccccgat ctcacatgtg agactccaaa
143761  actgtgagaa ataaatttct gttgtttcta aacacccagt ctgtgatatt ttgttatggc
143821  agcctgaacg gagggacacc tgcagagcct gggatgctca gaatacacac gtggcaggag
143881  gggtgtggac gggctctacg gaactgggag atgcctagaa atgctagagg ggttgagggg
143941  gaggcattca caagcccttg taggaaactg agatctgcgc tggttagggg tggggtgtca
144001  ctggaatggc aagatgcaga tataaatgct gacaagaccc aatttaaacc cagagatgct
144061  aaggtctgaa aacatttgga ttatactagg aatcaacgca aagcttaata acctaaaatc
144121  caaccactcg gaagtttttt caacattcct ctaaatagct cttaagttac tggaatcaaa
144181  atcataaatc tttttaaaat gatgacagtg agaattcagc acatcagaac ctgtggatga
144241  gaccaaagcc accaccagaa gcaagttcac aaccttctta attatagacc agagtgaaaa
144301  taaatgaagc cagtgctcca gtcaagaggg cagaagagag agcaaccata aacctaaaga
144361  tgttgataca aatagcatga gtgacaagat ctcacttctg agtgtgacat atatgtaaca
144421  agatggaaaa acggttagtt tgtatagctg taacaaatta ctgcaaatgt agtggcttaa
144481  aaacacaaat ttgtccaggc gcggtggctc acgcctgtaa tcccagcact ttgggaggcc
144541  aaggtgggtg aatcacgagg tcaggagatc gagaccatcc tggctaacac ggtgaaaccc
144601  catctctact aaaaatacaa aaaattagcc aggcgtggtg gcgggcgcct gtagtcccag
144661  ctacttggga ggctgaggca ggagaatggt gtgaacccag gaggcggagc ttgcagtgag
144721  ccaagatcac accacagcac tccagcctgg gcaacagatc aagactccaa ctcaaacaca
144781  cacacacaca cacacacaca cacacacaca cacacacaca catttattat ctgacagttc
144841  tagagatctg aagtccacaa tgggtctcac tgggctaaaa tcaaggtgtg gggagggctg
144901  cattccttct ggaagctcta aggagaatgt ttccttgttt ttttccagct tttagaggct
144961  acccacattc cttggcttgt ggccccctcc tccatcttca aagccagcac cggagcatct
145021  actgacccct ctctgactct gaacttctgc ctccatcttc tacttttatg aatccttgtc
145081  atggccagct cacacctgta atcccagcac tttgggaggc tgaggcgggc ggatcacaag
145141  gtcaggagat ggagaccatc ctggctaaca cagtgaaacc ccgtctctac taaaaataca
145201  aaaaattagc caggcgtggt ggcaggcgcc tgtagtccca gctactctgg aggctgaggc
145261  aggagaatca cttggaccca ggaggtggag cttgcagtga gcctgagatt atgccactgc
145321  actccagcct gggcgacaga gtgagactcc gtctcaaaaa aaaaaaaaaa aaaaaaagaa
145381  gaatccttgc cattacactg tgccatccag gataatctcc ttatcttaaa agtcaactaa
145441  ttagcaacct gacttccatc tgtaaccttc actgcccctg ctatgtcacc tgatttattc
145501  ccaggttctc gggactggga catggacaac tttgggagaa ggattattct gtctctcaca
145561  gagactatct caaaagggta ggatttcatg gtttttgctt tctccttaat acttttctac
145621  attattcaat gataatgacc atatgttttg tatgttcaaa agtaattttt aattgtgaat
145681  aatgtaaatt attgtgaatc atgttttgtc agttgttgtg aataatgttt aattgtaaac
145741  aatggaaaac taaagaaaca aaagaatagc atcctcttat agcacccatt gatgtctttg
145801  caacactttt tggctggtct tttgtccccg tccccctgac tttgagctgc ctgaggacaa
145861  gccagacccc ccttcacttc tgtggctcta gcagtaagca tgaggacttt ggcacagcag
145921  gctttagcag acatttctca aagtgaagat aaatccccta ataaaggagg ccctggttta
145981  agaagaatga tgtgcacact caaaagtgca ctttaaggcc aagctccgaa taaacacgat
146041  gatattattt tatttaagag tcttcataca tacaacttaa ttcagtaaca gtctgagaaa
146101  cgcaagccag cagacagata aaccgttatg gctctggctc tggcaaaaac tcttcatcta
146161  cgcggagcca gaagaaagcc aattaaaagt cggagaggtc ccgcaggaca gaggccggag
146221  gatgtcccca cacactgagc acaagcccca aacacaggcc tccccagtct ggagccggcg
146281  gccagccccc tcctggcctc agtgaagcct ggactcctca ctctgtccaa gtgggaggaa
146341  ctggtcccag ctgcaagaac cgcctactgt gatctgggca aaggttctgg aggctctgct
146401  cgctcctgtc ccccaggaaa aaaaaaaaaa aaaagacagc agagggcatt gctcaggggc
146461  ccagcctggc tgtcatccct gaacatcctg ggctgaagga aagaattgag cccagccgaa
146521  acttgagatc tttagactta aatccccact ctgtcacttg tggctatttg gcctctttcg
146581  acctctgctt ttccgtgtct aaaatggcac aatattacct actttacaga gttgtcaagg
146641  gattgaaaat aagataatga aggcaaagga agtgagctca gtatcattat gcccatttta
146701  cagattggga aacaggctcc aagagatgac atgactcttt caggattaga cagctaatga
```

```
146761  gtggtggatc cggatctgct cgcacagggc tgggctcctc cccagccccg cactgggaca
146821  ggggcatctc ttgagggctg ccctgtggcg cccagatgcc gcagggagac aaggctgtgt
146881  gcacagatct ctctccactg ggcagcacct gagtaactgg gggagagaag tgggtttcaa
146941  gcatctcctt tgtgaaccac tgggcttaag tatgctgaac ttcagttttg acgcagaact
147001  tggagacaac ccatcctctg ggaaaagaca caaatgaggg caggacccct gcaccatgtg
147061  ccctgctgcc ccagcagtgt cctctcatcc agcgtgtgaa gaaggagtgc agccggagag
147121  ccggtggcag cagggcgtgc gggatgcccc gctcacagtg tgctgtgcct gggagaggag
147181  cgagggcagg cccccagctg cttgggaaca gtcagcctgc acacctcccc cctgggtgcc
147241  cttccaaggc agccctcagg ccccaggctc cgggactccc tgcagaggaa ctgcaagcca
147301  gtcctggccc agcacagccc ttccgccagc ctctggccag cgtcaggaag gggagtgtag
147361  agtgagtagg aagccacaca ggagcagaag ccgggacttc tgcctctcac cccactgcat
147421  gtatgaaaat agacgggggt gatggccggg tgcggtggct catgcctgta atcccagcat
147481  tttgggaggc tgaggtgggc ggatcatgag gtcaggagat ggagaccatc ctggctaaca
147541  cagtgaaacc ccgtctctac taaaaaaata taaaacatta gccgggcgtg gtgggggcg
147601  cctgtagtcc cagctgctct gggcgacaga gcaagaccgt ctcaaaaaaa aaaaaaaaaa
147661  aaaaaaaaaa aagcgggggа gtgataaggc cccggacaac ccaaactgca gcaagattct
147721  ctgcggaggc agagctgcct cctcctgggg gtcctctgga ccaggaagga gccctgagga
147781  cttgtggccc agtgggtccg gcttcccaac ctccaccttg ccagcagcac cgatagatgt
147841  ggccacaaag gtgcattcac atttgcgacc tgtggctgaa tgcagaccct gggtgctatc
147901  tcccgggggg gcaaatggca gtaagcaagc aaagaggaag tcgacagaga gtgacgcagc
147961  cgtgaggaca acagcacaga gtattgttga ggggggcggg ggacttcctg gaagagatga
148021  cactggagct gaggcctaaa tgattggaaa gaggcagcga tggagagatc tggggaagtg
148081  ggctccagca cagagaacag cacatgcaga ggacccgagg tcagaacaga cctgccatgt
148141  ttgaggaaag ggaagaaggc caatgtgagt ggagtgtgga gagcaaaggg tgggcggggg
148201  cgagggacag gagggcagag tggtgggcct gggtggggta caggaggtca gagtggtggg
148261  cgggggcaga ctgcacagag cttcctctgc tgggggggagg agattggatt ttctcctctg
148321  tgcagtgggc agcccctgga gggtggaaga gacctgattc ccctgtcagt tgctctgggc
148381  atgttgtgag aattgctggg ggcaggatct ccctccctct ctctatgaaa ttcctgttca
148441  gcagggatct gcctatggct gtatttctgc tggtagaagt ccctccctga ttataaaccg
148501  ctcaacacat agagaggtcc ctaggagaag gttcaggttc cagtaggatg gtgtgagcac
148561  gcctcacctg catcccccac tgcctgcagc cacccaaatg cactggattc atgagcagct
148621  agctgaggac cctgcaaaat aaataacagc atgcagattg gggaagaaga ctagaatgtg
148681  aggttcagca aacccgcaga gtttactctt cattctctgg tattcctcag cctagataca
148741  aggcaggtca aactccagaa gcgggcactg ggtacagaca gacagagctc gagacaagcc
148801  ctgttgttgt agctcaagga tagaaaaagc atttccgaat gctcagagcc aagccaacac
148861  ctcatttttc tttcctattt ccttttttctt ttcttcgtgt tctcacacgc cagctcatgg
148921  cagcccacag gcacctaaaa ctctaagagg ggagcctggc tgtgtagctg gaagtgctgt
148981  ggtcctagaa aggtggagtg aaaccccatt gctctttcct cttttggtcc tcccaggagt
149041  gtagttgcag gaagtgtgca agacagcagg gtcaataaag ccccagcttt ctggccagag
149101  agatttaaca aggagccgca ggaaactgga cagggctagg aagatggcag agacagcaga
149161  gcttggggaa ctggcatcag aaagttggtt agaaactcct gggctcgtgc ttgagccgtg
149221  cacgagtggg tctgacccta aacaacacgc cataggttct ggggactgac ttaggaggtg
149281  gaccaatgcc caggtcccag acgtgccact gggttgtgtt tacatgggat tgatcagaat
149341  aggactgcac aggctttgaa aatggacctg acattgaacc gcaatccaca ggcacattgg
149401  aacttgcagc cggaacccaa ttaacccaag ggttaattac ctgatcaaac aaaaataatg
149461  accttctcca tagcatttaa acaagatcca aagtctcata gggtaatatc aaagtgtcca
149521  ggatacagtc caaaattact tggcatacca agaaccagga aaatctcaac tcctccaggc
149581  aaatacaacc aacagataac aagactgaga tagcacatat gttggaatta actgacaatg
149641  atcttaaagc agctattata aaaatactcc ataaagtaag ggcaaaaact ctggcaacta
149701  atggaaagat agtctcagca agaaacggaa gacatatttt taaaaaggac caaacggaaa
149761  ttttagaact gaaaaataca ataacagaaa ctttaagaac tcactggata ggctcaagag
149821  cagaatggat atgacagagg aatgagtcag tgaacttgag gatagagcaa tagaagttac
149881  ccaattcaaa ctgcagcgag taaaaatatt ttataatgcc aagagcctta gagactgtgg
149941  gaaaataccg aaagatctaa ctaacagtca tgtcccagaa ggagaagaga aagaatgtat
150001  tactaaacaa atatttggat aaataatggc tgaaaacttc tcaaattctg tgaaatgcat
150061  aaacctacca attcaacaga tcggcaaacc tcaaatgaga gaaatccaag gaaacacaat
150121  cccacacgtt ataaacacac tctgaaaact atagacaaaa aaaagtcttg aaagcagtca
150181  aagaaaaaca gtgcattact tataggggaa aaatggttca gataactgca gatttcttat
150241  caaaactgtg aagtccaaag gaagtgcaaa acattgttaa aatgctgaaa aaaaaaaaaa
150301  agaactgtca acccagaatt ctatctccag caaaaataca cttcaagaat taaggagaaa
150361  taaagacatt ctcagatgaa gcaaaactta tagaatgtgt ggccagcaga tctaccctaa
150421  gatggttgct gaaggaagtt cttcagacag ggggaaaatg atgctagaaa gaaattttga
150481  acatcaggaa taaaggaaga gcaacagaaa tacctgaaaa aatataacag attaggctct
150541  tgcgtatttt aaagaggaat gataatgctg tctgatgtag ttttccatgt atgtaggtgt
```

```
150601  ataaaagaca acaacattca ggggaggaca gagggaccta tatgatggca gggtctcaac
150661  attcaacttg aagtggtaaa atattgattt gaaaaagact ctgaagagtt acataggttt
150721  attataatcc ctggagcaac cagtaaacac tatacaaaga tatacaacca aacacaatag
150781  gtaaattaaa attgaatacc aaaacatgct caaatagaaa aagcaaaata agcccaaagc
150841  aagtagaagg gaggaaatga taagagtaaa aatcaatgaa actgaaaata tgaaaataat
150901  agagaagatc aatgaaacca aatttggttc tttgtaaaga tcagtcaact gataaatctc
150961  tagtgagact gaagaagaga aacagaaaaa aatatgaatt accagtatca gaatattttt
151021  aaaaaggata tcactaatga catcacagcc ataaaaaaga taatggaata gtataaacaa
151081  ttctatgcat ataaatccat cagtgttgaa gaaatgcatg atttcctcaa aaactataag
151141  ctaccaaaac ttacccaaga caaagtagat agcataaaaa gttctgtaac tattaaagaa
151201  aaagaattca tagtttaaaa tcctgcaaaa aagaaatttc caggtctaga cggttttact
151261  ggaaaattct actaacctct caggaaaaaa tggcaccaat tctcccattc attttatgag
151321  gtcaacatta ccctgatatt aaaaccagac aaagacagtt caataaaaaa aaaaacccta
151381  caaaccaata tccctcatga acctataaac caatatccct caatgaacat agacacaaaa
151441  atcctcagca aaacactggc aagtctagtc cagccatgta taaacagcag agtgcacaac
151501  agacaagtca tgtttgtcct ggatttgcag agtctggcac aatatccaaa agtcagtgta
151561  acccagcata ttaacagact gaagaaggaa aaaaaatatg cttatatcaa gtgatagaga
151621  aaaccatatg atatgattca ttcatgacta aaaattaaaa actctcaact aacagagaaa
151681  gaaacgtgct caacctggta agaatatcta caaaaaaact aaagctaaca caataccgca
151741  tcctgagaaa ctgttttccc ctaaaataag gagcattttc acgactccta ctcaaccttg
151801  ggttgagtcc tagacagcac ctctgtacac acccagcacc cagcacagac cctcaggcca
151861  gggcaggaaa gggccccaga gagcttcccc aaaacccgtg ttcctgggga aggtggatgt
151921  ccaggaaggg tgactggccc ctaaagccta ggggaagcgg gggccctcct gctccagcct
151981  catgaagctt tgatctccag tgccaagccc ggtgccagca gagagccagg cagatgaact
152041  caaccaggga aaggacaccc aggaaggaag caactccatg agatcgagtc tcatagcacc
152101  aagtgctccc acaggctctg aggacatggc tcttattcca ggaccaggcc tgacaggagc
152161  acagcctgag ggatgagagg gcagggcagt cttctgctgg gtggggaatt ggccaccagg
152221  gccagtccca catctgttgt ggccctggca ggatcaaccc tgggcctgag tccttggagg
152281  tgaggccagc acgtagtaga ggggcagccg agtaagaaga atctctcggg gaagtcagtg
152341  gccagccagc ctaagcccgg cccagaccct cgccctgcta gcatgagaca gacacagggg
152401  gcccgcactg cagagctgcc ccggcccacg cgcccctgcc ctgctgtgct ccgccatctg
152461  ccccagcagt gctgtgagag catcgcaccc tgcaagcctc agccttcagg gacggcaaga
152521  cctggggccc acaggaggtc caccggccct ctcagggctc gagcacccgg ccaaccctgg
152581  gtggccactg ctcagcactc caggacagct ccatgacaca gaagcagctc tgcccatgag
152641  cattcaacag cccggtccgg ggggcaccac cacgcagggg cttcccgggt catgctgcac
152701  catccactaa tagcaccatc acgtatgcca ggctgggagc ccgggcgtcc caagcctgtg
152761  acctcattct ctatgctcct cacggctgcc ccacagaatc tctgaaacac gactcagacc
152821  tgtcactgcc tgcccaaagc cctccagcgg cttcccacca catgactgcc ccggtccccg
152881  ctgatttctc cttcactcaa gtgccagccg tggagatctc ctctgtgtcc ttggcacact
152941  tcaactcagc acctgcctca gggcctttgc acctgctgct gcctccacct ggaatggcct
153001  tcttccagaa gtccaggtcc tagctccgat gcctcctcac aaggaccttg gtgaagggtg
153061  tcccttctcc atcacactcc acactgccat cctgtcctat ttttttgtaa caccatttcc
153121  caatcatcga cacgtgggtt ctttattggg tcactctctg ccccctgacc agggatctta
153181  cgagagcaaa gttgtccttg ctgggtccac gtcaccagac cagtgcctgg catctcacag
153241  gcatggagtt gagtacggga ggtcgccggc cctcccgagg ctcccttccc ctacttcggg
153301  atggtgtaag gtttccttgc caaggtccct gtggtgcaga gtgggccaag tttgccgcct
153361  tctggagcga caacaaggag aaaacagggg tttaagtgga ggatccggtg ctctgatttc
153421  tccccagtta gtaaagcatt caggctgctc ggtggaggtg ggaagacagg cgctgagagt
153481  tgtctgacac aattgtctta gcagcaggag acgctgatgg gatgtcggga gtcaccagga
153541  ccatctgaca aatgaccgcc ttggggatcc gtggagctca gcggtgccca gagagagcac
153601  tcgaaatgcc agctggaaag gtcacgcacg ccagctggaa ggggagccgc gcagcccctg
153661  ggcaggctga ggacaggaac gggcagccgc cactgttcac gagcaagggt gcaggggcac
153721  cagagcccac aggagctcct gcaatgcgat gaccatgcct gcaggccccc ataatagaca
153781  gcctcatttt ttttttctag gcaaaacttt gggaggatcc tttttaattg tatttgcaaa
153841  acagtttctc ccaacatgat gcccatgtgt atgtggattg ggggaaattc ccaaggcctc
153901  tcagagaagt gcctccttcc taaggtggtg tcccagcaga tgaatctggc tggcgtcctg
153961  agtggaagca gggcgcgggc tgccatggaa ccccaccctc ctgcaggttc ctggcccctc
154021  tgcctcctct tccttcccac cccaggggcc ctgggatgca gctaggccag ctgggagcca
154081  gacagccact gaagccctcg gggtactgtt ccctgccttt agcatccccc tcagctgccc
154141  attcattcag ccattcttct aggaggacag gccaggccat ggtgaggccc tgggtccagg
154201  gaaagatacg aagagggctg aggcgggcgt tcctgccctt gggtctcttc cgctgccctg
154261  gcagccccgt gcctcctgac tgtggactgg agttctgcag ctgcgccatc cacaggaagc
154321  tacatggaga gatgggccag ctcagcagag aggcgcaaac accaattcag ttgaaaactc
154381  tgtgttcccc gggtagaggc cagttaggag ccagcatgcc tcccaagggt tgtgcaggga
```

```
154441  gacttcagcc aggcacccac tggggcagac ccagtcccac tgcttctgcc ttcagtggcc
154501  acaggcctgg ggccattggt ggatagagct ggagaaaggc cacctcttcg ggacccaggt
154561  cacaggatgt ccccccaaag ccatcccagt cagatgtctg cagacacctg ctcccctggc
154621  aacagtgacc cagacctgac cttcaactct aactgtgcac agcttcctag cccggccccc
154681  aagcctgaag cctggtccct ccagacactg cagaaagctg gggctgactg taatcccagc
154741  actttgggag gccaaggtgg ggcgggtcac gaggtcagga aatagagacc atcgtggcta
154801  acatggtgaa accctgtctg tactaaaaat acaaaaaaaa tagccacgca tggtggcacg
154861  caccggtaac cccagctact caggaggcta aggcaggaga atcgcttgaa cctgggaggc
154921  ggagttgcag tgagccgaga tcatgccatt gtactccagc ctgggcaaca cagcaagact
154981  cagtctccaa aaaaaaaaaa aaaaaaaaaa aaaaaggctc tggccctgcc acttgaccgg
155041  gtgggtcacc tctccgtgcc tcagtttctt ctatttaaaa tgcatagggg aggagctctg
155101  agggcaaaac accctgggtt tgcctcaggg cagggcagga ccctggaccc agcaggcccc
155161  cactgcatgt ccctcctgtc ctccctgccc cacccctgcc ctctggcttc tggggttcaa
155221  gtcagggagg ccttgggagt agcctgcggc cctggggaca gacaagggtg cccctgaatg
155281  tcctgtggat ctgcccaggt tgatgccttg actgctcctt cctgtcaccc aggaccctcc
155341  aggagagacc accccggact acgcctgccc agggctccct gcacgtccca tgtccccaca
155401  gcgctcaggc gctgagatgc tctgctgtct gctgtggggg cctgtggacg gccctcctcc
155461  cccaccaggc tgcagctccc agcgggcagg gatctaggca tgccttgctc ataccacaag
155521  gcagaaacac agtgaagaaa gacagagaac tggtcttgtt gtctttgggg gctcagcccc
155581  ccagctccaa gctggaggat caggaggcat ctacaagcct ttccgaagcc cccccatagg
155641  ctgccttgca gggtacagta tggcctagag agccccagag ggctcccctg gtcattaaat
155701  atctcaggat ttccaggaac aaggagaggt tcaagtccac agaagaatct gattggcgtc
155761  tctgggccac ccaccggtgc tagaatcccg gctggggtga gggatggtgg tgcagagcct
155821  ggctatgcaa aatgtggcct ggagcagcct gggggccccc gggagcttgt tagagatgct
155881  gaatccaggc cccatccaga ccagctgaac taaaacctgc attttggcaa gttcccaggt
155941  ggtctgatga cattgaagtc tgggacacac tgctctagac cctcccaggg tccctcaaag
156001  gtgggtgtag aggccctact gccctgccct ggggacgcag aggcatcagg gccttagtcc
156061  tcctggggac agtgaaaggg ccaccacccc agaccatggc caaactgcag gggtcaggga
156121  ggcatggccc aggacagcag ctcagcaggg tgcccaaccc cacctgcccc tgcctgcccc
156181  aacccacttg ccggctgggt cctctggacc tccgcccctt tccaccccag gttggagcca
156241  aagaccaccc tctccactcc ccagcccccc acccccccaac ccaccgagtg cagggcccgt
156301  tgactcctat ctcaacaaca acaggaaacc atttttccag acagcattat ataaggggag
156361  gatgcgtatg ttcagcagat gttcactctg aggccgagcc tcccccgccc tctgaacagg
156421  aaggccacgt ccccatccct ctccccccagg gcctggcgct cctggcccag gtggagctgg
156481  cctctggctg gccacttctc tggaagggcc tcgtccagct ctgtcctgtg cagggtcatg
156541  cccctccact ctgctctctc tagcccatgg gcaggcgccg cctggctcag aggcacagca
156601  atgggccagg gtcagacagt ggtgagcagc atgccaagaa tcacagggac atccacctgc
156661  cagcaaagcc tcaatgacaa caaaggacct gaacagtgga cactgacagg gactctcctg
156721  cttgaccaaa ctttagtcca gctcctgaac cttctccttc gcccacttcc ttgtaagatc
156781  cagtttatca agaactctgc taagtcacga atgccccatc tctccatatc tgatcaccct
156841  tgatatctgg tcaggctcgt cctccccatc acccctctgg tgatgtctgg tcaccccagc
156901  ctgtcttcag ctagaatcat gttaggtgag tttagctaga atccccgacc cctgatgttg
156961  ctcttagtaa ttccccatcc cctggcccct accctgctcc ttggctatca ccccccactc
157021  gcccgtgctg tattcggagt tgagcccagt ctctctcccc gactgcaaga gcccactcta
157081  gcggttcctg tgtctatctc catggtcctg aataaagtcc gccttaccgc gctttaataa
157141  gtatcattga atcatttttc atttaacaac actctgcctt gctgaaggga aggtagaaat
157201  gacagcagtg gggaggaggg agaaggggca tgggaaccct gtgccgctaa gggcatactc
157261  tagaccctct gccccaggct aatgttagaa gctgcagagg tgcaaatata acagtcagac
157321  gaccatggca gtggtcagct gaaaaatggc ccccgaagac acgtccgggt cccaatccct
157381  ggaacccata aatgttacct tccatggcaa aaaagaactt tgtagatgcg gtgagtccaa
157441  ggatcctgag atggagtgac tgctggattt tccgggtggg cccagggata gacagaatgt
157501  ttatattccc cccaaattcc gatgttgaaa gctactcccc caaggtgata tattaggaag
157561  tggggccttt gggaggtgat tatgtcacca gattccatcc acacgaatgg gatttgtgcc
157621  ccgatcagag ggaccccaga gagctccctc acccttcag catgtgagga tgcaacaaga
157681  tgccttcttg aaccagggag cagaccctca ccacaaccat atgcacagct tccagaaccg
157741  tgagaaataa gcttccgatg cttttaagcc gctccgttta tggtatttgg ctatagcagc
157801  ctgcatggac taagacaggc cctaaatgca atcacacttc tctttatcag aggaaggcag
157861  agcaagatga gccaggcaga ggagaaggcc acgtacaggc agagcagagg gagatggagg
157921  atgtcggccc tgaagcccag agcgaagagg ccacaagcca agcactgctg gctgccacga
157981  ggacctggaa gagcccagga cgcatcctcc cctagaggct ccggagggag cgcggccctg
158041  ccgccacctg cgttttgccc tgttgaaact gatttcagcc tccagaaccg tgagaggata
158101  caattctaat gtttcaaacc agcaagcttg tagtaatttg caggcagcct cagaaaccaa
158161  tacaatgggg aactctgata tggactaaaa gtggtgagag aattatggta gaagaatggg
158221  gctgggaggg gcagcagtgt tgtcagtgag ctaaaccctc ctcttccagg gcaggaagtc
```

158281 aatggacaac atcgaaaccc gatacatcaa gaaacagcaa tagaatagca tttcaggact
158341 tcatggcaac cccagaacca gccagcagcc taaagcctta ccggggctcc ctcctcagga
158401 gtggcctgtg aagaggggac gcacacgcat tcacactcat gcacacacac acaccgagac
158461 agaggagggc ctggccagag caggggtgtc agcagagggg acgcacacgc attcacactc
158521 atgcacacac tcacaccgag acagaggagg gcctggccag agcaggggtg tcagcagagg
158581 ggacgcacac gcattcacac tcatgcacac acacactcac atcgagacag aggagggcct
158641 ggccagagca ggggtgtcag cagaggggac gcacacgcat tcacactcat gcacacacac
158701 actcacaccg agacagagga gggcctggcc ggagcagggg tgtccgcaga ggggacgcac
158761 acgcattcac actcgtgcac acacacactc acaccgagac agaggagggc ctggccggag
158821 caggggtgtc agcagagggg acgcacacgc attcacactc atgcacacac acactcacac
158881 cgagacagag gagggcctgg ccggagcagg ggtgtcagca gaggggacgc acacgcattc
158941 acactcgtgc acacacacac tcacaccgag acagaggagg gcctggccgg agcaggggtg
159001 tcagcagagg ggacgcacac gcattcacac tcgtgcacac acacactcac accgagacag
159061 aggagggcct ggccggagca ggggtgtcag ctccaggacc aggagttccc aggcagaacc
159121 tgatggtggg gcgggggggtt cctcacacac cccacacccc tgcctatgcc cagacctcca
159181 gcttcgggct ctgcatccac acggaggctt cggattgggc gcagcctggg agcacacaga
159241 ccggccaggg ccagggccag gactggcatt tcccgggctc ctggtcccat cctgcccctc
159301 ccaccgggtc ggccctgtcc ttgtcttgct cagctcgggg gaagcacctc tcgccagcca
159361 tctggggctt ggctgggcct cagcctcctg gctgccacgt ctcactggga gctgggcggc
159421 cgccagctct gagctaagtg agcgcagagg agagtgcagg gagcggcaag gccaggctcc
159481 tccccacccc gtggcgtggc gtggcgtggc cggaatactc agttttccct gctttttgag
159541 acaagagtag taaatgcacc gtgctgtact cagagcccag gaagcagccc tcccacccac
159601 agcgctcctg cctctgcagc cccccgggcc gtgtctctct ctcacgggcc cacatcctca
159661 ctggactgtc tccctttтac agatgaggtg agacagcatg cagaggccca tgtgcttgtc
159721 ccacagggtg acgggccaga attacaagcc cctgattctg ggggcttcca cgctcttcca
159781 ccaagccctt gtagccttcc tgcacccagg tggggctcct gtcccccgcc agtgccccca
159841 acctctactc cagcagacct ccacctacag acaggagtct tgggcacaca ctttttgtg
159901 ccaggcccaa ccaagagctg caagggacat aggaatgtcc cttagcatgg cccgggagcc
159961 tcaagcccag ggcctaccta gaagtaactc tctttcctga cattaagcga ctcccctccc
160021 agagcctaat cacagccagc tacgcccccc tctcccagtt attcaagcct ggaaggaacc
160081 tggaagtggt actggattcc tacacccacc ccccccacaa tccccaaggc cccaccccgg
160141 cctcctcctc cccctgcccc tgcatggagc aggcctcact cactctctct cttctgttcc
160201 tcctgggtcc ctgcctcaga ccctcccacc taacacagcc tctgccccac cccagagggc
160261 tcctcccaag acacgcgtcc acgtcgccat ggacaagatt aaatacccctg gcttctggaa
160321 agcactgagg ccacagttgg cttctggaaa gcactgaggc cacagttggc ttctggaaag
160381 cactgaggcc acagttggct tctggaaagc actgaggcca cagtgctttg ggaaggtcat
160441 gtcgggatcc cagggctgac tgcactcctg ccagtgaagt gggggtgtcc ccaaaggggg
160501 tttgtttccc accattggga gccaggatcc caggtcagga aacagagctt gggtgggagg
160561 gaagccatct ctggggactt tcctcccatc tcccttgtcc cgctcacgag gagaagccag
160621 agctagaagc tggcatgagc cctcctagca ccaccagcca cagtctccac ctccggggac
160681 acgagctggg atctgagtgg cgcaggtact atgttctaga gaggccgtac ccaggaccgc
160741 ccatggcacg cagaggaaaa ctgaaacaac gatccttcca gagacaaagc acagccccag
160801 atggccacag gaactggccg cccccaggag ctgctgagca caaacgccac tggagagagg
160861 gcttggtggc tgcaccgaag agcagaacag aggaactgaa cagccacagc caccgcagaa
160921 ctgggggatc tggacagagc tctcgctgtg tgctaagaaa ggagcaagag acagagggca
160981 gggagaaaag ctgcgagacg tggcaagtc ccagaagaga gtcggggagg tgagagaagg
161041 aatatttcaa aaaacaaaat tacatgaaag attccagcat ggatgggttc ctagaggcct
161101 tatcaataca tatataagaa aaagctccat agctagaccc acgataatga aacctaagaa
161161 catcaaagac aaagagaaag ttcaaaagct cccagaggga aagagcagat cagatcagtg
161221 taaacaggga ggcagcaggc agacatccaa gtcccagact ggggcgtggg caccgggcag
161281 cagacgggag acaagagccc aggaagtcct gctggcaaag aattcaaagg ctcttgcctg
161341 gagggaagag gctgccccat tccgaggcca gagccaccgc agcagaggac agctgtgtcc
161401 ctcagagggg tcggcaggga cagaggccac accagagcag cagagatcta gcaacccaga
161461 agggtgacac cctgggagat gctgagagca gcagggccct caggagcagg gctggggagt
161521 cggccacagc tcaggggtc attgcatgtg ggcatcccag gctcctgcct aggcccccta
161581 gggctcccca gccccacaga acaccctccc cactcccagg gatggcattt gagaccttcc
161641 tgctgtgtcc ctccaggaac ctgtgagctc caagagaaca gaaggctgcc tcttcaaccc
161701 cagtccagca aggcccaggg cagagcaggc acggagaact gctgtcgaac atgaagtggg
161761 gacgggacgc agtggtgtac acctataatt ccagcacttt gggaggccaa gaaccgctta
161821 agtccagaag ttcaagatca gcctgggcaa catagtgaga ccccatctct acaaaaaata
161881 aatttaaaaa attagccagg catggtggtg cacacctgta ctttcagcta ctttggaggc
161941 tgaggcagga ggatcccatg aaccaggagg tcaaggttgc agggagctac gattgcacca
162001 ctgccttcta gcccgggaga gagcaagacc ctgtctcaaa aaaaggaaat atatttaatt
162061 ttttaaaaag aatacacagt ggtgagaaag gatggaaaga agagaggaaa ggaaggaaag

```
162121  gatagggaaa gaacaaaaga aggaaagaaa gaaattccag ctaattctca gcaacagaca
162181  attacaggaa cacaaggaca aagcccagag ccccaacccc acgtggcctg ggtccccaca
162241  gcctccagcc ctcctgtcac tctgccagct ggcagcaggg ccacctctga gcatcctttt
162301  cctcagcact ttggcgtctt tcctcccagt ggtttcttgg tagttcctca taaatccatg
162361  cgtaggtctg gctacagcta tccttgtccc tgaagatgga ctcagctagc agagtcgctg
162421  atatggtaac acaatatcac acatctcatc caagcctgct cggacgctgc ccttctgacc
162481  ccgattcctg tcaccaacac aacaggaaag gagcttgaag acccaggagg ccacagcaca
162541  gttcctcgtg gagggagaga gatgcgagca ggtgggcgga gggtgcactc atgagacttc
162601  tataagcacg gacccagagg ccatcccagc gacactgtgt ggggactcct gcacctcttc
162661  ctgctgccca gaccatgggt ggccagcagc actgcagtgt tggtgtaatc tatgtccccc
162721  ggatggccag cgggcacaga gcatatgtgt gctgagggac acatgcccca cacaaacgcc
162781  cccacatgtg catcgcatac atcacccaca cacacacgtg tacatttcag cacgcgtcta
162841  ggggaggtta gcgtgccagc accagctgag actccctggc cagactcatc gccagttggg
162901  gagagtggag cagacgtaca ggatggaggg tagaggtggg gctggtccac agtgagggag
162961  ggaggcaggt gtagactggg ccagggaaag gttctggaaa cccagactga aggttccctg
163021  gggtccctgg ggctcatcca gggctggggt ggagccagga catgaggaac gggcagtgat
163081  gaatctgaag ccctgctggt cagcagagcc tccacctgca cgtcctcccc aaaggtcagg
163141  caggcttcac cctggccacg tctctaccct ggccattagc aaagaggccc cccttggacc
163201  aggaggaaca cagcaggcca gccctcctgc ccttcccatc caaggctcca gccactctca
163261  tggagactct gagctgagac actcccagca gaaagggtca tttatctcag agcttaacta
163321  gcccccttcca attagtgagg aataaaatgg cagcatttac tctgaagaac tgcgatgcga
163381  gagtattaat taaatgcgct gccgctgagc ctcagcacac aggaggctga gccctcatta
163441  aaaaggcatg agactaaagc aagacaggga ggagaggcgg ggccagctag acaggggatg
163501  gggagagaag gagatgccgg gcggggcggg gacagccagg gacggccaca gctgccctgc
163561  caggagggac agggcccact gcaaagtggg acagctgctt ctagccctct cacaagaagg
163621  ctggtgggga agaagccaag cacacgcaga gggtgctccc gcacacccct cgcctccgtc
163681  tttttggaat cttgacagtt agaagacgac aagggccact gtccagtggc tggcatttgt
163741  ccccatgaga ccacagagag gcagaggaca gctccttctc agaccagggc aggtggggca
163801  atgccaaggc cccctcggct caggatggag ctgagcctcc ccaggatgac tcccctgggg
163861  gaaacactga tgtcgctgtt tgagcgttga gacgttgggg cctggcctct gagaggcggg
163921  gccccgaagg gtcttccagg aaggtcagac cccagcccaa aagcagcagg cctgggccac
163981  aaagagagct ggtccctggg ccagaaagcc ctcttccacc atgcactctg ggcaaggggc
164041  gtgtgtgcca ttaggaacac agctgcacgc tatttctctc ctgtcttcct ccagctgaag
164101  atttcacaca gccctgttat gactgagggt tcccaacagc tattccctca acacacaggc
164161  ccccacacac atgcatgtgc actcatgcac tcccacatgc agcatgcatg cacccacata
164221  caaatgtcca tacgcatcac atgcaccacg tgtgcactca cacgcaggcg tcacacaggc
164281  accatgcaga cgcatgcaca cacacatcac tcatatgtgc atctcctgtg acacatgcat
164341  cacatacaca tgtccacaca tgtgcactac acacaagtac acacatgcac cagaaaaatg
164401  ccccatgcat gtgcatggca gacattaccc acacatacac atgtgcatcg gtcatacatg
164461  tgtatcatat gcaggtatca tatgtacagg catgcagtgc acacatgcat gcatcaagca
164521  catgcattat acatgcacac gcccgcacat gtgcacacat gcatgacact catgcactca
164581  cacatgcctc acatttgcac acatgcatca ctgacgtgct cacacatcag ccacacacat
164641  gcactcactc acaccctcct gctgctccca gcctcactgc ctgcttgctt actttcccag
164701  ttcctgccac tacctgagaa ggtgtttatt tggccttttg cttattgtat gtctctacca
164761  cctcatccta cccctcccag ccctccccat ccacactcaa ccagtagaat agaagcctct
164821  cccctctgtt gaggcaaaaa gctgtgaccc tcttttcacc cagaaaccac aggaagcatg
164881  cgtgcagact ggactcagcc ttcaccagcc cccgcagtca ttacgcctgg ctccccagca
164941  cccaaaccca ggtccccact ggtcagcacg ttcacaccca gcctgccaca tctccggcct
165001  ggcccacaga atgcctggtc ccagactcct aatgtaggaa gactgccctg cctgatctca
165061  aggcttgctt ctctgcattc aggccactcc tgctgcccag cctgacggct cccggagcag
165121  ccggtgatca gtcaacctcc ccagccttct gtttgccttg cagagccagc cgactcccag
165181  gagagctgta gaggctggtc agcagcctca ctgtccctgc cctgcctggt gagggaaggg
165241  aggccacgga ggaaattccc tcccgctcca tgtctgcctc gtgtccttct ctctcctgct
165301  gtgctcctgg gcagcagctc cctcctccag ccttccaggt ctcccaatcc tggccccagc
165361  cacttccttg ggaaccctaa gcctgcctgg agtccaccct cctccatttt tttgggtttt
165421  ttttgagacg gagtctcgct ctgtcactca ggctggagtg cagtggcacg atcttgactc
165481  actgcgagct ccacctcctg ggttcacacc attttcctgc ctcagcctcc tgagtagctg
165541  agactacagg tgtccaccac tacgcctggc taatttttt ttttttttt tgtattttta
165601  gtagagacga ggtttcacca ttttagccag gatggtctca atctcctgac cttgtgatcc
165661  gtccacctca gcctcccaaa gtgctgggat tacaggcatg agccactgtt tctggcccac
165721  ccttctcctt ctgatagcac agcccctgtg tcactcagga accagctctc atccctgcgt
165781  caccagtggg caaggagggc acatgaccca gcctaggcca ggtagaatac gttgtcatct
165841  gactacatga acatagctca gggatgagga cttgccacaa ggtattccat gaagttaaat
165901  ccaggaacta ttgctggaat tgttggaaag gaaaagctgt ttcccccggg ttgttgccct
```

```
165961  gtgaggaggt aatgcagcag ctgcctgcat ccatttttct gcctcagaga agagcaggcc
166021  tgagagtgaa atcgacatag aggagagcaa agccaagggt tggggatgtg ggaaaaaaaa
166081  caactgaaaa tttatttggg cacctggatc cagccacacc tgaagctaga tagttctaga
166141  tatttttctt tttgcagatt aaccaataag ttttttttttc ttttttctga agccactttt
166201  acttggattt ccaacacttg aggaataaca cctgactaat acactctctc ttctatagct
166261  tcaaactctc catctcccgg atcctcatcc tcggtccctg agcaaactca agccacctaa
166321  aatcctctgt gctcgaggca gggccacaca cacatctaca caagcgcaca cgtaaacact
166381  gcactcacat ctaagactgc acaccctccg cagctgatgt ctgccccacc acagcatgtg
166441  tgccatgcgc accagcttcc ctccactccc ttgcctctca ctggcccctc acctggtcag
166501  tctagcttcc accaactccc cagcgaccct gcaaagcccc ctcttggctg ctgggcctga
166561  tgccccctgc catcccaatt ccctgaaccc cctcctcttg aacctctctc atcctttagc
166621  aggtgggcag ccccgctcct aagaccccac tgcctcctcc acttgtctgc acatggtggg
166681  gggccaagga gcacttcctt ccccttctgc ctccctcttc ctttggtgcc cgcccaccca
166741  ccccaggatg tggaatccac agccctccat acagagcgct cccaacccga attctaccca
166801  gaccttgccc ctgcacctag gacctgcatt tccagctgcc agactccttc caagagacag
166861  ccccagtgac aaaccctctc tccaagctac ccttcctctc taccacccat ctgtgcaagt
166921  caaaagctgg ggagtgcttt tcctcagcct ctccctcagc ccccaggccc acagacccaa
166981  gtgcctggag atcccggcct ctccatgttt cctgagtaga ttatgctgcc tctattgaaa
167041  gatgttccgg cagaacactg gatgatccag aaatatttcc attatgtgtg gcatgggcag
167101  aggcagatca caaagggaag gtacaatacg acccttttgt cattaagtat gtttacacat
167161  atgtgcatgg acgtgggaga cacacaaaaa tgttgaaagc taatggcact gcagggattt
167221  ccatttttctc cttttggctt atttctgcat tctgttttat atgaaggcac atacgacagt
167281  ttttaactta aagacaggac aaaaagttgc cagccatcgt gagtcacccc aggactgccg
167341  gtgctgggaa tgccaaaatc tgatgggacc cagcgcaggt ggggagagga gcagaggatg
167401  cacccacggc ccgtgccttc tttgaatcag tcctcacggg gccatctcaa ggtggagact
167461  ctgaaagtgc agagaagtga aataacccgc ccatggtcac acaggaggga gtgcagggtc
167521  cagttctccc tcccccaccc aggtccgcac tacaggctct gatccacgcc ctcccttgag
167581  gacaaaccct gagccacgct gggtcctccc gcaggccctg aaatagagct tcattgccac
167641  atcagacacc gggagacgcg aggaggccgt gagccaattc cagatgactt gtcaaggctg
167701  cgccagccac agagtcaggg aagcctctgg ctgcctctgt aatataagaa ccaggactga
167761  aggcccctct gggagggcac tagacgaggg cctcggcagc tccgcaggca ggtggggccc
167821  aggccaggcg ggacagaaac ccaaatgtgg cgatgcaaac tggacagaaa gaggcctctc
167881  tgggctgcgg ctccctcact cggggcctga cggtaccagg gggagttaat ctctcacaca
167941  caagctggcg ccagacccct aactgcaggt gtccctaagg agaggtgcct ggcaagtcct
168001  ctcctgggag tggacgctct cctcctgagc acggtgtgga agcagggccg tgcccagcat
168061  gggtgcgtga ggactggatc ctgcctgcag acaggactgg cgggaggcag aacttgagct
168121  gcctaggact gaggccactc cagagccaag actgacagtc tccacaaaac caaggagccc
168181  tcacctgtct catggctggc aggggctgca caggaagtga cagaggcctg gtgccctcga
168241  gaggcaggca ccgagccagc cagtgtcagg gagcaggtct gcacatctga tggaaaatcc
168301  atccgtggtc ccccttctga caggcctttg gctgccttcc cttctaaata gctgcgaagg
168361  gaaatggcct ggcagaagga aagacaatgg ggccccaggg gcagcagtcc aggagggcct
168421  gggcccccca ccctccagct gtaggactcc caagctaagg acagagagaa tactttgggg
168481  aggagaaaga agcagacacc aggcttcgtg gcaggtgtca gcatggctga gggcaggcag
168541  aacagccgcc agcttgatct ggacacctgg tcctgccaca ggccacagca cttgccaggg
168601  gccgttggga cctgtcactg ccctgtggga gctccctgga gagttcttaa cctgggctcc
168661  ataaactggg aaaagagaac acttcaactt catctttact aactgggaac tgaaagctgc
168721  cattcccttc aactctggag agaggcagca accccagact taacagcacc tgcgcccgtc
168781  agggcagaaa tcacaggctt cggcaactgt cagcaccgct gctgcagacc agaccaaatg
168841  gtgtttacac tcagcacaac ttaaattata gaggctgtaa gatgcactcc taggtcttat
168901  tatttaatgc atcaattaaa agcacacaaa aaagttttac atgaatgttc ctggcagcat
168961  tattcacaag agctaaaggg tggaaacaac ccaatccatc aacccatgag tggatttaaa
169021  aaactgtggt acatccatgc aatggaatca tatctttcca tccaaagtaa tgaagctctg
169081  atgcatgctg caacctagat gaaccttgaa aacattatgc tgagtgaaag aagccagaca
169141  caaagggcaa atattgtgtg attcatttat actaatgaaa tgcccagaac aggcaaatct
169201  atacaggcag aaggtaggtc agtggttgcc taggcctggg aggacggggt aattgggggt
169261  tactaaaggg tctggggttt cttttcagag tcttgaacat gatctaaaat tgtggtgatg
169321  gttgcaccat tctgtgaaca tactaaagcc attcattgaa ttttacgtta taagttggta
169381  aaatacatag tatgtgaatt atgtctcaat aacattatta tcaaaaatgt gtaaggtata
169441  ataatgatta aaaatttaa aagcatgtgt atgttgatag ctttatttttt ctctttttttt
169501  tttttttga gacagagtct cactctatag ccccaactgg agtgcagtgg tgcgatctca
169561  gctcactgca acctccacct ccagggttca aacaattctc gtgcctcagc ctcctgaata
169621  gttggaacta cagatgcccg ccaccacgcc cggctagttc cttgtatttt agtagaggca
169681  gggtttcacc atgttgccca gggtggtctc aaactcctga gctcaggcca tcctcctgcc
169741  ttggcctccc aaagtgctgg gattataggc gtgaggcacc atgcctggcc gatagcttta
```

```
169801  tttcaatcag atttatttcc tttgtatttt gtagtgtaca ctaaacacat tattttgatc
169861  aggggtccat gggcctcacc aggctggcag gagggttcac gacatggaac agctgtgcta
169921  actaccagga cagaagacag gaaggtttgc tggaagaggg gtgatgagaa gttggccagg
169981  cctatggggt tcccagcatt caggcaaaag cccagaggtc ctcagggacc cccccactgt
170041  ctgctctgct aatgcaaagc ccatgaggcc caaggagtct cagcttcttc agccacccga
170101  tcacaccccg acacacacta ggccctggtt ccttcaagtc cttaggtcat tttcagattc
170161  aacttcagcc aagacaaatg gtcccctcct gcacctgcca caggcactgt ttccaacgtg
170221  ggcagagttg acagttgatg ggtgtgtgtg atctttcgga gctcctgtcc caggcccaca
170281  ggatgaacgg gaaggtggac atggtgggta gagcaagcag gaaatgatga tggtcaggag
170341  gggccttgaa tgctggttct gggggcctgt gctttaccct caaagtggag gagccatggg
170401  gagcatttcg ggtggggcac ggaagggaga ccgcgtgctt atcatgggca gctggaaggg
170461  agtgggagaa acgggggcag ggagaagaca gggcagatgt cctggagaca gaaggcaatg
170521  gggacccata gctcctcctg acacatcagc ctggctttcc tctggggccc atcctctccc
170581  cgacccactc ccagagggtc agaggacaga cgccagccct ggagccacag cagtcctgtg
170641  acgaggcctg gccagccgaa gtcctgctcc gctgtcctgg ccatagtgat ttgcctgaag
170701  catgtgaccc aacctgagcc agtgagaact caccactggg ctctcccaga aaccctcggg
170761  gaacctgggc ctctctctgc cgggcggctg gtgcactgcc caggcaggac ccacggggag
170821  ggcggctgag ctgaaaccgt gcgggaggcc tgggctgccg ccctgagccc cgcattcccc
170881  ctttggcccc agccgcttct gccccggttt tctgtcactt gcagtcacag gagtgtggac
170941  ctggggatgg cctgtgggag ggacaggggc acaggcacca gctgcacagg tgtggatggg
171001  aggacaggag cgaggccagc cgcctctggg ccacaccctc cggattcact cccaaaggag
171061  aacggccagg cggccaagtc ctcccagctg aggggtgcgg aggaagggat cagagcgctc
171121  ccccaacaaa ggctgcctct ccgtcctgca catcccctcg ccacactgac ctccatttcc
171181  cttcttgggg cctgcccgcc acgagactct tctcccattc cagactggaa atcttttccg
171241  caccttgact aattgttttc aggtgggaag gatttggtgg agaaatggcg tttgtgtgtg
171301  cgtgtgtgtg tgtgtgtgtg tgtgtgtgtc caccccccagc cgggcagctg ccccaggaat
171361  gctgtattgg cgggaagagc tagaggaccc ttggcctcag ccatgtcctg aggggctctc
171421  ggtgatgtca gcggctcctg gcctcttcca gtaaacatct gttcttattc tgacccagga
171481  attccatttc agaacagtaa cggcctccac tggcaacaca tcccaggccg gtgatgcctg
171541  gggcagggag agcatcctac cccggcctgt gccccgcccc cggccccgcc ccccactccc
171601  atgcccgccc aagccccgcc cacagagctc tcaaaaggga caaaatctgc acctggctcc
171661  gtgtgtccaa gcgctttcac actgtggtcc ctcctagcag cgccatcagg aaaatatgat
171721  cttgtagtaa caggcccttc gctgctcagt gctggccctc gcttcattta atcctcatca
171781  taacccacca gagtagttac cgtcatcagc ttttaccttt cacagatgag aaacaggagg
171841  ctcgctcgcc cagggaggga gggagcagaa aaccaagccc acgtgttgga gcgagatcgc
171901  gtctgactcc agcgcacggg accttgcagg ggctgatggc caaaaactga agtcatggga
171961  aggagaggga gagggagagg gagagagagg ggaggaagaa atgaccgttc caaagcccat
172021  gcagcactca tctcaaaata agagaaactc tcaggtgcct acacagggag tgaatgcgcg
172081  tgaagcccgc cagggtaatg atagggagca gcagagactc ccaaggcacc tggaactgtg
172141  ggacccttct agagggttcc atccttgctc agctctagcc ctccagcaca taggcccggc
172201  agatttcctg gttctcaaga gaaactggaa atcttgagct ttgtgagaaa ttttcaaaca
172261  ctggaaaagc caaacaaaac tcatctgtgg gtggacatgg cccgtggccc accagtgtgc
172321  aaactccgcc ctgcacaatg ggaaccctga agtgcagaaa attatctcat tgtgaagggt
172381  aaggcaggga ctcaaaacag ggctcctcag tccacattca tagagtctcc aggttgtacc
172441  accgaatcta ctcgccagcc ttctcctgaa agtgtctcac tgaaccacat cccccgtaga
172501  aactcagggc atctttcaaa gaccgcagtt ttcctgccag cctgcaaaca accctgtgca
172561  tgcccggtgc actgctcccc aaccacaggg gacacctaac agaccacgag ggactgagag
172621  agcctccttg actgaaaggg aaggtcaacc gccgccactc atccccataa aaccacaaca
172681  tgggcacatc ctgcgttcga agctctactt gatgcaagag agcagggaaa ggaaagccgt
172741  gccaccgtgg ggaaatgggc ctgggagatc cattcaggcc aaggtttgtc cactttgggt
172801  ctaccaccac cagcattcac agaagaagca gcacctggtt ctcaattccc ttagaagcgg
172861  ggctagatgc tctgaaggca tggttgtagc tcccacacaa aattactaaa gacataaaac
172921  gaaaacatgt tgaaaaagaa gagacaatat tatgaactgc agaaagtaac tgcacacgta
172981  gagaatcctc acccccaaaa acatccaaaa aaaggaacca aataataaca aggaagttca
173041  taaaaagtct agatgcaaaa taaatagaga aactcatata tctgggaacg caaacatggg
173101  aaacatccaa gcgagagatt taggtttgtt ttgttttgtt ttttgagaca gagtctcgct
173161  ctgtcgccca ggctggagtg cagtggtgca agcgatctga gctcactgca ggctccgcct
173221  cccgggttca cgccattctc ctgcctcagc ctcccgagta gctgggacta caggcgcgca
173281  ccaccacgcc cggctaattt tttgtatttt tagtagagac ggggtttcac cgtgttagcc
173341  aggatggtct cgatttcctg acctcgtgat ccacccgcct cggcctccca aagtgctggg
173401  attgcaggcg tgagccaccg cacccggcaa gagatttatt tcagaaggac tttttgtgat
173461  tatctgtggt tcatatttgt gccattctag taacagagag actgctttgc taagacatgg
173521  gaagatgcag gtcattggga gcaaaggatc tgaagcaggg gctgttgcca ggaagggcgc
173581  gccttgagga cagcaatgct ggggcttggg cttgccaggt caaccatggg tatcaagtgg
```

```
173641  ttcgtggcag ctctgcacat gcatgtatga tttgcactaa tgtgtcattt ttaactctgt
173701  tttctccctg ggaataaaga tgtctaaatt ctgagaatat cattagtctg aaagaagcag
173761  gtcccaggta ttctgagtaa ataatcacct actgtattat aaattaaaag tgttcccaga
173821  taacaatctg gtgtaaaata taatggaaaa gaccctattg acaatggcaa taacattcta
173881  agtctcttag taataaacct actgggctat gtttttaaac atctgaatca atcttcttat
173941  ttccgtgaga aaattaaaca tcatgaagat gtcgttcatt tgttcagcaa agatttgctg
174001  agggccttct gcaaagggga cactacttta ggcatttttt taaaacctca cgatggtgat
174061  acttgcccta tcagatgtca gaacatattg tcaaccaaca gcaattaaag acccctggac
174121  tggtgcaaaa gaaaaacaga aaaggccagg cacagtggct catgcctgca atcccagcac
174181  tttgggaggc caaggagggc ggatcacgag gtcaggagat ggagaccatc ctggctaaca
174241  cggtgaaacc ccgtctctac taaaaataca aaaaattagc cgggtgtggt ggcgggcgcc
174301  tgtagtccca gctactcttg aggctgaagc aggagaatcg cttgaaccca ggaggcagag
174361  cttgcagtga gccgagatag tgccactgcg ctccagcctg ggcaacagag tgagactccg
174421  tctcaaaaaa aaaaaaaaaa acaaaacaaa acccagaaag gccagaaata aaccccatat
174481  cctccatgaa cttcacagat gatggaatat acattccaaa gtcaagaaga aagagtgaat
174541  tagcaaacga atggtgttga gacaacagca tggcaattta gaaaaaaatg aacacttaaa
174601  accaacacct tatacagtat aagaaacaca tttcacttga attaaaggag ttacatattt
174661  aaaaatcaag tcaggaaaaa agcaaaacat ataatggagt atttctttga aaggctgata
174721  cttttctaca ggctgagtaa ccagaagaaa gcaactagag aggctgacag agctgaccga
174781  agaaacaaaa caccagcccg gcagaataaa aaaggaagct ctgcaaatat aaacccaccc
174841  aagctagcag agggttaatg actagcccca gggagaacca atcagcttca gaggaggaaa
174901  gttgggggcc gtaaccacca gccattaaag aaacaagttt caggccgggc gtggtggctc
174961  acgcctgtaa tcccagcact ttgggaggcc gaggcgggtg gatcatgagg tcaggagatc
175021  gagaccatcc tggctaacaa ggtgaaaccc cgtctctact aaaaatacaa aaaattagcc
175081  gggcgcggtg gcgggcgcct gtagtcccag ctactcggga ggctgaggca ggagaatggc
175141  gtgaacccgg gaagcggagc ttgcagtgag ccgagattgc gccactgcag tccgcagtcc
175201  ggcctgggcg acagagcgag actccgtctc aaaaaaaaaa aaaaaaaaaa aggaaacaag
175261  tttcaacaat aacacgattg cctgactccc accaagggtc ccaggccagc ccagccccag
175321  cggactcctg caggccttgg ggagccaggt gggcacctgc aggcaggttg ggggaaggct
175381  gtgaggactc tgagccccca gagtctatca ggacaggctg acaccaagac agagacggcc
175441  tacatctacc caccccatac catgcccagt cctggaccag ccatccctgg ccccaaaggc
175501  cacagcgtag tcaccacagc tgagactgcc ccaatcaggg ccacctgcaa tgtccagcag
175561  cctccctgca actgccccgg ctttggtttt taatgtccct agtcccgaga atgcagaagc
175621  tctgcaaaga gaagaacgca gcaactctgg caacctgact gtggaggcag acacctggca
175681  cacatttccc ctcccccagt gcccgtgatc tccacccagc gctgggcacc ctccaacctc
175741  cactccattc actcccagac ggagcaaagg ctggcctcat tggccacctt gcccagcaca
175801  ccacctgcac aaccttccca gcagccctgc tcatcgggcc accctcccca gtgaggacac
175861  agcccgtgac agcctgggca ccccaacagg aaagacagcc caaaggccaa gccgccctat
175921  ctgaggtgga ggatgctctg gcagggcagg gactcagcct tgaccttgtt tgctagaaaa
175981  tgcaccaaga actcagtagc aggccaagga gaggagacat gaattcccct tttcagcaat
176041  tcaccctgct tgtacaggtg gggagttatc tgtacctctg aggaggtaca gatttcatct
176101  ggtgctccag ctgcagtgaa aggagctggc tctgggctct gtgggacctg gggtgggtca
176161  tccccatcgc tgtgccctga tttcctccca gcacattggg atggctcgtt gttggttccc
176221  agaatgtacc aggaaggtac aggtgcagag tgcagctgac gacgaagggc ccccagccag
176281  gaagggtccc caggagtcct ggctgatgaa agactctggg aaagaaaggt gggaacaggg
176341  agaggacaga aggggcaggg aggggagagg acataaaggg agaatggaga gaaaagggaa
176401  aaaggggaga tgagggagaa gagaagggag gggagtggga aaaagaggaa tgagaaaaga
176461  aggggaaaga gagaggaggg aaggggagga gaagctggag ggagaggagg gggaagggag
176521  ggagaggagg gggaagggag ggagaggagg gggaagggag ggagaggagg gggaagggag
176581  ggagaggagg gggaagggag ggagaggagg gggaagggag ggagaggagg gggaagggag
176641  ggagaggagg gggaagggag ggagaggagg gggaagggag ggagaggagg gggaagggag
176701  ggagaggagg gggaagggag ggagaggagg gggaagggag ggaggggctc ccagcaccag
176761  gacccagcac aaccgtccta tgacagttgt ctctgcagct gcatttaggg ctgttctgga
176821  aactcaggcc ttctccctgt cggcagggct gagccctggt ctgggacctc cccttgttct
176881  atcagagccc ccaggctggg tgaggtccac tgggatctgt tttcactcac aatgcttctg
176941  acaccaaaca tgtggtttcc ctcacaccaa ccagttctcc aacctccaga cgctagctgg
177001  gtgccccaca gttgagtgca atgctcacgc caactacctg gggtcagctt agccctcagg
177061  ttaaggcctc agtcccacac agcagcccca cttgcggtgg caagttccag ctttccacct
177121  gtgcctctga ccaggcggct ataaattggg cgggtcccac aactccctcc tcaggttctg
177181  taatttgcta ttaggttggt gcaaaagtaa ctgtgacctt ggaatcagac agacatgtgt
177241  tcattaatag aacagatcac agaactcagg gaggcatttt acttactatt tccagttgat
177301  tattaaagac acaacccagg aacagctgca tgggagggat gggcagggca aggtaacggg
177361  aagggctgca gagcctccac gccctctctg ggcactcacc ctcccagaac ctccacctgt
177421  tcaccaaccc aaagctctcc aaaccttgtc atttaggggt tttcatggaa gttccatgac
```

```
177481  tcccatcccc agaggttggg gaagtgaggc tgaattctca acccaacaat ccagaaactc
177541  ttatatcagg aacaagggga ctcagaccaa atctgataat aaaaggtgtt tctatcaccc
177601  ttaacactca ggaaattaca aaggttttag gagctctgag gcaggaacca gagatgaaga
177661  acaaacatac atttataatt tcccactatc acagggtctc agacagtacc tcagtctgtg
177721  acccaacctg cattgcccca gaagcccaga cctcagctca gggccagtgt gctgggatca
177781  gtggccagtg gccagccatc gtgcagagag gggagggcag aggggaggga gggaggggat
177841  gggagaggaa gggagggagg agtgcagaga ggaagggagg ggaaggaagg gaaggagagg
177901  agaccaggag cctcccaggg cctgggcacc tgcctgggag ggcactgagg agcaccaagg
177961  aggatgccta ccactgcccc caccttgccc tgatcaggtc tgcaggatca gtgctcaacg
178021  cccatggagc tccaggtggc cgccaagtgt ggacagccct gcagcaaagg ccagctactg
178081  ccctgggagc cctcaccccc ttatcctgcc cgcttgcctg tgaggacccc tccctactgt
178141  gtggccttgg ggatagccat gcgacggcgg ctgccttcct tctgccgggg ctctgaattt
178201  ccaggtgaga gacccgagag cagagggcca ggagccgaca ccgctgtggc agcttcccgc
178261  atcccaagcc gggccatgcc cactggccat cgcttccttc cacctcaagc cccccatgga
178321  attccctttg actgaggcca gccagcctca tccccctctg ctccctcact gacacacacc
178381  ttgtgaggca ggtggtgtct taactgggaa aatggagggt cacaggccag caagagaaga
178441  gccaggcccc aagtctggtc tgtgagcccc cactccccac agccctcgct agtgagcacc
178501  cgtcatgctg tacaaaagac tctcctgtgt agcttttgaa aagtacagac cccagggctc
178561  acgcaggtct gataaagcag aatctctcag gatggggcct atgtacagat gctgtgcaaa
178621  gctcctcaaa tcccatgccc atcagtgggc aggcagagag atcacacaat ggaaatgctc
178681  ttctgcaaga caagccacag atttggtttt tttctgtttt ttttttttt ttttttttta
178741  gacagagtct cactctgctg cttggctgga gtgcagtggc gcaatttcag ctcactgcaa
178801  gctccgcctc ctgggttcaa gagattctcc tgcctcagcc tcccaagtag ctgggactac
178861  aggcgtgtgc caccatgccc agctaatttt tgtattttta atggagatgg ggtttcacca
178921  tattggccag gctggtctca aacacctgac ctcaagtgat ctgcccgcct cagcctcctc
178981  aagttacaca ggcgtgagcc actgtgcccc gcctacagat ttcttctaag gagggaaatg
179041  tctttgcttg gaaaaacacc ttctagaagc acgtgggata acagataaca gtgggactgg
179101  aagagcagga gactctgcag acagtgccac cacctcagag cagcgggcaa agtccgctgt
179161  taagacacag gaggagaatg gagggattgc tccagagaaa ctggacagag ggagggagac
179221  gccactggga gggaagaaag aacccacaga tgaaagtgga aatgccccca cacatggccc
179281  aaagggcttt ccaagaacag ggtcctgttc ttccagaagt cacccgcgtg gccgggaggt
179341  gctggctccc ccaccttctg caggaaggct gcccctccct acgagggctt cccatggtgc
179401  gtaaatgggg actgggtttc attcctggcc cagcaaagtg gacagctgag gccgaggctg
179461  agaacacaaa caccccggaa tcgcaacacc tctggctttt ggaggtgaga gaagggagcg
179521  ttaagagtta agacacattt tatcttgatt tcagctcctt tactgataaa aatgggatct
179581  tagaaaacga gaattcagag gatattgcct tcacatgaaa tccatcttaa tccacagcaa
179641  gcgctgtatt aagcagagaa ataccggggg cgttgccgtt aaagccaggc acagatgagg
179701  atgcgtgtag ccacggctgt gacttaacat cgctctgaag gttccagacg gtgcagattg
179761  gagatgagga tccaaaatta tcagtgttta cagagtgcaa ctgtatacct agaaaaccca
179821  agggactcca caaagatata ttagaattaa tgagttcaat caagctgctt gataaaagat
179881  agttctataa aaatcagtag ccttcctgtg taccaataga tggaaagtat tcaatgagca
179941  atggcaaaaa gaaaaaaaat ccttgaaata atcctgattt ttaaaaatgg atgacctgta
180001  taaaaatatg tatatataat acttcatggt acaacatcaa agcagaatga aataagctga
180061  aaaaatatac tatgttcctg atgaatactg taaattatgt caattcctcc tttaattagt
180121  ttctaagttt aatttactat caatcaaatt cacgagggat ttttctaccc gacaaaacaa
180181  ttataaaatt catttgaaag aataaacata tgtgaccagc caagaaaatt ttgtaagaga
180241  ataccagcaa agggggacgt atccagccag atgttccaaa gccacacagt ccaacagaaa
180301  tagaactcga gctttatatg tagccatgtt tttaaaaaaa aaagacacag gtgaaattaa
180361  tttcagaaat atattttatt taacccagta tgcccaaaat attaccattt caacctgtaa
180421  tcaatacttt aaaatgatct attaaacatt ccacattctt tttggggggt acgaagtctc
180481  tgaaatccaa tgtatatttt atactcaggg tacctctcaa ttcagaccag acacatttta
180541  agtcttcaat agccttgtgt ggcttatagc tactgtattg gacagcaaag cttcaaagta
180601  cttaatactt tgactattag agccttacag ttctaataat aaacacagct taatattggt
180661  acaagaacag aaagatggaa aagtagaatg tatctgcggt actgcttaac ctgaggtttc
180721  atttgcaact gactggcgat ggtgtactat aacccataaa atagacagat gtaaatacat
180781  accaatatgc tcacagctct caagcccctt ttcatcatat gtccagaagc tctgtcccaa
180841  tcagaatggc cactagcaag ccttagacaa gccttgcatg aaacgtgaag acaccctact
180901  ttccatgtgc tcccaatccc tgctttcaaa cagccgcgtg ggagggatgg gcagggcaag
180961  gtaacgggaa gggctgcaga gcctccacgc cctctctggg cactcaccct cccagcacct
181021  cacctgttca ccaacccaaa gctctccaaa ccttgtcgtt taggggtttt caaaggaaaa
181081  atacccgggt gtaaagatga caggctttaa cacttggaaa tacttttaat acattgaaat
181141  ttcagattag ggctttcaaa ggaaaaatac ccaggtttaa agatgaatcc cggacattct
181201  gcacagagct ggtgagggct ggtccctcca acacgcatct ttccatttcc caacccctga
181261  actgaggatg caatcggcgg gtctcaggcc ccggccctgg cccccgcctc ctgggccacg
```

```
181321  acacttccaa cgcagtccct cactgtcaac accctggaca ctcaaaatgt ctttgaagag
181381  tcacgctgtg aggtcaaaaa gttagggtgc acgcagaaag gcgcatgtag ctttgcattg
181441  gtgaggcaaa tacctatccc tggaggaagg accgctactt cgtaattcac aagaggaaga
181501  ccccccggagg cggacgaagc caaccgaact cagttcccgg gagccgtgac aagcgacggc
181561  caggcagcag aaatggccca cccattaggc tgcagacagc atcagagaaa ccaagcactg
181621  tggcagtggg gcccgcgcct ccagggaacc acaaggcaca gagttgcagt ttaaatggga
181681  gtgtctcctc tttcttggtg gcgtataaag taatggtgtg tcctgtaacc gatggcacct
181741  tagagctaat gatatgcaga cacggccacc gctttctcac ccccgggcct ggggtaggcg
181801  cttgctgcac acccaccctt tcactgccac tgaagtgcgt gcggacagaa cccatctttt
181861  gctattggag gaactaaggt tctcaggatc gtggtgcttg tccgccctgc cggtcacgag
181921  gagcacagcg gaccatgtga cccgcaacag cctccagccc acaataggcc cctgccttcc
181981  ctgggttaac ccgtgaaatg cacaaggcag ggtggggatg gcgtagagcc tgcctggctt
182041  cagcagcacc caggccttgg tcctggacac tagggttccc tgtgcctctg agcggaagct
182101  gtgcacccca ctctgcagcc ctggagtcgt cgtgcagtgt aattgaaatt catggacaag
182161  cccgaggagc cagctccggg ctcggtaata acttctccat attaatggca gcaccgcaga
182221  ccctgtggac agctgatatt taatatgaaa catacgcagc agagtgtgca gctcctacct
182281  ggatcctccc attccggggt aaccaccagt aggggatggg ggtgtctaac gtggcgccaa
182341  gattgagggg gctggggtcc tcctctcccc tgagtacctc aaccccactt aaggcccctc
182401  ttctacagag tgcaggaaac ccctcccgag aaatacataa acacatgctg gcccatgctc
182461  actcaaatgc acaccctccc atgcagacac actcatgtgc acacacgtgt acacactcat
182521  tcagacgtgc acaaacatat gcacccccac acgcacactg catgcacgta ctcctacatg
182581  caagacatgc agaggcaaca cgtacatgca cacactcccg ccatgcacag gcccaggaca
182641  cgcacacgtc cacatgcagc caccagcctg ctgtgccggc agcaacacag ggacccccag
182701  ggctgcccaa gccagagagg caggtggggt aaagaaggac atgtctgcct gccagcacag
182761  acccagggtc ccaggagggc tgccatgcac acttgcctct ttgggtcttc agataccaca
182821  gtgggcaggc ccagaccata gctcaggcag ccacgaggca aagccagcct cgctgctgag
182881  cggatgtccc tggctgattc ccttactcac ccaggtgtgg cccctgtgag cctcacagca
182941  ggcctgggtg aggacctggc cttcacctcc cagctgactc tgcacgaggg cctgaattca
183001  ctcactcacc caggtgaggc ccctgtgagc ctcacagcag gcctgggtga ggacctggcc
183061  ttcacctccc agctgactct gcaggagggc ctgcattcac tcaggcatga ctcgctaagc
183121  actggagaca tgggggacag ggaagccacg gcgagccatt gggcaggaga agcctgccac
183181  acctgaatga gcacatggcc gcgcacattt accagtgcca gaaacatacc cagccacaca
183241  atggagtgca gctctcccag ggagagctgg ccttggtggg ctccggctga gaccagtgct
183301  gactatgccg gccttcatga ggggctggga gccggctcca ctctgcccct ccctaaagga
183361  ttccaggaga gacgccagcc cacacagaga acctgcatat gtaactccta gagcctcggt
183421  ttcctacctg tgaaatgggg ccacggtggc tggctcacag gaaaaccgca gggactgggt
183481  tcaaagcccc aagcagaggt agatggtgtg gatgctgctc ccccgacccc ctcctgaggc
183541  tggccgccgc ctccagaggg actgcgctgc actgctggat ccctcaggca tctctgtagg
183601  ggccctcagc tcacgtaagg cagcagggga gggagtcatt gccccaccct cccaggggca
183661  cctgagggga acgctggagt tctgcctcct gcagcccttt ctcccggagt ctcattccag
183721  accagcagag caggcgactc aggccggagc tggagggccc tgaccaggtc acgggggcct
183781  tgaatgccag gccagtgggt ttggatgttt ttaagagcag taagaaccac tgagaggtct
183841  taagtgaagg cgtgacatga gttgctgcat ggtttctaaa aatccctctg gctgcagagt
183901  ggagaagggt tgtcggggag agaccatggg gcagtggggg gtacaagagc agaaagcagg
183961  ggttggcacc aggcgtggag ggaagccggg ccctgagaga gctctagaat tggagctggc
184021  taggggaggg cgatcctgga agggtggggt ctggaggaga gtggggagag ccacgtgact
184081  tgagtatggg gtcatccagg gaaggggttt ccagaggcag ccgagcaggc aagcctggag
184141  cccaggagga cttctaagcc caacatgggg tctggagtcc aggagaaggg tggccacaac
184201  cgtgttcacc accctgcaca attctcctcc cttcttgtat gataggcccc tcttcattcc
184261  agagtttggg agtctgtccc tccccctcag tcccaaaggt gggcaggaga cctgggctag
184321  gcccgcacca cagccatggg tttgaagatg ggcctccaat ccctccccca actctcacag
184381  gtgtcaccca gagaggaggg ctttccatct caaaggttgc ctccttggaa aacgagttgg
184441  gcctggagcc gctggtgggc cgggggttga ggggtggaga gcaattctga aatgaacact
184501  gagaggcagg gctgagaaat ggatagcatg ctctgagccc ctggattcag ccaggcctga
184561  agccaacact cctcaggacc cccagataat tggggccatg ctgtcccttg tttgtttcat
184621  ccaatatgag caggggtttc tgtcacttaa actgagcaag tcttaaggtg acaagtatgg
184681  cggaggctga gactggcctt agcagctgtg taggctgctt gcagctgggg cccacaggag
184741  cctctgctcc tacctgggga gccccgacac cctagggaac ccagaggttc ctgcagcccc
184801  tctttagtct tcctgacaac ctctcattgc gatccaggca gtgccaaggt ggggtgggag
184861  gaaggaagac cctaccagcg gcagctgcaa atctcaggtg cccctcaccc cactgcacag
184921  tcccaggacc cgctcacacc tgcctgatct gctctagcac ctgagcctgc tggagcccag
184981  tgtgtggcct cgaaggcagc agccttgctg ggaaaaatga aactcatctc gatcccttag
185041  gccggcttct gacttctctc tgtggccttt atgactctta atgtccagca agacagagtg
185101  ggtgcctggc ccagacagca gccccgcagg ggagccccag cctgaaaggc agcagccctg
```

185161 gatttcttct tgccatgcaa ccttgggtct ctctgagcct cagccacgca gtggggcagc
185221 cctatctcac agggttgtgg ggttcgcatc aagcatccag ggaagggcat acacttcctc
185281 ctttgggccc caggattgga ccaggccttg gagggcggac catctccacc gcccagccca
185341 tggaggcttc atccactgct gcccagcctg gcaggagagg atccccgtgc tgccctgagt
185401 ggggaggcag aggcgggcag ggttgcttcc atcccacgga agtcccagct gcagtccccc
185461 accagtgagg acttaggcca cccataggag ctgcagccca gcgcaggtca cgagccagtc
185521 aaggccactc agctcccagg cctgctcccg gctccactca cactgacgat ggtcaaaccc
185581 acaatgagaa cgtctccagg agtcaaataa gaaaggtggg aaatgttgta aagaaatgca
185641 tttttaaaat tctttttgta ggcatgcagg aaaaggcaac aaaacatagt gagcatggcc
185701 ttggaatcag atttgtgttc aaatactggc ttcgaagctt gaagcaagct atctcgactt
185761 ttggagcctc agtttattca tctgtagaag ggggatgatg tcgggatatg ttccgtaggg
185821 tgctgtgagg attaaacaag gcgaggtggc acaggggget cagctgagag cctggcacac
185881 aatgttaata ggaacacagt caactgtcac ttaccatcat tacctttac gccaaaaggc
185941 ttctcactgg gtttttaatg ggcatgtaaa aaccacgtga aattagcacg cctaccacgc
186001 tgcccaggag atactggaaa actcttccac agcaacgtga ggcacaacac cactctgtgc
186061 agcctgtttt gctcatgcct tgtgcaaagg gacattttgc tgtggatact atgaataacc
186121 cctcgctgtg gatattatta tgaataactt ccgtctagtc actcaacctc ccagagcctg
186181 agtgctccac ctgtaaccag ggatgagatg cctccccgac cagggctctg tgaggacaag
186241 aggtgccctg tgtaaagacc caggtcctta gcaaagaagc ctatcgtggt ggcagcagag
186301 ggggatttaa cagtaggaca gacacatacg cagcaacaaa gtcagaaaag gaaagaagag
186361 gccgggcgcg gtggctgagg cctgtaatcc cagcacttta ggaggccaag atgggcagat
186421 cgcttgaggt tgggagtttg agaccagcct gatcaaaagg aaagaaagaa agaaaaaaag
186481 gaaggaagga aggaaggaaa gagaagagaa gagaaagagg acaagcgaaa agaaaagagg
186541 ctgggcgcag tggctcatgc ctgtaatccc agcactttag gaggccgagg caggcagatc
186601 acaaggtcag gagattgaga ccatcctggc taacacggtg aaacaccgtc tctactaaaa
186661 attttaaaaa aaataaaaaa aaattagctg cacgtggtgg cgggcgcctg tagtccctgc
186721 tacttgggag gctgaggcag gagaatggcg tgaacccgga aggcagagcg cttgcagtga
186781 gctgagatcg cgccactgca ctccagcctg ggtaatagag tgagactccg tctcaaaaaa
186841 aaaaaaaaaa aagaaagaaa acagaaccaa tggtgctgtc ccactgtcca aggccattat
186901 tcagtgacag cattcaatgc cgctcaggca ggtcccagct cctcttccaa ccccaatatt
186961 cttcccagct ctgtctggta catgggacac ttcagcaggc ctgtcctgcc caggccaatc
187021 cacacctggt acctctgcac acgctcctcc ctctgcccgg gttgccaacc tgcgtctttt
187081 ccagctggcc actcattctt ccagccccca ttcaaacagc cccccaggag cacactctcc
187141 aagtcctggc cagagtgtcc gtcagccacc ctgacgacag gagccctggg tgggtaccag
187201 acctgcctca ttgctgacca gtacagggga taaacatatg agaaggtgct ggctgaaaaa
187261 tgaatcacca aatgaactgc tgaatgaatg aaacagtgac aagtcctccc caaaatgctc
187321 tccatcagga atgcatagta cacaggtgtt ggcccaccaa cagactgcaa ccccatgtca
187381 actcccacca ccttacctca ccctaagtcc gcagcaaaca tctcctttca tttaggaaat
187441 taacctccag cgtaaaatgg gacacacctc tgaggcccag gatgtcctca gagacagtgg
187501 gcgatgtcaa gggctcacca ttttaaccca gctcctccag ggatatttac agttgtttgc
187561 aatatggcca agttctaact aaatccagcc aaaggcagtg attttccaaa gcaacaagtg
187621 atattttctg tgtctccata gaaagaatga cagtggttgc agagccctgg tgtaattgcc
187681 ggctctgcag actgtaggat gagcctcagc tgcccgagta cgggcgtgct caggggccac
187741 gggggctggg agagtggcca ctcactcggg gcaggagttc cctgagtagc aattagagcg
187801 gaacccatgg tgggcggctt cagatgtctg gccagcacag ccagcctgac caccacacac
187861 ccaatccaaa atagaaaact gcagtggcct ctgctgtgtg ccaggccccg ggcagccgga
187921 cagagcaccg ccaatgtcag cctcctccct cagcatcgat ccaggcttcc tctgaggccc
187981 ccttgtgctg agccacggtc cctcctgccc tctccaggaa gcagagcttc ccagagctcc
188041 agtcacagga ctagagaggc gcaggcagtc tcaaaaggga tcccctagcc tctctcttgt
188101 ccttcaggcg ctgcccccaa aagatcgagc agctcatggg cactagagcc ttcatttcca
188161 aatgcacccc tcagctcaaa atagagaaaa ccaacttttc aaagaaccag ctggagttca
188221 acaggaaacc acagcagaaa aaccaatgat tcccggtcag ccaaggggca gagggctaac
188281 tgggcatttc agcatcactg ccagctccct gggctggtat tacccgcacg caaggaaaca
188341 ggaagactga ctgccagccc ataagtccac cacacacata tcacgccagt atgcacaagg
188401 acggacacaa actcaacaga tgctcaacac actgatgtgc agaaacccag acacatacgt
188461 gcacaagaga cactggcaca cgcacatgtt cacacaggtg cacgggcacc cagatgcagg
188521 tacacaccaa cgttccacaa cacatgtgca cacactcaca aaggtacaca cacatacacg
188581 gacccacccc cggatgcaag ccagagacct gttcaggcag gcaaaagaga gaggcgcacg
188641 ctcctgcctg ctgagccttt tggagacccg ggcgctcccc atgcataaat ggccccctgc
188701 tcagaccagt caaaacaacc tgctttccag ccaagccctt cagttggagc acgaggctca
188761 ctaaagcacg ggaagggcgc ggaaagtcct cagcgcaggc cttgccctcc caagggactc
188821 ccaggtaacc cttttccaaa acccaggcga gagcagcgga gagaaaggag ctagagaagt
188881 gcgtactcac cagcccatcg cagttgctga gcgccacaga ggaggcttcg gctaggccgg
188941 ccacgtctcc gacgtagaga cagctcccga gcaggggctc cacgcgggtg gtgcccttct

```
189001  cgccctgcca ctccatagtg gccccgggcg ccacgaggcg ggcgttgggc cgcagccgca
189061  ggtgcaggtc tcggccaaag accgtgacat tgtagaagag gtgRctgcca ggctcctcct
189121  cgttgcctcc gggRaagctc ggggtccgga ccggggcggc cctgcgggct cgtacccctg
189181  ctctggacgt agctgccgac accaYgtggg acaccaagcg gccctgggcg tcagtgcgca
189241  cgggcaccgc caggatgcgc tccgctccgt gccccagggg cccgcctgca acgggaaggg
189301  gcgttagatc ggcggagacc acggagcccc agtgcctcag agacccgccg gcaagccacg
189361  ccccccccaga ccccgcccca ctgcgaaggg aaggggcatt ccgccaggcg accccagaag
189421  ccagcctgca cctccccggc tttcctgcaa
```

[0254] Following are human cDNA sequences for transcript variant 1 (long form) and transcript variant 2 (short form) of *ADAMTS2* (cDNA sequences 1 and 2, respectively). Alternative splicing of the *ADAMTS2* gene generates two transcript variants, therefore, *ADAMTS2* exists in two forms: a "long" form comprising a molecule approximately 130 kDa in length, and a "short" form comprising a molecule approximately 70 kDa in length.

ADAMTS2 cDNA Sequence 1 (SEQ ID NO. 2)

NM_014244 Homo sapiens a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 2 (ADAMTS2), transcript variant 1, mRNA

```
   1 atggatccgc cggcgggagc cgctcgccgc ctgctctgcc ccgcgctgct gctgctgctg
  61 ctgctgctgc cgccgccgct cctgccgccg ccgccgccgc ccgcgaacgc caggctcgcc
 121 gccgccgccg acccccccagg cgggcccctg gggcacggag cggagcgcat cctggcggtg
 181 cccgtgcgca ctgacgccca gggccgcttg gtgtcccacg tggtgtcggc agctacgtcc
 241 agagcagggg tacgagcccg cagggccgcc ccggtccgga ccccgagctt ccccggaggc
 301 aacgaggagg agcctggcag tcacctcttc tacaatgtca cggtctttgg ccgagacctg
 361 cacctgcggc tgcggcccaa cgcccgcctc gtggcgcccg gggccactat ggagtggcag
 421 ggcgagaagg gcaccacccg cgtggagccc ctgctcggga gctgtctcta cgtcggagac
 481 gtggccggcc tagccgaagc ctcctctgtg gcgctcagca actgcgatgg gctggctggt
 541 ctgatccgga tggaggagga ggagttcttc atcgaaccct tggagaaggg gctggcggcg
 601 caggaggctg agcaaggccg tgtgcatgtg gtgtatcgcc ggccacccac gtcccctcct
 661 ctcgggggggc cacaggccct ggacacaggg gcctccctgg acagcctgga cagcctcagc
 721 cgcgccctgg gcgtcctaga ggagcacgcc aacagctcga ggcggagggc acgcaggcat
 781 gctgcagacg atgactacaa catcgaggtc ctgctgggcg tggatgactc tgtggtgcag
 841 ttccacggga aggagcacgt acagaagtac ctgctgacac tcatgaacat tgtcaatgaa
 901 atctaccatg acgagtcctt gggtgcccac atcaacgtgg tcctggtgcg gatcatcctc
 961 ctgagctatg gaaagtccat gagcctcatc gagatcggga acccctctca gagcctggag
1021 aatgtctgcc gctgggccta cctccagcag aagccagaca cgggccacga tgaataccac
1081 gatcacgcca tcttcctcac acggcaggac tttgggcctt ccggcatgca aggctatgct
1141 cctgtcaccg gcatgtgcca tccggtccgc agctgcaccc tgaaccatga ggacggcttc
1201 tcctcagcgt ttgtggtggc ccatgagact ggccacgtgc tgggcatgga gcacgacggg
1261 cagggcaacc gctgtggcga cgaggtgcgg ctgggcagca tcatggcgcc cctggtgcag
1321 gccgccttcc accgcttcca ctggtcccgc tgcagccagc aggagctgag ccgctacctg
1381 cactcctatg actgcctgct ggatgacccc ttcgcccacg actggccggc gctgccccag
1441 ctcccgggac tgcactactc catgaacgag caatgccgct ttgacttcgg cctgggctac
1501 atgatgtgca cggcgttccg gacctttgac ccctgcaagc agctgtggtg cagccatcct
1561 gacaacccct acttttgcaa gaccaagaag gggccccct tggacgggac tatgtgtgca
1621 cctggcaagc attgttttaa aggacactgc atctggctga cacctgacat cctcaaacgg
1681 gacggcagct ggggcgcttg gagtccgttt ggctcctgct cacgtacctg tggcacgggc
1741 gtgaagttca ggacccgcca gtgtgacaac ccacacccgg ccaacggggg ccgcacctgc
1801 tcgggccttg cctacgactt ccagctctgc agccgccagg actgccccga ctccctggct
1861 gacttccgcg aggagcagtg ccgccagtgg gacctgtact tcgagcacgg cgacgcccag
1921 caccactggc tgccccacga gcaccgggat gccaaggaga gatgccacct gtactgcgag
1981 tccagggaga ccggggaggt ggtgtccatg aagcgcatgg tgcatgatgg gacgcgctgc
2041 tcctacaagg acgccttcag cctctgtgtg cgcggggact gcaggaaggt gggctgtgac
2101 ggtgtgatcg gctccagcaa gcaggaagac aagtgtggcg tgtgcggagg ggacaacagc
```

```
2161 cactgcaaag tggtcaaggg cacgttcaca cggtcaccca agaagcatgg ttacatcaag
2221 atgtttgaga tccctgcagg agccagacac ctgctcattc aggaggtaga cgccaccagc
2281 caccatctgg ccgtcaagaa cctggagaca ggcaagttca tcttaaatga agagaatgac
2341 gtggatgcca gttccaaaac cttcattgcc atgggcgtgg agtgggagta cagagacgag
2401 gacggccggg agacgctgca gaccatgggc cccctccacg gcaccatcac cgttctggtc
2461 atcccggtgg gagacacccg ggtctcactg acgtacaaat acatgatcca tgaggactca
2521 ctgaatgtcg atgacaacaa cgtcctggaa gaggactctg tggtctacga gtgggccctg
2581 aagaagtggt ctccgtgctc caagccctgt ggcggagggt cccagttcac caagtatggc
2641 tgccgccgga ggctggacca caagatggta caccgtggct tctgtgccgc cctctcgaag
2701 cccaaagcca tccgcagagc gtgcaaccca caggaatgct cccagccagt gtgggtcaca
2761 ggcgaatggg agccatgtag ccagacctgt gggcggacag gcatgcaggt gcgctccgtg
2821 cgctgcattc agccgctaca cgacaacacc acccgctccg tgcacgccaa gcactgcaat
2881 gacgcccggc ccgagagccg ccgggcctgc agccgcgagc tctgccctgg tcgttggcga
2941 gccgggccct ggtcccagtg ctcagtaacc tgtggcaacg gcacccagga gcggccagtg
3001 ccctgccgca ccgcggacga cagcttcggc atctgccagg aggagcgtcc tgagacagcg
3061 aggacctgca ggcttggccc ctgtccccga aacatctcag atccctccaa gaagagctac
3121 gtagttcagt ggctgtcccg cccggacccc gactcgccca tccggaagat ctcgtcaaag
3181 ggccactgcc aaggcgacaa gtcaatattc tgtaggatgg aagtcttgtc ccgctattgc
3241 tccatcccag gctacaacaa gctgtcctgc aagtcctgta acctgtacaa caacctcacc
3301 aacgtggagg gcaggataga gccaccgcct gggaagcaca acgacattga cgtgttcatg
3361 cctaccctcc cagtgcccac tgtagccatg gaggtgcggc catcaccaag cacccccctg
3421 gaggtccctc tcaatgcctc cagcaccaat gccacagagg atcacccaga aaccaatgcc
3481 gtagatgaac cctacaaaat ccatggcctg gaagatgaag tccagccacc caacctaatc
3541 cctcgacgac cgagccccta tgaaaagacc agaaaccaaa gaatccaaga gctcattgat
3601 gagatgcgga agaaagagat gctcggaaag ttctaa
```

ADAMTS2 cDNA Sequence 2 (SEQ ID NO. 3)

NM_021599 Homo sapiens a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 2 (ADAMTS2), transcript variant 2, mRNA

```
   1 atggatccgc cggcgggagc cgctcgccgc ctgctctgcc ccgcgctgct gctgctgctg
  61 ctgctgctgc cgccgccgct cctgccgccg ccgccgccgc ccgcgaacgc caggctcgcc
 121 gccgccgccg acccccccagg cgggcccctg gggcacggag cggagcgcat cctggcggtg
 181 cccgtgcgca ctgacgccca gggccgcttg gtgtcccacg tggtgtcggc agctacgtcc
 241 agagcagggg tacgagcccg cagggccgcc ccggtccgga ccccgagctt ccccggaggc
 301 aacgaggagg agcctggcag tcacctcttc tacaatgtca cggtctttgg ccgagacctg
 361 cacctgcggc tgcggcccaa cgcccgcctc gtggcgcccg gggccactat ggagtggcag
 421 ggcgagaagg gcaccacccg cgtggagccc ctgctcggga gctgtctcta cgtcggagac
 481 gtggccggcc tagccgaagc ctcctctgtg gcgctcagca actgcgatgg gctggctggt
 541 ctgatccgga tggaggagga ggagttcttc atcgaaccct tggagaaggg gctggcggcg
 601 caggaggctg agcaaggccg tgtgcatgtg gtgtatcgcc ggccacccac gtcccctcct
 661 ctcgggggc cacaggccct ggacacaggg gcctccctgg acagcctgga cagcctcagc
 721 cgcgccctgg gcgtcctaga ggagcacgcc aacagctcga ggcggagggc acgcaggcat
 781 gctgcagacg atgactacaa catcgaggtc ctgctgggcg tggatgactc tgtggtgcag
 841 ttccacggga aggagcacgt acagaagtac ctgctgacac tcatgaacat tgtcaatgaa
 901 atctaccatg acgagtcctt gggtgcccac atcaacgtgg tcctggtgcg gatcatcctc
 961 ctgagctatg gaaagtccat gagcctcatc gagatcggga acccctctca gagcctggag
1021 aatgtctgcc gctgggccta cctccagcag aagccagaca cgggccacga tgaataccac
1081 gatcacgcca tcttcctcac acggcaggac tttgggcctt ccggcatgca aggctatgct
1141 cctgtcaccg gcatgtgcca tccggtccgc agctgcaccc tgaaccatga ggacggcttc
1201 tcctcagcgt ttgtggtggc ccatgagact ggccacgtgc tgggcatgga gcacgacggg
1261 cagggcaacc gctgtggcga cgaggtgcgg ctgggcagca tcatggcgcc cctggtgcag
1321 gccgccttcc accgcttcca ctggtcccgc tgcagccagc aggagctgag ccgctacctg
1381 cactcctatg actgcctgct ggatgacccc ttcgcccacg actggccggc gctgccccag
1441 ctcccgggac tgcactactc catgaacgag caatgccgct ttgacttcgg cctgggctac
1501 atgatgtgca cggcgttccg gacctttgac ccctgcaagc agctgtggtg cagccatcct
1561 gacaacccct acttttgcaa gaccaagaag gggcccccct tggacgggac tatgtgtgca
1621 cctggcaagt tcaggccggg cgcggtggct catgcctgtt atcccagcac tttgggaggc
1681 caaggtaggt ggatcgcctg a
```

[0255] Following are human polypeptide sequences for isoform 1 (long form) and isoform 2 (short form) of *ADAMTS2* (amino acid sequences 1 and 2, respectively).

ADAMTS2 Amino Acid Sequence 1 (SEQ ID NO. 4)

NP_055059 a disintegrin and metalloprotease with thrombospondin motifs-2 isoform 1; procollagen I N-proteinase; Procollagen N-endopeptidase [Homo sapiens]

MDPPAGAARRLLCPALLLLLLLLPPPLLPPPPPPANARLAAAADPPGGPLGHGAERILAV
PVRTDAQGRLVSHVVSAATSRAGVRARRAAPVRTPSFPGGNEEEPGSHLFYNVTVFGR
DLHLRLRPNARLVAPGATMEWQGEKGTTRVEPLLGSCLYVGDVAGLAEASSVALSNC
DGLAGLIRMEEEEFFIEPLEKGLAAQEAEQGRVHVVYRRPPTSPPLGGPQALDTGASLDS
LDSLSRALGVLEEHANSSRRRARRHAADDDYNIEVLLGVDDSVVQFHGKEHVQKYLLT
LMNIVNEIYHDESLGAHINVVLVRIILLSYGKSMSLIEIGNPSQSLENVCRWAYLQQKPD
TGHDEYHDHAIFLTRQDFGPSGMQGYAPVTGMCHPVRSCTLNHEDGFSSAFVVAHETG
HVLGMEHDGQGNRCGDEVRLGSIMAPLVQAAFHRFHWSRCSQQELSRYLHSYDCLLD
DPFAHDWPALPQLPGLHYSMNEQCRFDFGLGYMMCTAFRTFDPCKQLWCSHPDNPYF
CKTKKGPPLDGTMCAPGKHCFKGHCIWLTPDILKRDGSWGAWSPFGSCSRTCGTGVKF
RTRQCDNPHPANGGRTCSGLAYDFQLCSRQDCPDSLADFREEQCRQWDLYFEHGDAQ
HHWLPHEHRDAKERCHLYCESRETGEVVSMKRMVHDGTRCSYKDAFSLCVRGDCRK
VGCDGVIGSSKQEDKCGVCGGDNSHCKVVKGTFTRSPKKHGYIKMFEIPAGARHLLIQE
VDATSHHLAVKNLETGKFILNEENDVDASSKTFIAMGVEWEYRDEDGRETLQTMGPLH
GTITVLVIPVGDTRVSLTYKYMIHEDSLNVDDNNVLEEDSVVYEWALKKWSPCSKPCG
GGSQFTKYGCRRRLDHKMVHRGFCAALSKPKAIRRACNPQECSQPVWVTGEWEPCSQ
TCGRTGMQVRSVRCIQPLHDNTTRSVHAKHCNDARPESRRACSRELCPGRWRAGPWS
QCSVTCGNGTQERPVPCRTADDSFGICQEERPETARTCRLGPCPRNISDPSKKSYVVQW
LSRPDPDSPIRKISSKGHCQGDKSIFCRMEVLSRYCSIPGYNKLSCKSCNLYNNLTNVEG
RIEPPPGKHNDIDVFMPTLPVPTVAMEVRPSPSTPLEVPLNASSTNATEDHPETNAVDEP
YKIHGLEDEVQPPNLIPRRPSPYEKTRNQRIQELIDEMRKKEMLGKF

ADAMTS2 Amino Acid Sequence 2 (SEQ ID NO. 5)

NP_067610 a disintegrin and metalloprotease with thrombospondin motifs-2 isoform 2; procollagen I N-proteinase; Procollagen N-endopeptidase [Homo sapiens]

MDPPAGAARRLLCPALLLLLLLLPPPLLPPPPPPANARLAAAADPPGGPLGHGAERILAV
PVRTDAQGRLVSHVVSAATSRAGVRARRAAPVRTPSFPGGNEEEPGSHLFYNVTVFGR
DLHLRLRPNARLVAPGATMEWQGEKGTTRVEPLLGSCLYVGDVAGLAEASSVALSNC
DGLAGLIRMEEEEFFIEPLEKGLAAQEAEQGRVHVVYRRPPTSPPLGGPQALDTGASLDS
LDSLSRALGVLEEHANSSRRRARRHAADDDYNIEVLLGVDDSVVQFHGKEHVQKYLLT
LMNIVNEIYHDESLGAHINVVLVRIILLSYGKSMSLIEIGNPSQSLENVCRWAYLQQKPD
TGHDEYHDHAIFLTRQDFGPSGMQGYAPVTGMCHPVRSCTLNHEDGFSSAFVVAHETG
HVLGMEHDGQGNRCGDEVRLGSIMAPLVQAAFHRFHWSRCSQQELSRYLHSYDCLLD

DPFAHDWPALPQLPGLHYSMNEQCRFDFGLGYMMCTAFRTFDPCKQLWCSHPDNPYF
CKTKKGPPLDGTMCAPGKFRPGAVAHACYPSTLGGQGRWIA

[0256] Modifications may be made to the foregoing without departing from the basic aspects of the invention. Although the invention has been described in substantial detail with reference to one or more specific embodiments, those of skill in the art will recognize that changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the invention, as set forth in the aspects which follow. All publications or patent documents cited in this specification are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference.

[0257] Citation of the above publications or documents is not intended as an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents. U.S. patents and other publications referenced herein are hereby incorporated by reference.

What is claimed is:

1. A method for identifying a subject at risk of osteoarthritis, which comprises detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the one or more polymorphic variations are detected in a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-3;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(d) a fragment of a nucleotide sequence of (a), (b), or (c);

whereby the presence of the polymorphic variation is indicative of the subject being at risk of osteoarthritis.

2. The method of claim 1, which further comprises obtaining the nucleic acid sample from the subject.

3. The method of claim 1, wherein the one or more polymorphic variations are detected within a region spanning chromosome positions 178746000 to 178751000 in human genomic DNA.

4. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions selected from the group consisting of 210, 3608, 3609, 4318, 5593, 5629, 5639, 5640, 8943, 17968, 19887, 21034, 21085, , 21596, 23379, 23432, 24007, 26121, 26273, 26755, 27411, 27710, 27842, 28379, 29603, 31232, 31504, 32583, 32794, 32840, 33044, 33150, 33218, 33513, 33959, 34486, 36289, 36570, 38247, 38477, 38518, 38529, 38667, 39781, 39856, 39927, 40506, 41869, 42452, 44788, 46059, 46846, 47712, 48796, 49441, 49602, 49723, 50050, 50171, 50477, 50818, 50833, 50881, 50882, 51386, 51534, 52317, 52368, 52970, 53023, 53356, 53882, 54553, 55475, 55530, 55691, 55848, 55879, 56316, 56911, 57320, 57391, 57437, 57478, 57500, 59111, 59333, 59715, 59804, 59851, 59929, 60052, 60240, 60359, 60381, 60456, 60724, 60875, 60968, 60978, 60998, 61557, 62091, 62645, 62943, 63131, 63145, 63406, 63427, 63554, 63661, 64093, 64153, 64409, 64544, 65257, 65626,65739 , 66392, 66720, 69177, 69336, 69636, 69823, 69928, 70547, 70633, 71805, 72181, 72200, 72474, 72567, 72973, 73468, 73889, 75730, 75970, 76114, 76342, 76449, 76465, 76791, 78042, 80758, 80778, 81356, 81576, 81689, 81759, 81950, 82562, 83591, 83700, 83821, 83842, 83923, 83929, 84021, 84175, 84417, 84747, 85746, 86129, 86335, 87315, 87648, 87764, 87770, 88221, 90474, 91148, 91150, 91160, 91733, 91772, 91785,

93140, 93148, 96080, 96157, 96313, 96759, 97026, 97320, 97732, 98713, 99707, 99959, 100009, 100020, 100065, 100086, 101270, 101276, 101371, 101376, 101439, 101820, 102392, 102602, 102604, 102896, 189104, 189134 and 189205.

5. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions in SEQ ID NO: 1 selected from the group consisting of 5640, 33150, 38247, 38529, 46846, 49723, 50050, 63427, 73889, 189104 and rs428901.

6. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions in linkage disequilibrium with one or more positions in claim 3, 4 or 5.

7. The method of claim 1, wherein detecting the presence or absence of the one or more polymorphic variations comprises:

hybridizing an oligonucleotide to the nucleic acid sample, wherein the oligonucleotide is complementary to a nucleotide sequence in the nucleic acid and hybridizes to a region adjacent to the polymorphic variation;

extending the oligonucleotide in the presence of one or more nucleotides, yielding extension products; and

detecting the presence or absence of a polymorphic variation in the extension products.

8. The method of claim 1, wherein the subject is a human.

9. The method of claim 8, wherein the subject is a human female.

10. The method of claim 8, wherein the subject is a human male.

11. A method for identifying a polymorphic variation associated with osteoarthritis proximal to an incident polymorphic variation associated with osteoarthritis, which comprises:

identifying a polymorphic variation proximal to the incident polymorphic variation associated with osteoarthritis, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-3;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation;

determining the presence or absence of an association of the proximal polymorphic variant with osteoarthritis.

12. The method of claim 11, wherein the incident polymorphic variation is at one or more positions in claim 3, 4 or 5.

13. The method of claim 11, wherein the proximal polymorphic variation is within a region between about 5 kb 5' of the incident polymorphic variation and about 5 kb 3' of the incident polymorphic variation.

14. The method of claim 11, which further comprises determining whether the proximal polymorphic variation is in linkage disequilibrium with the incident polymorphic variation.

15. The method of claim 11, which further comprises identifying a second polymorphic variation proximal to the identified proximal polymorphic variation associated with osteoarthritis and determining if the second proximal polymorphic variation is associated with osteoarthritis.

16. The method of claim 15, wherein the second proximal polymorphic variant is within a region between about 5 kb 5' of the incident polymorphic variation and about 5 kb 3' of the proximal polymorphic variation associated with osteoarthritis.

17. An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-3;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

(e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d);

wherein the nucleotide sequence comprises a polymorphic variation associated with osteoarthritis selected from the group consisting of a cytosine at position 5640, a cytosine at position 33150, an adenine at position 38247, a thymine at position 38529, an adenine at position 46846, a cytosine at position 49723, a cytosine at position 50050, a cytosine a position 63427, a guanine at position 73889, a thymine at position 189104, and an adenine at position rs428901.

18. An oligonucleotide comprising a nucleotide sequence complementary to a portion of the nucleotide sequence of (a), (b), (c), or (d) in claim 17, wherein the 3' end of the oligonucleotide is adjacent to a polymorphic variation associated with osteoarthritis.

19. A microarray comprising an isolated nucleic acid of claim 17 linked to a solid support.

20. An isolated polypeptide encoded by the isolated nucleic acid sequence of claim 17.

21. A method for identifying a candidate therapeutic for treating osteoarthritis, which comprises:

(a) introducing a test molecule to a system which comprises a nucleic acid comprising a nucleotide sequence selected from the group consisting of:

(i) a nucleotide sequence in SEQ ID NO: 1-3;

(ii) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(iv) a fragment of a nucleotide sequence of (a), (b), or (c); or

introducing a test molecule to a system which comprises a protein encoded by a nucleotide sequence of (i), (ii), (iii), or (iv); and

(b) determining the presence or absence of an interaction between the test molecule and the nucleic acid or protein,

whereby the presence of an interaction between the test molecule and the nucleic acid or protein identifies the test molecule as a candidate therapeutic for treating osteoarthritis.

22. The method of claim 21, wherein the system is an animal.

23. The method of claim 21, wherein the system is a cell.

24. The method of claim 21, wherein the nucleotide sequence comprises one or more polymorphic variations associated with osteoarthritis.

25. The method of claim 24, wherein the one or more polymorphic variations associated with osteoarthritis are at one or more positions in claim 3, 4 or 5.

26. A method for treating osteoarthritis in a subject, which comprises contacting one or more cells of a subject in need thereof with a nucleic acid, wherein the nucleic acid comprises a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-3;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(d) a fragment of a nucleotide sequence of (a), (b), or (c); and

(e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d);

whereby contacting the one or more cells of the subject with the nucleic acid treats the osteoarthritis in the subject.

27. The method of claim 26, wherein the nucleic acid is RNA or PNA.

28. The method of claim 27, wherein the nucleic acid is duplex RNA.

29. A method for treating osteoarthritis in a subject, which comprises contacting one or more cells of a subject in need thereof with a protein, wherein the protein is encoded by a nucleotide sequence which comprises a polynucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-3;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(d) a fragment of a nucleotide sequence of (a), (b), or (c);

whereby contacting the one or more cells of the subject with the protein treats the osteoarthritis in the subject.

30. The method of claim 29, wherein the treatment comprises administration of an effective amount of a composition comprising an active *ADAMTS2* polypeptide or fragment thereof, wherein the polypeptide fragment is selected from the group consisting of: 252-1211, 253-1211, 254-1211, 255-1211, 256-1211, 257-1211, 258-1211, 259-1211 or 260-1211 of SEQ ID NO: 4.

31. The method of claim 30, wherein the polypeptide or fragment has biological activity.

32. A method for treating osteoarthritis in a subject, which comprises:

detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the one or more polymorphic variation are detected in a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-3;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

administering an osteoarthritis treatment to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

33. The method of claim 30, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

34. The method of claim 30, wherein the treatment is selected from the group consisting of administering a corticosteroid, a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) inhibitor, an antibody, a glucocorticoid, hyaluronic acid, chondrotin sulfate, glucosamine or acetaminophen; prescribing a heat/cold regimen or a joint protection regimen; performing joint surgery; prescribing a weight control regimen; and combinations of the foregoing.

35. A method for detecting or preventing osteoarthritis in a subject, which comprises:

detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-3;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

administering an osteoarthritis prevention or detection procedure to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

36. The method of claim 35, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

37. The method of claim 35, wherein the osteoarthritis prevention is selected from the group consisting of administering a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) inhibitor, an antibody, a glucocorticoid, hyaluronic acid, chondrotin sulfate, glucosamine or acetaminophen; prescribing a heat/cold regimen or a joint protection regimen; performing joint surgery; prescribing a weight control regimen; and combinations of the foregoing.

38. A method of targeting information for preventing or treating osteoarthritis to a subject in need thereof, which comprises:

detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence in SEQ ID NO: 1-3;

(b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;

(d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

directing information for preventing or treating osteoarthritis to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

39. The method of claim 38, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

40. A composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and an antibody that specifically binds to a protein, polypeptide or peptide encoded by a nucleotide sequence identical to or 90% or more identical to a nucleotide sequence in SEQ ID NO: 1-3.

41. A composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and a RNA, DNA, PNA or ribozyme molecule comprising a nucleotide sequence identical to or 90% or more identical to a portion of a nucleotide sequence in SEQ ID NO: 1-3.

42. The composition of claim 41, wherein the RNA molecule is a short inhibitory RNA molecule.

Abstract of the Disclosure

Provided herein are methods for identifying a risk of osteoarthritis in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating osteoarthritis, and therapeutic and preventative methods applicable to osteoarthritis. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

FIGURE 1

ADAMTS2 – DISCOVERY P-VALUES (female only)



Application Data Sheet

Application Information

Application Type::	Provisional
Subject Matter::	Utility
Suggested Group Art Unit::	Not Yet Assigned
CD-ROM or CD-R?::	None
Sequence submission?::	None
Computer Readable Form (CRF)?::	No
Title::	METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF
Attorney Docket Number::	524593008900
Request for Early Publication?::	No
Request for Non-Publication?::	No
Total Drawing Sheets?::	1
Small Entity?::	Yes
Petition included?::	No
Secrecy Order in Parent Appl.?::	No

Applicant Information

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	Steven
Family Name::	MAH
City of Residence::	San Diego
State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	12820 Via Nieve #74
City of mailing address::	San Diego
State or Province of mailing address::	CA

Postal or Zip Code of mailing address::	92130

Applicant Authority Type::	Inventor
Primary Citizenship Country::	Germany
Status::	Full Capacity
Given Name::	Andreas
Family Name::	BRAUN
City of Residence::	San Diego
State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	3935 Lago Di Grata Circle
City of mailing address::	San Diego
State or Province of mailing address::	CA
Postal or Zip Code of mailing address::	92130

Applicant Authority Type::	Inventor
Primary Citizenship Country::	Germany
Status::	Full Capacity
Given Name::	Stefan
Middle Name::	M.
Family Name::	KAMMERER
City of Residence::	San Diego
State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	3825 Elijah Court, Unit 334
City of mailing address::	San Diego
State or Province of mailing address::	CA
Postal or Zip Code of mailing address::	92130

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity

Given Name::	Matthew
Middle Name::	Roberts
Family Name::	NELSON
City of Residence::	San Marcos
State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	1250 Calle Prospero
City of mailing address::	San Marcos
State or Province of mailing address::	CA
Postal or Zip Code of mailing address::	92069

Applicant Authority Type::	Inventor
Primary Citizenship Country::	Sweden
Status::	Full Capacity
Given Name::	Rikard
Middle Name::	Henry
Family Name::	RENELAND
City of Residence::	San Diego
State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	7555 Charmant Drive, #1114
City of mailing address::	San Diego
State or Province of mailing address::	CA
Postal or Zip Code of mailing address::	92122

Applicant Authority Type::	Inventor
Primary Citizenship Country::	United Kingdom
Status::	Full Capacity
Given Name::	Maria
Middle Name::	L.
Family Name::	LANGDOWN
City of Residence::	San Diego

State or Province of Residence::	CA
Country of Residence::	US
Street of mailing address::	3701 Yosemite Street
City of mailing address::	San Diego
State or Province of mailing address::	CA
Postal or Zip Code of mailing address::	92109

Correspondence Information

Correspondence Customer Number::	25225

Representative Information

Representative Customer Number::	25225